US 20030036057A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2003/0036057 A1**

Braun et al. (43) **Pub. Date: Feb. 20, 2003**

(54) **GENES AND POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASE AND THEIR USE**

(76) Inventors: **Andreas Braun**, San Diego, CA (US); **Patrick W. Kleyn**, Concord, MA (US); **Aruna Bansal**, Landbeach (GB)

Correspondence Address:
HELLER EHRMAN WHITE & MCAULIFFE LLP
4250 EXECUTIVE SQ
7TH FLOOR
LA JOLLA, CA 92037 (US)

(21) Appl. No.: **09/802,640**

(22) Filed: **Mar. 9, 2001**

Publication Classification

(51) **Int. Cl.**[7] **C12Q 1/68**

(52) **U.S. Cl.** **435/6**

(57) **ABSTRACT**

Genes and polymorphisms associated with cardiovascular disease, methods that use the polymorphism to detect a predisposition to developing high cholesterol, low HDL or cardiovascular disease, to profile the response of subjects to therapeutic drugs and to develop therapeutic drugs are provided.


Results Pooling and Individual Genotyping Assay #50981
(Cytochrome C oxidase Vib)
Pooling: p-value 1.56E-04
Individual Genotyping: p-value 6.1E-06
Pool 1
Pool 2
32.00%
56.00%
0.022058824
15.44%
89.35%
0
4.55%
95.45%
9.93%
90.07%
97.73%
2.27%
7.65%
6.30%
9.05%
90.95%
97.25%
2.75%
no calls
GG GA
AA
GG GA
AA
G* A*
G* A*
Delta Pool1-Pool2
G* A*
G* A*
120.00%
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
percent

FIG. 1


Results Pooling and Individual Genotyping Assay # 52278
(N-acetylglucosaminyl transferase component)
Pooling: p-value 1.06E-04
Individual Genotyping: p-value 0.024
Pool 3
Pool 4
41.00%
46.50%
0.042372881
30.51%
65.24%
0.065420561
39.25%
54.21%
80.51%
19.49%
26.17%
73.83%
6.68%
11.33%
83.77%
16.25%
27.57%
72.43%
no calls
CC CT TT
CC CT TT
C* T*
C* T*
Delta Pool3-Pool4
C* T*
C* T*
90.00%
80.00%
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%
percent

FIG. 2

GENES AND POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASE AND THEIR USE

FIELD OF THE INVENTION

[0001] The field of the invention involves genes and polymorphisms of these genes that are associated with development of cardiovascular disease. Methods that use polymorphic markers for prognosticating, profiling drug response and drug discovery are provided.

BACKGROUND OF THE INVENTION

[0002] Diseases in all organisms have a genetic component, whether inherited or resulting from the body's response to environmental stresses, such as viruses and toxins. The ultimate goal of ongoing genomic research is to use this information to develop new ways to identify, treat and potentially cure these diseases. The first step has been to screen disease tissue and identify genomic changes at the level of individual samples. The identification of these "disease" markers has then fueled the development and commercialization of diagnostic tests that detect these errant genes or polymorphisms. With the increasing numbers of genetic markers, including single nucleotide polymorphisms (SNPs), microsatellites, tandem repeats, newly mapped introns and exons, the challenge to the medical and pharmaceutical communities is to identify genotypes which not only identify the disease but also follow the progression of the disease and are predictive of an organism's response to treatment.

[0003] Polymorphisms

[0004] Polymorphisms have been known since 1901 with the identification of blood types. In the 1950's they were identified on the level of proteins using large population genetic studies. In the 1980's and 1990's many of the known protein polymorphisms were correlated with genetic loci on genomic DNA. For example, the gene dose of the apolipoprotein E type 4 allele was correlated with the risk of Alzheimer's disease in late onset families (see, e.g., Corder et al. (1993) *Science* 261: 921-923; mutation in blood coagulation factor V was associated with resistance to activated protein C (see, e.g., Bertina et al. (1994) *Nature* 369:64-67); resistance to HIV-1 infection has been shown in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene (see, e.g., Samson et al. (1996) *Nature* 382:722-725); and a hypermutable tract in antigen presenting cells (APC, such as macrophages), has been identified in familial colorectal cancer in individuals of Ashkenzi jewish background (see, e.g., Laken et al. (1997) *Nature Genet.* 17:79-83). There may be more than three million polymorphic sites in the human genome. Many have been identified, but not yet characterized or mapped or associated with a disease. Polymorphisms of the genome can lead to altered gene function, protein function or mRNA instability. To identify those polymorphisms that have clinical relevance is the goal of a world-wide scientific effort. Discovery of such polymorphisms will have a fundamental impact on the identification and development of diagnostics and drug discovery.

[0005] Single nucleotide polymorphisms (SNPs) Much of the focus of genomics has been in the identification of SNPs, which are important for a variety of reasons. They allow indirect testing (association of haplotypes) and direct testing (functional variants). They are the most abundant and stable genetic markers. Common diseases are best explained by common genetic alterations, and the natural variation in the human population aids in understanding disease, therapy and environmental interactions.

[0006] The organization of SNPs in the primary sequence of a gene into one of the limited number of combinations that exist as units of inheritance is termed a haplotype. Each haplotype therefore contains significantly more information than individual unorganized polymorphisms and provides an accurate measurement of the genomic variation in the two chromosomes of an individual. While it is well-established that many diseases are associated with specific variation in gene sequences and there are examples in which individual polymorphisms act as genetic markers for a particular phenotype, in other cases an individual polymorphism may be found in a variety of genomic backgrounds and therefore shows no definitive coupling between the polymorphism and the phenotype. In these instances, the observed haplotype and its frequency of occurrence in various genotypes will provide a better genetic marker for the phenotype.

[0007] Although risk factors for the development of cardiovascular disease are known, such as high serum cholesterol levels and low serum high density lipoprotein (HDL) levels, the genetic basis for the manifestation of these phenotypes remains unknown. An understanding of the genes that are responsible for controlling cholesterol and HDL levels, along with useful genetic markers and mutations in these genes that affect these phenotypes, will allow for detection of a predisposition for these risk factors and/or cardiovascular disease and the development of therapeutics to modulate such alterations. Therefore, it is an object herein to provide methods for using polymorphic markers to detect a predisposition to the manifestation of high serum cholesterol, low serum HDL and cardiovascular disease. The ultimate goals are the elucidation of pathological pathways, developing new diagnostic assays, determining genetic profiles for positive responses to therapeutic drugs, identifying new potential drug targets and identifying new drug candidates.

SUMMARY OF THE INVENTION

[0008] A database of twins was screened for individuals which exhibit high or low levels of serum cholesterol or HDL. Using a full genome scanning approach SNPs present in DNA samples from these individuals were examined for alleles that associate with either high levels of cholesterol or low levels of HDL. This lead to the discovery of the association of the cytochrome C oxidase subunit VIb (COX6B) gene and the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene with these risks factors for developing cardiovascular disease. Specifically, a previously undetermined association of an allelic variant at nucleotide 86 of the COX6B gene and high serum cholesterol levels has been discovered. In addition, it has been discovered that an allelic variant at nucleotide 2577 of the GPI-1 gene is associated with low serum HDL levels. There was no previously known association between these two genes and risk factors related to cardiovascular disease.

[0009] Methods are provided for detecting the presence or absence of at least one allelic variant associated with high

cholesterol, low HDL and/or cardiovascular disease by detecting the presence or absence of at least one allelic variant of the COX6B gene or the GPI-1 gene, individually or in combination with one or more allelic variants of other genes associated with cardiovascular disease.

[0010] Also provided are methods for indicating a predisposition to manifesting high serum cholesterol, low serum HDL and/or cardiovascular disease based on detecting the presence or absence of at least one allelic variant of the COX6B or GPI-1 genes, alone or in combination with one or more allelic variants of other genes associated with cardiovascular disease. These methods, referred to as haplotyping, are based on assaying more than one polymorphism of the COX6B and/or GPI-1 genes. One or more polymorphisms of other genes associated with cardiovascular disease may also be assayed at the same time. A collection of allelic variants of one or more genes may be more informative than a single allelic variant of any one gene. A single polymorphism of a collection of polymorphisms present in the COX6B and/or GPI-1 genes and in other genes associated with cardiovascular disease may be assayed individually or the collection may be assayed simultaneously using a multiplex assay method.

[0011] Also provided are microarrays comprising a probe selected from among an oligonucleotide complementary to a polymorphic region surrounding position 86 of the sense strand of the COX6B gene coding sequence, an oligonucleotide complementary to a polymorphic region surrounding the position of the antisense strand of COX6B corresponding to position 86 of the sense strand of the COX6B gene coding sequence; an oligonucleotide complementary to a polymorphic region surrounding position 2577 of the sense strand of the GPI-1 gene and an oligonucleotide complementary to a polymorphic region surrounding the position of the antisense strand of GPI-1 corresponding to position 2577 of the sense strand of the GPI-1 gene. Micrarrays are well known and can be made, for example, using methods set forth in U.S. Pat. Nos. 5,837,832; 5,858,659; 6,043,136; 6,043,031 and 6,156,501.

[0012] Further provided are methods of utilizing allelic variants of the COX6B or GPI-1 gene individually or together with one or more allelic variants of other genes associated with cardiovascular disease to predict a subject's response to a biologically active agent that modulates serum cholesterol, serum HDL, or a cardiovascular drug.

[0013] Also provided are methods to screen candidate biologically active agents for modulation of cholesterol, HDL or other factors associated with cardiovascular disease. These methods utilize cells or transgenic animals containing one or more allelic variants of the COX6B gene and/or the GPI-1 gene alone or in combination with allelic variants of one or more other genes associated with cardiovascular disease. Such animals should exhibit high cholesterol, low HDL or other known phenotypes associated with cardiovascular disease. Also, provided are methods to construct transgenic animals that are useful as models for cardiovascular disease by using one or more allelic variants of the COX6B gene and/or the GPI-1 gene alone or in combination with allelic variants of one or more other genes associated with cardiovascular disease.

[0014] Further provided are combinations of probes and primers and kits for predicting a predisposition to high serum cholesterol, low HDL levels and/or cardiovascular disease. In particular, combinations and kits comprise probes or primers which are capable of hybridizing adjacent to or at polymorphic regions of the COX6B and/or GPI-1 gene. The combinations and kits can also contain probes or primers which are capable of hybridizing adjacent to or at polymorphic regions of other genes associated with cardiovascular disease. The kits also optionally contain instructions for carrying out assays, interpreting results and for aiding in diagnosing a subject as having a predisposition towards developing high serum cholesterol, low HDL levels and/or cardiovascular disease. Combinations and kits are also provided for predicting a subject's response to a therapeutic agent directed toward modulating cholesterol, HDL, or another phentopye associated with cardiovascular disease. Such combinations and kits comprise probes or primers as described above.

[0015] In particular for the methods, combinations, kits and arrays described above, the polymorphisms are SNPs. The detection or identification is of a T nucleotide at position 86 of the sense strand of the COX6B gene coding sequence or the detection or identification of an A nucleotide at the corresponding position in the antisense strand of the COX6B gene coding sequence. Also embodied is the detection or identification of an A nucleotide at position 2577 of the sense strand of the GPI-1 gene or the detection or identification of a T nucleotide at the corresponding position in the antisense strand of the GPI-1 gene. In addition to the SNPs discussed above, other polymorphisms of the COX6B and GPI-1 genes can be assayed for association with high cholesterol or low HDL, respectively, and utilized as disclosed above.

[0016] Other genes containing allelic variants associated with high serum cholesterol, low HDL and/or cardiovascular disease, include, but are not limited to: cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apopliporotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

[0017] The detection of the presence or absence of an allelic variant can utilize, but are not limited to, methods such as allele specific hybridization, primer specific extension, oligonucleotide ligation assay, restriction enzyme site analysis and single-stranded conformation polymorphism analysis.

[0018] In particular, primers utilized in primer specific extension hybridize adjacent to nucleotide 86 of the COX6B gene or nucleotide 2577 of the GPI-1 gene or the corresponding positions on the antisense strand (numbers refer to GenBank sequences, see pages 15-17). A primer can be extended in the presence of at least one dideoxynucleotide, particularly ddG, or two dideoxynucleotides, particularly ddG and ddC. Preferably, detection of extension products is by mass spectrometry. Detection of allelic variants can also involve signal moieties such as radioisotopes, enzymes, antigens, antibodies, spectrophotometric reagents, chemiluminescent reagents, fluorescent reagents and other light producing reagents.

[0019] Other probes and primers useful for the detection of allelic variants include those which hybridize at or adjacent to the SNPs described in Tables 1-3 and specifically those that comprise SEQ ID NOs.: 5, 10, 43, 48, 53, 58, 63, 68, 73, 78, 83, 88, 93, 98, 103, 108, 113, and 118.

DESCRIPTION OF THE DRAWINGS

[0020] **FIG. 1** depicts the allelic frequency and genotype for pools and individually determined samples of blood from individuals having low cholesterol levels and those with high cholesterol levels.

[0021] **FIG. 2** depicts the allelic frequency and genotype for pools and individually determined samples of blood from individuals having high HDL levels and those with low HDL levels.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0022] A. Definitions

[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, patent applications and publications referred to throughout the disclosure herein are, unless noted otherwise, incorporated by reference in their entirety. In the event that there are a plurality of definitions for terms herein, those in this section prevail.

[0024] As used herein, sequencing refers to the process of determining a nucleotide sequence and can be performed using any method known to those of skill in the art. For example, if a polymorphism is identified or known, and it is desired to assess its frequency or presence in nucleic acid samples taken from the subjects that comprise the database, the region of interest from the samples can be isolated, such as by PCR or restriction fragments, hybridization or other suitable method known to those of skill in the art, and sequenced. For purposes herein, sequencing analysis is preferably effected using mass spectrometry (see, e.g., U.S. Pat. Nos. 5,547,835, 5,622,824, 5,851,765, and 5,928,906). Nucleic acids can also be sequenced by hybridization (see, e.g., U.S. Pat. Nos. 5,503,980, 5,631,134, 5,795,714) and including analysis by mass spectrometry (see, U.S. application Ser. Nos. 08/419,994 and 09/395,409). Alternatively, sequencing may be performed using other known methods, such as set forth in U.S. Pat. Nos. 5,525,464; 5,695,940; 5,834,189; 5,869,242; 5,876,934; 5,908,755; 5,912,118; 5,952,174; 5,976,802; 5,981,186; 5,998,143; 6,004,744; 6,017,702; 6,018,041; 6,025,136; 6,046,005; 6,087,095; 6,117,634, 6,013,431, WO 98/30883; WO 98/56954; WO 99/09218; WO/00/58519, and the others.

[0025] As used herein, "polymorphism" refers to the coexistence of more than one form of a gene or portion thereof. A portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a "polymorphic region of a gene". A polymorphic region can be a single nucleotide, the identity of which differs in different alleles. A polymorphic region can also be several nucleotides in length.

[0026] As used herein, "polymorphic gene" refers to a gene having at least one polymorphic region.

[0027] As used herein, "allele", which is used interchangeably herein with "allelic variant" refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has two identical alleles of a gene, the subject is said to be homozygous for the gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. Alleles of a specific gene can differ from each other in a single nucleotide, or several nucleotides, and can include substitutions, deletions, and insertions of nucleotides. An allele of a gene can also be a form of a gene containing a mutation.

[0028] As used herein, the term "subject" refers to mammals and in particular human beings.

[0029] As used herein, the term "gene" or "recombinant gene" refers to a nucleic acid molecule comprising an open reading frame and including at least one exon and (optionally) at least one intron sequence. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and trailer).

[0030] As used herein, "intron" refers to a DNA sequence present in a given gene which is spliced out during mRNA maturation.

[0031] As used herein, the term "coding sequence" refers to that portion of a gene that encodes an amino acid sequence of a protein.

[0032] As used herein, the term "sense strand" refers to that strand of a double-stranded nucleic acid molecule that encodes the sequence of the mRNA that encodes the amino acid sequence encoded by the double-stranded nucleic acid molecule.

[0033] As used herein, the term "antisense strand" refers to that strand of a double-stranded nucleic acid molecule that is the complement of the sequence of the mRNA that encodes the amino acid sequence encoded by the double-stranded nucleic acid molecule.

[0034] As used herein, a DNA or nucleic acid homolog refers to a nucleic acid that includes a preselected conserved nucleotide sequence. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith or a less percentage of homology or identity and conserved biological activity or function.

[0035] Regarding hybridization, as used herein, stringency conditions to achieve specific hybridization refer to the washing conditions for removing the non-specific probes or primers and conditions that are equivalent to either high, medium, or low stringency as described below:

[0036] 1) high stringency: 0.1× SSPE, 0.1% SDS, 65° C.

[0037] 2) medium stringency: 0.2× SSPE, 0.1% SDS, 50° C.

[0038] 3) low stringency: 1.0× SSPE, 0.1% SDS, 50° C.

[0039] It is understood that equivalent stringencies may be achieved using alternative buffers, salts and temperatures.

[0040] As used herein, "heterologous DNA" is DNA that encodes RNA and proteins that are not normally produced in

vivo by the cell in which it is expressed or that mediates or encodes mediators that alter expression of endogenous DNA by affecting transcription, translation, or other regulatable biochemical processes or is not present in the exact orientation or position as the counterpart DNA in a wildtype cell. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which is expressed is herein encompassed by heterologous DNA. Examples of heterologous DNA include, but are not limited to, DNA that encodes traceable marker proteins, such as a protein that confers drug resistance, DNA that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and DNA that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous DNA may be secreted or expressed on the surface of the cell in which the heterologous DNA has been introduced.

[0041] As used herein, a "promoter region" refers to the portion of DNA of a gene that controls transcription of the DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be cis acting or may be responsive to trans acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.

[0042] As used herein, the phrase "operatively linked" generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form, whereby control or regulatory sequences on one segment control or permit expression or replication or other such control of other segments. The two segments are not necessarily contiguous. For gene expression a DNA sequence and a regulatory sequence(s) are connected in such a way to control or permit gene expression when the appropriate molecular, e.g., transcriptional activator proteins, are bound to the regulatory sequence(s).

[0043] As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. "Plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. Also included are other forms of expression vectors that serve equivalent functions and that become known in the art subsequently hereto.

[0044] As used herein, "indicating" or "determining" means that the presence or absence of an allelic variant may be one of many factors that are considered when a subject's predisposition to a disease or disorder is evaluated. Thus a predisposition to a disease or disorder is not necessarily conclusively determined by only ascertaining the presence or absence of one or more allelic variants, but the presence of one of more of such variants is among an number of factors considered.

[0045] As used herein, "predisposition to develop a disease or disorder" means that a subject having a particular genotype and/or haplotype has a higher likelihood than one not having such a genotype and/or haplotype for developing a particular disease or disorder.

[0046] As used herein, "transgenic animal" refers to any animal, preferably a non-human animal, e.g. a mammal, bird or an amphibian, in which one or more of the cells of the animal contain heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA. In the typical transgenic animals described herein, the transgene causes cells to express a recombinant form of a protein. However, transgenic animals in which the recombinant gene is silent are also contemplated, as for example, using the FLP or CRE recombinase dependent constructs. Moreover, "transgenic animal" also includes those recombinant animals in which gene disruption of one or more genes is caused by human intervention, including both recombination and antisense techniques.

[0047] As used herein, "associated" refers to coincidence with the development or manifestation of a disease, condition or phenotype. Association may be due to, but is not limited to, genes responsible for housekeeping functions, those that are part of a pathway that is involved in a specific disease, condition or phenotype and those that indirectly contribute to the manifestation of a disease, condition or phenotype.

[0048] As used herein, "high serum cholesterol" refers to a level of serum cholesterol that is greater than that considered to be in the normal range for a given age in a population, e.g., about 5.25 mmoles/L or greater, i.e., approximately one standard deviation or more away from the age-adjusted mean.

[0049] As used herein, "low serum HDL" refers to a level of serum HDL that is less than that considered to be in the normal range for a given age in a population, e.g. about 1.11 mmoles/L or less, i.e., approximately one standard deviation or more away from the age-adjusted mean.

[0050] As used herein, "cardiovascular disease" refers to any manifestation of or predisposition to cardiovascular disease including, but not limited to, coronary artery disease and myocardial infarction. Included in predisposition is the manifestation of risks factors such as high serum cholesterol levels and low serum HDL levels.

[0051] As used herein, "target nucleic acid" refers to a nucleic acid molecule which contains all or a portion of a polymorphic region of a gene of interest.

[0052] As used herein, "signal moiety" refers to any moiety that allows for the detection of a nucleic acid molecule. Included are moieties covalently attached to nucleic acids and those that are not.

[0053] As used herein, "biologically active agent that modulates serum cholesterol" refers to any drug, small molecule, nucleic acid (sense and antisense), protein, peptide, lipid, carbohydrate etc. or combination thereof, that exhibits some effect directly or indirectly on the cholesterol measured in a subject's serum.

[0054] As used herein, "biologically active agent that modulates serum HDL" refers to any drug, small molecule, nucleic acid (sense and antisense), protein, peptide, lipid, carbohydrate etc. or combination thereof that exhibits some effect directly or indirectly on the HDL measured in a subject's serum.

[0055] As used herein, "expression and/or activity" refers to the level of transcription or translation of the COX6B or GPI-1 gene, mRNA stability, protein stability or biological activity.

[0056] As used herein, "cardiovascular drug" refers to a drug used to treat cardiovascular disease or a risk factor for the disease, either prophylactically or after a risk factor or disease condition has developed. Cardiovascular drugs include those drugs used to lower serum cholesterol and those used to alter the level of serum HDL.

[0057] As used herein, "combining" refers to contacting the biologically active agent with a cell or animal such that the agent is introduced into the cell or animal. For a cell any method that results in an agent traversing the plasma membrane is useful. For an animal any of the standard routes of administration of an agent, e.g. oral, rectal, transmucosal, intestinal, intravenous, intraperitoneal, intraventricular, subcutaneous, intramuscular, etc., can be utilized.

[0058] As used herein, "positive response" refers to improving or ameliorating at least one symptom or detectable characteristic of a disease or condition, e.g., lowering serum cholesterol levels or raising serum HDL levels.

[0059] As used herein, "biological sample" refers to any cell type or tissue of a subject from which nucleic acid, particularly DNA, can be obtained.

[0060] As used herein, "array" refers to a collection of three or more items, such a collection of immobilized nucleic acid probes arranged on a solid substrate, such as silica, polymeric materials or glass.

[0061] As used herein, a composition refers to any mixture. It may be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous or any combination thereof.

[0062] As used herein, a combination refers to any association between two or among more items.

[0063] As used herein, "kit" refers to a package that contains a combination, such as one or more primers or probes used to amplify or detect polymorphic regions of genes associated with cardiovascular disease, optionally including instructions and/or reagents for their use.

[0064] As used herein "specifically hybridizes" refers to hybridization of a probe or primer only to a target sequence preferentially to a non-target sequence. Those of skill in the art are familiar with parameters that affect hybridization; such as temperature, probe or primer length and composition; buffer composition and salt concentration and can readily adjust these parameters to achieve specific hybridization of a nucleic acid to a target sequence.

[0065] As used herein "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The term should also be understood to include, as equivalents, derivatives, variants and analogs of either RNA or DNA made from nucleotide analogs, single (sense or antisense) and double-stranded polynucleotides. Deoxyribonucleotides include deoxyadenosine, deoxycytidine, deoxyguanosine and deoxythymidine. For RNA, the uracil base is uridine.

[0066] As used herein, "mass spectrometry" encompassses any suitable mass spectrometric format known to those of skill in the art. Such formats include, but are not limited to, Matrix-Assisted Laser Desorption/Ionization, Time-of-Flight (MALDI-TOF), Electrospray (ES), IR-MALDI (see, e.g., published International PCT Application No. 99/57318 and U.S. Pat. No. 5,118,937) Ion Cyclotron Resonance (ICR), Fourier Transform and combinations thereof. MALDI, particular UV and IR, are among the preferred formats.

[0067] B. Cytochrome c oxidase VIb gene

[0068] Cytochrome c oxidase (COX) is a mitochondrial enzyme complex integrated in the inner membrane. It transfers electrons from cytochrome to molecular oxygen in the terminal reaction of the respiratory chain in eukaryotic cells. COX contains of three large subunits encoded by the mitochondrial genome and 10 other subunits, encoded by nuclear genes. The three subunits encoded by mitochondrial genome are responsible for the catalytic activity. The cytochrome c oxidase subunit VIb (COX6B) is one of the nuclear gene products. The function of the nuclear encoded subunits is unknown. One proposed role is in the regulation of catalytic activity; specifically the rate of electron transport and stoichiometry of proton pumping. Other proposed roles are not directly related to electron transport and include energy-dependent calcium uptake and protein import by the mitochondrion. Proteolytic removal of subunits VIa and VIb has been associated with loss of calcium transport in reconstituted vesicles. Steady-state levels of the COX6B transcript are different in different tissues (Taanman et al., Gene (1990), 93:285).

[0069] The COX6B gene is generically used to include the human COX6B gene and its homologs from rat, mouse, guinea pig, etc.

[0070] Several single nucleotide polymorphism have been identified in the human COX6B gene. One of these is located at position 86 and is a C to T transversion which is manifested as a silent mutation in the coding region, ACC to ACT (threonine to threonine)(SEQ ID NO.: 2). Although this is a silent mutation at the amino acid level, it may represent an alteration that changes codon usage, or it may effect mRNA stability or it may be in linkage disequilibrium with a non-silent change. Other known single nucleotide polymorphisms of the COX6B gene include, but are not limited to, those listed in Table 1.

TABLE 1

Gene	GenBank Accession No.	SNP	SNP Location
COX6B	NM_001863	C/T	86
(SEQ ID NO.: 1)		A/G	60
		A/T	324
		A/T	123

[0071] Based on methods disclosed herein and those used in the art, one of skill would be able to utilize all the SNPs described and find additional polymorphic regions of the COX6B gene to determine whether allelic variants of these regions are associated with high cholesterol levels and cardiovascular disease.

[0072] C. GPI-1 Gene

[0073] Glycosylphosphatidylinositol (GPI) functions to anchor various eukaryotic proteins to membranes and is essential for their surface expression. Thus, a defect in GPI anchor synthesis affects various functions of cell, tissues and organs. Biosynthesis of glycosylphosphatidylinositol (GPI) is initiated by the transfer of N-acetylglucosamine (GlcNAc) from UDP-GlcNac to phosphatidylinositol (PI) and is catalyzed by a GlcNAc transferase, GPI-GlcNAc transferase (GPI-GnT). Four mammalian gene products form a protein complex that is responsible for this enzyme activity (PIG-A, PIG-H, PIG-C and GPI-1). PIG-A, PIG-H, PIG-C are required for the first step in GPI anchor biosynthesis; GPI-1 is not. Stabilization of the enzyme complex, rather than participation in GlcNAc transfer, has been suggested as a possible role for GPI-1 (Watanabe et al. EMBO 17:877, 1998).

[0074] The GPI-1 gene is generically used to include the human GPI-1 gene and its homologs from rat, mouse, guinea pig, etc.

[0075] A polymorphism has been identified at position 2577 of the human GPI-1 gene. This is a G to A transversion. This SNP is located in the 3' untranslated region of the mRNA, and does not affect protein structure, but may affect mRNA stability or may be in linkage disequilibrium with a non-silent change. Other known single nucleotide polymorphisms of the GPI-1 gene include, but are not limited to, those listed in Table 2.

TABLE 2

Gene	GenBank Accession No.	SNP	SNP Location
GPI-1	NM_004204	C/T	2829
(SEQ ID NOS.: 6, 7)		A/G	2577
		C/T	2519
		C/T	2289
		C/T	1938
		C/G	1563
		A/G/C/T	2664
		A/G	2656
		A/C/T	2167
		G/C/A	2166

[0076] Based on methods disclosed herein and those used in the art, one of skill would be able to use all the described SNPs and find additional polymorphic regions of the GPI-1 gene to determine whether allelic variants of these regions are associated with low levels of HDL and cardiovascular disease.

[0077] D. Other Genes and Polymorphism Associated with Cardiovascular Disease

[0078] Many other genes and polymorphisms contained within them have been associated with risks factors for cardiovascular disease (aberrations in lipid metabolism; specifically high levels of serum cholesterol and low levels of HDL, etc.) and/or the clinical phenotypes of atherosclerosis and cardiovascular disease. Table 3 presents a list of some of these genes and some associated polymorphisms (SNPs): cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-II (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase (LIPC); E-selectin; G protein beta 3 subunit and angiotensin II type 1 receptor gene. The SNP locations are based on the GenBank sequence. Table 3 is not meant to be exhaustive, as one of skill in the art based on the disclosure would be able to readily use other known polymorphisms in these and other genes, new polymorphisms discovered in previously identified genes and newly identified genes and polymorphisms in the methods and compositions disclosed herein.

TABLE 3

Gene	GenBank Accession No.	SNP	SNP Location
CETP	NM_000078	C/A	991
(SEQ ID NOS.: 11, 12)		C/T	196
		A/G	1586
		A/G	1394
		A/G	1439
		C/G	1297
		C/T	766
		G/A	1131
		G/A	1696
LPL	NM_000237	A/G	1127
(SEQ ID NOS.: 13, 14)		A/C	3447
		C/T	1973
		C/T	3343
		G/A	2851
		C/T	3272
		A/T	2428
		T/C	2743
		G/A	1453
		C/A	3449
		G/A	1282
		G/A	579
		A/C	1338
		A/G/T/C	2416–2426
		A/G	2427
		C/T	1302
		G/A	609
		G/C	1595
		G/A	1309
		C/T	2454
		C/T	2988
		G/A	280
		G/A	1036
APO A4	NM_000482	G/T	1122
(SEQ ID NOS.: 15, 16)		G/C	1033
		G/A	1002
		C/T	960

TABLE 3-continued

Gene	GenBank Accession No.	SNP	SNP Location
		C/T	894
		G/A	554
		G/A	950
		T/C	336
		G/A	334
		C/T	330
		A/G	201
		A/G	16
		A/T	1213
APO E	NM_000041	C/T	448
(SEQ ID NOS.: 17, 18)		G/A	448
(mRNA)		C/T	586
		C/T	197
		C/T	540
Hepatic Lipase	NM_000236	C/G	680
(SEQ ID NOS.: 19, 20)		G/A	1374
		G/A	701
		C/A	1492
		A/G	648
		G/C	729
		G/A	340
		G/T	522
PON 1	NM_000446	A/T	172
(SEQ ID NOS.: 21, 22)		A/G	584
		G/C	190
PON 2	XM_004947	C/G	475
(SEQ ID NOS.: 23, 24)		C/G	964
APO C3	NM_000040	C/T	148
(SEQ ID NOS.: 25, 26)		T/A	471
		G/G	386
		G/T	417
		T/A	95
ABC 1	XM_005567	G/A	8591
(SEQ ID NOS.: 27, 28)			
APO A1	NM_000039	C/G	770
(SEQ ID NOS.: 29, 30)		G/A	656
		C/G	589
		C/G	414
		A/T	430
		C/T	708
		C/T	221
		T/G	223
		C/T	597
		A/G	340
		G/C	690
APO B	NM_000384	A/G/C/T	13141
(SEQ ID NOS.: 31, 32)		A/G/C/T	12669
		C/T	11323
		G/C	10422
		A/C	10408
		C/G	10083
		C/T	7064
		C/T	6666
		C/T	1980
		C/G	5751
		C/T	7673
		C/A/G/T	8344
		G/C/T/A	4393
		A/C/T/G	5894
		A/T	12019
		C/T	11973
		G/C/T/A	7065
		C/G	947
		C/G	7331
		A/G	7221
		G/C	6402
		G/C	3780
		C/G	1661
		A/T	8167
		C/A	8126
		C/T	421
		C/T	1981
		G/A	12510

TABLE 3-continued

Gene	GenBank Accession No.	SNP	SNP Location
		G/C	12937
		G/A	11042
		C/T	2834
		A/G	5869
		A/G	11962
		C/G	4439
		G/A	7824
		G/A	13569
		G/A	9489
		G/A	2325
		G/A	10259
		C/G	14
MTHFR	NM_005957	G/A	5442
(SEQ ID NOS.: 33, 34)		A/G	5113
		A/G	5113
		A/G	5110
		A/G	5102
		A/C/T	5097
		A/C/T	5097
		C/T	5079
		C/T	5079
		T/C	5071
		T/C	5071
		T/C	5051
		G/A	5012
		C/A	5000
		A/G	4998
		A/G	4994
		A/G	4994
		A/G	4994
		C/T	4991
		C/T	4991
		C/T	4991
		A/C	4986
		A/G	4986
		A/G	4986
		C/T	4985
		T/A	4982
		T/G	4981
		T/C	4981
		T/C	4981
		G/C/A	4967
		G/A	4963
		A/G	4962
		G/C/T	4962
		A/C/G/T	4961
		A/C/T	4961
		A/C	4961
		A/C	4961
		A/C/T	4960
		T/C	4938
		T/C	4937
		T/C	4933
		G/C/T	4933
		C/T	4929
		C/T	4929
		T/A/G	4929
		A/G	4928
		G/C	4928
		C/G	4927
		G/A	4923
		C/T	4919
		A/T/G	4913
		C/T	4912
		A/T	4903
		C/T	4902
		A/G	4900
		G/A	4898
		G/T	4898
		C/T	4897
		G/T	4894
		T/C/G	4836
		C/T	3862

TABLE 3-continued

Gene	GenBank Accession No.	SNP	SNP Location
		C/T	4922
		C/T	4959
		T/C	4981
		A/G	4994
		A/G	5044
		T/C	5051
		G/C	5066
		C/T	5079
		C/A/G	5085
		C/T	5092
		A/G	5103
		A/G	5113
		C/T	1021
E-Selectin	NM_000450	G/A	3484
(SEQ ID NOS.: 35, 36)		G/A	3093
		T/G	2939
		T/C	2902
		C/T	1937
		C/T	1916
		C/T	1839
		C/T	1805
		C/T	1518
		G/C	1377
		C/T	1376
		G/A	999
		T/C	857
		A/C	561
		C/G	506
		A/G	392
		G/T	98

TABLE 3-continued

Gene	GenBank Accession No.	SNP	SNP Location
G protein β3 subunit	NM_002075	C/T	1828
(SEQ ID NOS.: 37, 38)		C/T	1546
		G/T	1431
		G/A	1231
		C/T	1230
Angiotensin II type 1	NM_00686	G/A	1453
receptor gene		C/G	968
(SEQ ID NOS.: 39, 40)		G/C	966
		T/C	941
		G/A	894
		T/C	659

[0079] Assays to identify the nucleotide present at the polymorphic site include those described herein and all others known to those who practice the art.

[0080] For some of the SNPs described above, there are provided a description of the MassEXTEND™ reaction components that can be utilized to determine the allelic variant that is present. Included are the forward and reverse primers used for amplification. Also included are the MassEXTEND™ primer used in the primer extension reaction and the extended MassEXTEND™ primers for each allele. MassEXTEND™ reactions are carried out and the products analyzed as described in Examples 2 and 3.

CETP

Position 991 (C/A)

PCR primers:

Forward:	ACTGCCTGATAACCATGCTG	(SEQ ID NO.: 41)
Reverse:	ATACTTACACACCAGGAGGG	(SEQ ID NO.: 42)
MassEXTEND™ Primer:	ATGCCTGCTCCAAAGGCAC	(SEQ ID NO.: 43)
Primer Mass:	5757.8	
Extended Primer-Allele C:	ATGCCTGCTCCAAAGGCACC	(SEQ ID NO.: 44)
Extended Primer Mass:	6030.9	
Extended Primer-Allele A:	ATGCCTGCTCCAAAGGCACAT	(SEQ ID NO.: 45)
Extended Primer Mass:	6359.2	

Position 196 (C/T)

PCR primers:

Forward:	TACTTCTGGTTCTCTGAGCG	(SEQ ID NO.: 46)
Reverse:	ACTCACCTTGAACTCGTCTC	(SEQ ID NO.: 47)
MassEXTEND™ Primer:	TGGTTCTCTGAGCGAGTCTT	(SEQ ID NO.: 48)
Primer Mass:	6130	
Extended Primer-Allele C:	TGGTTCTCTGAGCGAGTCTTC	(SEQ ID NO.: 49)
Extended Primer Mass:	6707.4	

-continued

Extended Primer-Allele T:	TGGTTCTCTGAGCGAGTCTTTC	(SEQ ID NO.: 50)
Extended Primer Mass:	6333.1	
Position 1586 (A/G)		
PCR primers:		
Forward:	TGCAGATGGACTTTGGCTTC	(SEQ ID NO.: 51)
Reverse:	TGCTTGCCTTCTGCTACAAG	(SEQ ID NO.: 52)
MassEXTEND™ Primer:	CTTCCCTGAGCACCTGCTG	(SEQ ID NO.: 53)
Primer Mass:	5715.7	
Extended Primer-Allele G:	CTTCCCTGAGCACCTGCTGGT	(SEQ ID NO.: 54)
Extended Primer Mass:	6333.1	
Extended Primer-Allele A:	CTTCCCTGAGCACCTGCTGA	(SEQ ID NO.: 55)
Extended Primer Mass:	6012.9	
APOA4		
Position 1122 (G/T)		
PCR primers:		
Forward:	AACAGCTCAGGACGAAACTG	(SEQ ID NO.: 56)
Reverse:	AGAAGGAGTTGACCTTGTCC	(SEQ ID NO.: 57)
MassEXTEND™ Primer:	GGAAGCTCAAGTGGCCTTC	(SEQ ID NO.: 58)
Primer Mass:	5828.8	
Extended Primer-Allele G:	GGAAGCTCAAGTGGCCTTCC	(SEQ ID NO.: 59)
Extended Primer Mass:	6102.0	
Extended Primer-Allele T:	GGAAGCTCAAGTGGCCTTCAAC	(SEQ ID NO.: 60)
Extended Primer Mass:	6728.4	
Position 1033 (G/C)		
PCR primers:		
Forward:	AAGTCACTGGCAGAGCTGG	(SEQ ID NO.: 61)
Reverse:	GCACCAGGGCTTTGTTGAAG	(SEQ ID NO.: 62)
MassEXTEND™ Primer:	TTTTCCCCGTAGGGCTCCA	(SEQ ID NO.: 63)
Primer Mass:	5730.7	
Extended Primer-Allele G:	TTTTCCCCGTAGGGCTCCAC	(SEQ ID NO.: 64)
Extended Primer Mass:	6003.9	
Extended Primer-Allele C:	TTTTCCCCGTAGGGCTCCAGC	(SEQ ID NO.: 65)
Extended Primer Mass:	6333.1	
Position 1002 (G/A)		
PCR primers:		
Forward:	TGCAGAAGTCACTGGCAGAG	(SEQ ID NO.: 66)
Reverse:	GTTGAAGTTTTCCCCGTAGG	(SEQ ID NO.: 67)
MassEXTEND™ Primer:	ACTCCTCCACCTGCTGGTC	(SEQ ID NO.: 68)

-continued

Primer Mass:	5675.7	
Extended Primer-Allele G:	ACTCCTCCACCTGCTGGTCC	(SEQ ID NO.: 69)
Extended Primer Mass:	5948.9	
Extended Primer-Allele A:	ACTCCTCCACCTGCTGGTCTA	(SEQ ID NO.: 70)
Extended Primer Mass:	6277.1	
Position 960 (C/T)		
PCR primers:		
Forward:	AGGACGTGCGTGGCAACCTG	(SEQ ID NO.: 71)
Reverse:	AGCTCTGCCAGTGACTTCTG	(SEQ ID NO.: 72)
MassEXTEND™ Primer:	GTGACTTCTGCAGCCCCTC	(SEQ ID NO.: 73)
Primer Mass:	5715.7	
Extended Primer-Allele T:	GTGACTTCTGCAGCCCCTCA	(SEQ ID NO.: 74)
Extended Primer Mass:	6012.9	
Extended Primer-Allele C:	GTGACTTCTGCAGCCCCTCGGT	(SEQ ID NO.: 75)
Extended Primer Mass:	6662.3	
Position 894 (C/T)		
PCR primers:		
Forward:	CCTGACCTTCCAGATGAAG	(SEQ ID NO.: 76)
Reverse:	TCAGGTTGCCACGCACGTC	(SEQ ID NO.: 77)
MassEXTEND™ Primer:	CAGGATCTCGGCCAGTGC	(SEQ ID NO.: 78)
Primer Mass:	5500.6	
Extended Primer-Allele C:	CAGGATCTCGGCCAGTGCC	(SEQ ID NO.: 79)
Extended Primer Mass:	5773.8	
Extended Primer-Allele T:	CAGGATCTCGGCCAGTGCTG	(SEQ ID NO.: 80)
Extended Primer Mass:	6118.0	
Position 554 (G/A)		
PCR primers:		
Forward:	ACCTGCGAGAGCTTCAGCAG	(SEQ ID NO.: 81)
Reverse:	TCTCCATGCGCTGTGCGTAG	(SEQ ID NO.: 82)
MassEXTEND™ Primer:	AGCTGCGCACCCAGGTCA	(SEQ ID NO.: 83)
Primer Mass:	5469.6	
Extended Primer-Allele A:	AGCTGCGCACCCAGGTCAA	(SEQ ID NO.: 84)
Extended Primer Mass:	5766.8	
Extended Primer-Allele G:	AGCTGCGCACCCAGGTCAGC	(SEQ ID NO.: 85)
Extended Primer Mass:	6072.0	
APOE		
Position 448 (C/T)		
PCR primers:		
Forward:	TGTCCAAGGAGCTGCAGGC	(SEQ ID NO.: 86)

-continued

Reverse:	CTTACGCAGCTTGCGCAGGT	(SEQ ID NO.: 87)
MassEXTEND™ Primer:	GCGGACATGGAGGACGTG	(SEQ ID NO.: 88)
Primer Mass:	5629.7	
Extended Primer-Allele C:	GCGGACATGGAGGACGTGC	(SEQ ID NO.: 89)
Extended Primer Mass:	5902.8	
Extended Primer-Allele T:	GCGGACATGGAGGACGTGTG	(SEQ ID NO.: 90)
Extended Primer Mass:	6247.1	

LPL

Position 1127 (A/G)

PCR primers:

Forward:	GTTGTAGAAAGAACCGCTGC	(SEQ ID NO.: 91)
Reverse:	GAGAACGAGTCTTCAGGTAC	(SEQ ID NO.: 92)
MassEXTEND™ Primer:	ACAATCTGGGCTATGAGATCA	(SEQ ID NO.: 93)
Primer Mass:	6454.2	
Extended Primer-Allele A:	ACAATCTGGGCTATGAGATCAA	(SEQ ID NO.: 94)
Extended Primer Mass:	6751.4	
Extended Primer-Allele G:	ACAATCTGGGCTATGAGATCAGT	(SEQ ID NO.: 95)
Extended Primer Mass:	7071.6	

Position 3447 (A/C)

PCR primers:

Forward:	CACTCTACACTGCATGTCTC	(SEQ ID NO.: 96)
Reverse:	ACCCTTCTGAAAAGGAGAGG	(SEQ ID NO.: 97)
MassEXTEND™ Primer:	GAGGAGAGACAAGGCAGATA	(SEQ ID NO.: 98)
Primer Mass:	6273.1	
Extended Primer-Allele A:	GAGGAGAGACAAGGCAGATAT	(SEQ ID NO.: 99)
Extended Primer Mass:	6561.3	
Extended Primer-Allele C:	GAGGAGAGACAAGGCAGATAGT	(SEQ ID NO.: 100)
Extended Primer Mass:	6890.5	

Position 1973 (C/T)

PCR primers:

Forward:	AAAGGTTCAGTTGCTGCTGC	(SEQ ID NO.: 101)
Reverse:	GCTGGGGAAGGTCTAATAAC	(SEQ ID NO.: 102)
MassEXTEND™ Primer:	GTTGCTGCTGCCTCGAATC	(SEQ ID NO.: 103)
Primer Mass:	5770.7	
Extended Primer-Allele C:	GTTGCTGCTGCCTCGAATCC	(SEQ ID NO.: 104)
Extended Primer Mass:	6043.9	
Extended Primer-Allele T:	GTTGCTGCTGCCTCGAATCTG	(SEQ ID NO.: 105)
Extended Primer Mass:	6388.2	

-continued

LIPC

Position 680 (C/G)

PCR primers:

Forward:	CGTCTTTCTCCAGATGATGC	(SEQ ID NO.: 106)
Reverse:	AGTGTCCTATGGGCTGTTTG	(SEQ ID NO.: 107)
MassEXTEND™ Primer:	GGATGCCATTCATACCTTTAC	(SEQ ID NO.: 108)
Primer Mass:	6556.1	
Extended Primer-Allele C:	GGATGCCATTCATACCTTTACC	(SEQ ID NO.: 109)
Extended Primer Mass:	6629.3	
Extended Primer-Allele G:	GGATGCCATTCATACCTTTACGC	(SEQ ID NO.: 110)
Extended Primer Mass:	6958.5	

Position 1374 (G/A)

PCR primers:

Forward:	TGGGAAAACAGTGCAGTGTG	(SEQ ID NO.: 111)
Reverse:	TGATCGTCTTCAGAACGAGG	(SEQ ID NO.: 112)
MassEXTEND™ Primer:	CCAGACCATCATCCCATGGA	(SEQ ID NO.: 113)
Primer Mass:	6030.9	
Extended Primer-Allele A:	CCAGACCATCATCCCATGGAA	(SEQ ID NO.: 114)
Extended Primer Mass:	6328.1	
Extended Primer-Allele G:	CCAGACCATCATCCCATGGAGC	(SEQ ID NO.: 115)
Extended Primer Mass:	6633.3	

Position 701 (G/A)

PCR primers:

Forward:	CAGCAATCGTCTTTCTCCAG	(SEQ ID NO.: 116)
Reverse:	TCCTATGGGCTGTTTGATGC	(SEQ ID NO.: 117)
MassEXTEND™ Primer:	GTCTTTCTCCAGATGATGCCA	(SEQ ID NO.: 118)
Primer Mass:	6372.2	
Extended Primer-Allele A:	GTCTTTCTCCAGATGATGCCAA	(SEQ ID NO.: 119)
Extended Primer Mass:	6669.4	
Extended Primer-Allele G:	GTCTTTCTCCAGATGATGCCAGT	(SEQ ID NO.: 120)
Extended Primer Mass:	6989.6	

[0081] E. Databases

[0082] Databases for determining an association between polymorphic regions of genes and intermediate and clinical phenotypes, comprise biological samples (e.g., blood) which provide a source of nucleic acid and clinical data covering diseases (e.g., age, sex, ethnicity medical history and family medical history) from both individuals exhibiting the phenotype (intermediate phenotype (risk factor) or clinical phenotype (disease)) and those who do not. These databases include human population groups such as twins, diverse affected families, isolated founder populations and drug trial subjects. The quality and consistency of the clinical resources are of primary importance.

[0083] F. Association Studies

[0084] The examples set forth below utilized an extreme trait analysis to discover an association between an allelic variant of the COX6B gene and high cholesterol and an association between an allelic variant of the GPI-1 gene and low HDL. This analysis is based on comparing a pair of pools of DNA from individuals who exhibit respectively hypo or hypernormal levels of a biochemical trait (e.g., cholesterol or HDL) and individually examining SNPs for a

difference in allelic frequency between the pools. An association is considered to be positive if a statistically significant value of at least 3.841 using a 1-degree-of-freedom chi-squared test of association, p=0.05, is obtained. Standard multiple testing corrections are applied if more than one SNP is considered at a time, i.e., multiple SNPs are tested during the same study. Although not always required, it may be necessary to further examine the frequency of allelic variants in other populations, including those exhibiting normal levels of the given trait.

[0085] For a qualitative trait (e.g., hypertension) association studies are based on determining the occurrence of certain alleles in a given population of diseased vs. healthy individuals.

[0086] Allelic variants of COX6B, GPI-1 and other genes found to associate with high cholesterol, low HDL and/or cardiovascular disease can represent useful markers for indicating a predisposition for developing a risk factor for cardiovascular disease. These allelic variants may not necessarily represent functional variants affecting the expression, stability, or activity of the encoded protein product. Those of skill in the art would be able to determine which allelic variants are to be used, alone or in conjunction with other variants, only for indicating a predisposition for cardiovascular disease or for profiling of drug reactivity and for determining those which may be also useful for screening for potential therapeutics.

[0087] Any method used to determine association can be utilized to discover or confirm the association of other polymorphic regions in the COX6B gene, the GPI-1 gene or any other gene that may be associated with cardiovascular disease.

[0088] G. Detection of Polymorphisms

[0089] 1. Nucleic Acid Detection Methods

[0090] Generally, these methods are based in sequence-specific polynucleotides, oligonucleotides, probes and primers. Any method known to those of skill in the art for detecting a specific nucleotide within a nucleic acid sequence or for determining the identity of a specific nucleotide in a nucleic acid sequence is applicable to the methods of determining the presence or absence of an allelic variant of a COX6B gene or GPI-1 gene or another gene associated with cardiovascular disease. Such methods include, but are not limited to, techniques utilizing nucleic acid hybridization of sequence-specific probes, nucleic acid sequencing, selective amplification, analysis of restriction enzyme digests of the nucleic acid, cleavage of mismatched heteroduplexes of nucleic acid and probe, alterations of electrophoretic mobility, primer specific extension, oligonucleotide ligation assay and single-stranded conformation polymorphism analysis. In particular, primer extension reactions that specifically terminate by incorporating a dideoxynucleotide are useful for detection. Several such general nucleic acid detection assays are described in U.S. Pat. No. 6,030,778.

[0091] a. Primer Extension-Based Methods

[0092] Several primer extension-based methods for determining the identity of a particular nucleotide in a nucleic acid sequence have been reported (see, e.g., PCT Application No. PCT/US96/03651 (WO96/29431), PCT Application No. PCT/US97/20444 (WO 98/20019), PCT Application No. PCT/US91/00046 (WO91/13075), and U.S. Pat. No. 5,856,092). In general, a primer is prepared that specifically hybridizes adjacent to a polymorphic site in a particular nucleic acid sequence. The primer is then extended in the presence of one or more dideoxynucleotides, typically with at least one of the dideoxynucleotides being the complement of the nucleotide that is polymorphic at the site. The primer and/or the dideoxynucleotides may be labeled to facilitate a determination of primer extension and identity of the extended nucleotide.

[0093] In a preferred method, primer extension and/or the identity of the extended nucleotide(s) are determined by mass spectrometry (see, e.g., PCT Application Nos. PCT/US96/03651 (WO96/29431) and PCT/US97/20444 (WO 98/20019)).

[0094] b. Polymorphism-Specific Probe Hybridization

[0095] A preferred detection method is allele specific hybridization using probes overlapping the polymorphic site and having about 5, 10, 15, 20, 25, or 30 nucleotides around the polymorphic region. The probes can contain aturally occurring or modified nucleotides (see U.S. Pat. No. 6,156,501). For example, oligonucleotide probes may be prepared in which the known polymorphic nucleotide is placed centrally (allele-specific probes) and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163; Saiki et al. (1989) Proc. Natl. Acad. Sci USA 86:6230; and Wallace et al. (1979) Nucl. Acids Res. 6:3543). Such allele specific oligonucleotide hybridization techniques may be used for the simultaneous detection of several nucleotide changes in different polymorphic regions. For example, oligonucleotides having nucleotide sequences of specific allelic variants are attached to a hybridizing membrane and this membrane is then hybridized with labeled sample nucleic acid. Analysis of the hybridization signal will then reveal the identity of the nucleotides of the sample nucleic acid. In a preferred embodiment, several probes capable of hybridizing specifically to allelic variants are attached to a solid phase support, e.g., a "chip". Oligonucleotides can be bound to a solid support by a variety of processes, including lithography. For example a chip can hold up to 250,000 oligonucleotides (GeneChip, Affymetrix, Santa Clara, Calif.). Mutation detection analysis using these chips comprising oligonucleotides, also termed "DNA probe arrays" is described e.g., in Cronin et al. (1996) Human Mutation 7:244 and in Kozal et al. (1996) Nature Medicine 2:753. In one embodiment, a chip includes all the allelic variants of at least one polymorphic region of a gene. The solid phase support is then contacted with a test nucleic acid and hybridization to the specific probes is detected. Accordingly, the identity of numerous allelic variants of one or more genes can be identified in a simple hybridization experiment.

[0096] C. Nucleic Acid Amplification-Based Methods

[0097] In other detection methods, it is necessary to first amplify at least a portion of a COX6B gene, GPI-1 gene or another gene associated with cardiovascular disease prior to identifying the allelic variant. Amplification can be performed, e.g., by PCR and/or LCR, according to methods known in the art. In one embodiment, genomic DNA of a cell is exposed to two PCR primers and amplification is performed for a number of cycles sufficient to produce the

required amount of amplified DNA. In preferred embodiments, the primers are located between 150 and 350 base pairs apart.

[0098] Alternative amplification methods include: self sustained sequence replication (Guatelli, J. C. et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1874-1878), transcriptional amplification system (Kwoh, D. Y. et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:1173-1177), Q-Beta Replicase (Lizardi, P. M. et al., 1988, Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

[0099] Alternatively, allele specific amplification technology, which depends on selective PCR amplification may be used in conjunction with the alleles provided herein. Oligonucleotides used as primers for specific amplification may carry the allelic variant of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238; Newton et al. (1989) Nucl. Acids Res. 17:2503). In addition it may be desirable to introduce a restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) Mol. Cell Probes 6:1).

[0100] d. Nucleic Acid Sequencing-Based Methods

[0101] In one embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence at least a portion of the COX6B gene, GPI-1 gene or other gene associated with cardiovascular disease and to detect allelic variants, e.g., mutations, by comparing the sequence of the sample sequence with the corresponding wild-type (control) sequence. Exemplary sequencing reactions include those based on techniques developed by Maxam and Gilbert (Proc. Natl. Acad. Sci. USA (1977) 74:560) or Sanger (Sanger et al. (1977) Proc. Natl. Acad. Sci 74:5463). It is also contemplated that any of a variety of automated sequencing procedures may be used when performing the subject assays (Biotechniques (1995) 19:448), including sequencing by mass spectrometry (see, for example, U.S. Pat. No. 5,547,835 and International PCT Application No. WO 94/16101, entitled DNA Sequencing by Mass Spectrometry by H. Koster; U.S. Pat. No. 5,547,835 and International PCT Application No. WO 94/21822, entitled "DNA Sequencing by Mass Spectrometry Via Exonuclease Degradation" by H. Koster), and U.S. Pat. No. 5,605,798 and International Patent Application No. PCT/US96/03651 entitled DNA Diagnostics Based on Mass Spectrometry by H. Koster; Cohen et al. (1996) Adv Chromatogr 36:127-162; and Griffin et al. (1993) Appl Biochem Biotechnol 38:147-159). It will be evident to one skilled in the art that, for certain embodiments, the occurrence of only one, two or three of the nucleic acid bases need be determined in the sequencing reaction. For instance, A-track sequencing or an equivalent, e.g., where only one nucleotide is detected, can be carried out. Other sequencing methods are disclosed, e.g., in U.S. Pat. No. 5,580,732 entitled "Method of DNA sequencing employing a mixed DNA-polymer chain probe" and U.S. Patent No. 5,571,676 entitled "Method for mismatch-directed in vitro DNA sequencing".

[0102] e. Restriction Enzyme Digest Analysis

[0103] In some cases, the presence of a specific allele in nucleic acid, particularly DNA, from a subject can be shown by restriction enzyme analysis. For example, a specific nucleotide polymorphism can result in a nucleotide sequence containing a restriction site which is absent from the nucleotide sequence of another allelic variant.

[0104] f. Mismatch Cleavage

[0105] Protection from cleavage agents, such as, but not limited to, a nuclease, hydroxylamine or osmium tetroxide and with piperidine, can be used to detect mismatched bases in RNA/RNA DNA/DNA, or RNA/DNA heteroduplexes (Myers, et al. (1985) Science 230:1242). In general, the technique of "mismatch cleavage" starts by providing heteroduplexes formed by hybridizing a control nucleic acid, which is optionally labeled, e.g., RNA or DNA, comprising a nucleotide sequence of an allelic variant with a sample nucleic acid, e.g, RNA or DNA, obtained from a tissue sample. The double-stranded duplexes are treated with an agent, which cleaves single-stranded regions of the duplex such as duplexes formed based on basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digest the mismatched regions.

[0106] In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine whether the control and sample nucleic acids have an identical nucleotide sequence or in which nucleotides they differ (see, for example, Cotton et al. (1988) Proc. Natl Acad Sci USA 85:4397; Saleeba et al. (1992) Methods Enzymod. 217:286-295). The control or sample nucleic acid is labeled for detection.

[0107] g. Electrophoretic Mobility Alterations

[0108] In other embodiments, alteration in electrophoretic mobility is used to identify the type of allelic variant in the COX6B gene, GPI-1 gene or other gene associated with cardiovascular disease. For example, single-strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc. Natl. Acad. Sci. USA 86:2766, see also Cotton (1993) Mutat Res 285:125-144; and Hayashi (1992) Genet Anal Tech Appl 9:73-79). Single-stranded DNA fragments of sample and control nucleic acids are denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In another preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5).

[0109] h. Polyacrylamide Gel Electrophoresis

[0110] In yet another embodiment, the identity of an allelic variant of a polymorphic region in the COX6B gene, GPI-1 gene or other gene associated with cardiovascular disease is obtained by analyzing the movement of a nucleic acid comprising the polymorphic region in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to ensure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing agent gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem 265:1275).

[0111] i. Oligonucleotide Ligation Assay (OLA)

[0112] In another embodiment, identification of the allelic variant is carried out using an oligonucleotide ligation assay (OLA), as described, e.g., in U.S. Pat. No. 4,998,617 and in Landegren, U. et al., Science 241:1077-1080 (1988). The OLA protocol uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target. One of the oligonucleotides is linked to a separation marker, e.g,. biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate. Ligation then permits the labeled oligonucleotide to be recovered using avidin, or another biotin ligand. Nickerson, D. A. et al. have described a nucleic acid detection assay that combines attributes of PCR and OLA (Nickerson, D. A. et al., Proc. Natl. Acad. Sci. (U.S.A.) 87:8923-8927 (1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

[0113] Several techniques based on this OLA method have been developed and can be used to detect specific allelic variants of a polymorphic region of a gene. For example, U.S. Pat. No. 5,593,826 discloses an OLA using an oligonucleotide having 3'-amino group and a 5'-phosphorylated oligonucleotide to form a conjugate having a phosphoramidate linkage. In another variation of OLA described in Tobe et al. (1996) Nucl. Acids Res. 24: 3728), OLA combined with PCR permits typing of two alleles in a single microtiter well. By marking each of the allele-specific primers with a unique hapten, i.e. digoxigenin and fluorescein, each OLA reaction can be detected by using hapten specific antibodies that are labeled with different enzyme reporters, alkaline phosphatase or horseradish peroxidase. This system permits the detection of the two alleles using a high throughput format that leads to the production of two different colors.

[0114] j. SNP Detection Methods

[0115] Also provided are methods for detecting single nucleotide polymorphisms. Because single nucleotide polymorphisms constitute sites of variation flanked by regions of invariant sequence, their analysis requires no more than the determination of the identity of the single nucleotide present at the site of variation and it is unnecessary to determine a complete gene sequence for each patient. Several methods have been developed to facilitate the analysis of such single nucleotide polymorphisms.

[0116] In one embodiment, the single base polymorphism can be detected by using a specialized exonuclease-resistant nucleotide, as disclosed, e.g., in Mundy, C. R. (U.S. Pat. No. 4,656,127). According to the method, a primer complementary to the allelic sequence immediately 3' to the polymorphic site is permitted to hybridize to a target molecule obtained from a particular animal or human. If the polymorphic site on the target molecule contains a nucleotide that is complementary to the particular exonuclease-resistant nucleotide derivative present, then that derivative will be incorporated onto the end of the hybridized primer. Such incorporation renders the primer resistant to exonuclease, and thereby permits its detection. Since the identity of the exonuclease-resistant derivative of the sample is known, a finding that the primer has become resistant to exonucleases reveals that the nucleotide present in the polymorphic site of the target molecule was complementary to that of the nucleotide derivative used in the reaction. This method has the advantage that it does not require the determination of large amounts of extraneous sequence data.

[0117] In another embodiment, a solution-based method for determining the identity of the nucleotide of a polymorphic site is employed (Cohen, D. et al. (French Patent 2,650,840; PCT Application No. WO91/02087)). As in the Mundy method of U.S. Pat. No. 4,656,127, a primer is employed that is complementary to allelic sequences immediately 3' to a polymorphic site. The method determines the identity of the nucleotide of that site using labeled dideoxynucleotide derivatives, which, if complementary to the nucleotide of the polymorphic site will become incorporated onto the terminus of the primer.

[0118] k. Genetic Bit Analysis

[0119] An alternative method, known as Genetic Bit Analysis or GBA™ is described by Goelet, et al. (U.S. Pat. No. 6,004,744, PCT Application No. 92/15712). The method of Goelet, et al. uses mixtures of labeled terminators and a primer that is complementary to the sequence 3' to a polymorphic site. The labeled terminator that is incorporated is thus determined by, and complementary to, the nucleotide present in the polymorphic site of the target molecule being evaluated. In contrast to the method of Cohen et al. (French Patent 2,650,840; PCT Application No. WO91/02087), the method of Goelet, et al. is preferably a heterogeneous phase assay, in which the primer or the target molecule is immobilized to a solid phase.

[0120] l. Other Primer-Guided Nucleotide Incorporation Procedures

[0121] Other primer-guided nucleotide incorporation procedures for assaying polymorphic sites in DNA have been described (Komher, J. S. et al., Nucl. Acids Res. 17:7779-7784 (1989); Sokolov, B. P., Nucl. Acids Res. 18:3671 (1990); Syvanen, A. C., et al., Genomics 8:684-692 (1990), Kuppuswamy, M. N. et al., Proc. Natl. Acad. Sci. (U.S.A.) 88:1143-1147 (1991); Prezant, T. R. et al., Hum. Mutat. 1:159-164 (1992); Ugozzoli, L. et al., GATA 9:107-112 (1992); Nyren, P. et al, Anal. Biochem. 208:171-175 (1993)). These methods differ from GBA T in that they all rely on the incorporation of labeled deoxynucleotides to discriminate between bases at a polymorphic site. In such a format, since the signal is proportional to the number of deoxynucleotides incorporated, polymorphisms that occur in runs of the same nucleotide can result in signals that are

proportional to the length of the run (Syvanen, A. C., et al., Amer. J. Hum. Genet. 52:46-59 (1993)).

[0122] For determining the identity of the allelic variant of a polymorphic region located in the coding region of a gene, yet other methods than those described above can be used. For example, identification of an allelic variant which encodes a mutated protein can be performed by using an antibody specifically recognizing the mutant protein in, e.g., immunohistochemistry or immunoprecipitation. Binding assays are known in the art and involve, e.g., obtaining cells from a subject, and performing binding experiments with a labeled lipid, to determine whether binding to the mutated form of the protein differs from binding to the wild-type protein.

[0123] m. Molecular Structure Determination

[0124] If a polymorphic region is located in an exon, either in a coding or non-coding region of the gene, the identity of the allelic variant can be determined by determining the molecular structure of the mRNA, pre-mRNA, or cDNA. The molecular structure can be determined using any of the above described methods for determining the molecular structure of the genomic DNA, e.g., sequencing and SSCP.

[0125] n. Mass Spectrometric Methods

[0126] Nucleic acids can also be analyzed by detection methods and protocols, particularly those that rely on mass spectrometry (see, e.g., U.S. Pat. No. 5,605,798, allowed co-pending U.S. application Ser. No. 08/617,256, allowed co-pending U.S. application Ser. No. 08/744,481, U.S. application Ser. No. 08/990,851, International PCT Application No. WO 98/20019). These methods can be automated (see, e.g., co-pending U.S. application Ser. No. 09/285,481, which describes an automated process line). Preferred among the methods of analysis herein are those involving the primer oligo base extension (PROBE) reaction with mass spectrometry for detection (described herein and elsewhere, see e.g., U.S. application Ser. Nos. 08/617,256, 09/287,681, 09/287,682, 09/287,141 and 09/287,679, allowed co-pending U.S. application Ser. No. 08/744,481, International PCT Application No. PCT/US97/20444, published as International PCT Application No. WO 98/20019, and based upon U.S. application Ser. Nos. 08/744,481, 08/744,590, 08/746,036, 08/746,055, 08/786,988, 08/787,639, 08/933,792, 08/746,055, 08/786,988 and 08/787,639; see, also U.S. application Ser. No. 09/074,936, allowed U.S. application Ser. No. 08/787,639, and U.S. application Ser. Nos. 08/746,055 and 08/786,988, and published International PCT Application No. WO 98/20020).

[0127] A preferred format for performing the analyses is a chip based format in which the biopolymer is linked to a solid support, such as a silicon or silicon-coated substrate, preferably in the form of an array. More preferably, when analyses are performed using mass spectrometry, particularly MALDI, nanoliter volumes of sample are loaded on, such that the resulting spot is about, or smaller than, the size of the laser spot. It has been found that when this is achieved, the results from the mass spectrometric analysis are quantitative. The area under the peaks in the resulting mass spectra are proportional to concentration (when normalized and corrected for background). Methods for preparing and using such chips are described in allowed co-pending U.S. application Ser. No. 08/787,639, co-pending U.S. application Ser. Nos. 08/786,988, 09/364,774, 09/371,150 and 09/297,575; see, also U.S. Application Serial No. PCT/US97/20195, which published as International PCT Application No. WO 98/20020. Chips and kits for performing these analyses are commercially available from SEQUENOM under the trademark MassARRAY™. MassARRAYT™ relies on the fidelity of the enzymatic primer extension reactions combined with the miniaturized array and MALDI-TOF (Matrix-Assisted Laser Desorption Ionization-Time of Flight) mass spectrometry to deliver results rapidly. It accurately distinguishes single base changes in the size of DNA fragments relating to genetic variants without tags.

[0128] Multiplex methods allow for the simultaneous detection of more than one polymorphic region in a particular gene or polymorphic regions in several genes. This is the preferred method for carrying out haplotype analysis of allelic variants of the COX6B and/or GPI-1 genes separately, or along with allelic variants of one or more other genes associated with cardiovascular disease.

[0129] Multiplexing can be achieved by several different methodologies. For example, several mutations can be simultaneously detected on one target sequence by employing corresponding detector (probe) molecules (e.g., oligonucleotides or oligonucleotide mimetics). The molecular weight differences between the detector oligonucleotides must be large enough so that simultaneous detection (multiplexing) is possible. This can be achieved either by the sequence itself (composition or length) or by the introduction of mass-modifying functionalities into the detector oligonucleotides (see below).

[0130] Mass modifying moieties can be attached, for instance, to either the 5'-end of the oligonucleotide, to the nucleobase (or bases), to the phosphate backbone, and to the 2'-position of the nucleoside (nucleosides) and/or to the terminal 3'-position. Examples of mass modifying moieties include, for example, a halogen, an azido, or of the type, XR, wherein X is a linking group and R is a mass-modifying functionality. The mass-modifying functionality can thus be used to introduce defined mass increments into the oligonucleotide molecule.

[0131] The mass-modifying functionality can be located at different positions within the nucleotide moiety (see, e.g., U.S. Pat. No. 5,547,835 and International PCT Application No. WO 94/21822). For example, the mass-modifying moiety, M, can be attached either to the nucleobase, (in case of the C^7-deazanucleosides also to C-7), to the triphosphate group at the alpha phosphate or to the 2'-position of the sugar ring of the nucleoside triphosphate. Modifications introduced at the phosphodiester bond, such as with alpha-thio nucleoside triphosphates, have the advantage that these modifications do not interfere with accurate Watson-Crick base-pairing and additionally allow for the one-step post-synthetic site-specific modification of the complete nucleic acid molecule e.g., via alkylation reactions (see, e.g., Nakamaye et al. (1988) Nucl. Acids Res. 16:9947-59). Particularly preferred mass-modifying functionalities are boron-modified nucleic acids since they are better incorporated into nucleic acids by polymerases (see, e.g., Porter et al. (1995) Biochemistry 34:11963-11969; Hasan et al. (1996) Nucleic Acids Res. 24:2150-2157; Li et al. (1995) Nucl. Acids Res. 23:4495-4501).

[0132] Furthermore, the mass-modifying functionality can be added so as to affect chain termination, such as by attaching it to the 3'-position of the sugar ring in the nucleoside triphosphate. For those skilled in the art, it is clear that many combinations can be used in the methods provided herein. In the same way, those skilled in the art will recognize that chain-elongating nucleoside triphosphates can also be mass-modified in a similar fashion with numerous variations and combinations in functionality and attachment positions.

[0133] For example, without being bound to any particular theory, the mass-modification can be introduced for X in XR as well as using oligo-/polyethylene glycol derivatives for R. The mass-modifying increment (m) in this case is 44, i.e. five different mass-modified species can be generated by just changing m from 0 to 4 thus adding mass units of 45 (m=0), 89 (m=1), 133 (m=2), 177 (m=3) and 221 (m=4) to the nucleic acid molecule (e.g., detector oligonucleotide (D) or the nucleoside triphosphates, respectively). The oligo/polyethylene glycols can also be monoalkylated by a lower alkyl such as, but are not limited to, methyl, ethyl, propyl, isopropyl and t-butyl. Other chemistries can be used in the mass-modified compounds (see, e.g., those described in Oligonucleotides and Analogues, A Practical Approach, F. Eckstein, editor, IRL Press, Oxford, 1991).

[0134] In yet another embodiment, various mass-modifying functionalities, R, other than oligo/polyethylene glycols, can be selected and attached via appropriate linking chemistries, X. A simple mass-modification can be achieved by substituting H for halogens, such as F, Cl, Br and/or 1, or pseudohalogens such as CN, SCN, NCS, or by using different alkyl, aryl or aralkyl moieties such as methyl, ethyl, propyl, isopropyl, t-butyl, hexyl, phenyl, substituted phenyl, benzyl, or functional groups such as CH_2F, CHF_2, CF_3, $Si(CH_3)_3$, $Si(CH_3)_2(C_2H_5)$, $Si(CH_3)(C_2H_5)_2$, $Si(C_2H_5)_3$. Yet another mass-modification can be obtained by attaching homo- or heteropeptides through the nucleic acid molecule (e.g., detector (D)) or nucleoside triphosphates). One example, useful in generating mass-modified species with a mass increment of 57, is the attachment of oligoglycines (m) to nucleic acid molecules (r), e.g., mass-modifications of 74 (r=1, m=0), 131 (r=1, m=1), 188 (r=1, m =2), 245 (r=1, m=3) are achieved. Simple oligoamides also can be used, e.g., mass-modifications of 74 (r=1, m=0), 88 (r=2, m=0), 102 (r=3, m =0), 116(r=4, m=0), etc. are obtainable. Variations in additions to those set forth herein will be apparent to the skilled artisan.

[0135] Different mass-modified detector oligonucleotides can be used to simultaneously detect all possible variants/mutants simultaneously. Alternatively, all four base permutations at the site of a mutation can be detected by designing and positioning a detector oligonucleotide, so that it serves as a primer for a DNA/RNA polymerase with varying combinations of elongating and terminating nucleoside triphosphates. For example, mass modifications also can be incorporated during the amplification process.

[0136] A different multiplex detection format is one in which differentiation is accomplished by employing different specific capture sequences which are position-specifically immobilized on a flat surface (e.g., a 'chip array'). If different target sequences T1-Tn are present, their target capture sites TCS1-TCSn will specifically interact with complementary immobilized capture sequences C1-Cn. Detection is achieved by employing appropriately mass differentiated detector oligonucleotides D1-Dn, which are mass modifying functionalities M1-Mn.

[0137] o. Other Methods

[0138] Additional methods of analyzing nucleic acids include amplification-based methods including polymerase chain reaction (PCR), ligase chain reaction (LCR), mini-PCR, rolling circle amplification, autocatalytic methods, such as those using QJ replicase, TAS, 3SR, and any other suitable method known to those of skill in the art.

[0139] Other methods for analysis and identification and detection of polymorphisms, include but are not limited to, allele specific probes, Southern analyses, and other such analyses.

[0140] 2. Primers and Probes

[0141] Primers refer to nucleic acids which are capable of specifically hybridizing to a nucleic acid sequence which is adjacent to a polymorphic region of interest or to a polymorphic region and are extended. A primer can be used alone in a detection method, or a primer can be used together with at least one other primer or probe in a detection method. Primers can also be used to amplify at least a portion of a nucleic acid. For amplifying at least a portion of a nucleic acid, a forward primer (i.e., 5' primer) and a reverse primer (i.e., 3' primer) will preferably be used. Forward and reverse primers hybridize to complementary stands of a double stranded nucleic acid, such that upon extension from each primer, a double stranded nucleic acid is amplified.

[0142] Probes refer to nucleic acids which hybridize to the region of interest and which are not further extended. For example, a probe is a nucleic acid which hybridizes adjacent to or at a polymorphic region of a COX6B gene, a GPI-1 gene or another gene associated with cardiovascular disease and which by hybridization or absence of hybridization to the DNA of a subject will be indicative of the identity of the allelic variant of the polymorphic region of the gene. Preferred probes have a number of nucleotides sufficient to allow specific hybridization to the target nucleotide sequence. Where the target nucleotide sequence is present in a large fragment of DNA, such as a genomic DNA fragment of several tens or hundreds of kilobases, the size of a probe may have to be longer to provide sufficiently specific hybridization, as compared to a probe which is used to detect a target sequence which is present in a shorter fragment of DNA. For example, in some diagnostic methods, a portion of a COX6B gene, a GPI-1 gene or another gene associated with cardiovascular disease may first be amplified and thus isolated from the rest of the chromosomal DNA and then hybridized to a probe. In such a situation, a shorter probe will likely provide sufficient specificity of hybridization. For example, a probe having a nucleotide sequence of about 10 nucleotides may be sufficient.

[0143] Preferred primers and probes hybridize adjacent to or at the polymorphic sites described in TABLES 1-3. In addition, preferred primers include SEQ ID NOS.: 5, 10, 43, 48, 53, 58, 63, 68, 73, 78, 83, 88, 93, 98, 103, 108, 113, and 118.

[0144] Primers and probes (RNA, DNA (single-stranded or double-stranded), PNA and their analogs) described

herein may be labeled with any detectable reporter or signal moiety including, but not limited to radioisotopes, enzymes, antigens, antibodies, spectrophotometric reagents, chemiluminescent reagents, fluorescent and any other light producing chemicals. Additionally, these probes may be modified without changing the substance of their purpose by terminal addition of nucleotides designed to incorporate restriction sites or other useful sequences, proteins, signal generating ligands such as acridinium esters, and/or paramagnetic particles.

[0145] These probes may also be modified by the addition of a capture moiety (including, but not limited to paramagnetic particles, biotin, fluorescein, dioxigenin, antigens, antibodies) or attached to the walls of microtiter trays to assist in the solid phase capture and purification of these probes and any DNA or RNA hybridized to these probes. Fluorescein may be used as a signal moiety as well as a capture moiety, the latter by interacting with an anti-fluorescein antibody.

[0146] Any probe or primer can be prepared according to methods well known in the art and described, e.g., in Sambrook, J. Fritsch, E. F., and Maniatis, T. (1989(Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. For example, discrete fragments of the DNA can be prepared and cloned using restriction enzymes. Alternatively, probes and primers can be prepared using the Polymerase Chain Reaction (PCR) using primers having an appropriate sequence.

[0147] Oligonucleotides may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch (Novato, Calif.); Applied Biosystems (Foster City, Calif.), etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[0148] H. Transgenic Animals

[0149] Methods for making transgenic animals using a variety of transgenes have been described in Wagner et al., Proc. Nat. Acad. Sc. U.S.A., Vol. 78, p. 5016, 1981; Stewart et al., Science, Vol. 217, p. 1046, 1982; Constantini et al., Nature, Vol. 294, p. 92, 1981; Lacy et al., Cell, Vol. 34, p. 343, 1983; McKnight et al., Cell, Vol. 34, p. 335, 1983; Brinstar et al., Nature, Vol. 306, p. 332, 1983; Palmiter et al., Nature, Vol. 300, p. 611, 1982; Palmiter et al., Cell, Vol. 29, p. 701, 1982 and Palmiter et al., Science, Vol. 222, p. 809, 1983. Such methods are described in U.S. Pat. Nos. 6,175,057; 6,180,849 and 6,133,502.

[0150] The term "transgene" is used herein to describe genetic material that has been or is about to be artificially inserted into the genome of a mammalian cell, particularly a mammalian cell of a living animal. The transgene is used to transform a cell, meaning that a permanent or transient genetic change, preferably a permanent genetic change, is induced in a cell following incorporation of exogenous DNA. A permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell. Vectors for stable integration include, but are not limited to, plasmids, retroviruses and other animal viruses and YACS. Of interest are transgenic mammals, including, but are not limited to, cows, pigs, goats, horses and others, and particularly rodents, including rats and mice. Preferably, the transgenic-animals are mice.

[0151] Transgenic animals contain an exogenous nucleic acid sequence present as an extrachromosomal element or stably integrated in all or a portion of its cells, especially germ cells. Unless otherwise indicated, it will be assumed that a transgenic animal comprises stable changes to the germline sequence. During the initial construction of the animal, "chimeras" or "chimeric animals" are generated, in which only a subset of cells have the altered genome. Chimeras are primarily used for breeding purposes in order to generate the desired transgenic animal. Animals having a heterozygous alteration are generated by breeding of chimeras. Male and female heterozygotes are typically bred to generate homozygous animals.

[0152] The exogenous gene is usually either from a different species than the animal host, or is otherwise altered in its coding or non-coding sequence. The introduced gene may be a wild-type gene, naturally occurring polymorphism (e.g., as described for COX6B, GPI-1 and other genes associated with cardiovascular disease) or a genetically manipulated sequence, for example having deletions, substitutions or insertions in the coding or non-coding regions. When the introduced gene is a coding sequence, it is usually operably linked to a promoter, which may be constitutive or inducible, and other regulatory sequences required for expression in the host animal.

[0153] Transgenic animals can comprise other genetic alterations in addition to the presence of alleles of COX6B and/or GPI-1 genes. For example, the genome can be altered to affect the function of the endogenous genes, contain marker genes, or contain other genetic alterations (e.g., alleles of other genes associated with cardiovascular disease).

[0154] A "knock-out" of a gene means an alteration in the sequence of the gene that results in a decrease of function of the target gene, preferably such that target gene expression is undetectable or insignificant. A knock-out of an endogenous COX6B or GPI-1 gene means that function of the gene has been substantially decreased so that expression is not detectable or only present at insignificant levels. "Knock-out" transgenics can be transgenic animals having a heterozygous knock-out of the COX6B or GPI-1 gene or a homozygous knock-out of one or both of these genes. "Knock-outs" also include conditional knock-outs, where alteration of the target gene can occur upon, for example, exposure of the animal to a substance that promotes target gene alteration, introduction of an enzyme that promotes recombination at the target gene site (e.g., Cre in the Cre-lox system), or other method for directing the target gene alteration postnatally.

[0155] A "knock-in" of a target gene means an alteration in a host cell genome that results in altered expression (e.g., increased (including ectopic)) of the target gene, e.g., by introduction of an additional copy of the target gene, or by operatively inserting a regulatory sequence that provides for enhanced expression of an endogenous copy of the target gene. "Knock-in" transgenics of interest can be transgenic animals having a knock-in of the COX6B or GPI-1. Such

transgenics can be heterozygous or homozygous for the knock-in gene. "Knock-ins" also encompass conditional knock-ins.

[0156] A construct is suitable for use in the generation of transgenic animals if it allows the desired level of expression of a COX6B or GPI-1 encoding sequence or the encoding sequence of another gene associated with cardiovascular disease. Methods of isolating and cloning a desired sequence, as well as suitable constructs for expression of a selected sequence in a host animal, are well known in the art and are described below.

[0157] For the introduction of a gene into the subject animal, it is generally advantageous to use the gene as a gene construct wherein the gene is ligated downstream of a promoter capable of and operably linked to expressing the gene in the subject animal cells. Specifically, a transgenic non-human mammal showing high expression of the desired gene can be created by microinjecting a vector ligated with said gene into a fertilized egg of the subject non-human mammal (e.g., rat fertilized egg) downstream of various promoters capable of expressing the protein and/or the corresponding protein derived from various mammals (rabbits, dogs, cats, guinea pigs, hamsters, rats, mice etc., preferably rats etc.)

[0158] Useful vectors include *Escherichia coli*-derived plasmids, *Bacillus subtilis*-derived plasmids, yeast-derived plasmids, bacteriophages such as lambda, phage, retroviruses such as Moloney leukemia virus, and animal viruses such as vaccinia virus or baculovirus.

[0159] Useful promoters for such gene expression regulation include, for example, promoters for genes derived from viruses (cytomegalovirus, Moloney leukemia virus, JC virus, breast cancer virus etc.), and promoters for genes derived from various mammals (humans, rabbits, dogs, cats, guinea pigs, hamsters, rats, mice etc.) and birds (chickens etc.) (e.g., genes for albumin, insulin II, erythropoietin, endothelin, osteocalcin, muscular creatine kinase, platelet-derived growth factor beta, keratins K1, K10 and K14, collagen types I and II, atrial natriuretic factor, dopamine beta-hydroxylase, endothelial receptor tyrosine kinase (generally abbreviated Tie2), sodium-potassium adenosine triphosphorylase (generally abbreviated Na, K-ATPase), neurofilament light chain, met allothioneins I and IIA, met alloproteinase I tissue inhibitor, MHC class I antigen (generally abbreviated H-2L), smooth muscle alpha actin, polypeptide chain elongation factor 1 alpha (EF-1 alpha), beta actin, alpha and beta myosin heavy chains, myosin light chains 1 and 2, myelin base protein, serum amyloid component, myoglobin, renin etc.).

[0160] It is preferable that the above-mentioned vectors have a sequence for terminating the transcription of the desired messenger RNA in the transgenic animal (generally referred to as terminator); for example, gene expression can be manipulated using a sequence with such function contained in various genes derived from viruses, mammals and birds. Preferably, the simian virus SV40 terminator etc. are commonly used. Additionally, for the purpose of increasing the expression of the desired gene, the splicing signal and enhancer region of each gene, a portion of the intron of a eukaryotic organism gene may be ligated 5' upstream of the promoter region, or between the promoter region and the translational region, or 3' downstream of the translational region as desired.

[0161] A translational region for a protein of interest can be obtained using the entire or portion of genomic DNA of blood, kidney or fibroblast origin from various mammals (humans, rabbits, dogs, cats, guinea pigs, hamsters, rats, mice etc.) or of various commercially available genomic DNA libraries, as a starting material, or using complementary DNA prepared by a known method from RNA of blood, kidney or fibroblast origin as a starting material. Also, an exogenous gene can be obtained using complementary DNA prepared by a known method from RNA of human fibroblast origin as a starting material. All these translational regions can be utilized in transgenic animals.

[0162] To obtain the translational region, it is possible to prepare DNA incorporating an exogenous gene encoding the protein of interest in which the gene is ligated downstream of the above-mentioned promoter (preferably upstream of the translation termination site) as a gene construct capable of being expressed in the transgenic animal.

[0163] DNA constructs for random integration need not include regions of homology to mediate recombination. Where homologous recombination is desired, the DNA constructs will comprise at least a portion of the target gene with the desired genetic modification, and will include regions of homology to the target locus. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown et al. (1990) Methods in Enzymology 185:527-537.

[0164] The transgenic animal can be created by introducing a COX6B or GPI-1 gene construct into, for example, an unfertilized egg, a fertilized egg, a spermatozoon or a germinal cell containing a primordial germinal cell thereof, preferably in the embryogenic stage in the development of a non-human mammal (more preferably in the single-cell or fertilized cell stage and generally before the 8-cell phase), by standard means, such as the calcium phosphate method, the electric pulse method, the lipofection method, the agglutination method, the microinjection method, the particle gun method, the DEAE-dextran method and other such method. Also, it is possible to introduce a desired COX6B or GPI-1 gene into a somatic cell, a living organ, a tissue cell, or the like, by gene transformation methods, and utilize it for cell culture, tissue culture etc. Furthermore, these cells may be fused with the above-described germinal cell by a commonly known cell fusion method to create a transgenic animal.

[0165] For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g. mouse, rat, guinea pig, etc. Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of appropriate growth factors, such as leukemia inhibiting factor (LIF). When ES cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and

blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting litters screened for mutant cells having the construct. By providing for a different phenotype of the blastocyst and the ES cells, chimeric progeny can be readily detected. The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in in vitro culture.

[0166] Animals containing more than one transgene, such as allelic variants of COX6B and/or GPI-1 and/or other genes associated with cardiovascular disease can be made by sequentially introducing individual alleles into an animal in order to produce the desired phenotype (manifestation or predisposition to cardiovascular disease).

[0167] I. Effect of Allelic Variants on the Encoded Protein and Disease Related Phenotype

[0168] The effect of an allelic variant on a COX6B or GPI-1 protein (altered amount, stability, location and/or activity) can be determined according to methods known in the art. Allelic variants of the COX6B and GPI-1 genes can be assayed individually or in combination with other variants known to be associated with cardiovascular disease.

[0169] If the mutation is located in an intron, the effect of the mutation can be determined, e.g., by producing transgenic animals in which the allelic variant linked to lipid metabolism and/or cardiovascular disease has been introduced and in which the wild-type gene or predominant allele may have been knocked out. Comparison of the level of expression of the protein in the mice transgenic for the allelic variant with mice transgenic for the predominant allele will reveal whether the mutation results in increased or decreased synthesis of the associated protein and/or aberrant tissue distribution of the associated protein. Such analysis could also be performed in cultured cells, in which the human variant allele gene is introduced and, e.g., replaces the endogenous gene in the cell. Thus, depending on the effect of the alteration a specific treatment can be administered to a subject having such a mutation. Accordingly, if the mutation results in decreased production of a COX6B or GPI-1 protein, the subject can be treated by administration of a compound which increases synthesis, such as by increasing COX6B or GPI-1 gene expression, and wherein the compound acts at a regulatory element different from the one which is mutated. Alternatively, if the mutation results in increased COX6B or GPI-1 protein levels, the subject can be treated by administration of a compound which reduces protein production, e.g., by reducing COX6B or GPI-1 gene expression or a compound which inhibits or reduces the activity of COX6B or GPI-1 protein.

[0170] J. Diagnostic and Prognostic Assays

[0171] Typically, an individual allelic variant that associates with a risk factor for cardiovascular disease will not be used in isolation as a prognosticator for a subject developing high cholesterol, low HDL or cardiovascular disease. An allelic variant typically will be one of a plurality of indicators that are utilized. The other indicators may be the manifestation of other risk factors for cardiovascular disease, e.g., family history, high blood pressure, weight, activity level, etc., or additional allelic variants in the same or other genes associated with altered lipid metabolism and/or cardiovascular disease.

[0172] Useful combinations of allelic variants of the COX6B gene and/or the GPI-1 gene can be determined by examining combinations of variants of these genes, which are assayed individually or assayed simultaneously using multiplexing methods as described above or any other labelling method that allows different variants to be identified. In particular, variants of COX6B gene and/or the GPI-1 gene may be assayed using kits (see below) or any of a variety microarrays known to those in the art. For example, oligonucleotide probes comprising the polymorphic regions surrounding any polymorphism in the COX6B or GPI-1 gene may be designed and fabricated using methods such as those described in U.S. Pat. Nos. 5,492,806; 5,525,464; 5,695,940; 6,018,041; 6,025,136; WO 98/30883; WO 98/56954; WO99/09218; WO 00/58516; WO 00/58519, or references cited therein. Similarly one of skill in the art can determine useful combinations of allelic variants of the COX6B and/or GPI-1 genes along with variants of other genes associated with cardiovascular disease.

[0173] K. Pharmacogenomics

[0174] It is likely that subjects having one or more different allelic variants of the COX6B or GPI-1 polymorphic regions will respond differently to therapeutic drugs to treat cardiovascular disease or conditions. For example, there are numerous drugs available for lowering cholesterol levels: including lovastatin (MEVACOR; Merck & Co.), simvastatin (XOCOR; Merck & Co.), dextrothyroxine (CHOLOXIN; Knoll Pharmaceutical Co.), pamaqueside (Pfizer), cholestryramine (QUESTRAN; Bristol-Myers Squibb), colestipol (COLESTID; Pharmacia & Upjohn), acipomox (Pharmacia & Upjohn), fenofibrate (LIPIDIL), gemfibrozil (LOPID; Warner-Lambert), cerivastatin (LIPOBAY; Bayer), fluvastatin (LESCOL; Novartis), atorvastatin (LIPITOR, Warner-Lambert), etofylline clofibrate (DUOLIP; Merckle (Germany)), probucol (LORELCO; Hoechst Marion Roussel), omacor (Pronova (Norway), etofibrate (Merz (Germany), clofibrate (ATROMID-S; Wyeth-Ayerst (AHP)), and niacin (numerous manufacturers). All patients do not respond identically to these drugs. Alleles of the COX6B or the GPI-1 gene which associate with altered lipid metabolism will be useful alone or in conjunction with markers in other genes associated with the development of cardiovascular disease to predict a subject's response to a therapeutic drug. For example, multiplex primer extension assays or microarrays comprising probes for alleles are useful formats for determining drug response. A correlation between drug responses and specific alleles or combinations of alleles of the COX6B or GPI-1 genes and other genes associated with cardiovascular disease can be shown, for example, by clinical studies wherein the response to specific drugs of subjects having different allelic variants of polymorphic regions of the COX6B or GPI-1 genes alone or in combination with allelic variants of other genes are compared. Such studies can also be performed using animal models, such as mice having various alleles and in which, e.g., the endogenous COX6B or GPI-1 genes have been

inactivated such as by a knock-out mutation. Test drugs are then administered to the mice having different alleles and the response of the different mice to a specific compound is compared. Accordingly, assays, microarrays and kits are provided for determining the drug which will be best suited for treating a specific disease or condition in a subject based on the individual's genotype. For example, it will be possible to select drugs which will be devoid of toxicity, or have the lowest level of toxicity possible for treating a subject having a disease or condition, e.g., cardiovascular disease or high cholesterol or low HDL.

[0175] L. Kits

[0176] Kits can be used to indicate whether a subject is at risk of developing high cholesterol, low HDL and/or cardiovascular disease. The kits can also be used to determine if a subject who has high cholesterol or low HDL carries associated variants in the COX6B or GPI-1 genes or other cardiovascular disease-related genes. This information could be used, e.g., to optimize treatment of such individuals as a particular genotype may be associated with drug response.

[0177] In preferred embodiments, the kits comprise a probe or primer which is capable of hybridizing adjacent to or at a polymorphic region of a COX6B or GPI-1 gene and thereby identifying whether the COX6B or GPI-1 gene contains an allelic variant which is associated with cardiovascular disease. Primers or probes that specifically hybridize at or adjacent to the SNPs described in Tables 1-3 could be included. In particular, primers or probes which comprise the sequences of SEQ ID NOs.: 5, 10, 43, 48, 53, 58, 63, 68, 73, 78, 83, 88, 93, 98, 103, 108, 113, and 118 could be included in the kits. The kits preferably further comprise instructions for use in carrying out assays, interpreting results and diagnosing a subject as having a predisposition toward developing high cholesterol, low HDL and/or cardiovascular disease.

[0178] Preferred kits for amplifying a region of a COX6B gene, GPI-1 gene, or other genes associated with cardiovascular disease (such as those listed in Table 3) comprise two primers which flank a polymorphic region of the gene of interest. For example primers can comprise the sequences of SEQ ID NOs.: 3, 4, 8, 9, 41, 42, 46, 47, 51, 52, 56, 57, 61, 62, 66, 67, 71, 72, 76, 77, 81, 82, 86, 87, 91, 92, 96, 97, 101, 102, 106, 107, 111, 112, 116, and 117. For other assays, primers or probes hybridize to a polymorphic region or 5' or 3' to a polymorphic region depending on which strand of the target nucleic acid is used. For example, specific probes and primers comprise sequences designated as SEQ ID NOs: 5, 10, 43, 48, 53, 58, 63, 68, 73, 78, 83, 88, 93, 98, 103, 108, 113, and 118. Those of skill in the art can synthesize primers and probes which hybridize adjacent to or at the polymorphic regions described in TABLES 1-3 and other SNPs in genes associated with cardiovascular disease.

[0179] Yet other kits comprise at least one reagent necessary to perform an assay. For example, the kit can comprise an enzyme, such as a nucleic acid polymerase. Alternatively the kit can comprise a buffer or any other necessary reagent.

[0180] Yet other kits comprise microarrays of probes to detect allelic variants of COX6B, GPI-1, and other genes associated with cardiovascular disease. The kits further comprise instructions for their use and interpreting the results.

[0181] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention. The practice of methods and development of the products provided herein employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and 11 (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridizatiion (B. D. Hames & S. J. Higgins eds. 1984); Transcription and Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., New York); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds., Immunochemical Methods In Cell and Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

EXAMPLE 1

[0182] Isolation of DNA from Blood Samples of a Stratified Population

[0183] Blood samples were obtained from a population of unrelated Caucasian women between the ages of 18-79 (average age =48). The women had, no response to media campaigns, attended the Twin Research Unit at the St. Thomas Hospital in London, England. For current purposes, only one member of a twin pair was used to insure that all observations were independent. Blood samples from 1400 unrelated individuals were measured for levels of cholesterol and HDL. Cholesterol and HDL level in blood samples were quantitated using standard assay methods.

[0184] The population was stratified into pools of 200 people, which represented the lower extreme and the upper extreme for serum levels of cholesterol and HDL.

Cholesterol	
Pool 1:	Individuals were considered to have low cholesterol (0.12–3.6 mmoles/L).
Pool 2:	Individuals were considered to have high cholesterol (5.25–11.57 mmoles/L).
HDL	
Pool 3:	Individuals were considered to have low levels of HDL (0.240–1.11 mmoles/L)
Pool 4:	Individuals were considered to have high levels of HDL (2.10–3.76 mmoles/L).

[0185] DNA Extraction Protocol

[0186] DNA was extracted from blood samples of each of the pools by utilizing the following protocol.

[0187] Section 1

[0188] 1. Blood was extracted into EDTA tubes.

[0189] 2. Blood sample was spun at 3,000 rpm for 10 minutes in a clinical centrifuge.

[0190] 3. The buffy coat (the leucocytes, a yellowish layer of cells on top of the red blood cells) was removed and pooled into a 1 ml conical tube.

[0191] 4. 0.9% saline was added to fill the tube and resuspend the leucocytes. Sample were immediately further processed or stored at 4° C. for 24 hrs.

[0192] 5. The sample was spun at 2,500 rpm for 10 minutes.

[0193] 6. The buffy coat was again removed as cleanly as possible leaving behind any red cells, the sample was suspended in red cell lysis buffer and left for 20 minutes at 4° C.

[0194] 7. The sample was spun again at 2,500 rpm for 10 minutes. If a pellet of unlysed red cells remained lying above the leucocytes the treatment with red cell lysis buffer was repeated.

[0195] 8. The leucocyte pellet was resuspended in 2 ml 0.9% saline.

[0196] 9. The DNA was liberated by the addition of leucocyte lysis buffer—the tube was capped and gently inverted several times, until the liquid became viscous with DNA. The samples were handled with care to avoid shearing and damage to the DNA.

[0197] 10. Samples were frozen for storage prior to full extraction.

[0198] Section 2

[0199] 11. 2 ml of 5 M sodium perchlorate was added to the thawed sample and mixed by inversion. The sample was heated to 60° C. for 30-40 minutes to fully denature proteins.

[0200] 12. An equal volume of chloroform/isoamyl alcohol (24:1) was added at room temperature and the sample mixed for 10 minutes.

[0201] 13. The sample was spun without a break at 3,000 rpm for 10 minutes.

[0202] 14. The top aqueous phase was removed into a clean tube and two volumes of cold 100% ethanol added and mixed by inversion to precipitate DNA.

[0203] 15. The DNA was removed using a sterile loop and resuspended in 1-5 ml TE buffer depending on the DNA yield.

[0204] 16. The optical density was measured at 260 and 280 nm to check yield and purity of the DNA sample. For use in Examples 2 and 3, all DNA had an absorbance ratio of 1.6 at 260/280, a total yield of 32 μg and a concentration of 10 ng/μl. If initial purity levels were unacceptable a re-extraction was carried out (sections 12-15 above).

EXAMPLE 2

[0205] Detection of an Association between an SNP at Position 86 of the Human COX6B Gene and High Cholesterol

[0206] DNA samples (as prepared in Example 1), representing 200 women, from the lower extreme, pool 1 (low levels of cholesterol) and the upper extreme, pool 2 (high levels of cholesterol) were amplified and analyzed for genetic differences using a MassEXTEND™ assay detection method. For each pool, single nucleotide polymorphisms were examined throughout the entire genome to detect differences in allelic frequency of a variant allele between the pools. PCR Amplification of Samples from Pools 1 and 2 PCR primers were synthesized by Operon (Alameda, Calif.) using phosphoramidite chemistry. Amplification of the COX6B target sequence was carried out in two 50 μl PCR reactions with 100 ng of pooled human genomic DNA, obtained as described in Example 1, taken from samples in pool 1 or pool 2, although amounts ranging from 100 ng to 1 ug could be used. Individual DNA concentrations within the pooled samples were present in equal concentration with a final concentration of 0.5 ng. Each reaction contained 1× PCR buffer (Qiagen, Valencia, Calif.), 200μM dNTPs, 1 U Hotstar Taq polymerase (Qiagen, Valencia, Calif.), 4 mM $MgCl_2$, and 25 pmols of the long primer containing both the universal primer sequence and the target specific sequence 5'-AGCGGATAACAATTTCACACAGG-TAGTCTGGTTCTGGTTGGGG-3' (SEQ ID NO.: 4), 2 pmoles of the short primer 5'-AGGATTCAGCAC-CATGGC-3' (SEQ ID NO.: 3) and 10 pmoles of a biotinylated universal primer complementary to the 5' end of the PCR amplicon 5'-AGCGGATAACAATTTCACACAGG-3' (SEQ ID NO.: 121). Alternatively, the biotinylated universal primer could be 5'-GGCGCACGCCTCCACG-3' (SEQ ID NO.: 122). After an initial round of amplification with the target with the specific forward (long) and reverse primer (short), the 5' biotinylated universal primer then hybridized and acted as a reverse primer thereby introducing a 3' biotin capture moiety into the molecule. The amplification protocol results in a 5'-biotinylated double stranded DNA amplicon and dramatically reduces the cost of high throughput genotyping by eliminating the need to 5' biotin label each forward primer used in a genotyping. Thermal cycling was performed in 0.2 mL tubes or 96 well plate using an MJ Research Thermal Cycler (Waltham, Mass.) (calculated temperature) with the following cycling parameters: 94° C. for 5 min; 45 cycles: 94° C. for 20 sec, 56° C. for 30 sec, 72° C. for 60 sec; 72° C. 3 min.

[0207] Immobilization of DNA

[0208] The 50 μl PCR reaction was added to 25 μl of streptavidin coated magnetic bead (Dynal, Lake Success, N.Y.) prewashed three times and resuspended in 1 M NH_4Cl, 0.06 M NH_4OH. The PCR amplicons were allowed to bind to the beads for 15 minutes at room temperature. The beads were then collected with a magnet and the supernatant containing unbound DNA was removed. The unbound strand was released from the double stranded amplicons by incubation in 100 mM NaOH and washing of the beads three times with 10 mM Tris pH 8.0. Genotyping The frequency of the alleles at position 86 in the COX6B gene was measured using the MassEXTEND™ assay and MALDI-TOF. The SNP identified at position 86 of COX6B in the

GenBank sequence is represented as a C to T transversion. The MassEXTEND™ assay used detected the sequence of the complementary strand, thus the SNP was represented as G to A in the primer extension products. The DNA coated magnetic beads were resuspended in 26 mM Tris-HCL pH 9.5, 6.5 mM $MgCl_2$ and 50 mM each of dTTPs and 50 mM each of ddCTP, ddATP, ddGTP, 2.5 U of a thermostable DNA polymerase (Amersham Pharmacia Biotech, Piscataway, N.J.) and 20 pmoles of a template specific oligonucleotide primer 5'-AATCAAGAACTACAAGAC-3' (SEQ ID NO.: 5) (Operon, Alameda, Calif.). Primer extension occurred with three cycles of oligonucleotide primer hybridization and extension. The extension products were analyzed after denaturation from the template with 50 mM NH_4Cl and transfer of 150 nl of each sample to a silicon chip preloaded with 150 nl of H3PA (3-hydroxy picolinic acid) (Sigma Aldrich, St Louis, Mo.) matrix material. The sample material was allowed to crystallize and analyzed by MALDI-TOF (Bruker Daltonics, Billerica, Mass.; PerSeptive, Foster City, Calif.). The mass of the primer used in the MassEXTEND™ reaction was 5493.70 daltons. The predominant allele is extended by the addition of ddC, which has a mass of 5766.90 daltons. The allelic variant results in the addition of dT and ddG to the primer to produce an extension product having a mass of 6111.10 daltons.

[0209] In addition to being analyzed as part of a pool, each individual sample (0.5 ng) was amplified as described above and analyzed individually using a MassEXTEND™ reaction as described above.

[0210] Pooled populations of women (200 women per pool) with high cholesterol (pool 2) showed an increase in the frequency of the A allele at nucleotide position 86 of COX6B as compared with those with low levels of cholesterol (pool 1) (see **FIG. 1**). The association of this allelic variant of the COX6B gene with high cholesterol gave a statistically significant value of 14.30 using a 1-degree-of-freedom chi-squared test of association. In other words, the increase of 2.75% to 9.05% is significant, with a p value of 0.000156 (see **FIG. 1**). The genotype of each of the individuals in the pooled population was also determined by carrying out MassEXTEND™ reactions on each DNA samples individually. These analysis confirmed the pooling data showing that there was an increase in the frequency of the A allele of 2.27% to 9.93%, (p=0.0000061). The genotypes in pool 2 showed a decrease in the homozygous GG genotype from 95.4% to 82.35% and an increase in the heterozygous GA genotype from 4.55% to 15.44%. None of the individuals with low levels of serum cholesterol exhibited the homozygous AA genotype.

EXAMPLE 3

[0211] Detection of an Association between an SNP at Position 2577 of the Human GPI-1 Gene and Low HDL

[0212] DNA samples (as prepared in Example 1), representing 200 women, from pool 3 (low level of HDL) and pool 4 (high levels of HDL) were amplified and analyzed for genetic differences using a MassEXTEND™ detection method. For each pool, SNPs were examined throughout the genome to detect differences in allelic frequency of variant alleles between the pools.

[0213] PCR Amplification of Samples from Pools 3 and 4

[0214] PCR primers were synthesized by Operon (Alameda, Calif.) using phosphoramidite chemistry. Amplification of the GPI-1 target sequence was carried out in single 50 μl PCR reaction with 100 ng of pooled human genomic DNA (200 samples), obtained as described in Example 1, taken from samples in pool 3 or pool 4, although amounts ranging from 100 ng to 1 ug could be used. Individual DNA concentrations within the pooled samples were present in equal concentration with the final concentration of 0.5 ng. Each reaction contained 1× PCR buffer (Qiagen, Valencia, Calif.), 200 uM dNTPs, 1 U Hotstar Taq polymerase (Qiagen, Valencia, Calif.), 4 mM $MgCl_2$, and 25 pmols of the forward primer containing both the universal primer sequence and the target specific short sequence 5'-AGCAGGGCTTCCTCCTTC-3' (SEQ ID NO.: 8) 2 pmoles of the long primer 5'-AGCGGATAACAATTTCACACAGGTGACCCAGCCGTACCTATTC-3' (SEQ ID NO.: 9) and 10 pmoles of a biotinylated universal primer complementary to the 5' end of the PCR amplicon 5'-AGCGGATAACAATTTCACACAGG-3' (SEQ ID NO.: 121). After an initial round of amplification with the target with the specific forward (long) and reverse primer (short), the 5' biotinylated universal primer then hybridized and acted as a reverse primer thereby introducing a 3' biotin capture moiety into the molecule. The amplification protocol results in a 5'-biotinylated double stranded DNA amplicon and dramatically reduces the cost of high throughput genotyping by eliminating the need to 5' biotin label each forward primer used in a genotyping. Thermal cycling was performed in 0.2 mL tubes or 96 well plate using an MJ Research Thermal Cycler (Watham, Mass.) (calculated temperature) with the following cycling parameters: 94° C. for 5 min; 45 cycles: 94° C. for 20 sec, 56° C. for 30 sec, 72° C. for 60 sec; 72° C. 3 min.

[0215] Immobilization of DNA

[0216] The 50 μl PCR reaction was added to 25 μl of streptavidin coated magnetic bead (Dynal, Lake Success, N.Y.) prewashed three times and resuspended in 1 M NH_4Cl, 0.06 M NH_4OH. The PCR amplicons were allowed to bind to the beads for 15 minutes at room temperature. The beads were then collected with a magnet and the supernatant containing unbound DNA was removed. The unbound strand was released from the double stranded amplicons by incubation in 100 mM NaOH and washing of the beads three times with 10 mM Tris pH 8.0.

[0217] Genotyping

[0218] The frequency of the alleles at position 2577 in the GPI-1 gene was measured using the MassEXTEND™ assay and MALDI-TOF. The SNP identified at position 2577 of GPI-1 in the GenBank sequence is represented as a G to A transversion. The MassEXTEND™ assay used detected this sequence, thus the SNP was represented as C to T in the primer extension products. The DNA coated magnetic beads were resuspended in 26 mM Tris-HCL pH 9.5, 6.5 mM $MgCl_2$ and 50 mM each of dTTPs and 50 mM each of ddCTP, ddATP, ddGTP, 2.5 U of a thermostable DNA polymerase (Amersham Pharmacia Biotech, Piscataway, N.J.) and 20 pmoles of a template specific oligonucleotide primer 5'-AAGGGAGACAGATTTGGC-3' (SEQ ID NO.: 10) (Operon, Alameda, Calif.). Primer extension occurred with three cycles of oligonucleotide primer hybridization

and extension. The extension products were analyzed after denaturation from the template with 50 mM NH_4Cl and transfer of 150 nl each sample to a silicon chip preloaded with 150 nl of H3PA matrix material. The sample material was allowed to crystallize and analyzed by MALDI-TOF (Bruker Daltonics, Billerica, Mass.; PerSeptive, Foster City, Calif.). The mass of the primer used in the MassEXTEND™ reaction was 5612.70 daltons. The predominant allele is extended by the addition of ddC, which has a mass of 5885.90 daltons. The allelic variant results in the addition of dT and ddG to the primer to produce an extension product having a mass of 6230.10 daltons.

[0219] In addition to being analyzed as a pool, each individual sample (0.5 ng) was amplified as described above and analyzed individually using the MassEXTEND™ reaction as described above.

[0220] Pooled populations of women (200 women per pool) with low HDL (pool 3) showed an increase in the T allele of 11.33% at nucleotide position 2577 as compared with those with high levels of HDL (pool 4). The association of this allelic variant of the GPI-1 gene with low HDL gave a statistically significant value of 15.04 using a 1-degree-of-freedom chi-squared test of association. In other words, the increase of 16.23% to 27.57% is significant, with a p value of 0.0001064 (see **FIG. 2**). The genotype of each of the individuals in the pooled population was also determined by carrying out individual MassEXTEND™ reactions on individual DNA samples. These analysis confirmed the pooling data showing that there was an increase in the frequency of the T allele of 19.49% to 26.1%, (p=0.024). The measured genotypes in pool 3 showed a decrease in the homozygous CC genotype from 65.24% to 54.21% and an increase in the heterozygous CT genotype from 30.51% to 39.25%. The homozygous TT genotypes increased 2.3%.

[0221] Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 122

<210> SEQ ID NO 1
<211> LENGTH: 439
<212> TYPE: DNA
<213> ORGANISM: Homo Sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (45)...(305)

<400> SEQUENCE: 1

```
ttgagctgca ggttgaatcc ggggtgcctt taggattcag cacc atg gcg gaa gac      56
                                                 Met Ala Glu Asp
                                                  1

atg gag acc aaa atc aag aac tac aag acc gcc cct ttt gac agc cgc      104
Met Glu Thr Lys Ile Lys Asn Tyr Lys Thr Ala Pro Phe Asp Ser Arg
 5                  10                  15                  20

ttc ccc aac cag aac cag act aga aac tgc tgg cag aac tac ctg gac      152
Phe Pro Asn Gln Asn Gln Thr Arg Asn Cys Trp Gln Asn Tyr Leu Asp
                25                  30                  35

ttc cac cgc tgt cag aag gca atg acc gct aaa gga ggc gat atc tct      200
Phe His Arg Cys Gln Lys Ala Met Thr Ala Lys Gly Gly Asp Ile Ser
            40                  45                  50

gtg tgc gaa tgg tac cag cgt gtg tac cag tcc ctc tgc ccc aca tcc      248
Val Cys Glu Trp Tyr Gln Arg Val Tyr Gln Ser Leu Cys Pro Thr Ser
        55                  60                  65

tgg gtc aca gac tgg gat gag caa cgg gct gaa ggc acg ttt ccc ggg      296
Trp Val Thr Asp Trp Asp Glu Gln Arg Ala Glu Gly Thr Phe Pro Gly
    70                  75                  80

aag atc tga actggctgca tctcctttc ctctgtcctc catccttctc              345
Lys Ile  *
 85

ccaggatggt gaaaggggac ctggtaccca gtgatcccca ccccaggatc ctaaatcatg    405

acttacctgc taataaaaac tcattggaaa agtg                               439
```

<210> SEQ ID NO 2
<211> LENGTH: 86

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo Sapien

<400> SEQUENCE: 2

Met Ala Glu Asp Met Glu Thr Lys Ile Lys Asn Tyr Lys Thr Ala Pro
1 5 10 15

Phe Asp Ser Arg Phe Pro Asn Gln Asn Gln Thr Arg Asn Cys Trp Gln
20 25 30

Asn Tyr Leu Asp Phe His Arg Cys Gln Lys Ala Met Thr Ala Lys Gly
35 40 45

Gly Asp Ile Ser Val Cys Glu Trp Tyr Gln Arg Val Tyr Gln Ser Leu
50 55 60

Cys Pro Thr Ser Trp Val Thr Asp Trp Asp Glu Gln Arg Ala Glu Gly
65 70 75 80

Thr Phe Pro Gly Lys Ile
85

<210> SEQ ID NO 3
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 3

aggattcagc accatggc 18

<210> SEQ ID NO 4
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 4

agcggataac aatttcacac aggtagtctg gttctggttg ggg 43

<210> SEQ ID NO 5
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: MassExtend primer

<400> SEQUENCE: 5

aatcaagaac tacaagac 18

<210> SEQ ID NO 6
<211> LENGTH: 2921
<212> TYPE: DNA
<213> ORGANISM: Homo Sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (103)...(1848)

<400> SEQUENCE: 6

cagcgagcgc cgtcgtctgc ccgggcccgc ccatcggggt ccccaacccc atccggaccc 60

cgccgcccga gcgcgcggcc ccggaagcac ccgcctcccg gc atg gtg ctc aag 114
Met Val Leu Lys
1

-continued

```
gcc ttc ttc ccc acg tgc tgc gtc tcg gcg gac agc ggg ctg ctg gtg      162
Ala Phe Phe Pro Thr Cys Cys Val Ser Ala Asp Ser Gly Leu Leu Val
 5                  10                  15                  20

gga cgg tgg gtg ccg gag cag agc agc gcc gtg gtc ctg gcg gtc ctg      210
Gly Arg Trp Val Pro Glu Gln Ser Ser Ala Val Val Leu Ala Val Leu
                25                  30                  35

cac ttt ccc ttc atc ccc atc cag gtc aag cag ctc ctg gcc cag gtg      258
His Phe Pro Phe Ile Pro Ile Gln Val Lys Gln Leu Leu Ala Gln Val
            40                  45                  50

cgg cag gcc agc cag gtg ggc gtg gcc gtg ctg ggc acc tgg tgc cac      306
Arg Gln Ala Ser Gln Val Gly Val Ala Val Leu Gly Thr Trp Cys His
        55                  60                  65

tgc cgg cag gag ccc gag gag agc ctg ggc cgc ttc ctg gag agc ctg      354
Cys Arg Gln Glu Pro Glu Glu Ser Leu Gly Arg Phe Leu Glu Ser Leu
    70                  75                  80

ggt gct gtc ttc ccc cat gag ccc tgg ctg cgg ctg tgc cgg gag aga      402
Gly Ala Val Phe Pro His Glu Pro Trp Leu Arg Leu Cys Arg Glu Arg
85                  90                  95                  100

ggc ggc acg ttc tgg agc tgc gag gcc acc cac cgg caa gcg ccc act      450
Gly Gly Thr Phe Trp Ser Cys Glu Ala Thr His Arg Gln Ala Pro Thr
                105                 110                 115

gcc ccc ggt gcc cct ggt gag gac cag gtc atg ctc atc ttc tat gac      498
Ala Pro Gly Ala Pro Gly Glu Asp Gln Val Met Leu Ile Phe Tyr Asp
            120                 125                 130

cag cgc cag gtg ttg ctg tca cag cta cac ctg ccc acc gtc ctg ccc      546
Gln Arg Gln Val Leu Leu Ser Gln Leu His Leu Pro Thr Val Leu Pro
        135                 140                 145

gac cgc cag gct gga gcc acc act gcc agc acg ggg ggc ctg gct gcc      594
Asp Arg Gln Ala Gly Ala Thr Thr Ala Ser Thr Gly Gly Leu Ala Ala
    150                 155                 160

gtc ttc gac acg gta gca cgc agt gag gtg ctc ttc cgc agt gac cgc      642
Val Phe Asp Thr Val Ala Arg Ser Glu Val Leu Phe Arg Ser Asp Arg
165                 170                 175                 180

ttt gat gag ggc ccc gtg cgg ctg agc cac tgg cag tcg gag ggc gtg      690
Phe Asp Glu Gly Pro Val Arg Leu Ser His Trp Gln Ser Glu Gly Val
                185                 190                 195

gag gcc agc atc ctc gcg gag ctg gcc agg cga gcc tcg gga ccc att      738
Glu Ala Ser Ile Leu Ala Glu Leu Ala Arg Arg Ala Ser Gly Pro Ile
            200                 205                 210

tgt ctg ctg ttg gcc agc ctg ctg tcg ctg gtc tca gct gtc agt gcc      786
Cys Leu Leu Leu Ala Ser Leu Leu Ser Leu Val Ser Ala Val Ser Ala
        215                 220                 225

tgc cga gtg ttc aag ctc tgg ccc ctg tcc ttc ctc ggg agc aaa ctc      834
Cys Arg Val Phe Lys Leu Trp Pro Leu Ser Phe Leu Gly Ser Lys Leu
    230                 235                 240

tcc acg tgc gaa cag ctc cgg cac cgg ctg gag cac ctc acg cta atc      882
Ser Thr Cys Glu Gln Leu Arg His Arg Leu Glu His Leu Thr Leu Ile
245                 250                 255                 260

ttc agt aca cgg aag gcg gag aac cct gcc cag ctg atg agg aag gcc      930
Phe Ser Thr Arg Lys Ala Glu Asn Pro Ala Gln Leu Met Arg Lys Ala
                265                 270                 275

aac acg gtg gcc tct gtg ctg ctg gac gtg gcc ctg ggc ctc atg ctg      978
Asn Thr Val Ala Ser Val Leu Leu Asp Val Ala Leu Gly Leu Met Leu
            280                 285                 290

ctg tcc tgg ctc cac ggg aga agc cgc atc ggg cat ctg gcc gac gcc     1026
Leu Ser Trp Leu His Gly Arg Ser Arg Ile Gly His Leu Ala Asp Ala
        295                 300                 305
```

-continued

```
ctc gtt cct gtg gct gac cac gtg gcc gag gag ctc cag cat ctg ctg     1074
Leu Val Pro Val Ala Asp His Val Ala Glu Glu Leu Gln His Leu Leu
    310                 315                 320

cag tgg ctg atg ggt gct ccc gcc ggg ctc aag atg aac cgt gca ctg     1122
Gln Trp Leu Met Gly Ala Pro Ala Gly Leu Lys Met Asn Arg Ala Leu
325                 330                 335                 340

gac cag gtg ctg ggc cgc ttc ttc ctc tac cac atc cac ctg tgg atc     1170
Asp Gln Val Leu Gly Arg Phe Phe Leu Tyr His Ile His Leu Trp Ile
                345                 350                 355

agc tac atc cac ctc atg tcc ccc ttc gtg gag cac atc ctt tgg cac     1218
Ser Tyr Ile His Leu Met Ser Pro Phe Val Glu His Ile Leu Trp His
            360                 365                 370

gtg ggc ctc tcg gcc tgc ctg ggc ctg acg gtg gcc ctg tcc ctc ctc     1266
Val Gly Leu Ser Ala Cys Leu Gly Leu Thr Val Ala Leu Ser Leu Leu
        375                 380                 385

tcg gac att atc gcc ctc ctc acc ttc cac atc tac tgc ttt tac gtc     1314
Ser Asp Ile Ile Ala Leu Leu Thr Phe His Ile Tyr Cys Phe Tyr Val
    390                 395                 400

tat gga gcc agg ctg tac tgc ctg aag atc cat ggc ctg tcc tca ctg     1362
Tyr Gly Ala Arg Leu Tyr Cys Leu Lys Ile His Gly Leu Ser Ser Leu
405                 410                 415                 420

tgg cgt ctg ttc cgg ggg aag aag tgg aac gtt ctg cgc cag cgc gtg     1410
Trp Arg Leu Phe Arg Gly Lys Lys Trp Asn Val Leu Arg Gln Arg Val
                425                 430                 435

gac tcc tgt tcc tat gac ctg gac cag ctg ttc atc ggg act ctg ctc     1458
Asp Ser Cys Ser Tyr Asp Leu Asp Gln Leu Phe Ile Gly Thr Leu Leu
            440                 445                 450

ttc acc atc ctg ctc ttc ctc ctg cct acc aca gcc ctg tac tac ctg     1506
Phe Thr Ile Leu Leu Phe Leu Leu Pro Thr Thr Ala Leu Tyr Tyr Leu
        455                 460                 465

gtg ttc acc ctg ctc cgg ctc ctg gtg gtc gcc gtg cag ggc ctg atc     1554
Val Phe Thr Leu Leu Arg Leu Leu Val Val Ala Val Gln Gly Leu Ile
    470                 475                 480

cat ctg ctg gtg gac ctc atc aac tcc ctg ccg ctg tac tca ctg ggt     1602
His Leu Leu Val Asp Leu Ile Asn Ser Leu Pro Leu Tyr Ser Leu Gly
485                 490                 495                 500

ctt cgg ctc tgc cgg ccc tac agg ctg gcg gct ggc gtg aag ttc cgt     1650
Leu Arg Leu Cys Arg Pro Tyr Arg Leu Ala Ala Gly Val Lys Phe Arg
                505                 510                 515

gtc ctc cgg cac gag gcc agc agg ccc ctc cgc ctc ctg atg cag ata     1698
Val Leu Arg His Glu Ala Ser Arg Pro Leu Arg Leu Leu Met Gln Ile
            520                 525                 530

aac cca ctg ccc tac agc cgc gtg gtg cac acc tac cgc ctc ccc agc     1746
Asn Pro Leu Pro Tyr Ser Arg Val Val His Thr Tyr Arg Leu Pro Ser
        535                 540                 545

tgt ggc tgc cac ccc aag cac tcc tgg ggc gcc ctg tgc cgc aag ctg     1794
Cys Gly Cys His Pro Lys His Ser Trp Gly Ala Leu Cys Arg Lys Leu
    550                 555                 560

ttc ctt ggg gag ctc atc tac ccc tgg agg cag aga ggg gac aag cag     1842
Phe Leu Gly Glu Leu Ile Tyr Pro Trp Arg Gln Arg Gly Asp Lys Gln
565                 570                 575                 580

gac tga gggaactgct ggctcgcctg gcaccaccac acggccacag ccagccatct      1898
Asp  *

gctctgccag ggtggcacca gctcagctgg cgcatgtccc gtgctttgtg gacgctgctg   1958

tgtgctcctg aacacggcag gccctgctat cacaccttgg gcttggaggt cattgggagt   2018

gagcagatgt gggggtggcc agccaggctg gccgcactcc atcactggca ctgcctgcct   2078
```

-continued

```
tgggacccgc ttcccacctg ctgcggtcac catggtggcg agcacagcaa ccccaggtgt   2138

ccagagcact gccccatgcc caccctgcat acccaggtcc agagggtccg tccaccacag   2198

cagccccagg tggagggctg gtctccctgg gggctcccca gtggctctgc cctggctgtg   2258

ggggtggagg gaccttgcca ggatgaaccc tccagtccca ggcaccctct agctccctca   2318

gccgaacagc accctgcatc tgggggattg aagcagtcgc tgacccccgt ccccagcggg   2378

cccgggccct cactccctga accacacggg gtttatttgc ggatgttccc tggagaggtc   2438

gctttgtgaa gaaaccatca gcaggctgtg agcatcgcca ggctgctgtg ggggcgggag   2498

cagcctcagt gtcaagggcc tgcccactga cccagccgta cctattcgtc cacggtgccc   2558

cgtagcagca ggtcctgcgg ccaaatctgt ctcccttcat gggcctccca gggaaggagg   2618

aagccctgct gtgcagacac ctctgtggcc ccccaggggt gtgagcggcc tggggagggg   2678

gccgtggcac tgaggccgaa agtgcctgcc agacggcacg gtctgggtgc gggtgttccc   2738

tgtgagcccg agtccgcttc aggaggggag cctgcaggtg ccggctggtg aggggatgac   2798

gcgctgtggg tgggaggagg cagcgcccat ctcagcagca ccaggactgc ctgggactcc   2858

ctggcaaccc agcaccgggg aagccgtcag ctgctgtgac aataaaacct gccccgtgtc   2918

tgg                                                                 2921
```

<210> SEQ ID NO 7
<211> LENGTH: 581
<212> TYPE: PRT
<213> ORGANISM: Homo Sapien

<400> SEQUENCE: 7

```
Met Val Leu Lys Ala Phe Phe Pro Thr Cys Cys Val Ser Ala Asp Ser
 1               5                  10                  15

Gly Leu Leu Val Gly Arg Trp Val Pro Glu Gln Ser Ser Ala Val Val
            20                  25                  30

Leu Ala Val Leu His Phe Pro Phe Ile Pro Ile Gln Val Lys Gln Leu
        35                  40                  45

Leu Ala Gln Val Arg Gln Ala Ser Gln Val Gly Val Ala Val Leu Gly
    50                  55                  60

Thr Trp Cys His Cys Arg Gln Glu Pro Glu Glu Ser Leu Gly Arg Phe
65                  70                  75                  80

Leu Glu Ser Leu Gly Ala Val Phe Pro His Glu Pro Trp Leu Arg Leu
                85                  90                  95

Cys Arg Glu Arg Gly Gly Thr Phe Trp Ser Cys Glu Ala Thr His Arg
            100                 105                 110

Gln Ala Pro Thr Ala Pro Gly Ala Pro Gly Glu Asp Gln Val Met Leu
        115                 120                 125

Ile Phe Tyr Asp Gln Arg Gln Val Leu Leu Ser Gln Leu His Leu Pro
    130                 135                 140

Thr Val Leu Pro Asp Arg Gln Ala Gly Ala Thr Thr Ala Ser Thr Gly
145                 150                 155                 160

Gly Leu Ala Ala Val Phe Asp Thr Val Ala Arg Ser Glu Val Leu Phe
                165                 170                 175

Arg Ser Asp Arg Phe Asp Glu Gly Pro Val Arg Leu Ser His Trp Gln
            180                 185                 190
```

-continued

```
Ser Glu Gly Val Glu Ala Ser Ile Leu Ala Glu Leu Ala Arg Arg Ala
        195                 200                 205

Ser Gly Pro Ile Cys Leu Leu Leu Ala Ser Leu Leu Ser Leu Val Ser
    210                 215                 220

Ala Val Ser Ala Cys Arg Val Phe Lys Leu Trp Pro Leu Ser Phe Leu
225                 230                 235                 240

Gly Ser Lys Leu Ser Thr Cys Glu Gln Leu Arg His Arg Leu Glu His
                245                 250                 255

Leu Thr Leu Ile Phe Ser Thr Arg Lys Ala Glu Asn Pro Ala Gln Leu
            260                 265                 270

Met Arg Lys Ala Asn Thr Val Ala Ser Val Leu Leu Asp Val Ala Leu
        275                 280                 285

Gly Leu Met Leu Leu Ser Trp Leu His Gly Arg Ser Arg Ile Gly His
    290                 295                 300

Leu Ala Asp Ala Leu Val Pro Val Ala Asp His Val Ala Glu Glu Leu
305                 310                 315                 320

Gln His Leu Leu Gln Trp Leu Met Gly Ala Pro Ala Gly Leu Lys Met
                325                 330                 335

Asn Arg Ala Leu Asp Gln Val Leu Gly Arg Phe Phe Leu Tyr His Ile
            340                 345                 350

His Leu Trp Ile Ser Tyr Ile His Leu Met Ser Pro Phe Val Glu His
        355                 360                 365

Ile Leu Trp His Val Gly Leu Ser Ala Cys Leu Gly Leu Thr Val Ala
    370                 375                 380

Leu Ser Leu Leu Ser Asp Ile Ile Ala Leu Leu Thr Phe His Ile Tyr
385                 390                 395                 400

Cys Phe Tyr Val Tyr Gly Ala Arg Leu Tyr Cys Leu Lys Ile His Gly
                405                 410                 415

Leu Ser Ser Leu Trp Arg Leu Phe Arg Gly Lys Lys Trp Asn Val Leu
            420                 425                 430

Arg Gln Arg Val Asp Ser Cys Ser Tyr Asp Leu Asp Gln Leu Phe Ile
        435                 440                 445

Gly Thr Leu Leu Phe Thr Ile Leu Leu Phe Leu Leu Pro Thr Thr Ala
    450                 455                 460

Leu Tyr Tyr Leu Val Phe Thr Leu Leu Arg Leu Leu Val Val Ala Val
465                 470                 475                 480

Gln Gly Leu Ile His Leu Leu Val Asp Leu Ile Asn Ser Leu Pro Leu
                485                 490                 495

Tyr Ser Leu Gly Leu Arg Leu Cys Arg Pro Tyr Arg Leu Ala Ala Gly
            500                 505                 510

Val Lys Phe Arg Val Leu Arg His Glu Ala Ser Arg Pro Leu Arg Leu
        515                 520                 525

Leu Met Gln Ile Asn Pro Leu Pro Tyr Ser Arg Val Val His Thr Tyr
    530                 535                 540

Arg Leu Pro Ser Cys Gly Cys His Pro Lys His Ser Trp Gly Ala Leu
545                 550                 555                 560

Cys Arg Lys Leu Phe Leu Gly Glu Leu Ile Tyr Pro Trp Arg Gln Arg
                565                 570                 575

Gly Asp Lys Gln Asp
            580
```

-continued

<210> SEQ ID NO 8
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer

<400> SEQUENCE: 8

agcagggctt cctccttc 18

<210> SEQ ID NO 9
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer

<400> SEQUENCE: 9

agcggataac aatttcacac aggtgaccca gccgtaccta ttc 43

<210> SEQ ID NO 10
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: MassExtend primer

<400> SEQUENCE: 10

aagggagaca gatttggc 18

<210> SEQ ID NO 11
<211> LENGTH: 1790
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (131)...(1612)
<223> OTHER INFORMATION: Nucleotide sequence encoding Cholesterol estertransfer protein (CETP)

<400> SEQUENCE: 11

gtgaatctct ggggccagga agaccctgct gcccggaaga gcctcatgtt ccgtgggggc 60

tgggcggaca tacatatacg ggctccaggc tgaacggctc gggccactta cacaccactg 120

cctgataacc atg ctg gct gcc aca gtc ctg acc ctg gcc ctg ctg ggc 169
Met Leu Ala Ala Thr Val Leu Thr Leu Ala Leu Leu Gly
1 5 10

aat gcc cat gcc tgc tcc aaa ggc acc tcg cac gag gca ggc atc gtg 217
Asn Ala His Ala Cys Ser Lys Gly Thr Ser His Glu Ala Gly Ile Val
15 20 25

tgc cgc atc acc aag cct gcc ctc ctg gtg ttg aac cac gag act gcc 265
Cys Arg Ile Thr Lys Pro Ala Leu Leu Val Leu Asn His Glu Thr Ala
30 35 40 45

aag gtg atc cag acc gcc ttc cag cga gcc agc tac cca gat atc acg 313
Lys Val Ile Gln Thr Ala Phe Gln Arg Ala Ser Tyr Pro Asp Ile Thr
50 55 60

ggc gag aag gcc atg atg ctc ctt ggc caa gtc aag tat ggg ttg cac 361
Gly Glu Lys Ala Met Met Leu Leu Gly Gln Val Lys Tyr Gly Leu His
65 70 75

aac atc cag atc agc cac ttg tcc atc gcc agc agc cag gtg gag ctg 409
Asn Ile Gln Ile Ser His Leu Ser Ile Ala Ser Ser Gln Val Glu Leu
80 85 90

-continued

```
gtg gaa gcc aag tcc att gat gtc tcc att cag aac gtg tct gtg gtc      457
Val Glu Ala Lys Ser Ile Asp Val Ser Ile Gln Asn Val Ser Val Val
     95                  100                 105

ttc aag ggg acc ctg aag tat ggc tac acc act gcc tgg tgg ctg ggt      505
Phe Lys Gly Thr Leu Lys Tyr Gly Tyr Thr Thr Ala Trp Trp Leu Gly
110                 115                 120                 125

att gat cag tcc att gac ttc gag atc gac tct gcc att gac ctc cag      553
Ile Asp Gln Ser Ile Asp Phe Glu Ile Asp Ser Ala Ile Asp Leu Gln
                130                 135                 140

atc aac aca cag ctg acc tgt gac tct ggt aga gtg cgg acc gat gcc      601
Ile Asn Thr Gln Leu Thr Cys Asp Ser Gly Arg Val Arg Thr Asp Ala
            145                 150                 155

cct gac tgc tac ctg tct ttc cat aag ctg ctc ctg cat ctc caa ggg      649
Pro Asp Cys Tyr Leu Ser Phe His Lys Leu Leu Leu His Leu Gln Gly
        160                 165                 170

gag cga gag cct ggg tgg atc aag cag ctg ttc aca aat ttc atc tcc      697
Glu Arg Glu Pro Gly Trp Ile Lys Gln Leu Phe Thr Asn Phe Ile Ser
    175                 180                 185

ttc acc ctg aag ctg gtc ctg aag gga cag atc tgc aaa gag atc aac      745
Phe Thr Leu Lys Leu Val Leu Lys Gly Gln Ile Cys Lys Glu Ile Asn
190                 195                 200                 205

gtc atc tct aac atc atg gcc gat ttt gtc cag aca agg gct gcc agc      793
Val Ile Ser Asn Ile Met Ala Asp Phe Val Gln Thr Arg Ala Ala Ser
                210                 215                 220

atc ctt tca gat gga gac att ggg gtg gac att tcc ctg aca ggt gat      841
Ile Leu Ser Asp Gly Asp Ile Gly Val Asp Ile Ser Leu Thr Gly Asp
            225                 230                 235

ccc gtc atc aca gcc tcc tac ctg gag tcc cat cac aag ggt cat ttc      889
Pro Val Ile Thr Ala Ser Tyr Leu Glu Ser His His Lys Gly His Phe
        240                 245                 250

atc tac aag aat gtc tca gag gac ctc ccc ctc ccc acc ttc tcg ccc      937
Ile Tyr Lys Asn Val Ser Glu Asp Leu Pro Leu Pro Thr Phe Ser Pro
    255                 260                 265

aca ctg ctg ggg gac tcc cgc atg ctg tac ttc tgg ttc tct gag cga      985
Thr Leu Leu Gly Asp Ser Arg Met Leu Tyr Phe Trp Phe Ser Glu Arg
270                 275                 280                 285

gtc ttc cac tcg ctg gcc aag gta gct ttc cag gat ggc cgc ctc atg     1033
Val Phe His Ser Leu Ala Lys Val Ala Phe Gln Asp Gly Arg Leu Met
                290                 295                 300

ctc agc ctg atg gga gac gag ttc aag gca gtg ctg gag acc tgg ggc     1081
Leu Ser Leu Met Gly Asp Glu Phe Lys Ala Val Leu Glu Thr Trp Gly
            305                 310                 315

ttc aac acc aac cag gaa atc ttc caa gag gtt gtc ggc ggc ttc ccc     1129
Phe Asn Thr Asn Gln Glu Ile Phe Gln Glu Val Val Gly Gly Phe Pro
        320                 325                 330

agc cag gcc caa gtc acc gtc cac tgc ctc aag atg ccc aag atc tcc     1177
Ser Gln Ala Gln Val Thr Val His Cys Leu Lys Met Pro Lys Ile Ser
    335                 340                 345

tgc caa aac aag gga gtc gtg gtc aat tct tca gtg atg gtg aaa ttc     1225
Cys Gln Asn Lys Gly Val Val Val Asn Ser Ser Val Met Val Lys Phe
350                 355                 360                 365

ctc ttt cca cgc cca gac cag caa cat tct gta gct tac aca ttt gaa     1273
Leu Phe Pro Arg Pro Asp Gln Gln His Ser Val Ala Tyr Thr Phe Glu
                370                 375                 380

gag gat atc gtg act acc gtc cag gcc tcc tat tct aag aaa aag ctc     1321
Glu Asp Ile Val Thr Thr Val Gln Ala Ser Tyr Ser Lys Lys Lys Leu
            385                 390                 395
```

-continued

```
ttc tta agc ctc ttg gat ttc cag att aca cca aag act gtt tcc aac     1369
Phe Leu Ser Leu Leu Asp Phe Gln Ile Thr Pro Lys Thr Val Ser Asn
        400                 405                 410

ttg act gag agc agc tcc gag tcc atc cag agc ttc ctg cag tca atg     1417
Leu Thr Glu Ser Ser Ser Glu Ser Ile Gln Ser Phe Leu Gln Ser Met
    415                 420                 425

atc acc gct gtg ggc atc cct gag gtc atg tct cgg ctc gag gta gtg     1465
Ile Thr Ala Val Gly Ile Pro Glu Val Met Ser Arg Leu Glu Val Val
430                 435                 440                 445

ttt aca gcc ctc atg aac agc aaa ggc gtg agc ctc ttc gac atc atc     1513
Phe Thr Ala Leu Met Asn Ser Lys Gly Val Ser Leu Phe Asp Ile Ile
                450                 455                 460

aac cct gag att atc act cga gat ggc ttc ctg ctg ctg cag atg gac     1561
Asn Pro Glu Ile Ile Thr Arg Asp Gly Phe Leu Leu Leu Gln Met Asp
            465                 470                 475

ttt ggc ttc cct gag cac ctg ctg gtg gat ttc ctc cag agc ttg agc     1609
Phe Gly Phe Pro Glu His Leu Leu Val Asp Phe Leu Gln Ser Leu Ser
        480                 485                 490

tag aagtctccaa ggaggtcggg atggggcttg tagcagaagg caagcaccag          1662
 *
gctcacagct ggaaccctgg tgtctcctcc agcgtggtgg aagttgggtt aggagtacgg   1722

agatggagat tggctcccaa ctcctcccta tcctaaaggc ccactggcat taaagtgctg   1782

tatccaag                                                            1790


<210> SEQ ID NO 12
<211> LENGTH: 493
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 12

Met Leu Ala Ala Thr Val Leu Thr Leu Ala Leu Leu Gly Asn Ala His
 1               5                  10                  15

Ala Cys Ser Lys Gly Thr Ser His Glu Ala Gly Ile Val Cys Arg Ile
            20                  25                  30

Thr Lys Pro Ala Leu Leu Val Leu Asn His Glu Thr Ala Lys Val Ile
        35                  40                  45

Gln Thr Ala Phe Gln Arg Ala Ser Tyr Pro Asp Ile Thr Gly Glu Lys
    50                  55                  60

Ala Met Met Leu Leu Gly Gln Val Lys Tyr Gly Leu His Asn Ile Gln
65                  70                  75                  80

Ile Ser His Leu Ser Ile Ala Ser Ser Gln Val Glu Leu Val Glu Ala
                85                  90                  95

Lys Ser Ile Asp Val Ser Ile Gln Asn Val Ser Val Val Phe Lys Gly
            100                 105                 110

Thr Leu Lys Tyr Gly Tyr Thr Thr Ala Trp Trp Leu Gly Ile Asp Gln
        115                 120                 125

Ser Ile Asp Phe Glu Ile Asp Ser Ala Ile Asp Leu Gln Ile Asn Thr
    130                 135                 140

Gln Leu Thr Cys Asp Ser Gly Arg Val Arg Thr Asp Ala Pro Asp Cys
145                 150                 155                 160

Tyr Leu Ser Phe His Lys Leu Leu Leu His Leu Gln Gly Glu Arg Glu
                165                 170                 175

Pro Gly Trp Ile Lys Gln Leu Phe Thr Asn Phe Ile Ser Phe Thr Leu
            180                 185                 190
```

-continued

```
Lys Leu Val Leu Lys Gly Gln Ile Cys Lys Glu Ile Asn Val Ile Ser
        195                 200                 205

Asn Ile Met Ala Asp Phe Val Gln Thr Arg Ala Ala Ser Ile Leu Ser
    210                 215                 220

Asp Gly Asp Ile Gly Val Asp Ile Ser Leu Thr Gly Asp Pro Val Ile
225                 230                 235                 240

Thr Ala Ser Tyr Leu Glu Ser His His Lys Gly His Phe Ile Tyr Lys
                245                 250                 255

Asn Val Ser Glu Asp Leu Pro Leu Pro Thr Phe Ser Pro Thr Leu Leu
            260                 265                 270

Gly Asp Ser Arg Met Leu Tyr Phe Trp Phe Ser Glu Arg Val Phe His
        275                 280                 285

Ser Leu Ala Lys Val Ala Phe Gln Asp Gly Arg Leu Met Leu Ser Leu
    290                 295                 300

Met Gly Asp Glu Phe Lys Ala Val Leu Glu Thr Trp Gly Phe Asn Thr
305                 310                 315                 320

Asn Gln Glu Ile Phe Gln Glu Val Val Gly Gly Phe Pro Ser Gln Ala
                325                 330                 335

Gln Val Thr Val His Cys Leu Lys Met Pro Lys Ile Ser Cys Gln Asn
            340                 345                 350

Lys Gly Val Val Val Asn Ser Ser Val Met Val Lys Phe Leu Phe Pro
        355                 360                 365

Arg Pro Asp Gln Gln His Ser Val Ala Tyr Thr Phe Glu Glu Asp Ile
    370                 375                 380

Val Thr Thr Val Gln Ala Ser Tyr Ser Lys Lys Lys Leu Phe Leu Ser
385                 390                 395                 400

Leu Leu Asp Phe Gln Ile Thr Pro Lys Thr Val Ser Asn Leu Thr Glu
                405                 410                 415

Ser Ser Ser Glu Ser Ile Gln Ser Phe Leu Gln Ser Met Ile Thr Ala
            420                 425                 430

Val Gly Ile Pro Glu Val Met Ser Arg Leu Glu Val Val Phe Thr Ala
        435                 440                 445

Leu Met Asn Ser Lys Gly Val Ser Leu Phe Asp Ile Ile Asn Pro Glu
    450                 455                 460

Ile Ile Thr Arg Asp Gly Phe Leu Leu Leu Gln Met Asp Phe Gly Phe
465                 470                 475                 480

Pro Glu His Leu Leu Val Asp Phe Leu Gln Ser Leu Ser
                485                 490


<210> SEQ ID NO 13
<211> LENGTH: 3549
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (175)...(1602)
<223> OTHER INFORMATION: Nucleotide sequence encoding lipoprotein
      lipase (LPL)

<400> SEQUENCE: 13

cccctcttcc tcctcctcaa gggaaagctg cccacttcta gctgccctgc catccccttt     60

aaagggcgac ttgctcagcg ccaaaccgcg gctccagccc tctccagcct ccggctcagc    120
```

-continued

```
cggctcatca gtcggtccgc gccttgcagc tcctccagag ggacgcgccc cgag atg      177
                                                           Met
                                                            1

gag agc aaa gcc ctg ctc gtg ctg act ctg gcc gtg tgg ctc cag agt      225
Glu Ser Lys Ala Leu Leu Val Leu Thr Leu Ala Val Trp Leu Gln Ser
             5                  10                  15

ctg acc gcc tcc cgc gga ggg gtg gcc gcc gcc gac caa aga aga gat      273
Leu Thr Ala Ser Arg Gly Gly Val Ala Ala Ala Asp Gln Arg Arg Asp
         20                  25                  30

ttt atc gac atc gaa agt aaa ttt gcc cta agg acc cct gaa gac aca      321
Phe Ile Asp Ile Glu Ser Lys Phe Ala Leu Arg Thr Pro Glu Asp Thr
     35                  40                  45

gct gag gac act tgc cac ctc att ccc gga gta gca gag tcc gtg gct      369
Ala Glu Asp Thr Cys His Leu Ile Pro Gly Val Ala Glu Ser Val Ala
 50                  55                  60                  65

acc tgt cat ttc aat cac agc agc aaa acc ttc atg gtg atc cat ggc      417
Thr Cys His Phe Asn His Ser Ser Lys Thr Phe Met Val Ile His Gly
                 70                  75                  80

tgg acg gta aca gga atg tat gag agt tgg gtg cca aaa ctt gtg gcc      465
Trp Thr Val Thr Gly Met Tyr Glu Ser Trp Val Pro Lys Leu Val Ala
             85                  90                  95

gcc ctg tac aag aga gaa cca gac tcc aat gtc att gtg gtg gac tgg      513
Ala Leu Tyr Lys Arg Glu Pro Asp Ser Asn Val Ile Val Val Asp Trp
        100                 105                 110

ctg tca cgg gct cag gag cat tac cca gtg tcc gcg ggc tac acc aaa      561
Leu Ser Arg Ala Gln Glu His Tyr Pro Val Ser Ala Gly Tyr Thr Lys
    115                 120                 125

ctg gtg gga cag gat gtg gcc cgg ttt atc aac tgg atg gag gag gag      609
Leu Val Gly Gln Asp Val Ala Arg Phe Ile Asn Trp Met Glu Glu Glu
130                 135                 140                 145

ttt aac tac cct ctg gac aat gtc cat ctc ttg gga tac agc ctt gga      657
Phe Asn Tyr Pro Leu Asp Asn Val His Leu Leu Gly Tyr Ser Leu Gly
                150                 155                 160

gcc cat gct gct ggc att gca gga agt ctg acc aat aag aaa gtc aac      705
Ala His Ala Ala Gly Ile Ala Gly Ser Leu Thr Asn Lys Lys Val Asn
            165                 170                 175

aga att act ggc ctc gat cca gct gga cct aac ttt gag tat gca gaa      753
Arg Ile Thr Gly Leu Asp Pro Ala Gly Pro Asn Phe Glu Tyr Ala Glu
        180                 185                 190

gcc ccg agt cgt ctt tct cct gat gat gca gat ttt gta gac gtc tta      801
Ala Pro Ser Arg Leu Ser Pro Asp Asp Ala Asp Phe Val Asp Val Leu
    195                 200                 205

cac aca ttc acc aga ggg tcc cct ggt cga agc att gga atc cag aaa      849
His Thr Phe Thr Arg Gly Ser Pro Gly Arg Ser Ile Gly Ile Gln Lys
210                 215                 220                 225

cca gtt ggg cat gtt gac att tac ccg aat gga ggt act ttt cag cca      897
Pro Val Gly His Val Asp Ile Tyr Pro Asn Gly Gly Thr Phe Gln Pro
                230                 235                 240

gga tgt aac att gga gaa gct atc cgc gtg att gca gag aga gga ctt      945
Gly Cys Asn Ile Gly Glu Ala Ile Arg Val Ile Ala Glu Arg Gly Leu
            245                 250                 255

gga gat gtg gac cag cta gtg aag tgc tcc cac gag cgc tcc att cat      993
Gly Asp Val Asp Gln Leu Val Lys Cys Ser His Glu Arg Ser Ile His
        260                 265                 270

ctc ttc atc gac tct ctg ttg aat gaa gaa aat cca agt aag gcc tac     1041
Leu Phe Ile Asp Ser Leu Leu Asn Glu Glu Asn Pro Ser Lys Ala Tyr
    275                 280                 285
```

-continued

```
agg tgc agt tcc aag gaa gcc ttt gag aaa ggg ctc tgc ttg agt tgt     1089
Arg Cys Ser Ser Lys Glu Ala Phe Glu Lys Gly Leu Cys Leu Ser Cys
290                 295                 300                 305

aga aag aac cgc tgc aac aat ctg ggc tat gag atc aat aaa gtc aga     1137
Arg Lys Asn Arg Cys Asn Asn Leu Gly Tyr Glu Ile Asn Lys Val Arg
                310                 315                 320

gcc aaa aga agc agc aaa atg tac ctg aag act cgt tct cag atg ccc     1185
Ala Lys Arg Ser Ser Lys Met Tyr Leu Lys Thr Arg Ser Gln Met Pro
            325                 330                 335

tac aaa gtc ttc cat tac caa gta aag att cat ttt tct ggg act gag     1233
Tyr Lys Val Phe His Tyr Gln Val Lys Ile His Phe Ser Gly Thr Glu
        340                 345                 350

agt gaa acc cat acc aat cag gcc ttt gag att tct ctg tat ggc acc     1281
Ser Glu Thr His Thr Asn Gln Ala Phe Glu Ile Ser Leu Tyr Gly Thr
    355                 360                 365

gtg gcc gag agt gag aac atc cca ttc act ctg cct gaa gtt tcc aca     1329
Val Ala Glu Ser Glu Asn Ile Pro Phe Thr Leu Pro Glu Val Ser Thr
370                 375                 380                 385

aat aag acc tac tcc ttc cta att tac aca gag gta gat att gga gaa     1377
Asn Lys Thr Tyr Ser Phe Leu Ile Tyr Thr Glu Val Asp Ile Gly Glu
                390                 395                 400

cta ctc atg ttg aag ctc aaa tgg aag agt gat tca tac ttt agc tgg     1425
Leu Leu Met Leu Lys Leu Lys Trp Lys Ser Asp Ser Tyr Phe Ser Trp
            405                 410                 415

tca gac tgg tgg agc agt ccc ggc ttc gcc att cag aag atc aga gta     1473
Ser Asp Trp Trp Ser Ser Pro Gly Phe Ala Ile Gln Lys Ile Arg Val
        420                 425                 430

aaa gca gga gag act cag aaa aag gtg atc ttc tgt tct agg gag aaa     1521
Lys Ala Gly Glu Thr Gln Lys Lys Val Ile Phe Cys Ser Arg Glu Lys
    435                 440                 445

gtg tct cat ttg cag aaa gga aag gca cct gcg gta ttt gtg aaa tgc     1569
Val Ser His Leu Gln Lys Gly Lys Ala Pro Ala Val Phe Val Lys Cys
450                 455                 460                 465

cat gac aag tct ctg aat aag aag tca ggc tga aactgggcga atctacagaa   1622
His Asp Lys Ser Leu Asn Lys Lys Ser Gly  *
                470                 475

caaagaacgg catgtgaatt ctgtgaagaa tgaagtggag gaagtaactt ttacaaaaca   1682

tacccagtgt ttggggtgtt tcaaaagtgg attttcctga atattaatcc cagccctacc   1742

cttgttagtt attttaggag acagtctcaa gcactaaaaa gtggctaatt caatttatgg   1802

ggtatagtgg ccaaatagca catcctccaa cgttaaaaga cagtggatca tgaaaagtgc   1862

tgttttgtcc tttgagaaag aaataattgt ttgagcgcag agtaaaataa ggctccttca   1922

tgtggcgtat tgggccatag cctataattg gttagaacct cctattttaa ttggaattct   1982

ggatctttcg gactgaggcc ttctcaaact ttactctaag tctccaagaa tacagaaaat   2042

gcttttccgc ggcacgaatc agactcatct acacagcagt atgaatgatg ttttagaatg   2102

attccctctt gctattggaa tgtggtccag acgtcaacca ggaacatgta acttggagag   2162

ggacgaagaa agggtctgat aaacacagag gttttaaaca gtccctacca ttggcctgca   2222

tcatgacaaa gttacaaatt caaggagata taaaatctag atcaattaat tcttaatagg   2282

ctttatcgtt tattgcttaa tccctctctc ccccttcttt tttgtctcaa gattatatta   2342

taataatgtt ctctgggtag gtgttgaaaa tgagcctgta atcctcagct gacacataat   2402

ttgaatggtg cagaaaaaaa aaagataccg taattttatt attagattct ccaaatgatt   2462
```

-continued

```
ttcatcaatt taaaatcatt caatatctga cagttactct tcagttttag gcttaccttg   2522

gtcatgcttc agttgtactt ccagtgcgtc tcttttgttc ctggctttga catgaaaaga   2582

taggtttgag ttcaaatttt gcattgtgtg agcttctaca gattttagac aaggaccgtt   2642

tttactaagt aaaagggtgg agaggttcct ggggtggatt cctaagcagt gcttgtaaac   2702

catcgcgtgc aatgagccag atggagtacc atgagggttg ttatttgttg tttttaacaa   2762

ctaatcaaga gtgagtgaac aactatttat aaactagatc tcctattttt cagaatgctc   2822

ttctacgtat aaatatgaaa tgataaagat gtcaaatatc tcagaggcta tagctgggaa   2882

cccgactgtg aaagtatgtg atatctgaac acatactaga aagctctgca tgtgtgttgt   2942

ccttcagcat aattcggaag ggaaaacagt cgatcaaggg atgtattgga acatgtcgga   3002

gtagaaattg ttcctgatgt gccagaactt cgacccttte tctgagagag atgatcgtgc   3062

ctataaatag taggaccaat gttgtgatta acatcatcag gcttggaatg aattctctct   3122

aaaaataaaa tgatgtatga tttgttgttg gcatcccctt tattaattca ttaaatttct   3182

ggatttgggt tgtgacccag ggtgcattaa cttaaaagat tcactaaagc agcacatagc   3242

actgggaact ctggctccga aaaactttgt tatatatatc aaggatgttc tggctttaca   3302

ttttatttat tagctgtaaa tacatgtgtg gatgtgtaaa tggagcttgt acatattgga   3362

aaggtcattg tggctatctg catttataaa tgtgtggtgc taactgtatg tgtctttatc   3422

agtgatggtc tcacagagcc aactcactct tatgaaatgg gctttaacaa aacaagaaag   3482

aaacgtactt aactgtgtga agaaatggaa tcagctttta ataaaattga caacatttta   3542

ttaccac                                                            3549
```

<210> SEQ ID NO 14
<211> LENGTH: 475
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 14

```
Met Glu Ser Lys Ala Leu Leu Val Leu Thr Leu Ala Val Trp Leu Gln
 1               5                  10                  15

Ser Leu Thr Ala Ser Arg Gly Gly Val Ala Ala Ala Asp Gln Arg Arg
            20                  25                  30

Asp Phe Ile Asp Ile Glu Ser Lys Phe Ala Leu Arg Thr Pro Glu Asp
        35                  40                  45

Thr Ala Glu Asp Thr Cys His Leu Ile Pro Gly Val Ala Glu Ser Val
    50                  55                  60

Ala Thr Cys His Phe Asn His Ser Ser Lys Thr Phe Met Val Ile His
65                  70                  75                  80

Gly Trp Thr Val Thr Gly Met Tyr Glu Ser Trp Val Pro Lys Leu Val
                85                  90                  95

Ala Ala Leu Tyr Lys Arg Glu Pro Asp Ser Asn Val Ile Val Val Asp
            100                 105                 110

Trp Leu Ser Arg Ala Gln Glu His Tyr Pro Val Ser Ala Gly Tyr Thr
        115                 120                 125

Lys Leu Val Gly Gln Asp Val Ala Arg Phe Ile Asn Trp Met Glu Glu
    130                 135                 140

Glu Phe Asn Tyr Pro Leu Asp Asn Val His Leu Leu Gly Tyr Ser Leu
145                 150                 155                 160
```

-continued

```
Gly Ala His Ala Ala Gly Ile Ala Gly Ser Leu Thr Asn Lys Lys Val
                165                 170                 175

Asn Arg Ile Thr Gly Leu Asp Pro Ala Gly Pro Asn Phe Glu Tyr Ala
            180                 185                 190

Glu Ala Pro Ser Arg Leu Ser Pro Asp Asp Ala Asp Phe Val Asp Val
        195                 200                 205

Leu His Thr Phe Thr Arg Gly Ser Pro Gly Arg Ser Ile Gly Ile Gln
    210                 215                 220

Lys Pro Val Gly His Val Asp Ile Tyr Pro Asn Gly Gly Thr Phe Gln
225                 230                 235                 240

Pro Gly Cys Asn Ile Gly Glu Ala Ile Arg Val Ile Ala Glu Arg Gly
                245                 250                 255

Leu Gly Asp Val Asp Gln Leu Val Lys Cys Ser His Glu Arg Ser Ile
            260                 265                 270

His Leu Phe Ile Asp Ser Leu Leu Asn Glu Glu Asn Pro Ser Lys Ala
        275                 280                 285

Tyr Arg Cys Ser Ser Lys Glu Ala Phe Glu Lys Gly Leu Cys Leu Ser
    290                 295                 300

Cys Arg Lys Asn Arg Cys Asn Asn Leu Gly Tyr Glu Ile Asn Lys Val
305                 310                 315                 320

Arg Ala Lys Arg Ser Ser Lys Met Tyr Leu Lys Thr Arg Ser Gln Met
                325                 330                 335

Pro Tyr Lys Val Phe His Tyr Gln Val Lys Ile His Phe Ser Gly Thr
            340                 345                 350

Glu Ser Glu Thr His Thr Asn Gln Ala Phe Glu Ile Ser Leu Tyr Gly
        355                 360                 365

Thr Val Ala Glu Ser Glu Asn Ile Pro Phe Thr Leu Pro Glu Val Ser
    370                 375                 380

Thr Asn Lys Thr Tyr Ser Phe Leu Ile Tyr Thr Glu Val Asp Ile Gly
385                 390                 395                 400

Glu Leu Leu Met Leu Lys Leu Lys Trp Lys Ser Asp Ser Tyr Phe Ser
                405                 410                 415

Trp Ser Asp Trp Trp Ser Ser Pro Gly Phe Ala Ile Gln Lys Ile Arg
            420                 425                 430

Val Lys Ala Gly Glu Thr Gln Lys Lys Val Ile Phe Cys Ser Arg Glu
        435                 440                 445

Lys Val Ser His Leu Gln Lys Gly Lys Ala Pro Ala Val Phe Val Lys
    450                 455                 460

Cys His Asp Lys Ser Leu Asn Lys Lys Ser Gly
465                 470                 475


<210> SEQ ID NO 15
<211> LENGTH: 1466
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (115)...(1305)
<223> OTHER INFORMATION: Nucleotide sequence encoding apolipoprotein
      A-IV (APOA4)
```

-continued

<400> SEQUENCE: 15

```
agttcccact gcagcgcagg tgagctctcc tgaggacctc tctgtcagct cccctgattg      60

tagggaggca tccagtgtgg caagaaactc ctccagccca gcaagcagct cagg atg       117
                                                              Met
                                                               1

ttc ctg aag gcc gtg gtc ctg acc ctg gcc ctg gtg gct gtc gcc gga       165
Phe Leu Lys Ala Val Val Leu Thr Leu Ala Leu Val Ala Val Ala Gly
              5                  10                  15

gcc agg gct gag gtc agt gct gac cag gtg gcc aca gtg atg tgg gac       213
Ala Arg Ala Glu Val Ser Ala Asp Gln Val Ala Thr Val Met Trp Asp
          20                  25                  30

tac ttc agc cag ctg agc aac aat gcc aag gag gcc gtg gaa cat ctc       261
Tyr Phe Ser Gln Leu Ser Asn Asn Ala Lys Glu Ala Val Glu His Leu
      35                  40                  45

cag aaa tct gaa ctc acc cag caa ctc aat gcc ctc ttc cag gac aaa       309
Gln Lys Ser Glu Leu Thr Gln Gln Leu Asn Ala Leu Phe Gln Asp Lys
 50                  55                  60                  65

ctt gga gaa gtg aac act tac gca ggt gac ctg cag aag aag ctg gtg       357
Leu Gly Glu Val Asn Thr Tyr Ala Gly Asp Leu Gln Lys Lys Leu Val
                 70                  75                  80

ccc ttt gcc acc gag ctg cat gaa cgc ctg gcc aag gac tcg gag aaa       405
Pro Phe Ala Thr Glu Leu His Glu Arg Leu Ala Lys Asp Ser Glu Lys
             85                  90                  95

ctg aag gag gag att ggg aag gag ctg gag gag ctg agg gcc cgg ctg       453
Leu Lys Glu Glu Ile Gly Lys Glu Leu Glu Glu Leu Arg Ala Arg Leu
        100                 105                 110

ctg ccc cat gcc aat gag gtg agc cag aag atc ggg gac aac ctg cga       501
Leu Pro His Ala Asn Glu Val Ser Gln Lys Ile Gly Asp Asn Leu Arg
    115                 120                 125

gag ctt cag cag cgc ctg gag ccc tac gcg gac cag ctg cgc acc cag       549
Glu Leu Gln Gln Arg Leu Glu Pro Tyr Ala Asp Gln Leu Arg Thr Gln
130                 135                 140                 145

gtc aac acg cag gcc gag cag ctg cgg cgc cag ctg acc ccc tac gca       597
Val Asn Thr Gln Ala Glu Gln Leu Arg Arg Gln Leu Thr Pro Tyr Ala
                150                 155                 160

cag cgc atg gag aga gtg ctg cgg gag aac gcc gac agc ctg cag gcc       645
Gln Arg Met Glu Arg Val Leu Arg Glu Asn Ala Asp Ser Leu Gln Ala
            165                 170                 175

tcg ctg agg ccc cac gcc gac gag ctc aag gcc aag atc gac cag aac       693
Ser Leu Arg Pro His Ala Asp Glu Leu Lys Ala Lys Ile Asp Gln Asn
        180                 185                 190

gtg gag gag ctc aag gga cgc ctt acg ccc tac gct gac gaa ttc aaa       741
Val Glu Glu Leu Lys Gly Arg Leu Thr Pro Tyr Ala Asp Glu Phe Lys
    195                 200                 205

gtc aag att gac cag acc gtg gag gag ctg cgc cgc agc ctg gct ccc       789
Val Lys Ile Asp Gln Thr Val Glu Glu Leu Arg Arg Ser Leu Ala Pro
210                 215                 220                 225

tat gct cag gac acg cag gag aag ctc aac cac cag ctt gag ggc ctg       837
Tyr Ala Gln Asp Thr Gln Glu Lys Leu Asn His Gln Leu Glu Gly Leu
                230                 235                 240

acc ttc cag atg aag aag aac gcc gag gag ctc aag gcc agg atc tcg       885
Thr Phe Gln Met Lys Lys Asn Ala Glu Glu Leu Lys Ala Arg Ile Ser
            245                 250                 255

gcc agt gcc gag gag ctg cgg cag agg ctg gcg ccc ttg gcc gag gac       933
Ala Ser Ala Glu Glu Leu Arg Gln Arg Leu Ala Pro Leu Ala Glu Asp
        260                 265                 270
```

-continued

```
gtg cgt ggc aac ctg agg ggc aac acc gag ggg ctg cag aag tca ctg      981
Val Arg Gly Asn Leu Arg Gly Asn Thr Glu Gly Leu Gln Lys Ser Leu
    275                 280                 285

gca gag ctg ggt ggg cac ctg gac cag cag gtg gag gag ttc cga cgc     1029
Ala Glu Leu Gly Gly His Leu Asp Gln Gln Val Glu Glu Phe Arg Arg
290                 295                 300                 305

cgg gtg gag ccc tac ggg gaa aac ttc aac aaa gcc ctg gtg cag cag     1077
Arg Val Glu Pro Tyr Gly Glu Asn Phe Asn Lys Ala Leu Val Gln Gln
                310                 315                 320

atg gaa cag ctc agg acg aaa ctg ggc ccc cat gcg ggg gac gtg gaa     1125
Met Glu Gln Leu Arg Thr Lys Leu Gly Pro His Ala Gly Asp Val Glu
            325                 330                 335

ggc cac ttg agc ttc ctg gag aag gac ctg agg gac aag gtc aac tcc     1173
Gly His Leu Ser Phe Leu Glu Lys Asp Leu Arg Asp Lys Val Asn Ser
        340                 345                 350

ttc ttc agc acc ttc aag gag aaa gag agc cag gac aag act ctc tcc     1221
Phe Phe Ser Thr Phe Lys Glu Lys Glu Ser Gln Asp Lys Thr Leu Ser
    355                 360                 365

ctc cct gag ctg gag caa cag cag gaa cag cat cag gag cag cag cag     1269
Leu Pro Glu Leu Glu Gln Gln Gln Glu Gln His Gln Glu Gln Gln Gln
370                 375                 380                 385

gag cag gtg cag atg ctg gcc cct ttg gag agc tga gctgcccctg          1315
Glu Gln Val Gln Met Leu Ala Pro Leu Glu Ser  *
                390                 395

gtgcactggc cccaccctcg tggacacctg ccctgccctg ccacctgtct gtctgtccca   1375

aagaagttct ggtatgaact tgaggacaca tgtccagtgg gaggtgagac cacctctcaa   1435

tattcaataa agctgctgag aatctagcct c                                  1466


<210> SEQ ID NO 16
<211> LENGTH: 396
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 16

Met Phe Leu Lys Ala Val Val Leu Thr Leu Ala Leu Val Ala Val Ala
 1               5                  10                  15

Gly Ala Arg Ala Glu Val Ser Ala Asp Gln Val Ala Thr Val Met Trp
            20                  25                  30

Asp Tyr Phe Ser Gln Leu Ser Asn Asn Ala Lys Glu Ala Val Glu His
        35                  40                  45

Leu Gln Lys Ser Glu Leu Thr Gln Gln Leu Asn Ala Leu Phe Gln Asp
    50                  55                  60

Lys Leu Gly Glu Val Asn Thr Tyr Ala Gly Asp Leu Gln Lys Lys Leu
65                  70                  75                  80

Val Pro Phe Ala Thr Glu Leu His Glu Arg Leu Ala Lys Asp Ser Glu
                85                  90                  95

Lys Leu Lys Glu Glu Ile Gly Lys Glu Leu Glu Glu Leu Arg Ala Arg
            100                 105                 110

Leu Leu Pro His Ala Asn Glu Val Ser Gln Lys Ile Gly Asp Asn Leu
        115                 120                 125

Arg Glu Leu Gln Gln Arg Leu Glu Pro Tyr Ala Asp Gln Leu Arg Thr
    130                 135                 140

Gln Val Asn Thr Gln Ala Glu Gln Leu Arg Arg Gln Leu Thr Pro Tyr
145                 150                 155                 160
```

-continued

```
Ala Gln Arg Met Glu Arg Val Leu Arg Glu Asn Ala Asp Ser Leu Gln
                165                 170                 175

Ala Ser Leu Arg Pro His Ala Asp Glu Leu Lys Ala Lys Ile Asp Gln
            180                 185                 190

Asn Val Glu Glu Leu Lys Gly Arg Leu Thr Pro Tyr Ala Asp Glu Phe
        195                 200                 205

Lys Val Lys Ile Asp Gln Thr Val Glu Glu Leu Arg Arg Ser Leu Ala
    210                 215                 220

Pro Tyr Ala Gln Asp Thr Gln Glu Lys Leu Asn His Gln Leu Glu Gly
225                 230                 235                 240

Leu Thr Phe Gln Met Lys Lys Asn Ala Glu Glu Leu Lys Ala Arg Ile
                245                 250                 255

Ser Ala Ser Ala Glu Glu Leu Arg Gln Arg Leu Ala Pro Leu Ala Glu
            260                 265                 270

Asp Val Arg Gly Asn Leu Arg Gly Asn Thr Glu Gly Leu Gln Lys Ser
        275                 280                 285

Leu Ala Glu Leu Gly Gly His Leu Asp Gln Gln Val Glu Glu Phe Arg
    290                 295                 300

Arg Arg Val Glu Pro Tyr Gly Glu Asn Phe Asn Lys Ala Leu Val Gln
305                 310                 315                 320

Gln Met Glu Gln Leu Arg Thr Lys Leu Gly Pro His Ala Gly Asp Val
                325                 330                 335

Glu Gly His Leu Ser Phe Leu Glu Lys Asp Leu Arg Asp Lys Val Asn
            340                 345                 350

Ser Phe Phe Ser Thr Phe Lys Glu Lys Glu Ser Gln Asp Lys Thr Leu
        355                 360                 365

Ser Leu Pro Glu Leu Glu Gln Gln Gln Glu Gln His Gln Glu Gln Gln
    370                 375                 380

Gln Glu Gln Val Gln Met Leu Ala Pro Leu Glu Ser
385                 390                 395


<210> SEQ ID NO 17
<211> LENGTH: 1156
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (61)...(1014)
<223> OTHER INFORMATION: Nucleotide Sequence encoding apolipoprotein
      E (APOE)

<400> SEQUENCE: 17

cgcagcggag gtgaaggacg tccttcccca ggagccgact ggccaatcac aggcaggaag     60

atg aag gtt ctg tgg gct gcg ttg ctg gtc aca ttc ctg gca gga tgc      108
Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys
 1               5                  10                  15

cag gcc aag gtg gag caa gcg gtg gag aca gag ccg gag ccc gag ctg      156
Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu
             20                  25                  30

cgc cag cag acc gag tgg cag agc ggc cag cgc tgg gaa ctg gca ctg      204
Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu
         35                  40                  45

ggt cgc ttt tgg gat tac ctg cgc tgg gtg cag aca ctg tct gag cag      252
Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln
     50                  55                  60
```

-continued

```
gtg cag gag gag ctg ctc agc tcc cag gtc acc cag gaa ctg agg gcg      300
Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala
 65                  70                  75                  80

ctg atg gac gag acc atg aag gag ttg aag gcc tac aaa tcg gaa ctg      348
Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu
                85                  90                  95

gag gaa caa ctg acc ccg gtg gcg gag gag acg cgg gca cgg ctg tcc      396
Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser
            100                 105                 110

aag gag ctg cag gcg gcg cag gcc cgg ctg ggc gcg gac atg gag gac      444
Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp
        115                 120                 125

gtg tgc ggc cgc ctg gtg cag tac cgc ggc gag gtg cag gcc atg ctc      492
Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
    130                 135                 140

ggc cag agc acc gag gag ctg cgg gtg cgc ctc gcc tcc cac ctg cgc      540
Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg
145                 150                 155                 160

aag ctg cgt aag cgg ctc ctc cgc gat gcc gat gac ctg cag aag cgc      588
Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg
                165                 170                 175

ctg gca gtg tac cag gcc ggg gcc cgc gag ggc gcc gag cgc ggc ctc      636
Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu
            180                 185                 190

agc gcc atc cgc gag cgc ctg ggg ccc ctg gtg gaa cag ggc cgc gtg      684
Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val
        195                 200                 205

cgg gcc gcc act gtg ggc tcc ctg gcc ggc cag ccg cta cag gag cgg      732
Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg
    210                 215                 220

gcc cag gcc tgg ggc gag cgg ctg cgc gcg cgg atg gag gag atg ggc      780
Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly
225                 230                 235                 240

agc cgg acc cgc gac cgc ctg gac gag gtg aag gag cag gtg gcg gag      828
Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
                245                 250                 255

gtg cgc gcc aag ctg gag gag cag gcc cag cag ata cgc ctg cag gcc      876
Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala
            260                 265                 270

gag gcc ttc cag gcc cgc ctc aag agc tgg ttc gag ccc ctg gtg gaa      924
Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu
        275                 280                 285

gac atg cag cgc cag tgg gcc ggg ctg gtg gag aag gtg cag gct gcc      972
Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala
    290                 295                 300

gtg ggc acc agc gcc gcc cct gtg ccc agc gac aat cac tga             1014
Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His  *
305                 310                 315

acgccgaagc ctgcagccat gcgaccccac gccacccccgt gcctcctgcc tccgcgcagc   1074

ctgcagcggg agaccctgtc cccgccccag ccgtcctcct ggggtggacc ctagtttaat   1134

aaagattcac caagtttcac gc                                            1156


<210> SEQ ID NO 18
<211> LENGTH: 317
<212> TYPE: PRT
<213> ORGANISM: Homo sapien
```

-continued

<400> SEQUENCE: 18

```
Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys
 1               5                  10                  15

Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu
            20                  25                  30

Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu
        35                  40                  45

Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln
    50                  55                  60

Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala
65                  70                  75                  80

Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu
                85                  90                  95

Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser
            100                 105                 110

Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp
        115                 120                 125

Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
    130                 135                 140

Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg
145                 150                 155                 160

Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg
                165                 170                 175

Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu
            180                 185                 190

Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val
        195                 200                 205

Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg
    210                 215                 220

Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly
225                 230                 235                 240

Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
                245                 250                 255

Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala
            260                 265                 270

Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu
        275                 280                 285

Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala
    290                 295                 300

Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His
305                 310                 315
```

<210> SEQ ID NO 19
<211> LENGTH: 1603
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (58)...(1557)
<223> OTHER INFORMATION: Nucleotide sequence encoding hepatic lipase (LIPC)

-continued

<400> SEQUENCE: 19

```
ggtctctttg gcttcagaaa ttaccaagaa agcctggacc ccgggtgaaa cggagaa atg     60
                                                                 Met
                                                                  1

gac aca agt ccc ctg tgt ttc tcc att ctg ttg gtt tta tgc atc ttt      108
Asp Thr Ser Pro Leu Cys Phe Ser Ile Leu Leu Val Leu Cys Ile Phe
             5                  10                  15

atc caa tca agt gcc ctt gga caa agc ctg aaa cca gag cca ttt gga      156
Ile Gln Ser Ser Ala Leu Gly Gln Ser Leu Lys Pro Glu Pro Phe Gly
         20                  25                  30

aga aga gct caa gct gtt gaa aca aac aaa acg ctg cat gag atg aag      204
Arg Arg Ala Gln Ala Val Glu Thr Asn Lys Thr Leu His Glu Met Lys
     35                  40                  45

acc aga ttc ctg ctc ttt gga gaa acc aat cag ggc tgt cag att cga      252
Thr Arg Phe Leu Leu Phe Gly Glu Thr Asn Gln Gly Cys Gln Ile Arg
 50                  55                  60                  65

atc aat cat ccg gac acg tta cag gag tgc ggc ttc aac tcc tcc ctg      300
Ile Asn His Pro Asp Thr Leu Gln Glu Cys Gly Phe Asn Ser Ser Leu
                 70                  75                  80

cct ctg gtg atg ata atc cac ggg tgg tcg gtg gac ggc gtg cta gaa      348
Pro Leu Val Met Ile Ile His Gly Trp Ser Val Asp Gly Val Leu Glu
             85                  90                  95

aac tgg atc tgg cag atg gtg gcc gcg ctg aag tct cag ccg gcc cag      396
Asn Trp Ile Trp Gln Met Val Ala Ala Leu Lys Ser Gln Pro Ala Gln
        100                 105                 110

cca gtg aac gtg ggg ctg gtg gac tgg atc acc ctg gcc cac gac cac      444
Pro Val Asn Val Gly Leu Val Asp Trp Ile Thr Leu Ala His Asp His
    115                 120                 125

tac acc atc gcc gtc cgc aac acc cgc ctt gtg ggc aag gag gtc gcg      492
Tyr Thr Ile Ala Val Arg Asn Thr Arg Leu Val Gly Lys Glu Val Ala
130                 135                 140                 145

gct ctt ctc cgg tgg ctg gag gaa tct gtt caa ctc tct cga agc cat      540
Ala Leu Leu Arg Trp Leu Glu Glu Ser Val Gln Leu Ser Arg Ser His
                150                 155                 160

gtt cac cta att ggg tac agc ctg ggt gca cac gtg tca gga ttt gcc      588
Val His Leu Ile Gly Tyr Ser Leu Gly Ala His Val Ser Gly Phe Ala
            165                 170                 175

ggc agt tcc atc ggt gga acg cac aag att ggg aga atc aca ggg ctg      636
Gly Ser Ser Ile Gly Gly Thr His Lys Ile Gly Arg Ile Thr Gly Leu
        180                 185                 190

gat gcc gcg gga cct ttg ttt gag gga agt gcc ccc agc aat cgt ctt      684
Asp Ala Ala Gly Pro Leu Phe Glu Gly Ser Ala Pro Ser Asn Arg Leu
    195                 200                 205

tct cca gat gat gcc aat ttt gtg gat gcc att cat acc ttt acg cgg      732
Ser Pro Asp Asp Ala Asn Phe Val Asp Ala Ile His Thr Phe Thr Arg
210                 215                 220                 225

gag cac atg ggc ctg agc gtg ggc atc aaa cag ccc ata gga cac tat      780
Glu His Met Gly Leu Ser Val Gly Ile Lys Gln Pro Ile Gly His Tyr
                230                 235                 240

gac ttc tat ccc aac ggg ggc tcc ttc cag cct ggc tgc cac ttc cta      828
Asp Phe Tyr Pro Asn Gly Gly Ser Phe Gln Pro Gly Cys His Phe Leu
            245                 250                 255

gag ctc tac aga cat att gcc cag cac ggc ttc aat gcc atc acc cag      876
Glu Leu Tyr Arg His Ile Ala Gln His Gly Phe Asn Ala Ile Thr Gln
        260                 265                 270
```

-continued

```
acc ata aaa tgc tcc cac gag cga tcg gtg cac ctt ttc atc gac tcc      924
Thr Ile Lys Cys Ser His Glu Arg Ser Val His Leu Phe Ile Asp Ser
    275                 280                 285

ttg ctg cac gcc ggc acg cag agc atg gcc tac ccg tgt ggt gac atg      972
Leu Leu His Ala Gly Thr Gln Ser Met Ala Tyr Pro Cys Gly Asp Met
290                 295                 300                 305

aac agc ttc agc cag ggc ctg tgc ctg agc tgc aag aag ggc cgc tgc     1020
Asn Ser Phe Ser Gln Gly Leu Cys Leu Ser Cys Lys Lys Gly Arg Cys
                310                 315                 320

aac acg ctg ggc tac cac gtc cgc cag gag ccg cgg agc aag agc aag     1068
Asn Thr Leu Gly Tyr His Val Arg Gln Glu Pro Arg Ser Lys Ser Lys
            325                 330                 335

agg ctc ttc ctc gta acg cga gcc cag tcc ccc ttc aaa gtt tat cat     1116
Arg Leu Phe Leu Val Thr Arg Ala Gln Ser Pro Phe Lys Val Tyr His
        340                 345                 350

tac cag tta aag atc cag ttc atc aac caa act gag acg cca ata caa     1164
Tyr Gln Leu Lys Ile Gln Phe Ile Asn Gln Thr Glu Thr Pro Ile Gln
    355                 360                 365

aca act ttt acc atg tca cta ctc gga aca aaa gag aaa atg cag aaa     1212
Thr Thr Phe Thr Met Ser Leu Leu Gly Thr Lys Glu Lys Met Gln Lys
370                 375                 380                 385

att ccc atc act ctg ggc aaa gga att gct agt aat aaa acg tat tcc     1260
Ile Pro Ile Thr Leu Gly Lys Gly Ile Ala Ser Asn Lys Thr Tyr Ser
                390                 395                 400

ttt ctt atc acg ctg gat gtg gat atc ggc gag ctg atc atg atc aag     1308
Phe Leu Ile Thr Leu Asp Val Asp Ile Gly Glu Leu Ile Met Ile Lys
            405                 410                 415

ttc aag tgg gaa aac agt gca gtg tgg gcc aat gtc tgg gac acg gtc     1356
Phe Lys Trp Glu Asn Ser Ala Val Trp Ala Asn Val Trp Asp Thr Val
        420                 425                 430

cag acc atc atc cca tgg agc aca ggg ccg cgc cac tca ggc ctc gtt     1404
Gln Thr Ile Ile Pro Trp Ser Thr Gly Pro Arg His Ser Gly Leu Val
    435                 440                 445

ctg aag acg atc aga gtc aaa gca gga gaa acc cag caa aga atg aca     1452
Leu Lys Thr Ile Arg Val Lys Ala Gly Glu Thr Gln Gln Arg Met Thr
450                 455                 460                 465

ttt tgt tca gaa aac aca gat gac cta cta ctt cgc cca acc cag gaa     1500
Phe Cys Ser Glu Asn Thr Asp Asp Leu Leu Leu Arg Pro Thr Gln Glu
                470                 475                 480

aaa atc ttc gtg aaa tgt gaa ata aag tct aaa aca tca aag cga aag     1548
Lys Ile Phe Val Lys Cys Glu Ile Lys Ser Lys Thr Ser Lys Arg Lys
            485                 490                 495

atc aga tga gatttaatga agacccagtg taaagaataa atgaatctta             1597
Ile Arg  *

ctcctt                                                             1603


<210> SEQ ID NO 20
<211> LENGTH: 499
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 20

Met Asp Thr Ser Pro Leu Cys Phe Ser Ile Leu Leu Val Leu Cys Ile
 1               5                  10                  15

Phe Ile Gln Ser Ser Ala Leu Gly Gln Ser Leu Lys Pro Glu Pro Phe
            20                  25                  30
```

-continued

```
Gly Arg Arg Ala Gln Ala Val Glu Thr Asn Lys Thr Leu His Glu Met
        35                  40                  45

Lys Thr Arg Phe Leu Leu Phe Gly Glu Thr Asn Gln Gly Cys Gln Ile
    50                  55                  60

Arg Ile Asn His Pro Asp Thr Leu Gln Glu Cys Gly Phe Asn Ser Ser
65                  70                  75                  80

Leu Pro Leu Val Met Ile Ile His Gly Trp Ser Val Asp Gly Val Leu
                85                  90                  95

Glu Asn Trp Ile Trp Gln Met Val Ala Ala Leu Lys Ser Gln Pro Ala
            100                 105                 110

Gln Pro Val Asn Val Gly Leu Val Asp Trp Ile Thr Leu Ala His Asp
        115                 120                 125

His Tyr Thr Ile Ala Val Arg Asn Thr Arg Leu Val Gly Lys Glu Val
    130                 135                 140

Ala Ala Leu Leu Arg Trp Leu Glu Glu Ser Val Gln Leu Ser Arg Ser
145                 150                 155                 160

His Val His Leu Ile Gly Tyr Ser Leu Gly Ala His Val Ser Gly Phe
                165                 170                 175

Ala Gly Ser Ser Ile Gly Gly Thr His Lys Ile Gly Arg Ile Thr Gly
            180                 185                 190

Leu Asp Ala Ala Gly Pro Leu Phe Glu Gly Ser Ala Pro Ser Asn Arg
        195                 200                 205

Leu Ser Pro Asp Asp Ala Asn Phe Val Asp Ala Ile His Thr Phe Thr
    210                 215                 220

Arg Glu His Met Gly Leu Ser Val Gly Ile Lys Gln Pro Ile Gly His
225                 230                 235                 240

Tyr Asp Phe Tyr Pro Asn Gly Gly Ser Phe Gln Pro Gly Cys His Phe
                245                 250                 255

Leu Glu Leu Tyr Arg His Ile Ala Gln His Gly Phe Asn Ala Ile Thr
            260                 265                 270

Gln Thr Ile Lys Cys Ser His Glu Arg Ser Val His Leu Phe Ile Asp
        275                 280                 285

Ser Leu Leu His Ala Gly Thr Gln Ser Met Ala Tyr Pro Cys Gly Asp
    290                 295                 300

Met Asn Ser Phe Ser Gln Gly Leu Cys Leu Ser Cys Lys Lys Gly Arg
305                 310                 315                 320

Cys Asn Thr Leu Gly Tyr His Val Arg Gln Glu Pro Arg Ser Lys Ser
                325                 330                 335

Lys Arg Leu Phe Leu Val Thr Arg Ala Gln Ser Pro Phe Lys Val Tyr
            340                 345                 350

His Tyr Gln Leu Lys Ile Gln Phe Ile Asn Gln Thr Glu Thr Pro Ile
        355                 360                 365

Gln Thr Thr Phe Thr Met Ser Leu Leu Gly Thr Lys Glu Lys Met Gln
    370                 375                 380

Lys Ile Pro Ile Thr Leu Gly Lys Gly Ile Ala Ser Asn Lys Thr Tyr
385                 390                 395                 400

Ser Phe Leu Ile Thr Leu Asp Val Asp Ile Gly Glu Leu Ile Met Ile
                405                 410                 415

Lys Phe Lys Trp Glu Asn Ser Ala Val Trp Ala Asn Val Trp Asp Thr
            420                 425                 430
```

-continued

```
Val Gln Thr Ile Ile Pro Trp Ser Thr Gly Pro Arg His Ser Gly Leu
        435                 440                 445

Val Leu Lys Thr Ile Arg Val Lys Ala Gly Glu Thr Gln Gln Arg Met
    450                 455                 460

Thr Phe Cys Ser Glu Asn Thr Asp Asp Leu Leu Leu Arg Pro Thr Gln
465                 470                 475                 480

Glu Lys Ile Phe Val Lys Cys Glu Ile Lys Ser Lys Thr Ser Lys Arg
                485                 490                 495

Lys Ile Arg
```

<210> SEQ ID NO 21
<211> LENGTH: 1346
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (10)...(1077)
<223> OTHER INFORMATION: Nucleotide sequence encoding paraoxonase 1 (PON1)

<400> SEQUENCE: 21

```
ccccgacc atg gcg aag ctg att gcg ctc acc ctc ttg ggg atg gga ctg     51
          Met Ala Lys Leu Ile Ala Leu Thr Leu Leu Gly Met Gly Leu
           1               5                  10

gca ctc ttc agg aac cac cag tct tct tac caa aca cga ctt aat gct      99
Ala Leu Phe Arg Asn His Gln Ser Ser Tyr Gln Thr Arg Leu Asn Ala
 15                  20                  25                  30

ctc cga gag gta caa ccc gta gaa ctt cct aac tgt aat tta gtt aaa     147
Leu Arg Glu Val Gln Pro Val Glu Leu Pro Asn Cys Asn Leu Val Lys
                35                  40                  45

gga atc gaa act ggc tct gaa gac atg gag ata ctg cct aat gga ctg     195
Gly Ile Glu Thr Gly Ser Glu Asp Met Glu Ile Leu Pro Asn Gly Leu
            50                  55                  60

gct ttc att agc tct gga tta aag tat cct gga ata aag agc ttc aac     243
Ala Phe Ile Ser Ser Gly Leu Lys Tyr Pro Gly Ile Lys Ser Phe Asn
        65                  70                  75

ccc aac agt cct gga aaa ata ctt ctg atg gac ctg aat gaa gaa gat     291
Pro Asn Ser Pro Gly Lys Ile Leu Leu Met Asp Leu Asn Glu Glu Asp
    80                  85                  90

cca aca gtg ttg gaa ttg ggg atc act gga agt aaa ttt gat gta tct     339
Pro Thr Val Leu Glu Leu Gly Ile Thr Gly Ser Lys Phe Asp Val Ser
 95                  100                 105                 110

tca ttt aac cct cat ggg att agc aca ttc aca gat gaa gat aat gcc     387
Ser Phe Asn Pro His Gly Ile Ser Thr Phe Thr Asp Glu Asp Asn Ala
                115                 120                 125

atg tac ctc ctg gtg gtg aac cat cca gat gcc aag tcc aca gtg gag     435
Met Tyr Leu Leu Val Val Asn His Pro Asp Ala Lys Ser Thr Val Glu
            130                 135                 140

ttg ttt aaa ttt caa gaa gaa gaa aaa tcg ctt ttg cat cta aaa acc     483
Leu Phe Lys Phe Gln Glu Glu Glu Lys Ser Leu Leu His Leu Lys Thr
        145                 150                 155

atc aga cat aaa ctt ctg cct aat ttg aat gat att gtt gct gtg gga     531
Ile Arg His Lys Leu Leu Pro Asn Leu Asn Asp Ile Val Ala Val Gly
    160                 165                 170

cct gag cac ttt tat ggc aca aat gat cac tat ttt ctt gac ccc tac     579
Pro Glu His Phe Tyr Gly Thr Asn Asp His Tyr Phe Leu Asp Pro Tyr
175                 180                 185                 190
```

-continued

```
tta caa tcc tgg gag atg tat ttg ggt tta gcg tgg tcg tat gtt gtc      627
Leu Gln Ser Trp Glu Met Tyr Leu Gly Leu Ala Trp Ser Tyr Val Val
                195                 200                 205

tac tat agt cca agt gaa gtt cga gtg gtg gca gaa gga ttt gat ttt      675
Tyr Tyr Ser Pro Ser Glu Val Arg Val Val Ala Glu Gly Phe Asp Phe
            210                 215                 220

gct aat gga atc aac att tca ccc gat ggc aag tat gtc tat ata gct      723
Ala Asn Gly Ile Asn Ile Ser Pro Asp Gly Lys Tyr Val Tyr Ile Ala
        225                 230                 235

gag ttg ctg gct cat aag att cat gtg tat gaa aag cat gct aat tgg      771
Glu Leu Leu Ala His Lys Ile His Val Tyr Glu Lys His Ala Asn Trp
    240                 245                 250

act tta act cca ttg aag tcc ctt gac ttt aat acc ctc gtg gat aac      819
Thr Leu Thr Pro Leu Lys Ser Leu Asp Phe Asn Thr Leu Val Asp Asn
255                 260                 265                 270

ata tct gtg gat cct gag aca gga gac ctt tgg gtt gga tgc cat ccc      867
Ile Ser Val Asp Pro Glu Thr Gly Asp Leu Trp Val Gly Cys His Pro
                275                 280                 285

aat ggc atg aaa atc ttc ttc tat gac tca gag aat cct cct gca tca      915
Asn Gly Met Lys Ile Phe Phe Tyr Asp Ser Glu Asn Pro Pro Ala Ser
            290                 295                 300

gag gtg ctt cga atc cag aac att cta aca gaa gaa cct aaa gtg aca      963
Glu Val Leu Arg Ile Gln Asn Ile Leu Thr Glu Glu Pro Lys Val Thr
        305                 310                 315

cag gtt tat gca gaa aat ggc aca gtg ttg caa ggc agt aca gtt gcc     1011
Gln Val Tyr Ala Glu Asn Gly Thr Val Leu Gln Gly Ser Thr Val Ala
    320                 325                 330

tct gtg tac aaa ggg aaa ctg ctg att ggc aca gtg ttt cac aaa gct     1059
Ser Val Tyr Lys Gly Lys Leu Leu Ile Gly Thr Val Phe His Lys Ala
335                 340                 345                 350

ctt tac tgt gag ctc taa cagaccgatt tgcacccatg ccatagaaac            1107
Leu Tyr Cys Glu Leu  *
                355

tgaggccatt atttcaaccg cttgccatat tccgaggacc cagtgttctt agctgaacaa   1167

tgaatgctga ccctaaatgt ggacatcatg aagcatcaaa gcactgttta actgggagtg   1227

atatgatgtg tagggctttt ttttgagaat acactatcaa atcagtcttg gaatacttga   1287

aaacctcatt taccataaaa atccttctca ctaaaatgga taaatcagtt aaaaaaaaa    1346


<210> SEQ ID NO 22
<211> LENGTH: 355
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 22

Met Ala Lys Leu Ile Ala Leu Thr Leu Leu Gly Met Gly Leu Ala Leu
 1               5                  10                  15

Phe Arg Asn His Gln Ser Ser Tyr Gln Thr Arg Leu Asn Ala Leu Arg
            20                  25                  30

Glu Val Gln Pro Val Glu Leu Pro Asn Cys Asn Leu Val Lys Gly Ile
        35                  40                  45

Glu Thr Gly Ser Glu Asp Met Glu Ile Leu Pro Asn Gly Leu Ala Phe
    50                  55                  60

Ile Ser Ser Gly Leu Lys Tyr Pro Gly Ile Lys Ser Phe Asn Pro Asn
65                  70                  75                  80
```

-continued

```
Ser Pro Gly Lys Ile Leu Leu Met Asp Leu Asn Glu Glu Asp Pro Thr
                85                  90                  95

Val Leu Glu Leu Gly Ile Thr Gly Ser Lys Phe Asp Val Ser Ser Phe
            100                 105                 110

Asn Pro His Gly Ile Ser Thr Phe Thr Asp Glu Asp Asn Ala Met Tyr
        115                 120                 125

Leu Leu Val Val Asn His Pro Asp Ala Lys Ser Thr Val Glu Leu Phe
    130                 135                 140

Lys Phe Gln Glu Glu Glu Lys Ser Leu Leu His Leu Lys Thr Ile Arg
145                 150                 155                 160

His Lys Leu Leu Pro Asn Leu Asn Asp Ile Val Ala Val Gly Pro Glu
                165                 170                 175

His Phe Tyr Gly Thr Asn Asp His Tyr Phe Leu Asp Pro Tyr Leu Gln
            180                 185                 190

Ser Trp Glu Met Tyr Leu Gly Leu Ala Trp Ser Tyr Val Val Tyr Tyr
        195                 200                 205

Ser Pro Ser Glu Val Arg Val Val Ala Glu Gly Phe Asp Phe Ala Asn
    210                 215                 220

Gly Ile Asn Ile Ser Pro Asp Gly Lys Tyr Val Tyr Ile Ala Glu Leu
225                 230                 235                 240

Leu Ala His Lys Ile His Val Tyr Glu Lys His Ala Asn Trp Thr Leu
                245                 250                 255

Thr Pro Leu Lys Ser Leu Asp Phe Asn Thr Leu Val Asp Asn Ile Ser
            260                 265                 270

Val Asp Pro Glu Thr Gly Asp Leu Trp Val Gly Cys His Pro Asn Gly
        275                 280                 285

Met Lys Ile Phe Phe Tyr Asp Ser Glu Asn Pro Pro Ala Ser Glu Val
    290                 295                 300

Leu Arg Ile Gln Asn Ile Leu Thr Glu Glu Pro Lys Val Thr Gln Val
305                 310                 315                 320

Tyr Ala Glu Asn Gly Thr Val Leu Gln Gly Ser Thr Val Ala Ser Val
                325                 330                 335

Tyr Lys Gly Lys Leu Leu Ile Gly Thr Val Phe His Lys Ala Leu Tyr
            340                 345                 350

Cys Glu Leu
        355


<210> SEQ ID NO 23
<211> LENGTH: 1570
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1097)
<223> OTHER INFORMATION: Nucleotide sequence encoding paraoxonase 2
      (PON2)

<400> SEQUENCE: 23

cgg agc gag gca gcg cgc ccg gct ccc gcg cca tgg ggc ggc tgg tgg       48
Arg Ser Glu Ala Ala Arg Pro Ala Pro Ala Pro Trp Gly Gly Trp Trp
 1               5                  10                  15

ctg tgg gct tgc tgg gga tcg cgc tgg cgc tcc tgg gcg aga ggc ttc       96
Leu Trp Ala Cys Trp Gly Ser Arg Trp Arg Ser Trp Ala Arg Gly Phe
            20                  25                  30
```

-continued

```
tgg cac tca gaa atc gac tta aag cct cca gag aag tag aat ctg tag      144
Trp His Ser Glu Ile Asp Leu Lys Pro Pro Glu Lys  *  Asn Leu  *
         35                  40                  45

acc ttc cac act gcc acc tga tta aag gaa ttg aag ctg gct ctg aag      192
Thr Phe His Thr Ala Thr  *  Leu Lys Glu Leu Lys Leu Ala Leu Lys
             50                  55                  60

ata ttg aca tac ttc cca atg gtc tgg ctt ttt tta gtg tgg gtc taa      240
Ile Leu Thr Tyr Phe Pro Met Val Trp Leu Phe Leu Val Trp Val  *
             65                  70                  75

aat tcc cag gac tcc aca gct ttg cac cag ata agc ctg gag gaa tac      288
Asn Ser Gln Asp Ser Thr Ala Leu His Gln Ile Ser Leu Glu Glu Tyr
             80                  85                  90

taa tga tgg atc taa aag aag aaa aac caa ggg cac ggg aat taa gaa      336
 *   *  Trp Ile  *  Lys Lys Lys Asn Gln Gly His Gly Asn  *  Glu
                95                  100

tca gtc gtg ggt ttg att tgg cct cat tca atc cac atg gca tca gca      384
Ser Val Val Gly Leu Ile Trp Pro His Ser Ile His Met Ala Ser Ala
105                 110                 115                 120

ctt tca tag aca acg atg aca cag ttt atc tct ttg ttg taa acc acc      432
Leu Ser  *  Thr Thr Met Thr Gln Phe Ile Ser Leu Leu  *  Thr Thr
                125                 130

cag aat tca aga ata cag tgg aaa ttt tta aat ttg aag aag cag aaa      480
Gln Asn Ser Arg Ile Gln Trp Lys Phe Leu Asn Leu Lys Lys Gln Lys
135                 140                 145                 150

att ctc tgt tgc atc tga aaa cag tca aac atg agc ttc ttc caa gtg      528
Ile Leu Cys Cys Ile  *  Lys Gln Ser Asn Met Ser Phe Phe Gln Val
                155                 160                 165

tga atg aca tca cag ctg ttg gac cgg cac att tct atg cca caa atg      576
 *  Met Thr Ser Gln Leu Leu Asp Arg His Ile Ser Met Pro Gln Met
               170                 175                 180

acc act act tct ctg atc ctt tct taa agt att tag aaa cat act tga      624
Thr Thr Thr Ser Leu Ile Leu Ser  *  Ser Ile  *  Lys His Thr  *
               185                 190

act tac act ggg caa atg ttg ttt act aca gtc caa atg aag tta aag      672
Thr Tyr Thr Gly Gln Met Leu Phe Thr Thr Val Gln Met Lys Leu Lys
    195                 200                 205

tgg tag cag aag gat ttg att cag caa atg gga tca ata ttt cac ctg      720
Trp  *  Gln Lys Asp Leu Ile Gln Gln Met Gly Ser Ile Phe His Leu
210                 215                 220

atg ata agt ata tct atg ttg ctg aca tat tgg ctc atg aaa ttc atg      768
Met Ile Ser Ile Ser Met Leu Leu Thr Tyr Trp Leu Met Lys Phe Met
225                 230                 235                 240

ttt tgg aaa aac aca cta ata tga att taa ctc agt tga agg tac ttg      816
Phe Trp Lys Asn Thr Leu Ile  *  Ile  *  Leu Ser  *  Arg Tyr Leu
                245                 250

agc tgg ata cac tgg tgg ata att tat cta ttg atc ctt cct cgg ggg      864
Ser Trp Ile His Trp Trp Ile Ile Tyr Leu Leu Ile Leu Pro Arg Gly
    255                 260                 265

aca tct ggg tag gct gtc atc cta atg gcc aga agc tct tcg tgt atg      912
Thr Ser Gly  *  Ala Val Ile Leu Met Ala Arg Ser Ser Ser Cys Met
270                 275                 280

acc cga aca atc ctc cct cgt cag agg ttc tcc gca tcc aga aca ttc      960
Thr Arg Thr Ile Leu Pro Arg Gln Arg Phe Ser Ala Ser Arg Thr Phe
285                 290                 295                 300

tat ctg aga agc cta cag tga cta cag ttt atg cca aca atg ggt ctg     1008
Tyr Leu Arg Ser Leu Gln  *  Leu Gln Phe Met Pro Thr Met Gly Leu
                305                 310                 315
```

-continued

```
ttc tcc aag gaa gtt ctg tag cct cag tgt atg atg gga agc tgc tca     1056
Phe Ser Lys Glu Val Leu  *  Pro Gln Cys Met Met Gly Ser Cys Ser
                320                     325                 330

tag gca ctt tat acc aca gag cct tgt att gtg aac tct aa attgtacttt   1107
 *  Ala Leu Tyr Thr Thr Glu Pro Cys Ile Val Asn Ser
                335                     340

tggcatgaaa gtgcgataac ttaacaatta attttctatg aattgctaat tctgagggaa   1167

tttaaccagc aacattgacc cagaaatgta tggcatgtgt agttaatttt attccagtaa   1227

ggaacggccc ttttagttct tagagcactt ttaacaaaaa aggaaaatga acaggttctt   1287

taaaatgcca agcaagggac agaaaagaaa gctgctttcg aataaagtga atacattttg   1347

cacaaagtaa gcctcacctt tgccttccaa ctgccagaac atggattcca ctgaaataga   1407

gtgaattata tttccttaaa atgtgagtga cctcacttct ggcactgtga ctactatggc   1467

tgtttagaac tactgataac gtattttgat gttttgtact tacatctttg tttaccatta   1527

aaaagttgga gttatattaa agactaacta aaatcccagt ttt                     1570


<210> SEQ ID NO 24
<211> LENGTH: 342
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 24

Arg Ser Glu Ala Ala Arg Pro Ala Pro Ala Pro Trp Gly Gly Trp Trp
 1               5                  10                  15

Leu Trp Ala Cys Trp Gly Ser Arg Trp Arg Ser Trp Ala Arg Gly Phe
            20                  25                  30

Trp His Ser Glu Ile Asp Leu Lys Pro Pro Glu Lys Asn Leu Thr Phe
        35                  40                  45

His Thr Ala Thr Leu Lys Glu Leu Lys Leu Ala Leu Lys Ile Leu Thr
    50                  55                  60

Tyr Phe Pro Met Val Trp Leu Phe Leu Val Trp Val Asn Ser Gln Asp
65                  70                  75                  80

Ser Thr Ala Leu His Gln Ile Ser Leu Glu Glu Tyr Trp Ile Lys Lys
                85                  90                  95

Lys Asn Gln Gly His Gly Asn Glu Ser Val Val Gly Leu Ile Trp Pro
            100                 105                 110

His Ser Ile His Met Ala Ser Ala Leu Ser Thr Thr Met Thr Gln Phe
        115                 120                 125

Ile Ser Leu Leu Thr Thr Gln Asn Ser Arg Ile Gln Trp Lys Phe Leu
    130                 135                 140

Asn Leu Lys Lys Gln Lys Ile Leu Cys Cys Ile Lys Gln Ser Asn Met
145                 150                 155                 160

Ser Phe Phe Gln Val Met Thr Ser Gln Leu Leu Asp Arg His Ile Ser
                165                 170                 175

Met Pro Gln Met Thr Thr Thr Ser Leu Ile Leu Ser Ser Ile Lys His
            180                 185                 190

Thr Thr Tyr Thr Gly Gln Met Leu Phe Thr Thr Val Gln Met Lys Leu
        195                 200                 205

Lys Trp Gln Lys Asp Leu Ile Gln Gln Met Gly Ser Ile Phe His Leu
    210                 215                 220

Met Ile Ser Ile Ser Met Leu Leu Thr Tyr Trp Leu Met Lys Phe Met
225                 230                 235                 240
```

-continued

```
Phe Trp Lys Asn Thr Leu Ile Ile Leu Ser Arg Tyr Leu Ser Trp Ile
                245                 250                 255

His Trp Trp Ile Ile Tyr Leu Leu Ile Leu Pro Arg Gly Thr Ser Gly
            260                 265                 270

Ala Val Ile Leu Met Ala Arg Ser Ser Ser Cys Met Thr Arg Thr Ile
        275                 280                 285

Leu Pro Arg Gln Arg Phe Ser Ala Ser Arg Thr Phe Tyr Leu Arg Ser
    290                 295                 300

Leu Gln Leu Gln Phe Met Pro Thr Met Gly Leu Phe Ser Lys Glu Val
305                 310                 315                 320

Leu Pro Gln Cys Met Met Gly Ser Cys Ser Ala Leu Tyr Thr Thr Glu
                325                 330                 335

Pro Cys Ile Val Asn Ser
            340
```

<210> SEQ ID NO 25
<211> LENGTH: 533
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (47)...(346)
<223> OTHER INFORMATION: Nucleotide sequence encoding apolipoprotein C-III(APOC3)

<400> SEQUENCE: 25

```
tgctcagttc atccctagag gcagctgctc caggaacaga ggtgcc atg cag ccc        55
                                                    Met Gln Pro
                                                     1

cgg gta ctc ctt gtt gtt gcc ctc ctg gcg ctc ctg gcc tct gcc cga      103
Arg Val Leu Leu Val Val Ala Leu Leu Ala Leu Leu Ala Ser Ala Arg
  5                  10                  15

gct tca gag gcc gag gat gcc tcc ctt ctc agc ttc atg cag ggt tac      151
Ala Ser Glu Ala Glu Asp Ala Ser Leu Leu Ser Phe Met Gln Gly Tyr
 20                  25                  30                  35

atg aag cac gcc acc aag acc gcc aag gat gca ctg agc agc gtg cag      199
Met Lys His Ala Thr Lys Thr Ala Lys Asp Ala Leu Ser Ser Val Gln
                 40                  45                  50

gag tcc cag gtg gcc cag cag gcc agg ggc tgg gtg acc gat ggc ttc      247
Glu Ser Gln Val Ala Gln Gln Ala Arg Gly Trp Val Thr Asp Gly Phe
             55                  60                  65

agt tcc ctg aaa gac tac tgg agc acc gtt aag gac aag ttc tct gag      295
Ser Ser Leu Lys Asp Tyr Trp Ser Thr Val Lys Asp Lys Phe Ser Glu
         70                  75                  80

ttc tgg gat ttg gac cct gag gtc aga cca act tca gcc gtg gct gcc      343
Phe Trp Asp Leu Asp Pro Glu Val Arg Pro Thr Ser Ala Val Ala Ala
 85                  90                  95

tga gacctcaata ccccaagtcc acctgcctat ccatcctgcg agctccttgg           396
 *
gtcctgcaat ctccagggct gcccctgtag gttgcttaaa agggacagta ttctcagtgc    456

tctcctaccc cacctcatgc ctggcccccc tccaggcatg ctggcctccc aataaagctg    516

gacaagaagc tgctatg                                                  533
```

<210> SEQ ID NO 26
<211> LENGTH: 99

-continued

<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 26

Met Gln Pro Arg Val Leu Leu Val Val Ala Leu Leu Ala Leu Leu Ala
 1   5   10   15

Ser Ala Arg Ala Ser Glu Ala Glu Asp Ala Ser Leu Leu Ser Phe Met
            20   25   30

Gln Gly Tyr Met Lys His Ala Thr Lys Thr Ala Lys Asp Ala Leu Ser
        35   40   45

Ser Val Gln Glu Ser Gln Val Ala Gln Gln Ala Arg Gly Trp Val Thr
    50   55   60

Asp Gly Phe Ser Ser Leu Lys Asp Tyr Trp Ser Thr Val Lys Asp Lys
65   70   75   80

Phe Ser Glu Phe Trp Asp Leu Asp Pro Glu Val Arg Pro Thr Ser Ala
                85   90   95

Val Ala Ala

<210> SEQ ID NO 27
<211> LENGTH: 8925
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (5020)...(6162)
<223> OTHER INFORMATION: Nucleotide encoding ATP-binding cassette
      (ABC1)
<223> OTHER INFORMATION: n= a or g or c or t

<400> SEQUENCE: 27

ctcagtgtca gctgctgctg gaagtggcct ggcctctatt tatcttcctg atcctgatct 60

ctgttcggct gagctaccca ccctatgaac aacatgaatg ccattttcca aataaagcca 120

tgccctctgc aggaacactt ccttgggttc aggggattat ctgtaatgcc aacaacccct 180

gtttccgtta cccgactcct ggggaggctc ccggagttgt tggaaacttt aacaaatcca 240

ttgtggctcg cctgttctca gatgctcgga ggcttctttt atacagccag aaagacacca 300

gcatgaagga catgcgcaaa gttctgagaa cattacagca gatcaagaaa tccagctcaa 360

acttgaagct tcaagatttc ctggtggaca atgaaacctt ctctgggttc ctgtatcaca 420

acctctctct cccaaagtct actgtggaca agatgctgag ggctgatgtc attctccaca 480

aggtattttt gcaaggctac cagttacatt tgacaagtct gtgcaatgga tcaaaatcag 540

aagagatgat tcaacttggt gaccaagaag tttctgagct ttgtggccta ccaagggaga 600

aactggctgc agcagagcga gtacttcgtt ccaacatgga catcctgaag ccaatcctga 660

gaacactaaa ctctacatct cccttcccga gcaaggagct ggctgaagcc acaaaaacat 720

tgctgcatag tcttgggact ctggcccagg agctgttcag catgagaagc tggagtgaca 780

tgcgacagga ggtgatgttt ctgaccaatg tgaacagctc cagctcctcc acccaaatct 840

accaggctgt gtctcgtatt gtctgcgggc atcccgaggg agggggggctg aagatcaagt 900

ctctcaactg gtatgaggac aacaactaca aagccctctt tggaggcaat ggcactgagg 960

aagatgctga aaccttctat gacaactcta caactcctta ctgcaatgat ttgatgaaga 1020

atttggagtc tagtcctctt tcccgcatta tctggaaagc tctgaagccg ctgctcgttg 1080

ggaagatcct gtatacacct gacactccag ccacaaggca ggtcatggct gaggtgaaca 1140

-continued

agaccttcca ggaactggct gtgttccatg atctggaagg catgtgggag gaactcagcc 1200

ccaagatctg gaccttcatg gagaacagcc aagaaatgga ccttgtccgg atgctgttgg 1260

acagcaggga caatgaccac ttttgggaac agcagttgga tggcttagat tggacagccc 1320

aagacatcgt ggcgtttttg gccaagcacc cagaggatgt ccagtccagt aatggttctg 1380

tgtacacctg gagagaagct ttcaacgaga ctaaccaggc aatccggacc atatctcgct 1440

tcatggagtg tgtcaacctg aacaagctag aacccatagc aacagaagtc tggctcatca 1500

acaagtccat ggagctgctg gatgagagga agttctgggc tggtattgtg ttcactggaa 1560

ttactccagg cagcattgag ctgccccatc atgtcaagta caagatccga atggacattg 1620

acaatgtgga gaggacaaat aaaatcaagg atgggtactg ggaccctggt cctcgagctg 1680

acccctttga ggacatgcgg tacgtctggg ggggcttcgc ctacttgcag gatgtggtgg 1740

agcaggcaat catcagggtg ctgacgggca ccgagaagaa aactggtgtc tatatgcaac 1800

agatgcccta tccctgttac gttgatgaca tctttctgcg ggtgatgagc cggtcaatgc 1860

ccctcttcat gacgctggcc tggatttact cagtggctgt gatcatcaag ggcatcgtgt 1920

atgagaagga ggcacggctg aaagagacca tgcggatcat gggcctggac aacagcatcc 1980

tctggtttag ctggttcatt agtagcctca ttcctcttct tgtgagcgct ggcctgctag 2040

tggtcatcct gaagttagga aacctgctgc cctacagtga tcccagcgtg gtgtttgtct 2100

tcctgtccgt gtttgctgtg gtgacaatcc tgcagtgctt cctgattagc acactcttct 2160

ccagagccaa cctggcagca gcctgtgggg gcatcatcta cttcacgctg tacctgccct 2220

acgtcctgtg tgtggcatgg caggactacg tgggcttcac actcaagatc ttcgctagcc 2280

tgctgtctcc tgtggctttt gggtttggct gtgagtactt tgccctttt gaggagcagg 2340

gcattggagt gcagtgggac aacctgtttg agagtcctgt ggaggaagat ggcttcaatc 2400

tcaccacttc ggtctccatg atgctgtttg acaccttcct ctatggggtg atgacctggt 2460

acattgaggc tgtctttcca ggccagtacg gaattcccag gccctggtat tttccttgca 2520

ccaagtccta ctggtttggc gaggaaagtg atgagaagag ccaccctggt tccaaccaga 2580

agagaatatc agaaatctgc atggaggagg aacccaccca cttgaagctg ggcgtgtcca 2640

ttcagaacct ggtaaaagtc taccgagatg ggatgaaggt ggctgtcgat ggcctggcac 2700

tgaattttta tgagggccag atcacctcct tcctgggcca caatggagcg gggaagacga 2760

ccaccatgtc aatcctgacc gggttgttcc ccccgacctc gggcaccgcc tacatcctgg 2820

gaaaagacat tcgctctgag atgagcacca tccggcagaa cctgggggtc tgtccccagc 2880

ataacgtgct gtttgacatg ctgactgtcg aagaacacat ctggttctat gcccgcttga 2940

aagggctctc tgagaagcac gtgaaggcgg agatggagca gatggccctg gatgttggtt 3000

tgccatcaag caagctgaaa agcaaaacaa gccagctgtc aggtggaatg cagagaaagc 3060

tatctgtggc cttggccttt gtcgggggat ctaaggttgt cattctggat gaacccacag 3120

ctggtgtgga cccttactcc cgcaggggaa tatgggagct gctgctgaaa taccgacaag 3180

gccgcaccat tattctctct acacaccaca tggatgaagc ggacgtcctg ggggacagga 3240

ttgccatcat ctcccatggg aagctgtgct gtgtgggctc ctccctgttt ctgaagaacc 3300

agctgggaac aggctactac ctgaccttgg tcaagaaaga tgtggaatcc tccctcagtt 3360

cctgcagaaa cagtagtagc actgtgtcat acctgaaaaa ggaggacagt gtttctcaga 3420

-continued

```
gcagttctga tgctggcctg ggcagcgacc atgagagtga cacgctgacc atcgatgtct   3480

ctgctatctc caacctcatc aggaagcatg tgtctgaagc ccggctggtg gaagacatag   3540

ggcatgagct gacctatgtg ctgccatatg aagctgctaa ggagggagcc tttgtggaac   3600

tctttcatga gattgatgac cggctctcag acctgggcat ttctagttat ggcatctcag   3660

agacgaccct ggaagaaata ttcctcaagg tggccgaaga gagtggggtg gatgctgaga   3720

cctcagatgg taccttgcca gcaagacgaa acaggcgggc cttcggggac aagcagagct   3780

gtcttcgccc gttcactgaa gatgatgctg ctgatccaaa tgattctgac atagacccag   3840

aatccagaga gacagacttg ctcagtggga tggatggcaa agggtcctac caggtgaaag   3900

gctggaaact tacacagcaa cagtttgtgg ccctttgtg gaagagactg ctaattgcca   3960

gacggagtcg gaaaggattt tttgctcaga ttgtcttgcc agctgtgttt gtctgcattg   4020

ccttgtgtt cagcctgatc gtgccaccct ttggcaagta ccccagcctg gaacttcagc   4080

cctggatgta caacgaacag tacacatttg tcagcaatga tgctcctgag gacacgggaa   4140

ccctggaact cttaaacgcc ctcaccaaag accctggctt cgggacccgc tgtatggaag   4200

gaaacccaat cccagacacg ccctgccagg caggggagga agagtggacc actgccccag   4260

ttccccagac catcatggac ctcttccaga atgggaactg gacaatgcag aacccttcac   4320

ctgcatgcca gtgtagcagc gacaaaatca agaagatgct gcctgtgtgt cccccagggg   4380

caggggggct gcctcctcca caaagaaaac aaaacactgc agatatcctt caggacctga   4440

caggaagaaa catttcggat tatctggtga agacgtatgt gcagatcata gccaaaagct   4500

taaagaacaa gatctgggtg aatgagttta ggtatggcgg cttttccctg ggtgtcagta   4560

atactcaagc acttcctccg agtcaagaag ttaatgatgc catcaaacaa atgaagaaac   4620

acctaaagct ggccaaggac agttctgcag atcgatttct caacagcttg ggaagattta   4680

tgacaggact ggacaccaaa aataatgtca aggtgtggtt caataacaag ggctggcatg   4740

caatcagctc tttcctgaat gtcatcaaca atgccattct ccgggccaac ctgcaaaagg   4800

gagagaaccc tagccattat ggaattactg ctttcaatca tcccctgaat ctcaccaagc   4860

agcagctctc agaggtggct cggatgacca catcagtgga tgtccttgtg tccatctgtg   4920

tcatctttgc aatgtccttc gtcccagcca gctttgtcgt attcctgatc caggagcggg   4980

tcagcaaagc aaaacacctg cagttcatca gtggagtga agc ctg tca tct act      5034
                                            Ser Leu Ser Ser Thr
                                             1               5

ggc tct cta att ttg tct ggg ata tgt gca att aag ttg ttt cca ann      5082
Gly Ser Leu Ile Leu Ser Gly Ile Cys Ala Ile Lys Leu Phe Pro Xaa
                 10                  15                  20

nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn      5130
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
             25                  30                  35

nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn nnn      5178
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
         40                  45                  50

nta atc ttt cct ttt cag tgc ttt ggg ctc ctg gga gtt aat ggg gct      5226
Xaa Ile Phe Pro Phe Gln Cys Phe Gly Leu Leu Gly Val Asn Gly Ala
     55                  60                  65

gga aaa tca tca act ttc aag atg tta aca gga gat acc act gtt acc      5274
Gly Lys Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr Val Thr
 70                  75                  80                  85
```

-continued

```
aga gga gat gct ttc ctt aac att tgc agt atc tta tca aac atc cat     5322
Arg Gly Asp Ala Phe Leu Asn Ile Cys Ser Ile Leu Ser Asn Ile His
                 90                  95                  100

gaa gta cat cag aac atg ggc tac tgc cct cag ttt gat gcc atc aca     5370
Glu Val His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala Ile Thr
            105                 110                 115

gag ctg ttg act ggg aga gaa cac gtg gag ttc ttt gcc ctt ttg aga     5418
Glu Leu Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu Leu Arg
        120                 125                 130

gga gtc cca gag aaa gaa gtt ggc aag gtt ggt gag tgg gcg att cgg     5466
Gly Val Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala Ile Arg
    135                 140                 145

aaa ctg ggc ctc gtg aag tat gga gaa aaa tat gct ggt aac tat agt     5514
Lys Leu Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn Tyr Ser
150                 155                 160                 165

gga ggc aac aaa cgc aag ctc tct aca gcc atg gct ttg atc ggc ggg     5562
Gly Gly Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile Gly Gly
                170                 175                 180

cct cct gtg gtg ttt ctg gat gaa ccc acc aca ggc atg gat ccc aaa     5610
Pro Pro Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp Pro Lys
            185                 190                 195

gcc cgg cgg ttc ttg tgg aat tgt gcc cta agt gtt gtc aag gag ggg     5658
Ala Arg Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys Glu Gly
        200                 205                 210

aga tca gta gtg ctt aca tct cat agt atg gaa gaa tgt gaa gct ctt     5706
Arg Ser Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu Ala Leu
    215                 220                 225

tgc act agg atg gca atc atg gtc aat gga agg ttc agg tgc ctt ggc     5754
Cys Thr Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys Leu Gly
230                 235                 240                 245

agt gtc cag cat cta aaa aat agg ttt gga gat ggt tat aca ata gtt     5802
Ser Val Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr Ile Val
                250                 255                 260

gta cga ata gca ggg tcc aac ccg gac ctg aag cct gtc cag gat ttc     5850
Val Arg Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln Asp Phe
            265                 270                 275

ttt gga ctt gca ttt cct gga agt gtt cta aaa gag aaa cac cgg aac     5898
Phe Gly Leu Ala Phe Pro Gly Ser Val Leu Lys Glu Lys His Arg Asn
        280                 285                 290

atg cta caa tac cag ctt cca tct tca tta tct tct ctg gcc agg ata     5946
Met Leu Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala Arg Ile
    295                 300                 305

ttc agc atc ctc tcc cag agc aaa aag cga ctc cac ata gaa gac tac     5994
Phe Ser Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu Asp Tyr
310                 315                 320                 325

tct gtt tct cag aca aca ctt gac caa gta ttt gtg aac ttt gcc aag     6042
Ser Val Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe Ala Lys
                330                 335                 340

gac caa agt gat gat gac cac tta aaa gac ctc tca tta cac aaa aac     6090
Asp Gln Ser Asp Asp Asp His Leu Lys Asp Leu Ser Leu His Lys Asn
            345                 350                 355

cag aca gta gtg gac gtt gca gtt ctc aca tct ttt cta cag gat gag     6138
Gln Thr Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln Asp Glu
        360                 365                 370

aaa gtg aaa gaa agc tat gta tga agaatcctgt tcatacgggg tggctgaaag    6192
Lys Val Lys Glu Ser Tyr Val  *
    375                 380
```

-continued

taaagaggaa ctagactttc ctttgcacca tgtgaagtgt tgtggagaaa agagccagaa 6252

gttgatgtgg gaagaagtaa actggatact gtactgatac tattcaatgc aatgcaattc 6312

aatgcaatga aaacaaaatt ccattacagg ggcagtgcct ttgtagccta tgtcttgtat 6372

ggctctcaag tgaaagactt gaatttagtt ttttacctat acctatgtga aactctatta 6432

tggaacccaa tggacatatg ggtttgaact cacacttttt ttttttttt tgttcctgtg 6492

tattctcatt ggggttgcaa caataattca tcaagtaatc atggccagcg attattgatc 6552

aaaatcaaaa ggtaatgcac atcctcattc actaagccat gccatgccca ggagactggt 6612

ttcccggtga cacatccatt gctggcaatg agtgtgccag agttattagt gccaagtttt 6672

tcagaaagtt tgaagcacca tggtgtgtca tgctcacttt tgtgaaagct gctctgctca 6732

gagtctatca acattgaata tcagttgaca gaatggtgcc atgcgtggct aacatcctgc 6792

tttgattccc tctgataagc tgttctggtg gcagtaacat gcaacaaaaa tgtgggtgtc 6852

tccaggcacg ggaaacttgg ttccattgtt atattgtcct atgcttcgag ccatgggtct 6912

acagggtcat ccttatgaga ctcttaaata tacttagatc ctggtaagag gcaaagaatc 6972

aacagccaaa ctgctggggc tgcaagctgc tgaagccagg gcatgggatt aaagagattg 7032

tgcgttcaaa cctagggaag cctgtgccca tttgtcctga ctgtctgcta acatggtaca 7092

ctgcatctca agatgtttat ctgacacaag tgtattattt ctggcttttt gaattaatct 7152

agaaaatgaa aagatggagt tgtattttga caaaaatgtt tgtacttttt aatgttattt 7212

ggaattttaa gttctatcag tgacttctga atccttagaa tggcctcttt gtagaaccct 7272

gtggtataga ggagtatggc cactgcccca ctatttttat tttcttatgt aagtttgcat 7332

atcagtcatg actagtgcct agaaagcaat gtgatggtca ggatctcatg acattatatt 7392

tgagtttctt tcagatcatt taggatactc ttaatctcac ttcatcaatc aaatattttt 7452

tgagtgtatg ctgtagctga aagagtatgt acgtacgtat aagactagag agatattaag 7512

tctcagtaca cttcctgtgc catgttattc agctcactgg tttacaaata taggttgtct 7572

tgtggttgta ggagcccact gtaacaatac tgggcagcct ttttttttct ttttttaatt 7632

gcaacaatgc aaaagccaag aaagtataag ggtcacaagt ctaaacaatg aattcttcaa 7692

cagggaaaac agctagcttg aaaacttgct gaaaaacaca acttgtgttt atggcattta 7752

gtaccttcaa ataattggct ttgcagatat tggatacccc attaaatctg acagtctcaa 7812

atttttcatc tcttcaatca ctagtcaaga aaaatataaa aacaacaaat acttccatat 7872

ggagcatttt tcagagtttt ctaacccagt cttatttttc tagtcagtaa acatttgtaa 7932

aaatactgtt tcactaatac ttactgttaa ctgtcttgag agaaaagaaa aatatgagag 7992

aactattgtt tggggaagtt caagtgatct ttcaatatca ttactaactt cttccacttt 8052

ttccagaatt tgaatattaa cgctaaaggt gtaagacttc agatttcaaa ttaatctttc 8112

tatatttttt aaatttacag aatattatat aacccactgc tgaaaaagaa aaaaatgatt 8172

gttttagaag ttaaagtcaa tattgatttt aaatataagt aatgaaggca tatttccaat 8232

aactagtgat atggcatcgt tgcattttac agtatcttca aaaatacaga atttatagaa 8292

taatttctcc tcatttaata tttttcaaaa tcaaagttat ggtttcctca ttttactaaa 8352

atcgtattct aattcttcat tatagtaaat ctatgagcaa ctccttactt cggttcctct 8412

gatttcaagg ccatatttta aaaaatcaaa aggcactgtg aactattttg aagaaaacac 8472

-continued

```
aacattttaa tacagattga aaggacctct tctgaagcta gaaacaatct atagttatac   8532

atcttcatta atactgtgtt acctttaaa atagtaattt tttacatttt cctgtgtaaa   8592

cctaattgtg gtagaaattt ttaccaactc tatactcaat caagcaaaat ttctgtatat   8652

tccctgtgga atgtacctat gtgagtttca gaaattctca aaatacgtgt tcaaaaattt   8712

ctgcttttgc atctttggga cacctcagaa aacttattaa caactgtgaa tatgagaaat   8772

acagaagaaa ataataagcc ctctatacat aaatgcccag cacaattcat tgttaaaaaa   8832

caaccaaacc tcacactact gtatttcatt atctgtactg aaagcaaatg ctttgtgact   8892

attaaatgtt gcacatcatt cattcactgt ata                                8925
```

<210> SEQ ID NO 28
<211> LENGTH: 380
<212> TYPE: PRT
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: UNSURE
<222> LOCATION: (21)...(54)
<223> OTHER INFORMATION: Xaa = unknown

<400> SEQUENCE: 28

```
Ser Leu Ser Ser Thr Gly Ser Leu Ile Leu Ser Gly Ile Cys Ala Ile
 1               5                  10                  15

Lys Leu Phe Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
            20                  25                  30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
        35                  40                  45

Xaa Xaa Xaa Xaa Xaa Xaa Ile Phe Pro Phe Gln Cys Phe Gly Leu Leu
    50                  55                  60

Gly Val Asn Gly Ala Gly Lys Ser Ser Thr Phe Lys Met Leu Thr Gly
65                  70                  75                  80

Asp Thr Thr Val Thr Arg Gly Asp Ala Phe Leu Asn Ile Cys Ser Ile
                85                  90                  95

Leu Ser Asn Ile His Glu Val His Gln Asn Met Gly Tyr Cys Pro Gln
            100                 105                 110

Phe Asp Ala Ile Thr Glu Leu Leu Thr Gly Arg Glu His Val Glu Phe
        115                 120                 125

Phe Ala Leu Leu Arg Gly Val Pro Glu Lys Glu Val Gly Lys Val Gly
    130                 135                 140

Glu Trp Ala Ile Arg Lys Leu Gly Leu Val Lys Tyr Gly Glu Lys Tyr
145                 150                 155                 160

Ala Gly Asn Tyr Ser Gly Gly Asn Lys Arg Lys Leu Ser Thr Ala Met
                165                 170                 175

Ala Leu Ile Gly Gly Pro Pro Val Val Phe Leu Asp Glu Pro Thr Thr
            180                 185                 190

Gly Met Asp Pro Lys Ala Arg Arg Phe Leu Trp Asn Cys Ala Leu Ser
        195                 200                 205

Val Val Lys Glu Gly Arg Ser Val Val Leu Thr Ser His Ser Met Glu
    210                 215                 220

Glu Cys Glu Ala Leu Cys Thr Arg Met Ala Ile Met Val Asn Gly Arg
225                 230                 235                 240

Phe Arg Cys Leu Gly Ser Val Gln His Leu Lys Asn Arg Phe Gly Asp
                245                 250                 255
```

-continued

```
Gly Tyr Thr Ile Val Val Arg Ile Ala Gly Ser Asn Pro Asp Leu Lys
            260                 265                 270

Pro Val Gln Asp Phe Phe Gly Leu Ala Phe Pro Gly Ser Val Leu Lys
        275                 280                 285

Glu Lys His Arg Asn Met Leu Gln Tyr Gln Leu Pro Ser Ser Leu Ser
    290                 295                 300

Ser Leu Ala Arg Ile Phe Ser Ile Leu Ser Gln Ser Lys Lys Arg Leu
305                 310                 315                 320

His Ile Glu Asp Tyr Ser Val Ser Gln Thr Thr Leu Asp Gln Val Phe
                325                 330                 335

Val Asn Phe Ala Lys Asp Gln Ser Asp Asp Asp His Leu Lys Asp Leu
            340                 345                 350

Ser Leu His Lys Asn Gln Thr Val Val Asp Val Ala Val Leu Thr Ser
        355                 360                 365

Phe Leu Gln Asp Glu Lys Val Lys Glu Ser Tyr Val
    370                 375                 380


<210> SEQ ID NO 29
<211> LENGTH: 897
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (39)...(842)
<223> OTHER INFORMATION: Nucleotide sequence encoding apolipoprotein A-1
      (APOA1)

<400> SEQUENCE: 29

agagactgcg agaaggaggt cccccacggc ccttcagg atg aaa gct gcg gtg ctg     56
                                          Met Lys Ala Ala Val Leu
                                           1               5

acc ttg gcc gtg ctc ttc ctg acg ggg agc cag gct cgg cat ttc tgg      104
Thr Leu Ala Val Leu Phe Leu Thr Gly Ser Gln Ala Arg His Phe Trp
             10                  15                  20

cag caa gat gaa ccc ccc cag agc ccc tgg gat cga gtg aag gac ctg      152
Gln Gln Asp Glu Pro Pro Gln Ser Pro Trp Asp Arg Val Lys Asp Leu
         25                  30                  35

gcc act gtg tac gtg gat gtg ctc aaa gac agc ggc aga gac tat gtg      200
Ala Thr Val Tyr Val Asp Val Leu Lys Asp Ser Gly Arg Asp Tyr Val
     40                  45                  50

tcc cag ttt gaa ggc tcc gcc ttg gga aaa cag cta aac cta aag ctc      248
Ser Gln Phe Glu Gly Ser Ala Leu Gly Lys Gln Leu Asn Leu Lys Leu
 55                  60                  65                  70

ctt gac aac tgg gac agc gtg acc tcc acc ttc agc aag ctg cgc gaa      296
Leu Asp Asn Trp Asp Ser Val Thr Ser Thr Phe Ser Lys Leu Arg Glu
                 75                  80                  85

cag ctc ggc cct gtg acc cag gag ttc tgg gat aac ctg gaa aag gag      344
Gln Leu Gly Pro Val Thr Gln Glu Phe Trp Asp Asn Leu Glu Lys Glu
             90                  95                  100

aca gag ggc ctg agg cag gag atg agc aag gat ctg gag gag gtg aag      392
Thr Glu Gly Leu Arg Gln Glu Met Ser Lys Asp Leu Glu Glu Val Lys
         105                 110                 115

gcc aag gtg cag ccc tac ctg gac gac ttc cag aag aag tgg cag gag      440
Ala Lys Val Gln Pro Tyr Leu Asp Asp Phe Gln Lys Lys Trp Gln Glu
     120                 125                 130
```

-continued

```
gag atg gag ctc tac cgc cag aag gtg gag ccg ctg cgc gca gag ctc      488
Glu Met Glu Leu Tyr Arg Gln Lys Val Glu Pro Leu Arg Ala Glu Leu
135                 140                 145                 150

caa gag ggc gcg cgc cag aag ctg cac gag ctg caa gag aag ctg agc      536
Gln Glu Gly Ala Arg Gln Lys Leu His Glu Leu Gln Glu Lys Leu Ser
                155                 160                 165

cca ctg ggc gag gag atg cgc gac cgc gcg cgc gcc cat gtg gac gcg      584
Pro Leu Gly Glu Glu Met Arg Asp Arg Ala Arg Ala His Val Asp Ala
            170                 175                 180

ctg cgc acg cat ctg gcc ccc tac agc gac gag ctg cgc cag cgc ttg      632
Leu Arg Thr His Leu Ala Pro Tyr Ser Asp Glu Leu Arg Gln Arg Leu
        185                 190                 195

gcc gcg cgc ctt gag gct ctc aag gag aac ggc ggc gcc aga ctg gcc      680
Ala Ala Arg Leu Glu Ala Leu Lys Glu Asn Gly Gly Ala Arg Leu Ala
    200                 205                 210

gag tac cac gcc aag gcc acc gag cat ctg agc acg ctc agc gag aag      728
Glu Tyr His Ala Lys Ala Thr Glu His Leu Ser Thr Leu Ser Glu Lys
215                 220                 225                 230

gcc aag ccc gcg ctc gag gac ctc cgc caa ggc ctg ctg ccc gtg ctg      776
Ala Lys Pro Ala Leu Glu Asp Leu Arg Gln Gly Leu Leu Pro Val Leu
                235                 240                 245

gag agc ttc aag gtc agc ttc ctg agc gct ctc gag gag tac act aag      824
Glu Ser Phe Lys Val Ser Phe Leu Ser Ala Leu Glu Glu Tyr Thr Lys
            250                 255                 260

aag ctc aac acc cag tga ggcgcccgcc gccgcccccc ttcccggtgc            872
Lys Leu Asn Thr Gln  *
        265

tcagaataaa cgtttccaaa gtggg                                        897


<210> SEQ ID NO 30
<211> LENGTH: 267
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 30

Met Lys Ala Ala Val Leu Thr Leu Ala Val Leu Phe Leu Thr Gly Ser
 1               5                  10                  15

Gln Ala Arg His Phe Trp Gln Gln Asp Glu Pro Pro Gln Ser Pro Trp
            20                  25                  30

Asp Arg Val Lys Asp Leu Ala Thr Val Tyr Val Asp Val Leu Lys Asp
        35                  40                  45

Ser Gly Arg Asp Tyr Val Ser Gln Phe Glu Gly Ser Ala Leu Gly Lys
    50                  55                  60

Gln Leu Asn Leu Lys Leu Leu Asp Asn Trp Asp Ser Val Thr Ser Thr
65                  70                  75                  80

Phe Ser Lys Leu Arg Glu Gln Leu Gly Pro Val Thr Gln Glu Phe Trp
                85                  90                  95

Asp Asn Leu Glu Lys Glu Thr Glu Gly Leu Arg Gln Glu Met Ser Lys
            100                 105                 110

Asp Leu Glu Glu Val Lys Ala Lys Val Gln Pro Tyr Leu Asp Asp Phe
        115                 120                 125

Gln Lys Lys Trp Gln Glu Glu Met Glu Leu Tyr Arg Gln Lys Val Glu
    130                 135                 140

Pro Leu Arg Ala Glu Leu Gln Glu Gly Ala Arg Gln Lys Leu His Glu
145                 150                 155                 160
```

-continued

```
Leu Gln Glu Lys Leu Ser Pro Leu Gly Glu Glu Met Arg Asp Arg Ala
                165                 170                 175

Arg Ala His Val Asp Ala Leu Arg Thr His Leu Ala Pro Tyr Ser Asp
            180                 185                 190

Glu Leu Arg Gln Arg Leu Ala Ala Arg Leu Glu Ala Leu Lys Glu Asn
        195                 200                 205

Gly Gly Ala Arg Leu Ala Glu Tyr His Ala Lys Ala Thr Glu His Leu
    210                 215                 220

Ser Thr Leu Ser Glu Lys Ala Lys Pro Ala Leu Glu Asp Leu Arg Gln
225                 230                 235                 240

Gly Leu Leu Pro Val Leu Glu Ser Phe Lys Val Ser Phe Leu Ser Ala
                245                 250                 255

Leu Glu Glu Tyr Thr Lys Lys Leu Asn Thr Gln
            260                 265


<210> SEQ ID NO 31
<211> LENGTH: 14121
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (129)...(13820)
<223> OTHER INFORMATION: Nucleotide sequence encoding apolipoprotein B
      (APOB)

<400> SEQUENCE: 31

attcccaccg ggacctgcgg ggctgagtgc ccttctcggt tgctgccgct gaggagcccg     60

cccagccagc cagggccgcg aggccgaggc caggccgcag cccaggagcc gccccaccgc    120

agctggcg atg gac ccg ccg agg ccc gcg ctg ctg gcg ctg ctg gcg ctg     170
         Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu
          1               5                  10

cct gcg ctg ctg ctg ctg ctg ctg gcg ggc gcc agg gcc gaa gag gaa      218
Pro Ala Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu
 15                  20                  25                  30

atg ctg gaa aat gtc agc ctg gtc tgt cca aaa gat gcg acc cga ttc      266
Met Leu Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe
                35                  40                  45

aag cac ctc cgg aag tac aca tac aac tat gag gct gag agt tcc agt      314
Lys His Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser
            50                  55                  60

gga gtc cct ggg act gct gat tca aga agt gcc acc agg atc aac tgc      362
Gly Val Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys
         65                  70                  75

aag gtt gag ctg gag gtt ccc cag ctc tgc agc ttc atc ctg aag acc      410
Lys Val Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr
     80                  85                  90

agc cag tgc acc ctg aaa gag gtg tat ggc ttc aac cct gag ggc aaa      458
Ser Gln Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys
 95                  100                 105                 110

gcc ttg ctg aag aaa acc aag aac tct gag gag ttt gct gca gcc atg      506
Ala Leu Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Ala Met
                115                 120                 125

tcc agg tat gag ctc aag ctg gcc att cca gaa ggg aag cag gtt ttc      554
Ser Arg Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe
            130                 135                 140
```

-continued

```
ctt tac ccg gag aaa gat gaa cct act tac atc ctg aac atc aag agg      602
Leu Tyr Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn Ile Lys Arg
        145                 150                 155

ggc atc att tct gcc ctc ctg gtt ccc cca gag aca gaa gaa gcc aag      650
Gly Ile Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys
    160                 165                 170

caa gtg ttg ttt ctg gat acc gtg tat gga aac tgc tcc act cac ttt      698
Gln Val Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His Phe
175                 180                 185                 190

acc gtc aag acg agg aag ggc aat gtg gca aca gaa ata tcc act gaa      746
Thr Val Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile Ser Thr Glu
                195                 200                 205

aga gac ctg ggg cag tgt gat cgc ttc aag ccc atc cgc aca ggc atc      794
Arg Asp Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg Thr Gly Ile
            210                 215                 220

agc cca ctt gct ctc atc aaa ggc atg acc cgc ccc ttg tca act ctg      842
Ser Pro Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu Ser Thr Leu
        225                 230                 235

atc agc agc agc cag tcc tgt cag tac aca ctg gac gct aag agg aag      890
Ile Ser Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala Lys Arg Lys
    240                 245                 250

cat gtg gca gaa gcc atc tgc aag gag caa cac ctc ttc ctg cct ttc      938
His Val Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe Leu Pro Phe
255                 260                 265                 270

tcc tac aac aat aag tat ggg atg gta gca caa gtg aca cag act ttg      986
Ser Tyr Asn Asn Lys Tyr Gly Met Val Ala Gln Val Thr Gln Thr Leu
                275                 280                 285

aaa ctt gaa gac aca cca aag atc aac agc cgc ttc ttt ggt gaa ggt     1034
Lys Leu Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe Gly Glu Gly
            290                 295                 300

act aag aag atg ggc ctc gca ttt gag agc acc aaa tcc aca tca cct     1082
Thr Lys Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser Thr Ser Pro
        305                 310                 315

cca aag cag gcc gaa gct gtt ttg aag act ctc cag gaa ctg aaa aaa     1130
Pro Lys Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu Leu Lys Lys
    320                 325                 330

cta acc atc tct gag caa aat atc cag aga gct aat ctc ttc aat aag     1178
Leu Thr Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu Phe Asn Lys
335                 340                 345                 350

ctg gtt act gag ctg aga ggc ctc agt gat gaa gca gtc aca tct ctc     1226
Leu Val Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val Thr Ser Leu
                355                 360                 365

ttg cca cag ctg att gag gtg tcc agc ccc atc act tta caa gcc ttg     1274
Leu Pro Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu Gln Ala Leu
            370                 375                 380

gtt cag tgt gga cag cct cag tgc tcc act cac atc ctc cag tgg ctg     1322
Val Gln Cys Gly Gln Pro Gln Cys Ser Thr His Ile Leu Gln Trp Leu
        385                 390                 395

aaa cgt gtg cat gcc aac ccc ctt ctg ata gat gtg gtc acc tac ctg     1370
Lys Arg Val His Ala Asn Pro Leu Leu Ile Asp Val Val Thr Tyr Leu
    400                 405                 410

gtg gcc ctg atc ccc gag ccc tca gca cag cag ctg cga gag atc ttc     1418
Val Ala Leu Ile Pro Glu Pro Ser Ala Gln Gln Leu Arg Glu Ile Phe
415                 420                 425                 430

aac atg gcg agg gat cag cgc agc cga gcc acc ttg tat gcg ctg agc     1466
Asn Met Ala Arg Asp Gln Arg Ser Arg Ala Thr Leu Tyr Ala Leu Ser
                435                 440                 445
```

-continued

```
cac gcg gtc aac aac tat cat aag aca aac cct aca ggg acc cag gag     1514
His Ala Val Asn Asn Tyr His Lys Thr Asn Pro Thr Gly Thr Gln Glu
            450                 455                 460

ctg ctg gac att gct aat tac ctg atg gaa cag att caa gat gac tgc     1562
Leu Leu Asp Ile Ala Asn Tyr Leu Met Glu Gln Ile Gln Asp Asp Cys
        465                 470                 475

act ggg gat gaa gat tac acc tat ttg att ctg cgg gtc att gga aat     1610
Thr Gly Asp Glu Asp Tyr Thr Tyr Leu Ile Leu Arg Val Ile Gly Asn
    480                 485                 490

atg ggc caa acc atg gag cag tta act cca gaa ctc aag tct tca atc     1658
Met Gly Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys Ser Ser Ile
495                 500                 505                 510

ctc aaa tgt gtc caa agt aca aag cca tca ctg atg atc cag aaa gct     1706
Leu Lys Cys Val Gln Ser Thr Lys Pro Ser Leu Met Ile Gln Lys Ala
                515                 520                 525

gcc atc cag gct ctg cgg aaa atg gag cct aaa gac aag gac cag gag     1754
Ala Ile Gln Ala Leu Arg Lys Met Glu Pro Lys Asp Lys Asp Gln Glu
            530                 535                 540

gtt ctt ctt cag act ttc ctt gat gat gct tct ccg gga gat aag cga     1802
Val Leu Leu Gln Thr Phe Leu Asp Asp Ala Ser Pro Gly Asp Lys Arg
        545                 550                 555

ctg gct gcc tat ctt atg ttg atg agg agt cct tca cag gca gat att     1850
Leu Ala Ala Tyr Leu Met Leu Met Arg Ser Pro Ser Gln Ala Asp Ile
    560                 565                 570

aac aaa att gtc caa att cta cca tgg gaa cag aat gag caa gtg aag     1898
Asn Lys Ile Val Gln Ile Leu Pro Trp Glu Gln Asn Glu Gln Val Lys
575                 580                 585                 590

aac ttt gtg gct tcc cat att gcc aat atc ttg aac tca gaa gaa ttg     1946
Asn Phe Val Ala Ser His Ile Ala Asn Ile Leu Asn Ser Glu Glu Leu
                595                 600                 605

gat atc caa gat ctg aaa aag tta gtg aaa gaa gct ctg aaa gaa tct     1994
Asp Ile Gln Asp Leu Lys Lys Leu Val Lys Glu Ala Leu Lys Glu Ser
            610                 615                 620

caa ctt cca act gtc atg gac ttc aga aaa ttc tct cgg aac tat caa     2042
Gln Leu Pro Thr Val Met Asp Phe Arg Lys Phe Ser Arg Asn Tyr Gln
        625                 630                 635

ctc tac aaa tct gtt tct ctt cca tca ctt gac cca gcc tca gcc aaa     2090
Leu Tyr Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala Ser Ala Lys
    640                 645                 650

ata gaa ggg aat ctt ata ttt gat cca aat aac tac ctt cct aaa gaa     2138
Ile Glu Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu Pro Lys Glu
655                 660                 665                 670

agc atg ctg aaa act acc ctc act gcc ttt gga ttt gct tca gct gac     2186
Ser Met Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala Ser Ala Asp
                675                 680                 685

ctc atc gag att ggc ttg gaa gga aaa ggc ttt gag cca aca ttg gaa     2234
Leu Ile Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu
            690                 695                 700

gct ctt ttt ggg aag caa gga ttt ttc cca gac agt gtc aac aaa gct     2282
Ala Leu Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val Asn Lys Ala
        705                 710                 715

ttg tac tgg gtt aat ggt caa gtt cct gat ggt gtc tct aag gtc tta     2330
Leu Tyr Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser Lys Val Leu
    720                 725                 730

gtg gac cac ttt ggc tat acc aaa gat gat aaa cat gag cag gat atg     2378
Val Asp His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu Gln Asp Met
735                 740                 745                 750
```

-continued

```
gta aat gga ata atg ctc agt gtt gag aag ctg att aaa gat ttg aaa     2426
Val Asn Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys Asp Leu Lys
                755                 760                 765

tcc aaa gaa gtc ccg gaa gcc aga gcc tac ctc cgc atc ttg gga gag     2474
Ser Lys Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile Leu Gly Glu
            770                 775                 780

gag ctt ggt ttt gcc agt ctc cat gac ctc cag ctc ctg gga aag ctg     2522
Glu Leu Gly Phe Ala Ser Leu His Asp Leu Gln Leu Leu Gly Lys Leu
        785                 790                 795

ctt ctg atg ggt gcc cgc act ctg cag ggg atc ccc cag atg att gga     2570
Leu Leu Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln Met Ile Gly
    800                 805                 810

gag gtc atc agg aag ggc tca aag aat gac ttt ttt ctt cac tac atc     2618
Glu Val Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu His Tyr Ile
815                 820                 825                 830

ttc atg gag aat gcc ttt gaa ctc ccc act gga gct gga tta cag ttg     2666
Phe Met Glu Asn Ala Phe Glu Leu Pro Thr Gly Ala Gly Leu Gln Leu
                835                 840                 845

caa ata tct tca tct gga gtc att gct ccc gga gcc aag gct gga gta     2714
Gln Ile Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys Ala Gly Val
            850                 855                 860

aaa ctg gaa gta gcc aac atg cag gct gaa ctg gtg gca aaa ccc tcc     2762
Lys Leu Glu Val Ala Asn Met Gln Ala Glu Leu Val Ala Lys Pro Ser
        865                 870                 875

gtg tct gtg gag ttt gtg aca aat atg ggc atc atc att ccg gac ttc     2810
Val Ser Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile Pro Asp Phe
    880                 885                 890

gct agg agt ggg gtc cag atg aac acc aac ttc ttc cac gag tcg ggt     2858
Ala Arg Ser Gly Val Gln Met Asn Thr Asn Phe Phe His Glu Ser Gly
895                 900                 905                 910

ctg gag gct cat gtt gcc cta aaa gct ggg aag ctg aag ttt atc att     2906
Leu Glu Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys Phe Ile Ile
                915                 920                 925

cct tcc cca aag aga cca gtc aag ctg ctc agt gga ggc aac aca tta     2954
Pro Ser Pro Lys Arg Pro Val Lys Leu Leu Ser Gly Gly Asn Thr Leu
            930                 935                 940

cat ttg gtc tct acc acc aaa acg gag gtg atc cca cct ctc att gag     3002
His Leu Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro Leu Ile Glu
        945                 950                 955

aac agg cag tcc tgg tca gtt tgc aag caa gtc ttt cct ggc ctg aat     3050
Asn Arg Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro Gly Leu Asn
    960                 965                 970

tac tgc acc tca ggc gct tac tcc aac gcc agc tcc aca gac tcc gcc     3098
Tyr Cys Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr Asp Ser Ala
975                 980                 985                 990

tcc tac tat ccg ctg acc ggg gac acc aga tta gag ctg gaa ctg agg     3146
Ser Tyr Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu Glu Leu Arg
                995                1000                1005

cct aca gga gag att gag cag tat tct gtc agc gca acc tat gag ctc     3194
Pro Thr Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr Tyr Glu Leu
            1010                1015                1020

cag aga gag gac aga gcc ttg gtg gat acc ctg aag ttt gta act caa     3242
Gln Arg Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe Val Thr Gln
        1025                1030                1035

gca gaa ggt gcg aag cag act gag gct acc atg aca ttc aaa tat aat     3290
Ala Glu Gly Ala Lys Gln Thr Glu Ala Thr Met Thr Phe Lys Tyr Asn
    1040                1045                1050
```

-continued

```
cgg cag agt atg acc ttg tcc agt gaa gtc caa att ccg gat ttt gat     3338
Arg Gln Ser Met Thr Leu Ser Ser Glu Val Gln Ile Pro Asp Phe Asp
1055                1060                1065                1070

gtt gac ctc gga aca atc ctc aga gtt aat gat gaa tct act gag ggc     3386
Val Asp Leu Gly Thr Ile Leu Arg Val Asn Asp Glu Ser Thr Glu Gly
                1075                1080                1085

aaa acg tct tac aga ctc acc ctg gac att cag aac aag aaa att act     3434
Lys Thr Ser Tyr Arg Leu Thr Leu Asp Ile Gln Asn Lys Lys Ile Thr
            1090                1095                1100

gag gtc gcc ctc atg ggc cac cta agt tgt gac aca aag gaa gaa aga     3482
Glu Val Ala Leu Met Gly His Leu Ser Cys Asp Thr Lys Glu Glu Arg
        1105                1110                1115

aaa atc aag ggt gtt att tcc ata ccc cgt ttg caa gca gaa gcc aga     3530
Lys Ile Lys Gly Val Ile Ser Ile Pro Arg Leu Gln Ala Glu Ala Arg
    1120                1125                1130

agt gag atc ctc gcc cac tgg tcg cct gcc aaa ctg ctt ctc caa atg     3578
Ser Glu Ile Leu Ala His Trp Ser Pro Ala Lys Leu Leu Leu Gln Met
1135                1140                1145                1150

gac tca tct gct aca gct tat ggc tcc aca gtt tcc aag agg gtg gca     3626
Asp Ser Ser Ala Thr Ala Tyr Gly Ser Thr Val Ser Lys Arg Val Ala
                1155                1160                1165

tgg cat tat gat gaa gag aag att gaa ttt gaa tgg aac aca ggc acc     3674
Trp His Tyr Asp Glu Glu Lys Ile Glu Phe Glu Trp Asn Thr Gly Thr
            1170                1175                1180

aat gta gat acc aaa aaa atg act tcc aat ttc cct gtg gat ctc tcc     3722
Asn Val Asp Thr Lys Lys Met Thr Ser Asn Phe Pro Val Asp Leu Ser
        1185                1190                1195

gat tat cct aag agc ttg cat atg tat gct aat aga ctc ctg gat cac     3770
Asp Tyr Pro Lys Ser Leu His Met Tyr Ala Asn Arg Leu Leu Asp His
    1200                1205                1210

aga gtc cct gaa aca gac atg act ttc cgg cac gtg ggt tcc aaa tta     3818
Arg Val Pro Glu Thr Asp Met Thr Phe Arg His Val Gly Ser Lys Leu
1215                1220                1225                1230

ata gtt gca atg agc tca tgg ctt cag aag gca tct ggg agt ctt cct     3866
Ile Val Ala Met Ser Ser Trp Leu Gln Lys Ala Ser Gly Ser Leu Pro
                1235                1240                1245

tat acc cag act ttg caa gac cac ctc aat agc ctg aag gag ttc aac     3914
Tyr Thr Gln Thr Leu Gln Asp His Leu Asn Ser Leu Lys Glu Phe Asn
            1250                1255                1260

ctc cag aac atg gga ttg cca gac ttc cac atc cca gaa aac ctc ttc     3962
Leu Gln Asn Met Gly Leu Pro Asp Phe His Ile Pro Glu Asn Leu Phe
        1265                1270                1275

tta aaa agc gat ggc cgg gtc aaa tat acc ttg aac aag aac agt ttg     4010
Leu Lys Ser Asp Gly Arg Val Lys Tyr Thr Leu Asn Lys Asn Ser Leu
    1280                1285                1290

aaa att gag att cct ttg cct ttt ggt ggc aaa tcc tcc aga gat cta     4058
Lys Ile Glu Ile Pro Leu Pro Phe Gly Gly Lys Ser Ser Arg Asp Leu
1295                1300                1305                1310

aag atg tta gag act gtt agg aca cca gcc ctc cac ttc aag tct gtg     4106
Lys Met Leu Glu Thr Val Arg Thr Pro Ala Leu His Phe Lys Ser Val
                1315                1320                1325

gga ttc cat ctg cca tct cga gag ttc caa gtc cct act ttt acc att     4154
Gly Phe His Leu Pro Ser Arg Glu Phe Gln Val Pro Thr Phe Thr Ile
            1330                1335                1340

ccc aag ttg tat caa ctg caa gtg cct ctc ctg ggt gtt cta gac ctc     4202
Pro Lys Leu Tyr Gln Leu Gln Val Pro Leu Leu Gly Val Leu Asp Leu
        1345                1350                1355
```

-continued

```
tcc acg aat gtc tac agc aac ttg tac aac tgg tcc gcc tcc tac agt     4250
Ser Thr Asn Val Tyr Ser Asn Leu Tyr Asn Trp Ser Ala Ser Tyr Ser
    1360                1365                1370

ggt ggc aac acc agc aca gac cat ttc agc ctt cgg gct cgt tac cac     4298
Gly Gly Asn Thr Ser Thr Asp His Phe Ser Leu Arg Ala Arg Tyr His
1375                1380                1385                1390

atg aag gct gac tct gtg gtt gac ctg ctt tcc tac aat gtg caa gga     4346
Met Lys Ala Asp Ser Val Val Asp Leu Leu Ser Tyr Asn Val Gln Gly
                1395                1400                1405

tct gga gaa aca aca tat gac cac aag aat acg ttc aca cta tca tgt     4394
Ser Gly Glu Thr Thr Tyr Asp His Lys Asn Thr Phe Thr Leu Ser Cys
            1410                1415                1420

gat ggg tct cta cgc cac aaa ttt cta gat tcg aat atc aaa ttc agt     4442
Asp Gly Ser Leu Arg His Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser
        1425                1430                1435

cat gta gaa aaa ctt gga aac aac cca gtc tca aaa ggt tta cta ata     4490
His Val Glu Lys Leu Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile
    1440                1445                1450

ttc gat gca tct agt tcc tgg gga cca cag atg tct gct tca gtt cat     4538
Phe Asp Ala Ser Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His
1455                1460                1465                1470

ttg gac tcc aaa aag aaa cag cat ttg ttt gtc aaa gaa gtc aag att     4586
Leu Asp Ser Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile
                1475                1480                1485

gat ggg cag ttc aga gtc tct tcg ttc tat gct aaa ggc aca tat ggc     4634
Asp Gly Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly
            1490                1495                1500

ctg tct tgt cag agg gat cct aac act ggc cgg ctc aat gga gag tcc     4682
Leu Ser Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser
        1505                1510                1515

aac ctg agg ttt aac tcc tcc tac ctc caa ggc acc aac cag ata aca     4730
Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile Thr
    1520                1525                1530

gga aga tat gaa gat gga acc ctc tcc ctc acc tcc acc tct gat ctg     4778
Gly Arg Tyr Glu Asp Gly Thr Leu Ser Leu Thr Ser Thr Ser Asp Leu
1535                1540                1545                1550

caa agt ggc atc att aaa aat act gct tcc cta aag tat gag aac tac     4826
Gln Ser Gly Ile Ile Lys Asn Thr Ala Ser Leu Lys Tyr Glu Asn Tyr
                1555                1560                1565

gag ctg act tta aaa tct gac acc aat ggg aag tat aag aac ttt gcc     4874
Glu Leu Thr Leu Lys Ser Asp Thr Asn Gly Lys Tyr Lys Asn Phe Ala
            1570                1575                1580

act tct aac aag atg gat atg acc ttc tct aag caa aat gca ctg ctg     4922
Thr Ser Asn Lys Met Asp Met Thr Phe Ser Lys Gln Asn Ala Leu Leu
        1585                1590                1595

cgt tct gaa tat cag gct gat tac gag tca ttg agg ttc ttc agc ctg     4970
Arg Ser Glu Tyr Gln Ala Asp Tyr Glu Ser Leu Arg Phe Phe Ser Leu
    1600                1605                1610

ctt tct gga tca cta aat tcc cat ggt ctt gag tta aat gct gac atc     5018
Leu Ser Gly Ser Leu Asn Ser His Gly Leu Glu Leu Asn Ala Asp Ile
1615                1620                1625                1630

tta ggc act gac aaa att aat agt ggt gct cac aag gcg aca cta agg     5066
Leu Gly Thr Asp Lys Ile Asn Ser Gly Ala His Lys Ala Thr Leu Arg
                1635                1640                1645

att ggc caa gat gga ata tct acc agt gca acg acc aac ttg aag tgt     5114
Ile Gly Gln Asp Gly Ile Ser Thr Ser Ala Thr Thr Asn Leu Lys Cys
            1650                1655                1660
```

-continued

```
agt ctc ctg gtg ctg gag aat gag ctg aat gca gag ctt ggc ctc tct     5162
Ser Leu Leu Val Leu Glu Asn Glu Leu Asn Ala Glu Leu Gly Leu Ser
        1665                1670                1675

ggg gca tct atg aaa tta aca aca aat ggc cgc ttc agg gaa cac aat     5210
Gly Ala Ser Met Lys Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn
    1680                1685                1690

gca aaa ttc agt ctg gat ggg aaa gcc gcc ctc aca gag cta tca ctg     5258
Ala Lys Phe Ser Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu
1695                1700                1705                1710

gga agt gct tat cag gcc atg att ctg ggt gtc gac agc aaa aac att     5306
Gly Ser Ala Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn Ile
                1715                1720                1725

ttc aac ttc aag gtc agt caa gaa gga ctt aag ctc tca aat gac atg     5354
Phe Asn Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn Asp Met
            1730                1735                1740

atg ggc tca tat gct gaa atg aaa ttt gac cac aca aac agt ctg aac     5402
Met Gly Ser Tyr Ala Glu Met Lys Phe Asp His Thr Asn Ser Leu Asn
        1745                1750                1755

att gca ggc tta tca ctg gac ttc tct tca aaa ctt gac aac att tac     5450
Ile Ala Gly Leu Ser Leu Asp Phe Ser Ser Lys Leu Asp Asn Ile Tyr
    1760                1765                1770

agc tct gac aag ttt tat aag caa act gtt aat tta cag cta cag ccc     5498
Ser Ser Asp Lys Phe Tyr Lys Gln Thr Val Asn Leu Gln Leu Gln Pro
1775                1780                1785                1790

tat tct ctg gta act act tta aac agt gac ctg aaa tac aat gct ctg     5546
Tyr Ser Leu Val Thr Thr Leu Asn Ser Asp Leu Lys Tyr Asn Ala Leu
                1795                1800                1805

gat ctc acc aac aat ggg aaa cta cgg cta gaa ccc ctg aag ctg cat     5594
Asp Leu Thr Asn Asn Gly Lys Leu Arg Leu Glu Pro Leu Lys Leu His
            1810                1815                1820

gtg gct ggt aac cta aaa gga gcc tac caa aat aat gaa ata aaa cac     5642
Val Ala Gly Asn Leu Lys Gly Ala Tyr Gln Asn Asn Glu Ile Lys His
        1825                1830                1835

atc tat gcc atc tct tct gct gcc tta tca gca agc tat aaa gca gac     5690
Ile Tyr Ala Ile Ser Ser Ala Ala Leu Ser Ala Ser Tyr Lys Ala Asp
    1840                1845                1850

act gtt gct aag gtt cag ggt gtg gag ttt agc cat cgg ctc aac aca     5738
Thr Val Ala Lys Val Gln Gly Val Glu Phe Ser His Arg Leu Asn Thr
1855                1860                1865                1870

gac atc gct ggg ctg gct tca gcc att gac atg agc aca aac tat aat     5786
Asp Ile Ala Gly Leu Ala Ser Ala Ile Asp Met Ser Thr Asn Tyr Asn
                1875                1880                1885

tca gac tca ctg cat ttc agc aat gtc ttc cgt tct gta atg gcc ccg     5834
Ser Asp Ser Leu His Phe Ser Asn Val Phe Arg Ser Val Met Ala Pro
            1890                1895                1900

ttt acc atg acc atc gat gca cat aca aat ggc aat ggg aaa ctc gct     5882
Phe Thr Met Thr Ile Asp Ala His Thr Asn Gly Asn Gly Lys Leu Ala
        1905                1910                1915

ctc tgg gga gaa cat act ggg cag ctg tat agc aaa ttc ctg ttg aaa     5930
Leu Trp Gly Glu His Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys
    1920                1925                1930

gca gaa cct ctg gca ttt act ttc tct cat gat tac aaa ggc tcc aca     5978
Ala Glu Pro Leu Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr
1935                1940                1945                1950

agt cat cat ctc gtg tct agg aaa agc atc agt gca gct ctt gaa cac     6026
Ser His His Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu His
                1955                1960                1965
```

-continued

```
aaa gtc agt gcc ctg ctt act cca gct gag cag aca ggc acc tgg aaa     6074
Lys Val Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr Trp Lys
            1970                1975                1980

ctc aag acc caa ttt aac aac aat gaa tac agc cag gac ttg gat gct     6122
Leu Lys Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp Leu Asp Ala
        1985                1990                1995

tac aac act aaa gat aaa att ggc gtg gag ctt act gga cga act ctg     6170
Tyr Asn Thr Lys Asp Lys Ile Gly Val Glu Leu Thr Gly Arg Thr Leu
    2000                2005                2010

gct gac cta act cta cta gac tcc cca att aaa gtg cca ctt tta ctc     6218
Ala Asp Leu Thr Leu Leu Asp Ser Pro Ile Lys Val Pro Leu Leu Leu
2015                2020                2025                2030

agt gag ccc atc aat atc att gat gct tta gag atg aga gat gcc gtt     6266
Ser Glu Pro Ile Asn Ile Ile Asp Ala Leu Glu Met Arg Asp Ala Val
                2035                2040                2045

gag aag ccc caa gaa ttt aca att gtt gct ttt gta aag tat gat aaa     6314
Glu Lys Pro Gln Glu Phe Thr Ile Val Ala Phe Val Lys Tyr Asp Lys
            2050                2055                2060

aac caa gat gtt cac tcc att aac ctc cca ttt ttt gag acc ttg caa     6362
Asn Gln Asp Val His Ser Ile Asn Leu Pro Phe Phe Glu Thr Leu Gln
        2065                2070                2075

gaa tat ttt gag agg aat cga caa acc att ata gtt gta gtg gaa aac     6410
Glu Tyr Phe Glu Arg Asn Arg Gln Thr Ile Ile Val Val Val Glu Asn
    2080                2085                2090

gta cag aga aac ctg aag cac atc aat att gat caa ttt gta aga aaa     6458
Val Gln Arg Asn Leu Lys His Ile Asn Ile Asp Gln Phe Val Arg Lys
2095                2100                2105                2110

tac aga gca gcc ctg gga aaa ctc cca cag caa gct aat gat tat ctg     6506
Tyr Arg Ala Ala Leu Gly Lys Leu Pro Gln Gln Ala Asn Asp Tyr Leu
                2115                2120                2125

aat tca ttc aat tgg gag aga caa gtt tca cat gcc aag gag aaa ctg     6554
Asn Ser Phe Asn Trp Glu Arg Gln Val Ser His Ala Lys Glu Lys Leu
            2130                2135                2140

act gct ctc aca aaa aag tat aga att aca gaa aat gat ata caa att     6602
Thr Ala Leu Thr Lys Lys Tyr Arg Ile Thr Glu Asn Asp Ile Gln Ile
        2145                2150                2155

gca tta gat gat gcc aaa atc aac ttt aat gaa aaa cta tct caa ctg     6650
Ala Leu Asp Asp Ala Lys Ile Asn Phe Asn Glu Lys Leu Ser Gln Leu
    2160                2165                2170

cag aca tat atg ata caa ttt gat cag tat att aaa gat agt tat gat     6698
Gln Thr Tyr Met Ile Gln Phe Asp Gln Tyr Ile Lys Asp Ser Tyr Asp
2175                2180                2185                2190

tta cat gat ttg aaa ata gct att gct aat att att gat gaa atc att     6746
Leu His Asp Leu Lys Ile Ala Ile Ala Asn Ile Ile Asp Glu Ile Ile
                2195                2200                2205

gaa aaa tta aaa agt ctt gat gag cac tat cat atc cgt gta aat tta     6794
Glu Lys Leu Lys Ser Leu Asp Glu His Tyr His Ile Arg Val Asn Leu
            2210                2215                2220

gta aaa aca atc cat gat cta cat ttg ttt att gaa aat att gat ttt     6842
Val Lys Thr Ile His Asp Leu His Leu Phe Ile Glu Asn Ile Asp Phe
        2225                2230                2235

aac aaa agt gga agt agt act gca tcc tgg att caa aat gtg gat act     6890
Asn Lys Ser Gly Ser Ser Thr Ala Ser Trp Ile Gln Asn Val Asp Thr
    2240                2245                2250

aag tac caa atc aga atc cag ata caa gaa aaa ctg cag cag ctt aag     6938
Lys Tyr Gln Ile Arg Ile Gln Ile Gln Glu Lys Leu Gln Gln Leu Lys
2255                2260                2265                2270
```

-continued

```
aga cac ata cag aat ata gac atc cag cac cta gct gga aag tta aaa     6986
Arg His Ile Gln Asn Ile Asp Ile Gln His Leu Ala Gly Lys Leu Lys
                2275                2280                2285

caa cac att gag gct att gat gtt aga gtg ctt tta gat caa ttg gga     7034
Gln His Ile Glu Ala Ile Asp Val Arg Val Leu Leu Asp Gln Leu Gly
            2290                2295                2300

act aca att tca ttt gaa aga ata aat gat gtt ctt gag cat gtc aaa     7082
Thr Thr Ile Ser Phe Glu Arg Ile Asn Asp Val Leu Glu His Val Lys
        2305                2310                2315

cac ttt gtt ata aat ctt att ggg gat ttt gaa gta gct gag aaa atc     7130
His Phe Val Ile Asn Leu Ile Gly Asp Phe Glu Val Ala Glu Lys Ile
    2320                2325                2330

aat gcc ttc aga gcc aaa gtc cat gag tta atc gag agg tat gaa gta     7178
Asn Ala Phe Arg Ala Lys Val His Glu Leu Ile Glu Arg Tyr Glu Val
2335                2340                2345                2350

gac caa caa atc cag gtt tta atg gat aaa tta gta gag ttg acc cac     7226
Asp Gln Gln Ile Gln Val Leu Met Asp Lys Leu Val Glu Leu Thr His
                2355                2360                2365

caa tac aag ttg aag gag act att cag aag cta agc aat gtc cta caa     7274
Gln Tyr Lys Leu Lys Glu Thr Ile Gln Lys Leu Ser Asn Val Leu Gln
            2370                2375                2380

caa gtt aag ata aaa gat tac ttt gag aaa ttg gtt gga ttt att gat     7322
Gln Val Lys Ile Lys Asp Tyr Phe Glu Lys Leu Val Gly Phe Ile Asp
        2385                2390                2395

gat gct gtg aag aag ctt aat gaa tta tct ttt aaa aca ttc att gaa     7370
Asp Ala Val Lys Lys Leu Asn Glu Leu Ser Phe Lys Thr Phe Ile Glu
    2400                2405                2410

gat gtt aac aaa ttc ctt gac atg ttg ata aag aaa tta aag tca ttt     7418
Asp Val Asn Lys Phe Leu Asp Met Leu Ile Lys Lys Leu Lys Ser Phe
2415                2420                2425                2430

gat tac cac cag ttt gta gat gaa acc aat gac aaa atc cgt gag gtg     7466
Asp Tyr His Gln Phe Val Asp Glu Thr Asn Asp Lys Ile Arg Glu Val
                2435                2440                2445

act cag aga ctc aat ggt gaa att cag gct ctg gaa cta cca caa aaa     7514
Thr Gln Arg Leu Asn Gly Glu Ile Gln Ala Leu Glu Leu Pro Gln Lys
            2450                2455                2460

gct gaa gca tta aaa ctg ttt tta gag gaa acc aag gcc aca gtt gca     7562
Ala Glu Ala Leu Lys Leu Phe Leu Glu Glu Thr Lys Ala Thr Val Ala
        2465                2470                2475

gtg tat ctg gaa agc cta cag gac acc aaa ata acc tta atc atc aat     7610
Val Tyr Leu Glu Ser Leu Gln Asp Thr Lys Ile Thr Leu Ile Ile Asn
    2480                2485                2490

tgg tta cag gag gct tta agt tca gca tct ttg gct cac atg aag gcc     7658
Trp Leu Gln Glu Ala Leu Ser Ser Ala Ser Leu Ala His Met Lys Ala
2495                2500                2505                2510

aaa ttc cga gag act cta gaa gat aca cga gac cga atg tat caa atg     7706
Lys Phe Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr Gln Met
                2515                2520                2525

gac att cag cag gaa ctt caa cga tac ctg tct ctg gta ggc cag gtt     7754
Asp Ile Gln Gln Glu Leu Gln Arg Tyr Leu Ser Leu Val Gly Gln Val
            2530                2535                2540

tat agc aca ctt gtc acc tac att tct gat tgg tgg act ctt gct gct     7802
Tyr Ser Thr Leu Val Thr Tyr Ile Ser Asp Trp Trp Thr Leu Ala Ala
        2545                2550                2555

aag aac ctt act gac ttt gca gag caa tat tct atc caa gat tgg gct     7850
Lys Asn Leu Thr Asp Phe Ala Glu Gln Tyr Ser Ile Gln Asp Trp Ala
    2560                2565                2570
```

-continued

```
aaa cgt atg aaa gca ttg gta gag caa ggg ttc act gtt cct gaa atc     7898
Lys Arg Met Lys Ala Leu Val Glu Gln Gly Phe Thr Val Pro Glu Ile
2575                2580                2585                2590

aag acc atc ctt ggg acc atg cct gcc ttt gaa gtc agt ctt cag gct     7946
Lys Thr Ile Leu Gly Thr Met Pro Ala Phe Glu Val Ser Leu Gln Ala
                2595                2600                2605

ctt cag aaa gct acc ttc cag aca cct gat ttt ata gtc ccc cta aca     7994
Leu Gln Lys Ala Thr Phe Gln Thr Pro Asp Phe Ile Val Pro Leu Thr
            2610                2615                2620

gat ttg agg att cca tca gtt cag ata aac ttc aaa gac tta aaa aat     8042
Asp Leu Arg Ile Pro Ser Val Gln Ile Asn Phe Lys Asp Leu Lys Asn
        2625                2630                2635

ata aaa atc cca tcc agg ttt tcc aca cca gaa ttt acc atc ctt aac     8090
Ile Lys Ile Pro Ser Arg Phe Ser Thr Pro Glu Phe Thr Ile Leu Asn
    2640                2645                2650

acc ttc cac att cct tcc ttt aca att gac ttt gtc gaa atg aaa gta     8138
Thr Phe His Ile Pro Ser Phe Thr Ile Asp Phe Val Glu Met Lys Val
2655                2660                2665                2670

aag atc atc aga acc att gac cag atg cag aac agt gag ctg cag tgg     8186
Lys Ile Ile Arg Thr Ile Asp Gln Met Gln Asn Ser Glu Leu Gln Trp
                2675                2680                2685

ccc gtt cca gat ata tat ctc agg gat ctg aag gtg gag gac att cct     8234
Pro Val Pro Asp Ile Tyr Leu Arg Asp Leu Lys Val Glu Asp Ile Pro
            2690                2695                2700

cta gcg aga atc acc ctg cca gac ttc cgt tta cca gaa atc gca att     8282
Leu Ala Arg Ile Thr Leu Pro Asp Phe Arg Leu Pro Glu Ile Ala Ile
        2705                2710                2715

cca gaa ttc ata atc cca act ctc aac ctt aat gat ttt caa gtt cct     8330
Pro Glu Phe Ile Ile Pro Thr Leu Asn Leu Asn Asp Phe Gln Val Pro
    2720                2725                2730

gac ctt cac ata cca gaa ttc cag ctt ccc cac atc tca cac aca att     8378
Asp Leu His Ile Pro Glu Phe Gln Leu Pro His Ile Ser His Thr Ile
2735                2740                2745                2750

gaa gta cct act ttt ggc aag cta tac agt att ctg aaa atc caa tct     8426
Glu Val Pro Thr Phe Gly Lys Leu Tyr Ser Ile Leu Lys Ile Gln Ser
                2755                2760                2765

cct ctt ttc aca tta gat gca aat gct gac ata ggg aat gga acc acc     8474
Pro Leu Phe Thr Leu Asp Ala Asn Ala Asp Ile Gly Asn Gly Thr Thr
            2770                2775                2780

tca gca aac gaa gca ggt atc gca gct tcc atc act gcc aaa gga gag     8522
Ser Ala Asn Glu Ala Gly Ile Ala Ala Ser Ile Thr Ala Lys Gly Glu
        2785                2790                2795

tcc aaa tta gaa gtt ctc aat ttt gat ttt caa gca aat gca caa ctc     8570
Ser Lys Leu Glu Val Leu Asn Phe Asp Phe Gln Ala Asn Ala Gln Leu
    2800                2805                2810

tca aac cct aag att aat ccg ctg gct ctg aag gag tca gtg aag ttc     8618
Ser Asn Pro Lys Ile Asn Pro Leu Ala Leu Lys Glu Ser Val Lys Phe
2815                2820                2825                2830

tcc agc aag tac ctg aga acg gag cat ggg agt gaa atg ctg ttt ttt     8666
Ser Ser Lys Tyr Leu Arg Thr Glu His Gly Ser Glu Met Leu Phe Phe
                2835                2840                2845

gga aat gct att gag gga aaa tca aac aca gtg gca agt tta cac aca     8714
Gly Asn Ala Ile Glu Gly Lys Ser Asn Thr Val Ala Ser Leu His Thr
            2850                2855                2860

gaa aaa aat aca ctg gag ctt agt aat gga gtg att gtc aag ata aac     8762
Glu Lys Asn Thr Leu Glu Leu Ser Asn Gly Val Ile Val Lys Ile Asn
        2865                2870                2875
```

-continued

```
aat cag ctt acc ctg gat agc aac act aaa tac ttc cac aaa ttg aac     8810
Asn Gln Leu Thr Leu Asp Ser Asn Thr Lys Tyr Phe His Lys Leu Asn
    2880                2885                2890

atc ccc aaa ctg gac ttc tct agt cag gct gac ctg cgc aac gag atc     8858
Ile Pro Lys Leu Asp Phe Ser Ser Gln Ala Asp Leu Arg Asn Glu Ile
2895                2900                2905                2910

aag aca ctg ttg aaa gct ggc cac ata gca tgg act tct tct gga aaa     8906
Lys Thr Leu Leu Lys Ala Gly His Ile Ala Trp Thr Ser Ser Gly Lys
                2915                2920                2925

ggg tca tgg aaa tgg gcc tgc ccc aga ttc tca gat gag gga aca cat     8954
Gly Ser Trp Lys Trp Ala Cys Pro Arg Phe Ser Asp Glu Gly Thr His
            2930                2935                2940

gaa tca caa att agt ttc acc ata gaa gga ccc ctc act tcc ttt gga     9002
Glu Ser Gln Ile Ser Phe Thr Ile Glu Gly Pro Leu Thr Ser Phe Gly
        2945                2950                2955

ctg tcc aat aag atc aat agc aaa cac cta aga gta aac caa aac ttg     9050
Leu Ser Asn Lys Ile Asn Ser Lys His Leu Arg Val Asn Gln Asn Leu
    2960                2965                2970

gtt tat gaa tct ggc tcc ctc aac ttt tct aaa ctt gaa att caa tca     9098
Val Tyr Glu Ser Gly Ser Leu Asn Phe Ser Lys Leu Glu Ile Gln Ser
2975                2980                2985                2990

caa gtc gat tcc cag cat gtg ggc cac agt gtt cta act gct aaa ggc     9146
Gln Val Asp Ser Gln His Val Gly His Ser Val Leu Thr Ala Lys Gly
                2995                3000                3005

atg gca ctg ttt gga gaa ggg aag gca gag ttt act ggg agg cat gat     9194
Met Ala Leu Phe Gly Glu Gly Lys Ala Glu Phe Thr Gly Arg His Asp
            3010                3015                3020

gct cat tta aat gga aag gtt att gga act ttg aaa aat tct ctt ttc     9242
Ala His Leu Asn Gly Lys Val Ile Gly Thr Leu Lys Asn Ser Leu Phe
        3025                3030                3035

ttt tca gcc cag cca ttt gag atc acg gca tcc aca aac aat gaa ggg     9290
Phe Ser Ala Gln Pro Phe Glu Ile Thr Ala Ser Thr Asn Asn Glu Gly
    3040                3045                3050

aat ttg aaa gtt cgt ttt cca tta agg tta aca ggg aag ata gac ttc     9338
Asn Leu Lys Val Arg Phe Pro Leu Arg Leu Thr Gly Lys Ile Asp Phe
3055                3060                3065                3070

ctg aat aac tat gca ctg ttt ctg agt ccc agt gcc cag caa gca agt     9386
Leu Asn Asn Tyr Ala Leu Phe Leu Ser Pro Ser Ala Gln Gln Ala Ser
                3075                3080                3085

tgg caa gta agt gct agg ttc aat cag tat aag tac aac caa aat ttc     9434
Trp Gln Val Ser Ala Arg Phe Asn Gln Tyr Lys Tyr Asn Gln Asn Phe
            3090                3095                3100

tct gct gga aac aac gag aac att atg gag gcc cat gta gga ata aat     9482
Ser Ala Gly Asn Asn Glu Asn Ile Met Glu Ala His Val Gly Ile Asn
        3105                3110                3115

gga gaa gca aat ctg gat ttc tta aac att cct tta aca att cct gaa     9530
Gly Glu Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu
    3120                3125                3130

atg cgt cta cct tac aca ata atc aca act cct cca ctg aaa gat ttc     9578
Met Arg Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe
3135                3140                3145                3150

tct cta tgg gaa aaa aca ggc ttg aag gaa ttc ttg aaa acg aca aag     9626
Ser Leu Trp Glu Lys Thr Gly Leu Lys Glu Phe Leu Lys Thr Thr Lys
                3155                3160                3165

caa tca ttt gat tta agt gta aaa gct cag tat aag aaa aac aaa cac     9674
Gln Ser Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys Lys Asn Lys His
            3170                3175                3180
```

-continued

```
agg cat tcc atc aca aat cct ttg gct gtg ctt tgt gag ttt atc agt     9722
Arg His Ser Ile Thr Asn Pro Leu Ala Val Leu Cys Glu Phe Ile Ser
        3185                3190                3195

cag agc atc aaa tcc ttt gac agg cat ttt gaa aaa aac aga aac aat     9770
Gln Ser Ile Lys Ser Phe Asp Arg His Phe Glu Lys Asn Arg Asn Asn
    3200                3205                3210

gca tta gat ttt gtc acc aaa tcc tat aat gaa aca aaa att aag ttt     9818
Ala Leu Asp Phe Val Thr Lys Ser Tyr Asn Glu Thr Lys Ile Lys Phe
3215                3220                3225                3230

gat aag tac aaa gct gaa aaa tct cac gac gag ctc ccc agg acc ttt     9866
Asp Lys Tyr Lys Ala Glu Lys Ser His Asp Glu Leu Pro Arg Thr Phe
                3235                3240                3245

caa att cct gga tac act gtt cca gtt gtc aat gtt gaa gtg tct cca     9914
Gln Ile Pro Gly Tyr Thr Val Pro Val Val Asn Val Glu Val Ser Pro
            3250                3255                3260

ttc acc ata gag atg tcg gca ttc ggc tat gtg ttc cca aaa gca gtc     9962
Phe Thr Ile Glu Met Ser Ala Phe Gly Tyr Val Phe Pro Lys Ala Val
        3265                3270                3275

agc atg cct agt ttc tcc atc cta ggt tct gac gtc cgt gtg cct tca    10010
Ser Met Pro Ser Phe Ser Ile Leu Gly Ser Asp Val Arg Val Pro Ser
    3280                3285                3290

tac aca tta atc ctg cca tca tta gag ctg cca gtc ctt cat gtc cct    10058
Tyr Thr Leu Ile Leu Pro Ser Leu Glu Leu Pro Val Leu His Val Pro
3295                3300                3305                3310

aga aat ctc aag ctt tct ctt cca cat ttc aag gaa ttg tgt acc ata    10106
Arg Asn Leu Lys Leu Ser Leu Pro His Phe Lys Glu Leu Cys Thr Ile
                3315                3320                3325

agc cat att ttt att cct gcc atg ggc aat att acc tat gat ttc tcc    10154
Ser His Ile Phe Ile Pro Ala Met Gly Asn Ile Thr Tyr Asp Phe Ser
            3330                3335                3340

ttt aaa tca agt gtc atc aca ctg aat acc aat gct gaa ctt ttt aac    10202
Phe Lys Ser Ser Val Ile Thr Leu Asn Thr Asn Ala Glu Leu Phe Asn
        3345                3350                3355

cag tca gat att gtt gct cat ctc ctt tct tca tct tca tct gtc att    10250
Gln Ser Asp Ile Val Ala His Leu Leu Ser Ser Ser Ser Ser Val Ile
    3360                3365                3370

gat gca ctg cag tac aaa tta gag ggc acc aca aga ttg aca aga aaa    10298
Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys
3375                3380                3385                3390

agg gga ttg aag tta gcc aca gct ctg tct ctg agc aac aaa ttt gtg    10346
Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val
                3395                3400                3405

gag ggt agt cat aac agt act gtg agc tta acc acg aaa aat atg gaa    10394
Glu Gly Ser His Asn Ser Thr Val Ser Leu Thr Thr Lys Asn Met Glu
            3410                3415                3420

gtg tca gtg gca aaa acc aca aaa gcc gaa att cca att ttg aga atg    10442
Val Ser Val Ala Lys Thr Thr Lys Ala Glu Ile Pro Ile Leu Arg Met
        3425                3430                3435

aat ttc aag caa gaa ctt aat gga aat acc aag tca aaa cct act gtc    10490
Asn Phe Lys Gln Glu Leu Asn Gly Asn Thr Lys Ser Lys Pro Thr Val
    3440                3445                3450

tct tcc tcc atg gaa ttt aag tat gat ttc aat tct tca atg ctg tac    10538
Ser Ser Ser Met Glu Phe Lys Tyr Asp Phe Asn Ser Ser Met Leu Tyr
3455                3460                3465                3470

tct acc gct aaa gga gca gtt gac cac aag ctt agc ttg gaa agc ctc    10586
Ser Thr Ala Lys Gly Ala Val Asp His Lys Leu Ser Leu Glu Ser Leu
                3475                3480                3485
```

-continued

```
acc tct tac ttt tcc att gag tca tct acc aaa gga gat gtc aag ggt    10634
Thr Ser Tyr Phe Ser Ile Glu Ser Ser Thr Lys Gly Asp Val Lys Gly
            3490                3495                3500

tcg gtt ctt tct cgg gaa tat tca gga act att gct agt gag gcc aac    10682
Ser Val Leu Ser Arg Glu Tyr Ser Gly Thr Ile Ala Ser Glu Ala Asn
        3505                3510                3515

act tac ttg aat tcc aag agc aca cgg tct tca gtg aag ctg cag ggc    10730
Thr Tyr Leu Asn Ser Lys Ser Thr Arg Ser Ser Val Lys Leu Gln Gly
    3520                3525                3530

act tcc aaa att gat gat atc tgg aac ctt gaa gta aaa gaa aat ttt    10778
Thr Ser Lys Ile Asp Asp Ile Trp Asn Leu Glu Val Lys Glu Asn Phe
3535                3540                3545                3550

gct gga gaa gcc aca ctc caa cgc ata tat tcc ctc tgg gag cac agt    10826
Ala Gly Glu Ala Thr Leu Gln Arg Ile Tyr Ser Leu Trp Glu His Ser
                3555                3560                3565

acg aaa aac cac tta cag cta gag ggc ctc ttt ttc acc aac gga gaa    10874
Thr Lys Asn His Leu Gln Leu Glu Gly Leu Phe Phe Thr Asn Gly Glu
            3570                3575                3580

cat aca agc aaa gcc acc ctg gaa ctc tct cca tgg caa atg tca gct    10922
His Thr Ser Lys Ala Thr Leu Glu Leu Ser Pro Trp Gln Met Ser Ala
        3585                3590                3595

ctt gtt cag gtc cat gca agt cag ccc agt tcc ttc cat gat ttc cct    10970
Leu Val Gln Val His Ala Ser Gln Pro Ser Ser Phe His Asp Phe Pro
    3600                3605                3610

gac ctt ggc cag gaa gtg gcc ctg aat gct aac act aag aac cag aag    11018
Asp Leu Gly Gln Glu Val Ala Leu Asn Ala Asn Thr Lys Asn Gln Lys
3615                3620                3625                3630

atc aga tgg aaa aat gaa gtc cgg att cat tct ggg tct ttc cag agc    11066
Ile Arg Trp Lys Asn Glu Val Arg Ile His Ser Gly Ser Phe Gln Ser
                3635                3640                3645

cag gtc gag ctt tcc aat gac caa gaa aag gca cac ctt gac att gca    11114
Gln Val Glu Leu Ser Asn Asp Gln Glu Lys Ala His Leu Asp Ile Ala
            3650                3655                3660

gga tcc tta gaa gga cac cta agg ttc ctc aaa aat atc atc cta cca    11162
Gly Ser Leu Glu Gly His Leu Arg Phe Leu Lys Asn Ile Ile Leu Pro
        3665                3670                3675

gtc tat gac aag agc tta tgg gat ttc cta aag ctg gat gta acc acc    11210
Val Tyr Asp Lys Ser Leu Trp Asp Phe Leu Lys Leu Asp Val Thr Thr
    3680                3685                3690

agc att ggt agg aga cag cat ctt cgt gtt tca act gcc ttt gtg tac    11258
Ser Ile Gly Arg Arg Gln His Leu Arg Val Ser Thr Ala Phe Val Tyr
3695                3700                3705                3710

acc aaa aac ccc aat ggc tat tca ttc tcc atc cct gta aaa gtt ttg    11306
Thr Lys Asn Pro Asn Gly Tyr Ser Phe Ser Ile Pro Val Lys Val Leu
                3715                3720                3725

gct gat aaa ttc att act cct ggg ctg aaa cta aat gat cta aat tca    11354
Ala Asp Lys Phe Ile Thr Pro Gly Leu Lys Leu Asn Asp Leu Asn Ser
            3730                3735                3740

gtt ctt gtc atg cct acg ttc cat gtc cca ttt aca gat ctt cag gtt    11402
Val Leu Val Met Pro Thr Phe His Val Pro Phe Thr Asp Leu Gln Val
        3745                3750                3755

cca tcg tgc aaa ctt gac ttc aga gaa ata caa atc tat aag aag ctg    11450
Pro Ser Cys Lys Leu Asp Phe Arg Glu Ile Gln Ile Tyr Lys Lys Leu
    3760                3765                3770

aga act tca tca ttt gcc ctc aac cta cca aca ctc ccc gag gta aaa    11498
Arg Thr Ser Ser Phe Ala Leu Asn Leu Pro Thr Leu Pro Glu Val Lys
3775                3780                3785                3790
```

-continued

```
ttc cct gaa gtt gat gtg tta aca aaa tat tct caa cca gaa gac tcc    11546
Phe Pro Glu Val Asp Val Leu Thr Lys Tyr Ser Gln Pro Glu Asp Ser
                3795                3800                3805

ttg att ccc ttt ttt gag ata acc gtg cct gaa tct cag tta act gtg    11594
Leu Ile Pro Phe Phe Glu Ile Thr Val Pro Glu Ser Gln Leu Thr Val
            3810                3815                3820

tcc cag ttc acg ctt cca aaa agt gtt tca gat ggc att gct gct ttg    11642
Ser Gln Phe Thr Leu Pro Lys Ser Val Ser Asp Gly Ile Ala Ala Leu
        3825                3830                3835

gat cta aat gca gta gcc aac aag atc gca gac ttt gag ttg ccc acc    11690
Asp Leu Asn Ala Val Ala Asn Lys Ile Ala Asp Phe Glu Leu Pro Thr
    3840                3845                3850

atc atc gtg cct gag cag acc att gag att ccc tcc att aag ttc tct    11738
Ile Ile Val Pro Glu Gln Thr Ile Glu Ile Pro Ser Ile Lys Phe Ser
3855                3860                3865                3870

gta cct gct gga att gtc att cct tcc ttt caa gca ctg act gca cgc    11786
Val Pro Ala Gly Ile Val Ile Pro Ser Phe Gln Ala Leu Thr Ala Arg
                3875                3880                3885

ttt gag gta gac tct ccc gtg tat aat gcc act tgg agt gcc agt ttg    11834
Phe Glu Val Asp Ser Pro Val Tyr Asn Ala Thr Trp Ser Ala Ser Leu
            3890                3895                3900

aaa aac aaa gca gat tat gtt gaa aca gtc ctg gat tcc aca tgc agc    11882
Lys Asn Lys Ala Asp Tyr Val Glu Thr Val Leu Asp Ser Thr Cys Ser
        3905                3910                3915

tca acc gta cag ttc cta gaa tat gaa cta aat gtt ttg gga aca cac    11930
Ser Thr Val Gln Phe Leu Glu Tyr Glu Leu Asn Val Leu Gly Thr His
    3920                3925                3930

aaa atc gaa gat ggt acg tta gcc tct aag act aaa gga aca ctt gca    11978
Lys Ile Glu Asp Gly Thr Leu Ala Ser Lys Thr Lys Gly Thr Leu Ala
3935                3940                3945                3950

cac cgt gac ttc agt gca gaa tat gaa gaa gat ggc aaa ttt gaa gga    12026
His Arg Asp Phe Ser Ala Glu Tyr Glu Glu Asp Gly Lys Phe Glu Gly
                3955                3960                3965

ctt cag gaa tgg gaa gga aaa gcg cac ctc aat atc aaa agc cca gcg    12074
Leu Gln Glu Trp Glu Gly Lys Ala His Leu Asn Ile Lys Ser Pro Ala
            3970                3975                3980

ttc acc gat ctc cat ctg cgc tac cag aaa gac aag aaa ggc atc tcc    12122
Phe Thr Asp Leu His Leu Arg Tyr Gln Lys Asp Lys Lys Gly Ile Ser
        3985                3990                3995

acc tca gca gcc tcc cca gcc gta ggc acc gtg ggc atg gat atg gat    12170
Thr Ser Ala Ala Ser Pro Ala Val Gly Thr Val Gly Met Asp Met Asp
    4000                4005                4010

gaa gat gac gac ttt tct aaa tgg aac ttc tac tac agc cct cag tcc    12218
Glu Asp Asp Asp Phe Ser Lys Trp Asn Phe Tyr Tyr Ser Pro Gln Ser
4015                4020                4025                4030

tct cca gat aaa aaa ctc acc ata ttc aaa act gag ttg agg gtc cgg    12266
Ser Pro Asp Lys Lys Leu Thr Ile Phe Lys Thr Glu Leu Arg Val Arg
                4035                4040                4045

gaa tct gat gag gaa act cag atc aaa gtt aat tgg gaa gaa gag gca    12314
Glu Ser Asp Glu Glu Thr Gln Ile Lys Val Asn Trp Glu Glu Glu Ala
            4050                4055                4060

gct tct ggc ttg cta acc tct ctg aaa gac aac gtg ccc aag gcc aca    12362
Ala Ser Gly Leu Leu Thr Ser Leu Lys Asp Asn Val Pro Lys Ala Thr
        4065                4070                4075

ggg gtc ctt tat gat tat gtc aac aag tac cac tgg gaa cac aca ggg    12410
Gly Val Leu Tyr Asp Tyr Val Asn Lys Tyr His Trp Glu His Thr Gly
    4080                4085                4090
```

-continued

```
ctc acc ctg aga gaa gtg tct tca aag ctg aga aga aat ctg cag aac    12458
Leu Thr Leu Arg Glu Val Ser Ser Lys Leu Arg Arg Asn Leu Gln Asn
4095                4100                4105                4110

aat gct gag tgg gtt tat caa ggg gcc att agg caa att gat gat atc    12506
Asn Ala Glu Trp Val Tyr Gln Gly Ala Ile Arg Gln Ile Asp Asp Ile
                4115                4120                4125

gac gtg agg ttc cag aaa gca gcc agt ggc acc act ggg acc tac caa    12554
Asp Val Arg Phe Gln Lys Ala Ala Ser Gly Thr Thr Gly Thr Tyr Gln
            4130                4135                4140

gag tgg aag gac aag gcc cag aat ctg tac cag gaa ctg ttg act cag    12602
Glu Trp Lys Asp Lys Ala Gln Asn Leu Tyr Gln Glu Leu Leu Thr Gln
        4145                4150                4155

gaa ggc caa gcc agt ttc cag gga ctc aag gat aac gtg ttt gat ggc    12650
Glu Gly Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn Val Phe Asp Gly
    4160                4165                4170

ttg gta cga gtt act caa aaa ttc cat atg aaa gtc aag cat ctg att    12698
Leu Val Arg Val Thr Gln Lys Phe His Met Lys Val Lys His Leu Ile
4175                4180                4185                4190

gac tca ctc att gat ttt ctg aac ttc ccc aga ttc cag ttt ccg ggg    12746
Asp Ser Leu Ile Asp Phe Leu Asn Phe Pro Arg Phe Gln Phe Pro Gly
                4195                4200                4205

aaa cct ggg ata tac act agg gag gaa ctt tgc act atg ttc ata agg    12794
Lys Pro Gly Ile Tyr Thr Arg Glu Glu Leu Cys Thr Met Phe Ile Arg
            4210                4215                4220

gag gta ggg acg gta ctg tcc cag gta tat tcg aaa gtc cat aat ggt    12842
Glu Val Gly Thr Val Leu Ser Gln Val Tyr Ser Lys Val His Asn Gly
        4225                4230                4235

tca gaa ata ctg ttt tcc tat ttc caa gac cta gtg att aca ctt cct    12890
Ser Glu Ile Leu Phe Ser Tyr Phe Gln Asp Leu Val Ile Thr Leu Pro
    4240                4245                4250

ttc gag tta agg aaa cat aaa cta ata gat gta atc tcg atg tat agg    12938
Phe Glu Leu Arg Lys His Lys Leu Ile Asp Val Ile Ser Met Tyr Arg
4255                4260                4265                4270

gaa ctg ttg aaa gat tta tca aaa gaa gcc caa gag gta ttt aaa gcc    12986
Glu Leu Leu Lys Asp Leu Ser Lys Glu Ala Gln Glu Val Phe Lys Ala
                4275                4280                4285

att cag tct ctc aag acc aca gag gtg cta cgt aat ctt cag gac ctt    13034
Ile Gln Ser Leu Lys Thr Thr Glu Val Leu Arg Asn Leu Gln Asp Leu
            4290                4295                4300

tta caa ttc att ttc caa cta ata gaa gat aac att aaa cag ctg aaa    13082
Leu Gln Phe Ile Phe Gln Leu Ile Glu Asp Asn Ile Lys Gln Leu Lys
        4305                4310                4315

gag atg aaa ttt act tat ctt att aat tat atc caa gat gag atc aac    13130
Glu Met Lys Phe Thr Tyr Leu Ile Asn Tyr Ile Gln Asp Glu Ile Asn
    4320                4325                4330

aca atc ttc aat gat tat atc cca tat gtt ttt aaa ttg ttg aaa gaa    13178
Thr Ile Phe Asn Asp Tyr Ile Pro Tyr Val Phe Lys Leu Leu Lys Glu
4335                4340                4345                4350

aac cta tgc ctt aat ctt cat aag ttc aat gaa ttt att caa aac gag    13226
Asn Leu Cys Leu Asn Leu His Lys Phe Asn Glu Phe Ile Gln Asn Glu
                4355                4360                4365

ctt cag gaa gct tct caa gag tta cag cag atc cat caa tac att atg    13274
Leu Gln Glu Ala Ser Gln Glu Leu Gln Gln Ile His Gln Tyr Ile Met
            4370                4375                4380

gcc ctt cgt gaa gaa tat ttt gat cca agt ata gtt ggc tgg aca gtg    13322
Ala Leu Arg Glu Glu Tyr Phe Asp Pro Ser Ile Val Gly Trp Thr Val
        4385                4390                4395
```

-continued

```
aaa tat tat gaa ctt gaa gaa aag ata gtc agt ctg atc aag aac ctg    13370
Lys Tyr Tyr Glu Leu Glu Glu Lys Ile Val Ser Leu Ile Lys Asn Leu
    4400                4405                4410

tta gtt gct ctt aag gac ttc cat tct gaa tat att gtc agt gcc tct    13418
Leu Val Ala Leu Lys Asp Phe His Ser Glu Tyr Ile Val Ser Ala Ser
4415                4420                4425                4430

aac ttt act tcc caa ctc tca agt caa gtt gag caa ttt ctg cac aga    13466
Asn Phe Thr Ser Gln Leu Ser Ser Gln Val Glu Gln Phe Leu His Arg
                4435                4440                4445

aat att cag gaa tat ctt agc atc ctt acc gat cca gat gga aaa ggg    13514
Asn Ile Gln Glu Tyr Leu Ser Ile Leu Thr Asp Pro Asp Gly Lys Gly
            4450                4455                4460

aaa gag aag att gca gag ctt tct gcc act gct cag gaa ata att aaa    13562
Lys Glu Lys Ile Ala Glu Leu Ser Ala Thr Ala Gln Glu Ile Ile Lys
        4465                4470                4475

agc cag gcc att gcg acg aag aaa ata att tct gat tac cac cag cag    13610
Ser Gln Ala Ile Ala Thr Lys Lys Ile Ile Ser Asp Tyr His Gln Gln
    4480                4485                4490

ttt aga tat aaa ctg caa gat ttt tca gac caa ctc tct gat tac tat    13658
Phe Arg Tyr Lys Leu Gln Asp Phe Ser Asp Gln Leu Ser Asp Tyr Tyr
4495                4500                4505                4510

gaa aaa ttt att gct gaa tcc aaa aga ttg att gac ctg tcc att caa    13706
Glu Lys Phe Ile Ala Glu Ser Lys Arg Leu Ile Asp Leu Ser Ile Gln
                4515                4520                4525

aac tac cac aca ttt ctg ata tac atc acg gag tta ctg aaa aag ctg    13754
Asn Tyr His Thr Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu
            4530                4535                4540

caa tca acc aca gtc atg aac ccc tac atg aag ctt gct cca gga gaa    13802
Gln Ser Thr Thr Val Met Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu
        4545                4550                4555

ctt act atc atc ctc taa ttttttaaaa gaaatcttca tttattcttc           13850
Leu Thr Ile Ile Leu  *
    4560

ttttccaatt gaactttcac atagcacaga aaaaattcaa actgcctata ttgataaaac  13910

catacagtga gccagccttg cagtaggcag tagactataa gcagaagcac atatgaactg  13970

gacctgcacc aaagctggca ccagggctcg gaaggtctct gaactcagaa ggatggcatt  14030

ttttgcaagt taaagaaaat caggatctga gttattttgc taaacttggg ggaggaggaa  14090

caaataaatg gagtctttat tgtgtatcat a                                 14121


<210> SEQ ID NO 32
<211> LENGTH: 4563
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 32

Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu Pro Ala
 1               5                  10                  15

Leu Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu Met Leu
            20                  25                  30

Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe Lys His
        35                  40                  45

Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser Gly Val
    50                  55                  60
```

-continued

```
Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys Lys Val
65                  70                  75                  80

Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr Ser Gln
                85                  90                  95

Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys Ala Leu
            100                 105                 110

Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Ala Met Ser Arg
        115                 120                 125

Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe Leu Tyr
    130                 135                 140

Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn Ile Lys Arg Gly Ile
145                 150                 155                 160

Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys Gln Val
                165                 170                 175

Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His Phe Thr Val
            180                 185                 190

Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile Ser Thr Glu Arg Asp
        195                 200                 205

Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg Thr Gly Ile Ser Pro
    210                 215                 220

Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu Ser Thr Leu Ile Ser
225                 230                 235                 240

Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala Lys Arg Lys His Val
                245                 250                 255

Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe Leu Pro Phe Ser Tyr
            260                 265                 270

Asn Asn Lys Tyr Gly Met Val Ala Gln Val Thr Gln Thr Leu Lys Leu
        275                 280                 285

Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe Gly Glu Gly Thr Lys
    290                 295                 300

Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser Thr Ser Pro Pro Lys
305                 310                 315                 320

Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu Leu Lys Lys Leu Thr
                325                 330                 335

Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu Phe Asn Lys Leu Val
            340                 345                 350

Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val Thr Ser Leu Leu Pro
        355                 360                 365

Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu Gln Ala Leu Val Gln
    370                 375                 380

Cys Gly Gln Pro Gln Cys Ser Thr His Ile Leu Gln Trp Leu Lys Arg
385                 390                 395                 400

Val His Ala Asn Pro Leu Leu Ile Asp Val Val Thr Tyr Leu Val Ala
                405                 410                 415

Leu Ile Pro Glu Pro Ser Ala Gln Gln Leu Arg Glu Ile Phe Asn Met
            420                 425                 430

Ala Arg Asp Gln Arg Ser Arg Ala Thr Leu Tyr Ala Leu Ser His Ala
        435                 440                 445

Val Asn Asn Tyr His Lys Thr Asn Pro Thr Gly Thr Gln Glu Leu Leu
    450                 455                 460
```

-continued

```
Asp Ile Ala Asn Tyr Leu Met Glu Gln Ile Gln Asp Asp Cys Thr Gly
465                 470                 475                 480

Asp Glu Asp Tyr Thr Tyr Leu Ile Leu Arg Val Ile Gly Asn Met Gly
                485                 490                 495

Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys Ser Ser Ile Leu Lys
            500                 505                 510

Cys Val Gln Ser Thr Lys Pro Ser Leu Met Ile Gln Lys Ala Ala Ile
        515                 520                 525

Gln Ala Leu Arg Lys Met Glu Pro Lys Asp Lys Asp Gln Glu Val Leu
    530                 535                 540

Leu Gln Thr Phe Leu Asp Asp Ala Ser Pro Gly Asp Lys Arg Leu Ala
545                 550                 555                 560

Ala Tyr Leu Met Leu Met Arg Ser Pro Ser Gln Ala Asp Ile Asn Lys
                565                 570                 575

Ile Val Gln Ile Leu Pro Trp Glu Gln Asn Glu Gln Val Lys Asn Phe
            580                 585                 590

Val Ala Ser His Ile Ala Asn Ile Leu Asn Ser Glu Glu Leu Asp Ile
        595                 600                 605

Gln Asp Leu Lys Lys Leu Val Lys Glu Ala Leu Lys Glu Ser Gln Leu
    610                 615                 620

Pro Thr Val Met Asp Phe Arg Lys Phe Ser Arg Asn Tyr Gln Leu Tyr
625                 630                 635                 640

Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala Ser Ala Lys Ile Glu
                645                 650                 655

Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu Pro Lys Glu Ser Met
            660                 665                 670

Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala Ser Ala Asp Leu Ile
        675                 680                 685

Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu Ala Leu
    690                 695                 700

Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val Asn Lys Ala Leu Tyr
705                 710                 715                 720

Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser Lys Val Leu Val Asp
                725                 730                 735

His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu Gln Asp Met Val Asn
            740                 745                 750

Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys Asp Leu Lys Ser Lys
        755                 760                 765

Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile Leu Gly Glu Glu Leu
    770                 775                 780

Gly Phe Ala Ser Leu His Asp Leu Gln Leu Leu Gly Lys Leu Leu Leu
785                 790                 795                 800

Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln Met Ile Gly Glu Val
                805                 810                 815

Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu His Tyr Ile Phe Met
            820                 825                 830

Glu Asn Ala Phe Glu Leu Pro Thr Gly Ala Gly Leu Gln Leu Gln Ile
        835                 840                 845

Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys Ala Gly Val Lys Leu
    850                 855                 860
```

-continued

```
Glu Val Ala Asn Met Gln Ala Glu Leu Val Ala Lys Pro Ser Val Ser
865                 870                 875                 880

Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile Pro Asp Phe Ala Arg
                885                 890                 895

Ser Gly Val Gln Met Asn Thr Asn Phe Phe His Glu Ser Gly Leu Glu
            900                 905                 910

Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys Phe Ile Ile Pro Ser
        915                 920                 925

Pro Lys Arg Pro Val Lys Leu Leu Ser Gly Gly Asn Thr Leu His Leu
    930                 935                 940

Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro Leu Ile Glu Asn Arg
945                 950                 955                 960

Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro Gly Leu Asn Tyr Cys
                965                 970                 975

Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr Asp Ser Ala Ser Tyr
            980                 985                 990

Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu Glu Leu Arg Pro Thr
        995                 1000                1005

Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr Tyr Glu Leu Gln Arg
    1010                1015                1020

Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe Val Thr Gln Ala Glu
1025                1030                1035                1040

Gly Ala Lys Gln Thr Glu Ala Thr Met Thr Phe Lys Tyr Asn Arg Gln
                1045                1050                1055

Ser Met Thr Leu Ser Ser Glu Val Gln Ile Pro Asp Phe Asp Val Asp
            1060                1065                1070

Leu Gly Thr Ile Leu Arg Val Asn Asp Glu Ser Thr Glu Gly Lys Thr
        1075                1080                1085

Ser Tyr Arg Leu Thr Leu Asp Ile Gln Asn Lys Lys Ile Thr Glu Val
    1090                1095                1100

Ala Leu Met Gly His Leu Ser Cys Asp Thr Lys Glu Glu Arg Lys Ile
1105                1110                1115                1120

Lys Gly Val Ile Ser Ile Pro Arg Leu Gln Ala Glu Ala Arg Ser Glu
                1125                1130                1135

Ile Leu Ala His Trp Ser Pro Ala Lys Leu Leu Leu Gln Met Asp Ser
            1140                1145                1150

Ser Ala Thr Ala Tyr Gly Ser Thr Val Ser Lys Arg Val Ala Trp His
        1155                1160                1165

Tyr Asp Glu Glu Lys Ile Glu Phe Glu Trp Asn Thr Gly Thr Asn Val
    1170                1175                1180

Asp Thr Lys Lys Met Thr Ser Asn Phe Pro Val Asp Leu Ser Asp Tyr
1185                1190                1195                1200

Pro Lys Ser Leu His Met Tyr Ala Asn Arg Leu Leu Asp His Arg Val
                1205                1210                1215

Pro Glu Thr Asp Met Thr Phe Arg His Val Gly Ser Lys Leu Ile Val
            1220                1225                1230

Ala Met Ser Ser Trp Leu Gln Lys Ala Ser Gly Ser Leu Pro Tyr Thr
        1235                1240                1245

Gln Thr Leu Gln Asp His Leu Asn Ser Leu Lys Glu Phe Asn Leu Gln
    1250                1255                1260
```

-continued

```
Asn Met Gly Leu Pro Asp Phe His Ile Pro Glu Asn Leu Phe Leu Lys
1265                1270                1275                1280

Ser Asp Gly Arg Val Lys Tyr Thr Leu Asn Lys Asn Ser Leu Lys Ile
                1285                1290                1295

Glu Ile Pro Leu Pro Phe Gly Gly Lys Ser Ser Arg Asp Leu Lys Met
            1300                1305                1310

Leu Glu Thr Val Arg Thr Pro Ala Leu His Phe Lys Ser Val Gly Phe
        1315                1320                1325

His Leu Pro Ser Arg Glu Phe Gln Val Pro Thr Phe Thr Ile Pro Lys
    1330                1335                1340

Leu Tyr Gln Leu Gln Val Pro Leu Leu Gly Val Leu Asp Leu Ser Thr
1345                1350                1355                1360

Asn Val Tyr Ser Asn Leu Tyr Asn Trp Ser Ala Ser Tyr Ser Gly Gly
                1365                1370                1375

Asn Thr Ser Thr Asp His Phe Ser Leu Arg Ala Arg Tyr His Met Lys
            1380                1385                1390

Ala Asp Ser Val Val Asp Leu Leu Ser Tyr Asn Val Gln Gly Ser Gly
        1395                1400                1405

Glu Thr Thr Tyr Asp His Lys Asn Thr Phe Thr Leu Ser Cys Asp Gly
    1410                1415                1420

Ser Leu Arg His Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser His Val
1425                1430                1435                1440

Glu Lys Leu Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile Phe Asp
                1445                1450                1455

Ala Ser Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His Leu Asp
            1460                1465                1470

Ser Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile Asp Gly
        1475                1480                1485

Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly Leu Ser
    1490                1495                1500

Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser Asn Leu
1505                1510                1515                1520

Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile Thr Gly Arg
                1525                1530                1535

Tyr Glu Asp Gly Thr Leu Ser Leu Thr Ser Thr Ser Asp Leu Gln Ser
            1540                1545                1550

Gly Ile Ile Lys Asn Thr Ala Ser Leu Lys Tyr Glu Asn Tyr Glu Leu
        1555                1560                1565

Thr Leu Lys Ser Asp Thr Asn Gly Lys Tyr Lys Asn Phe Ala Thr Ser
    1570                1575                1580

Asn Lys Met Asp Met Thr Phe Ser Lys Gln Asn Ala Leu Leu Arg Ser
1585                1590                1595                1600

Glu Tyr Gln Ala Asp Tyr Glu Ser Leu Arg Phe Phe Ser Leu Leu Ser
                1605                1610                1615

Gly Ser Leu Asn Ser His Gly Leu Glu Leu Asn Ala Asp Ile Leu Gly
            1620                1625                1630

Thr Asp Lys Ile Asn Ser Gly Ala His Lys Ala Thr Leu Arg Ile Gly
        1635                1640                1645

Gln Asp Gly Ile Ser Thr Ser Ala Thr Thr Asn Leu Lys Cys Ser Leu
    1650                1655                1660
```

-continued

```
Leu Val Leu Glu Asn Glu Leu Asn Ala Glu Leu Gly Leu Ser Gly Ala
1665                1670                1675                1680

Ser Met Lys Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn Ala Lys
                1685                1690                1695

Phe Ser Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu Gly Ser
            1700                1705                1710

Ala Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn Ile Phe Asn
        1715                1720                1725

Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn Asp Met Met Gly
    1730                1735                1740

Ser Tyr Ala Glu Met Lys Phe Asp His Thr Asn Ser Leu Asn Ile Ala
1745                1750                1755                1760

Gly Leu Ser Leu Asp Phe Ser Ser Lys Leu Asp Asn Ile Tyr Ser Ser
                1765                1770                1775

Asp Lys Phe Tyr Lys Gln Thr Val Asn Leu Gln Leu Gln Pro Tyr Ser
            1780                1785                1790

Leu Val Thr Thr Leu Asn Ser Asp Leu Lys Tyr Asn Ala Leu Asp Leu
        1795                1800                1805

Thr Asn Asn Gly Lys Leu Arg Leu Glu Pro Leu Lys Leu His Val Ala
    1810                1815                1820

Gly Asn Leu Lys Gly Ala Tyr Gln Asn Asn Glu Ile Lys His Ile Tyr
1825                1830                1835                1840

Ala Ile Ser Ser Ala Ala Leu Ser Ala Ser Tyr Lys Ala Asp Thr Val
                1845                1850                1855

Ala Lys Val Gln Gly Val Glu Phe Ser His Arg Leu Asn Thr Asp Ile
            1860                1865                1870

Ala Gly Leu Ala Ser Ala Ile Asp Met Ser Thr Asn Tyr Asn Ser Asp
        1875                1880                1885

Ser Leu His Phe Ser Asn Val Phe Arg Ser Val Met Ala Pro Phe Thr
    1890                1895                1900

Met Thr Ile Asp Ala His Thr Asn Gly Asn Gly Lys Leu Ala Leu Trp
1905                1910                1915                1920

Gly Glu His Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys Ala Glu
                1925                1930                1935

Pro Leu Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr Ser His
            1940                1945                1950

His Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu His Lys Val
        1955                1960                1965

Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr Trp Lys Leu Lys
    1970                1975                1980

Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp Leu Asp Ala Tyr Asn
1985                1990                1995                2000

Thr Lys Asp Lys Ile Gly Val Glu Leu Thr Gly Arg Thr Leu Ala Asp
                2005                2010                2015

Leu Thr Leu Leu Asp Ser Pro Ile Lys Val Pro Leu Leu Leu Ser Glu
            2020                2025                2030

Pro Ile Asn Ile Ile Asp Ala Leu Glu Met Arg Asp Ala Val Glu Lys
        2035                2040                2045

Pro Gln Glu Phe Thr Ile Val Ala Phe Val Lys Tyr Asp Lys Asn Gln
    2050                2055                2060
```

-continued

```
Asp Val His Ser Ile Asn Leu Pro Phe Phe Glu Thr Leu Gln Glu Tyr
2065                2070                2075                2080

Phe Glu Arg Asn Arg Gln Thr Ile Ile Val Val Val Glu Asn Val Gln
                2085                2090                2095

Arg Asn Leu Lys His Ile Asn Ile Asp Gln Phe Val Arg Lys Tyr Arg
            2100                2105                2110

Ala Ala Leu Gly Lys Leu Pro Gln Gln Ala Asn Asp Tyr Leu Asn Ser
        2115                2120                2125

Phe Asn Trp Glu Arg Gln Val Ser His Ala Lys Glu Lys Leu Thr Ala
    2130                2135                2140

Leu Thr Lys Lys Tyr Arg Ile Thr Glu Asn Asp Ile Gln Ile Ala Leu
2145                2150                2155                2160

Asp Asp Ala Lys Ile Asn Phe Asn Glu Lys Leu Ser Gln Leu Gln Thr
                2165                2170                2175

Tyr Met Ile Gln Phe Asp Gln Tyr Ile Lys Asp Ser Tyr Asp Leu His
            2180                2185                2190

Asp Leu Lys Ile Ala Ile Ala Asn Ile Ile Asp Glu Ile Ile Glu Lys
        2195                2200                2205

Leu Lys Ser Leu Asp Glu His Tyr His Ile Arg Val Asn Leu Val Lys
    2210                2215                2220

Thr Ile His Asp Leu His Leu Phe Ile Glu Asn Ile Asp Phe Asn Lys
2225                2230                2235                2240

Ser Gly Ser Ser Thr Ala Ser Trp Ile Gln Asn Val Asp Thr Lys Tyr
                2245                2250                2255

Gln Ile Arg Ile Gln Ile Gln Glu Lys Leu Gln Gln Leu Lys Arg His
            2260                2265                2270

Ile Gln Asn Ile Asp Ile Gln His Leu Ala Gly Lys Leu Lys Gln His
        2275                2280                2285

Ile Glu Ala Ile Asp Val Arg Val Leu Leu Asp Gln Leu Gly Thr Thr
    2290                2295                2300

Ile Ser Phe Glu Arg Ile Asn Asp Val Leu Glu His Val Lys His Phe
2305                2310                2315                2320

Val Ile Asn Leu Ile Gly Asp Phe Glu Val Ala Glu Lys Ile Asn Ala
                2325                2330                2335

Phe Arg Ala Lys Val His Glu Leu Ile Glu Arg Tyr Glu Val Asp Gln
            2340                2345                2350

Gln Ile Gln Val Leu Met Asp Lys Leu Val Glu Leu Thr His Gln Tyr
        2355                2360                2365

Lys Leu Lys Glu Thr Ile Gln Lys Leu Ser Asn Val Leu Gln Gln Val
    2370                2375                2380

Lys Ile Lys Asp Tyr Phe Glu Lys Leu Val Gly Phe Ile Asp Asp Ala
2385                2390                2395                2400

Val Lys Lys Leu Asn Glu Leu Ser Phe Lys Thr Phe Ile Glu Asp Val
                2405                2410                2415

Asn Lys Phe Leu Asp Met Leu Ile Lys Lys Leu Lys Ser Phe Asp Tyr
            2420                2425                2430

His Gln Phe Val Asp Glu Thr Asn Asp Lys Ile Arg Glu Val Thr Gln
        2435                2440                2445

Arg Leu Asn Gly Glu Ile Gln Ala Leu Glu Leu Pro Gln Lys Ala Glu
    2450                2455                2460
```

-continued

```
Ala Leu Lys Leu Phe Leu Glu Glu Thr Lys Ala Thr Val Ala Val Tyr
2465                2470                2475                2480

Leu Glu Ser Leu Gln Asp Thr Lys Ile Thr Leu Ile Ile Asn Trp Leu
                2485                2490                2495

Gln Glu Ala Leu Ser Ser Ala Ser Leu Ala His Met Lys Ala Lys Phe
            2500                2505                2510

Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr Gln Met Asp Ile
        2515                2520                2525

Gln Gln Glu Leu Gln Arg Tyr Leu Ser Leu Val Gly Gln Val Tyr Ser
    2530                2535                2540

Thr Leu Val Thr Tyr Ile Ser Asp Trp Trp Thr Leu Ala Ala Lys Asn
2545                2550                2555                2560

Leu Thr Asp Phe Ala Glu Gln Tyr Ser Ile Gln Asp Trp Ala Lys Arg
                2565                2570                2575

Met Lys Ala Leu Val Glu Gln Gly Phe Thr Val Pro Glu Ile Lys Thr
            2580                2585                2590

Ile Leu Gly Thr Met Pro Ala Phe Glu Val Ser Leu Gln Ala Leu Gln
        2595                2600                2605

Lys Ala Thr Phe Gln Thr Pro Asp Phe Ile Val Pro Leu Thr Asp Leu
    2610                2615                2620

Arg Ile Pro Ser Val Gln Ile Asn Phe Lys Asp Leu Lys Asn Ile Lys
2625                2630                2635                2640

Ile Pro Ser Arg Phe Ser Thr Pro Glu Phe Thr Ile Leu Asn Thr Phe
                2645                2650                2655

His Ile Pro Ser Phe Thr Ile Asp Phe Val Glu Met Lys Val Lys Ile
            2660                2665                2670

Ile Arg Thr Ile Asp Gln Met Gln Asn Ser Glu Leu Gln Trp Pro Val
        2675                2680                2685

Pro Asp Ile Tyr Leu Arg Asp Leu Lys Val Glu Asp Ile Pro Leu Ala
    2690                2695                2700

Arg Ile Thr Leu Pro Asp Phe Arg Leu Pro Glu Ile Ala Ile Pro Glu
2705                2710                2715                2720

Phe Ile Ile Pro Thr Leu Asn Leu Asn Asp Phe Gln Val Pro Asp Leu
                2725                2730                2735

His Ile Pro Glu Phe Gln Leu Pro His Ile Ser His Thr Ile Glu Val
            2740                2745                2750

Pro Thr Phe Gly Lys Leu Tyr Ser Ile Leu Lys Ile Gln Ser Pro Leu
        2755                2760                2765

Phe Thr Leu Asp Ala Asn Ala Asp Ile Gly Asn Gly Thr Thr Ser Ala
    2770                2775                2780

Asn Glu Ala Gly Ile Ala Ala Ser Ile Thr Ala Lys Gly Glu Ser Lys
2785                2790                2795                2800

Leu Glu Val Leu Asn Phe Asp Phe Gln Ala Asn Ala Gln Leu Ser Asn
                2805                2810                2815

Pro Lys Ile Asn Pro Leu Ala Leu Lys Glu Ser Val Lys Phe Ser Ser
            2820                2825                2830

Lys Tyr Leu Arg Thr Glu His Gly Ser Glu Met Leu Phe Phe Gly Asn
        2835                2840                2845

Ala Ile Glu Gly Lys Ser Asn Thr Val Ala Ser Leu His Thr Glu Lys
    2850                2855                2860
```

-continued

```
Asn Thr Leu Glu Leu Ser Asn Gly Val Ile Val Lys Ile Asn Asn Gln
2865                2870                2875                2880

Leu Thr Leu Asp Ser Asn Thr Lys Tyr Phe His Lys Leu Asn Ile Pro
                2885                2890                2895

Lys Leu Asp Phe Ser Ser Gln Ala Asp Leu Arg Asn Glu Ile Lys Thr
            2900                2905                2910

Leu Leu Lys Ala Gly His Ile Ala Trp Thr Ser Ser Gly Lys Gly Ser
        2915                2920                2925

Trp Lys Trp Ala Cys Pro Arg Phe Ser Asp Glu Gly Thr His Glu Ser
    2930                2935                2940

Gln Ile Ser Phe Thr Ile Glu Gly Pro Leu Thr Ser Phe Gly Leu Ser
2945                2950                2955                2960

Asn Lys Ile Asn Ser Lys His Leu Arg Val Asn Gln Asn Leu Val Tyr
                2965                2970                2975

Glu Ser Gly Ser Leu Asn Phe Ser Lys Leu Glu Ile Gln Ser Gln Val
            2980                2985                2990

Asp Ser Gln His Val Gly His Ser Val Leu Thr Ala Lys Gly Met Ala
        2995                3000                3005

Leu Phe Gly Glu Gly Lys Ala Glu Phe Thr Gly Arg His Asp Ala His
    3010                3015                3020

Leu Asn Gly Lys Val Ile Gly Thr Leu Lys Asn Ser Leu Phe Phe Ser
3025                3030                3035                3040

Ala Gln Pro Phe Glu Ile Thr Ala Ser Thr Asn Asn Glu Gly Asn Leu
                3045                3050                3055

Lys Val Arg Phe Pro Leu Arg Leu Thr Gly Lys Ile Asp Phe Leu Asn
            3060                3065                3070

Asn Tyr Ala Leu Phe Leu Ser Pro Ser Ala Gln Gln Ala Ser Trp Gln
        3075                3080                3085

Val Ser Ala Arg Phe Asn Gln Tyr Lys Tyr Asn Gln Asn Phe Ser Ala
    3090                3095                3100

Gly Asn Asn Glu Asn Ile Met Glu Ala His Val Gly Ile Asn Gly Glu
3105                3110                3115                3120

Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu Met Arg
                3125                3130                3135

Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe Ser Leu
            3140                3145                3150

Trp Glu Lys Thr Gly Leu Lys Glu Phe Leu Lys Thr Thr Lys Gln Ser
        3155                3160                3165

Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys Lys Asn Lys His Arg His
    3170                3175                3180

Ser Ile Thr Asn Pro Leu Ala Val Leu Cys Glu Phe Ile Ser Gln Ser
3185                3190                3195                3200

Ile Lys Ser Phe Asp Arg His Phe Glu Lys Asn Arg Asn Asn Ala Leu
                3205                3210                3215

Asp Phe Val Thr Lys Ser Tyr Asn Glu Thr Lys Ile Lys Phe Asp Lys
            3220                3225                3230

Tyr Lys Ala Glu Lys Ser His Asp Glu Leu Pro Arg Thr Phe Gln Ile
        3235                3240                3245

Pro Gly Tyr Thr Val Pro Val Val Asn Val Glu Val Ser Pro Phe Thr
    3250                3255                3260
```

-continued

```
Ile Glu Met Ser Ala Phe Gly Tyr Val Phe Pro Lys Ala Val Ser Met
3265                3270                3275                3280

Pro Ser Phe Ser Ile Leu Gly Ser Asp Val Arg Val Pro Ser Tyr Thr
                3285                3290                3295

Leu Ile Leu Pro Ser Leu Glu Leu Pro Val Leu His Val Pro Arg Asn
            3300                3305                3310

Leu Lys Leu Ser Leu Pro His Phe Lys Glu Leu Cys Thr Ile Ser His
        3315                3320                3325

Ile Phe Ile Pro Ala Met Gly Asn Ile Thr Tyr Asp Phe Ser Phe Lys
    3330                3335                3340

Ser Ser Val Ile Thr Leu Asn Thr Asn Ala Glu Leu Phe Asn Gln Ser
3345                3350                3355                3360

Asp Ile Val Ala His Leu Leu Ser Ser Ser Ser Ser Val Ile Asp Ala
                3365                3370                3375

Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys Arg Gly
            3380                3385                3390

Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val Glu Gly
        3395                3400                3405

Ser His Asn Ser Thr Val Ser Leu Thr Thr Lys Asn Met Glu Val Ser
    3410                3415                3420

Val Ala Lys Thr Thr Lys Ala Glu Ile Pro Ile Leu Arg Met Asn Phe
3425                3430                3435                3440

Lys Gln Glu Leu Asn Gly Asn Thr Lys Ser Lys Pro Thr Val Ser Ser
                3445                3450                3455

Ser Met Glu Phe Lys Tyr Asp Phe Asn Ser Ser Met Leu Tyr Ser Thr
            3460                3465                3470

Ala Lys Gly Ala Val Asp His Lys Leu Ser Leu Glu Ser Leu Thr Ser
        3475                3480                3485

Tyr Phe Ser Ile Glu Ser Ser Thr Lys Gly Asp Val Lys Gly Ser Val
    3490                3495                3500

Leu Ser Arg Glu Tyr Ser Gly Thr Ile Ala Ser Glu Ala Asn Thr Tyr
3505                3510                3515                3520

Leu Asn Ser Lys Ser Thr Arg Ser Ser Val Lys Leu Gln Gly Thr Ser
                3525                3530                3535

Lys Ile Asp Asp Ile Trp Asn Leu Glu Val Lys Glu Asn Phe Ala Gly
            3540                3545                3550

Glu Ala Thr Leu Gln Arg Ile Tyr Ser Leu Trp Glu His Ser Thr Lys
        3555                3560                3565

Asn His Leu Gln Leu Glu Gly Leu Phe Phe Thr Asn Gly Glu His Thr
    3570                3575                3580

Ser Lys Ala Thr Leu Glu Leu Ser Pro Trp Gln Met Ser Ala Leu Val
3585                3590                3595                3600

Gln Val His Ala Ser Gln Pro Ser Ser Phe His Asp Phe Pro Asp Leu
                3605                3610                3615

Gly Gln Glu Val Ala Leu Asn Ala Asn Thr Lys Asn Gln Lys Ile Arg
            3620                3625                3630

Trp Lys Asn Glu Val Arg Ile His Ser Gly Ser Phe Gln Ser Gln Val
        3635                3640                3645

Glu Leu Ser Asn Asp Gln Glu Lys Ala His Leu Asp Ile Ala Gly Ser
    3650                3655                3660
```

-continued

```
Leu Glu Gly His Leu Arg Phe Leu Lys Asn Ile Ile Leu Pro Val Tyr
3665                3670                3675                3680

Asp Lys Ser Leu Trp Asp Phe Leu Lys Leu Asp Val Thr Thr Ser Ile
                3685                3690                3695

Gly Arg Arg Gln His Leu Arg Val Ser Thr Ala Phe Val Tyr Thr Lys
            3700                3705                3710

Asn Pro Asn Gly Tyr Ser Phe Ser Ile Pro Val Lys Val Leu Ala Asp
        3715                3720                3725

Lys Phe Ile Thr Pro Gly Leu Lys Leu Asn Asp Leu Asn Ser Val Leu
    3730                3735                3740

Val Met Pro Thr Phe His Val Pro Phe Thr Asp Leu Gln Val Pro Ser
3745                3750                3755                3760

Cys Lys Leu Asp Phe Arg Glu Ile Gln Ile Tyr Lys Lys Leu Arg Thr
                3765                3770                3775

Ser Ser Phe Ala Leu Asn Leu Pro Thr Leu Pro Glu Val Lys Phe Pro
            3780                3785                3790

Glu Val Asp Val Leu Thr Lys Tyr Ser Gln Pro Glu Asp Ser Leu Ile
        3795                3800                3805

Pro Phe Phe Glu Ile Thr Val Pro Glu Ser Gln Leu Thr Val Ser Gln
    3810                3815                3820

Phe Thr Leu Pro Lys Ser Val Ser Asp Gly Ile Ala Ala Leu Asp Leu
3825                3830                3835                3840

Asn Ala Val Ala Asn Lys Ile Ala Asp Phe Glu Leu Pro Thr Ile Ile
                3845                3850                3855

Val Pro Glu Gln Thr Ile Glu Ile Pro Ser Ile Lys Phe Ser Val Pro
            3860                3865                3870

Ala Gly Ile Val Ile Pro Ser Phe Gln Ala Leu Thr Ala Arg Phe Glu
        3875                3880                3885

Val Asp Ser Pro Val Tyr Asn Ala Thr Trp Ser Ala Ser Leu Lys Asn
    3890                3895                3900

Lys Ala Asp Tyr Val Glu Thr Val Leu Asp Ser Thr Cys Ser Ser Thr
3905                3910                3915                3920

Val Gln Phe Leu Glu Tyr Glu Leu Asn Val Leu Gly Thr His Lys Ile
                3925                3930                3935

Glu Asp Gly Thr Leu Ala Ser Lys Thr Lys Gly Thr Leu Ala His Arg
            3940                3945                3950

Asp Phe Ser Ala Glu Tyr Glu Glu Asp Gly Lys Phe Glu Gly Leu Gln
        3955                3960                3965

Glu Trp Glu Gly Lys Ala His Leu Asn Ile Lys Ser Pro Ala Phe Thr
    3970                3975                3980

Asp Leu His Leu Arg Tyr Gln Lys Asp Lys Lys Gly Ile Ser Thr Ser
3985                3990                3995                4000

Ala Ala Ser Pro Ala Val Gly Thr Val Gly Met Asp Met Asp Glu Asp
                4005                4010                4015

Asp Asp Phe Ser Lys Trp Asn Phe Tyr Tyr Ser Pro Gln Ser Ser Pro
            4020                4025                4030

Asp Lys Lys Leu Thr Ile Phe Lys Thr Glu Leu Arg Val Arg Glu Ser
        4035                4040                4045

Asp Glu Glu Thr Gln Ile Lys Val Asn Trp Glu Glu Glu Ala Ala Ser
    4050                4055                4060
```

-continued

```
Gly Leu Leu Thr Ser Leu Lys Asp Asn Val Pro Lys Ala Thr Gly Val
4065                4070                4075                4080

Leu Tyr Asp Tyr Val Asn Lys Tyr His Trp Glu His Thr Gly Leu Thr
                4085                4090                4095

Leu Arg Glu Val Ser Ser Lys Leu Arg Arg Asn Leu Gln Asn Asn Ala
            4100                4105                4110

Glu Trp Val Tyr Gln Gly Ala Ile Arg Gln Ile Asp Asp Ile Asp Val
        4115                4120                4125

Arg Phe Gln Lys Ala Ala Ser Gly Thr Thr Gly Thr Tyr Gln Glu Trp
    4130                4135                4140

Lys Asp Lys Ala Gln Asn Leu Tyr Gln Glu Leu Leu Thr Gln Glu Gly
4145                4150                4155                4160

Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn Val Phe Asp Gly Leu Val
                4165                4170                4175

Arg Val Thr Gln Lys Phe His Met Lys Val Lys His Leu Ile Asp Ser
            4180                4185                4190

Leu Ile Asp Phe Leu Asn Phe Pro Arg Phe Gln Phe Pro Gly Lys Pro
        4195                4200                4205

Gly Ile Tyr Thr Arg Glu Glu Leu Cys Thr Met Phe Ile Arg Glu Val
    4210                4215                4220

Gly Thr Val Leu Ser Gln Val Tyr Ser Lys Val His Asn Gly Ser Glu
4225                4230                4235                4240

Ile Leu Phe Ser Tyr Phe Gln Asp Leu Val Ile Thr Leu Pro Phe Glu
                4245                4250                4255

Leu Arg Lys His Lys Leu Ile Asp Val Ile Ser Met Tyr Arg Glu Leu
            4260                4265                4270

Leu Lys Asp Leu Ser Lys Glu Ala Gln Glu Val Phe Lys Ala Ile Gln
        4275                4280                4285

Ser Leu Lys Thr Thr Glu Val Leu Arg Asn Leu Gln Asp Leu Leu Gln
    4290                4295                4300

Phe Ile Phe Gln Leu Ile Glu Asp Asn Ile Lys Gln Leu Lys Glu Met
4305                4310                4315                4320

Lys Phe Thr Tyr Leu Ile Asn Tyr Ile Gln Asp Glu Ile Asn Thr Ile
                4325                4330                4335

Phe Asn Asp Tyr Ile Pro Tyr Val Phe Lys Leu Leu Lys Glu Asn Leu
            4340                4345                4350

Cys Leu Asn Leu His Lys Phe Asn Glu Phe Ile Gln Asn Glu Leu Gln
        4355                4360                4365

Glu Ala Ser Gln Glu Leu Gln Gln Ile His Gln Tyr Ile Met Ala Leu
    4370                4375                4380

Arg Glu Glu Tyr Phe Asp Pro Ser Ile Val Gly Trp Thr Val Lys Tyr
4385                4390                4395                4400

Tyr Glu Leu Glu Glu Lys Ile Val Ser Leu Ile Lys Asn Leu Leu Val
                4405                4410                4415

Ala Leu Lys Asp Phe His Ser Glu Tyr Ile Val Ser Ala Ser Asn Phe
            4420                4425                4430

Thr Ser Gln Leu Ser Ser Gln Val Glu Gln Phe Leu His Arg Asn Ile
        4435                4440                4445

Gln Glu Tyr Leu Ser Ile Leu Thr Asp Pro Asp Gly Lys Gly Lys Glu
    4450                4455                4460
```

-continued

```
Lys Ile Ala Glu Leu Ser Ala Thr Ala Gln Glu Ile Ile Lys Ser Gln
4465                4470                4475                4480

Ala Ile Ala Thr Lys Lys Ile Ile Ser Asp Tyr His Gln Gln Phe Arg
                4485                4490                4495

Tyr Lys Leu Gln Asp Phe Ser Asp Gln Leu Ser Asp Tyr Tyr Glu Lys
            4500                4505                4510

Phe Ile Ala Glu Ser Lys Arg Leu Ile Asp Leu Ser Ile Gln Asn Tyr
        4515                4520                4525

His Thr Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu Gln Ser
    4530                4535                4540

Thr Thr Val Met Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu Leu Thr
4545                4550                4555                4560

Ile Ile Leu


<210> SEQ ID NO 33
<211> LENGTH: 2196
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (13)...(1983)
<223> OTHER INFORMATION: Nucleotide sequence encoding
      5,10-methylenetetrahydofolate reductase (MTHFR)

<400> SEQUENCE: 33

aattccggag cc atg gtg aac gaa gcc aga gga aac agc agc ctc aac ccc     51
              Met Val Asn Glu Ala Arg Gly Asn Ser Ser Leu Asn Pro
               1               5                  10

tgc ttg gag ggc agt gcc agc agt ggc agt gag agc tcc aaa gat agt       99
Cys Leu Glu Gly Ser Ala Ser Ser Gly Ser Glu Ser Ser Lys Asp Ser
     15                  20                  25

tcg aga tgt tcc acc ccg ggc ctg gac cct gag cgg cat gag aga ctc      147
Ser Arg Cys Ser Thr Pro Gly Leu Asp Pro Glu Arg His Glu Arg Leu
 30                  35                  40                  45

cgg gag aag atg agg cgg cga ttg gaa tct ggt gac aag tgg ttc tcc      195
Arg Glu Lys Met Arg Arg Arg Leu Glu Ser Gly Asp Lys Trp Phe Ser
                 50                  55                  60

ctg gaa ttc ttc cct cct cga act gct gag gga gct gtc aat ctc atc      243
Leu Glu Phe Phe Pro Pro Arg Thr Ala Glu Gly Ala Val Asn Leu Ile
             65                  70                  75

tca agg ttt gac cgg atg gca gca ggt ggc ccc ctc tac ata gac gtg      291
Ser Arg Phe Asp Arg Met Ala Ala Gly Gly Pro Leu Tyr Ile Asp Val
         80                  85                  90

acc tgg cac cca gca ggt gac cct ggc tca gac aag gag acc tcc tcc      339
Thr Trp His Pro Ala Gly Asp Pro Gly Ser Asp Lys Glu Thr Ser Ser
     95                  100                 105

atg atg atc gcc agc acc gcc gtg aac tac tgt ggc ctg gag acc atc      387
Met Met Ile Ala Ser Thr Ala Val Asn Tyr Cys Gly Leu Glu Thr Ile
110                 115                 120                 125

ctg cac atg acc tgc tgc cgt cag cgc ctg gag gag atc acg ggc cat      435
Leu His Met Thr Cys Cys Arg Gln Arg Leu Glu Glu Ile Thr Gly His
                130                 135                 140

ctg cac aaa gct aag cag ctg ggc ctg aag aac atc atg gcg ctg cgg      483
Leu His Lys Ala Lys Gln Leu Gly Leu Lys Asn Ile Met Ala Leu Arg
            145                 150                 155
```

-continued

```
gga gac cca ata ggt gac cag tgg gaa gag gag gag gga ggc ttc aac      531
Gly Asp Pro Ile Gly Asp Gln Trp Glu Glu Glu Glu Gly Gly Phe Asn
        160                 165                 170

tac gca gtg gac ctg gtg aag cac atc cga agt gag ttt ggt gac tac      579
Tyr Ala Val Asp Leu Val Lys His Ile Arg Ser Glu Phe Gly Asp Tyr
    175                 180                 185

ttt gac atc tgt gtg gca ggt tac ccc aaa ggc cac ccc gaa gca ggg      627
Phe Asp Ile Cys Val Ala Gly Tyr Pro Lys Gly His Pro Glu Ala Gly
190                 195                 200                 205

agc ttt gag gct gac ctg aag cac ttg aag gag aag gtg tct gcg gga      675
Ser Phe Glu Ala Asp Leu Lys His Leu Lys Glu Lys Val Ser Ala Gly
                210                 215                 220

gcc gat ttc atc atc acg cag ctt ttc ttt gag gct gac aca ttc ttc      723
Ala Asp Phe Ile Ile Thr Gln Leu Phe Phe Glu Ala Asp Thr Phe Phe
            225                 230                 235

cgc ttt gtg aag gca tgc acc gac atg ggc atc act tgc ccc atc gtc      771
Arg Phe Val Lys Ala Cys Thr Asp Met Gly Ile Thr Cys Pro Ile Val
        240                 245                 250

ccc ggg atc ttt ccc atc cag ggc tac cac tcc ctt cgg cag ctt gtg      819
Pro Gly Ile Phe Pro Ile Gln Gly Tyr His Ser Leu Arg Gln Leu Val
    255                 260                 265

aag ctg tcc aag ctg gag gtg cca cag gag atc aag gac gtg att gag      867
Lys Leu Ser Lys Leu Glu Val Pro Gln Glu Ile Lys Asp Val Ile Glu
270                 275                 280                 285

cca atc aaa gac aac gat gct gcc atc cgc aac tat ggc atc gag ctg      915
Pro Ile Lys Asp Asn Asp Ala Ala Ile Arg Asn Tyr Gly Ile Glu Leu
                290                 295                 300

gcc gtg agc ctg tgc cag gag ctt ctg gcc agt ggc ttg gtg cca ggc      963
Ala Val Ser Leu Cys Gln Glu Leu Leu Ala Ser Gly Leu Val Pro Gly
            305                 310                 315

ctc cac ttc tac acc ctc aac cgc gag atg gct acc aca gag gtg ctg     1011
Leu His Phe Tyr Thr Leu Asn Arg Glu Met Ala Thr Thr Glu Val Leu
        320                 325                 330

aag cgc ctg ggg atg tgg act gag gac ccc agg cgt ccc cta ccc tgg     1059
Lys Arg Leu Gly Met Trp Thr Glu Asp Pro Arg Arg Pro Leu Pro Trp
    335                 340                 345

gct ctc agt gcc cac ccc aag cgc cga gag gaa gat gta cgt ccc atc     1107
Ala Leu Ser Ala His Pro Lys Arg Arg Glu Glu Asp Val Arg Pro Ile
350                 355                 360                 365

ttc tgg gcc tcc aga cca aag agt tac atc tac cgt acc cag gag tgg     1155
Phe Trp Ala Ser Arg Pro Lys Ser Tyr Ile Tyr Arg Thr Gln Glu Trp
                370                 375                 380

gac gag ttc cct aac ggc cgc tgg ggc aat tcc tct tcc cct gcc ttt     1203
Asp Glu Phe Pro Asn Gly Arg Trp Gly Asn Ser Ser Ser Pro Ala Phe
            385                 390                 395

ggg gag ctg aag gac tac tac ctc ttc tac ctg aag agc aag tcc ccc     1251
Gly Glu Leu Lys Asp Tyr Tyr Leu Phe Tyr Leu Lys Ser Lys Ser Pro
        400                 405                 410

aag gag gag ctg ctg aag atg tgg ggg gag gag ctg acc agt gaa gca     1299
Lys Glu Glu Leu Leu Lys Met Trp Gly Glu Glu Leu Thr Ser Glu Ala
    415                 420                 425

agt gtc ttt gaa gtc ttt gtt ctt tac ctc tcg gga gaa cca aac cgg     1347
Ser Val Phe Glu Val Phe Val Leu Tyr Leu Ser Gly Glu Pro Asn Arg
430                 435                 440                 445

aat ggt cac aaa gtg act tgc ctg ccc tgg aac gat gag ccc ctg gcg     1395
Asn Gly His Lys Val Thr Cys Leu Pro Trp Asn Asp Glu Pro Leu Ala
                450                 455                 460
```

-continued

```
gct gag acc agc ctg ctg aag gag gag ctg ctg cgg gtg aac cgc cag     1443
Ala Glu Thr Ser Leu Leu Lys Glu Glu Leu Leu Arg Val Asn Arg Gln
            465                 470                 475

ggc atc ctc acc atc aac tca cag ccc aac atc aac ggg aag ccg tcc     1491
Gly Ile Leu Thr Ile Asn Ser Gln Pro Asn Ile Asn Gly Lys Pro Ser
        480                 485                 490

tcc gac ccc atc gtg ggc tgg ggc ccc agc ggg ggc tat gtc ttc cag     1539
Ser Asp Pro Ile Val Gly Trp Gly Pro Ser Gly Gly Tyr Val Phe Gln
    495                 500                 505

aag gcc tac tta gag ttt ttc act tcc cgc gag aca gcg gaa gca ctt     1587
Lys Ala Tyr Leu Glu Phe Phe Thr Ser Arg Glu Thr Ala Glu Ala Leu
510                 515                 520                 525

ctg caa gtg ctg aag aag tac gag ctc cgg gtt aat tac cac ctt gtc     1635
Leu Gln Val Leu Lys Lys Tyr Glu Leu Arg Val Asn Tyr His Leu Val
                530                 535                 540

aat gtg aag ggt gaa aac atc acc aat gcc cct gaa ctg cag ccg aat     1683
Asn Val Lys Gly Glu Asn Ile Thr Asn Ala Pro Glu Leu Gln Pro Asn
            545                 550                 555

gct gtc act tgg ggc atc ttc cct ggg cga gag atc atc cag ccc acc     1731
Ala Val Thr Trp Gly Ile Phe Pro Gly Arg Glu Ile Ile Gln Pro Thr
        560                 565                 570

gta gtg gat ccc gtc agc ttc atg ttc tgg aag gac gag gcc ttt gcc     1779
Val Val Asp Pro Val Ser Phe Met Phe Trp Lys Asp Glu Ala Phe Ala
    575                 580                 585

ctg tgg att gag cgg tgg gga aag ctg tat gag gag gag tcc ccg tcc     1827
Leu Trp Ile Glu Arg Trp Gly Lys Leu Tyr Glu Glu Glu Ser Pro Ser
590                 595                 600                 605

cgc acc atc atc cag tac atc cac gac aac tac ttc ctg gtc aac ctg     1875
Arg Thr Ile Ile Gln Tyr Ile His Asp Asn Tyr Phe Leu Val Asn Leu
                610                 615                 620

gtg gac aat gac ttc cca ctg gac aac tgc ctc tgg cag gtg gtg gaa     1923
Val Asp Asn Asp Phe Pro Leu Asp Asn Cys Leu Trp Gln Val Val Glu
            625                 630                 635

gac aca ttg gag ctt ctc aac agg ccc acc cag aat gcg aga gaa acg     1971
Asp Thr Leu Glu Leu Leu Asn Arg Pro Thr Gln Asn Ala Arg Glu Thr
        640                 645                 650

gag gct cca tga ccctgcgtcc tgacgccctg cgttggagcc actcctgtcc        2023
Glu Ala Pro  *
    655

cgccttcctc ctccacagtg ctgcttctct tgggaactcc actctccttc gtgtctctcc   2083

caccccggcc tccactcccc cacctgacaa tggcagctag actggagtga ggcttccagg   2143

ctcttcctgg acctgagtcg gccccacatg ggaacctagt actctctgct cta          2196


<210> SEQ ID NO 34
<211> LENGTH: 656
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 34

Met Val Asn Glu Ala Arg Gly Asn Ser Ser Leu Asn Pro Cys Leu Glu
 1               5                  10                  15

Gly Ser Ala Ser Ser Gly Ser Glu Ser Ser Lys Asp Ser Ser Arg Cys
            20                  25                  30

Ser Thr Pro Gly Leu Asp Pro Glu Arg His Glu Arg Leu Arg Glu Lys
        35                  40                  45
```

-continued

```
Met Arg Arg Arg Leu Glu Ser Gly Asp Lys Trp Phe Ser Leu Glu Phe
    50                  55                  60

Phe Pro Pro Arg Thr Ala Glu Gly Ala Val Asn Leu Ile Ser Arg Phe
65                  70                  75                  80

Asp Arg Met Ala Ala Gly Gly Pro Leu Tyr Ile Asp Val Thr Trp His
                85                  90                  95

Pro Ala Gly Asp Pro Gly Ser Asp Lys Glu Thr Ser Ser Met Met Ile
            100                 105                 110

Ala Ser Thr Ala Val Asn Tyr Cys Gly Leu Glu Thr Ile Leu His Met
        115                 120                 125

Thr Cys Cys Arg Gln Arg Leu Glu Glu Ile Thr Gly His Leu His Lys
    130                 135                 140

Ala Lys Gln Leu Gly Leu Lys Asn Ile Met Ala Leu Arg Gly Asp Pro
145                 150                 155                 160

Ile Gly Asp Gln Trp Glu Glu Glu Glu Gly Gly Phe Asn Tyr Ala Val
                165                 170                 175

Asp Leu Val Lys His Ile Arg Ser Glu Phe Gly Asp Tyr Phe Asp Ile
            180                 185                 190

Cys Val Ala Gly Tyr Pro Lys Gly His Pro Glu Ala Gly Ser Phe Glu
        195                 200                 205

Ala Asp Leu Lys His Leu Lys Glu Lys Val Ser Ala Gly Ala Asp Phe
    210                 215                 220

Ile Ile Thr Gln Leu Phe Phe Glu Ala Asp Thr Phe Phe Arg Phe Val
225                 230                 235                 240

Lys Ala Cys Thr Asp Met Gly Ile Thr Cys Pro Ile Val Pro Gly Ile
                245                 250                 255

Phe Pro Ile Gln Gly Tyr His Ser Leu Arg Gln Leu Val Lys Leu Ser
            260                 265                 270

Lys Leu Glu Val Pro Gln Glu Ile Lys Asp Val Ile Glu Pro Ile Lys
        275                 280                 285

Asp Asn Asp Ala Ala Ile Arg Asn Tyr Gly Ile Glu Leu Ala Val Ser
    290                 295                 300

Leu Cys Gln Glu Leu Leu Ala Ser Gly Leu Val Pro Gly Leu His Phe
305                 310                 315                 320

Tyr Thr Leu Asn Arg Glu Met Ala Thr Thr Glu Val Leu Lys Arg Leu
                325                 330                 335

Gly Met Trp Thr Glu Asp Pro Arg Arg Pro Leu Pro Trp Ala Leu Ser
            340                 345                 350

Ala His Pro Lys Arg Arg Glu Glu Asp Val Arg Pro Ile Phe Trp Ala
        355                 360                 365

Ser Arg Pro Lys Ser Tyr Ile Tyr Arg Thr Gln Glu Trp Asp Glu Phe
    370                 375                 380

Pro Asn Gly Arg Trp Gly Asn Ser Ser Ser Pro Ala Phe Gly Glu Leu
385                 390                 395                 400

Lys Asp Tyr Tyr Leu Phe Tyr Leu Lys Ser Lys Ser Pro Lys Glu Glu
                405                 410                 415

Leu Leu Lys Met Trp Gly Glu Glu Leu Thr Ser Glu Ala Ser Val Phe
            420                 425                 430

Glu Val Phe Val Leu Tyr Leu Ser Gly Glu Pro Asn Arg Asn Gly His
        435                 440                 445
```

-continued

```
Lys Val Thr Cys Leu Pro Trp Asn Asp Glu Pro Leu Ala Ala Glu Thr
    450                 455                 460

Ser Leu Leu Lys Glu Glu Leu Leu Arg Val Asn Arg Gln Gly Ile Leu
465                 470                 475                 480

Thr Ile Asn Ser Gln Pro Asn Ile Asn Gly Lys Pro Ser Ser Asp Pro
                485                 490                 495

Ile Val Gly Trp Gly Pro Ser Gly Gly Tyr Val Phe Gln Lys Ala Tyr
            500                 505                 510

Leu Glu Phe Phe Thr Ser Arg Glu Thr Ala Glu Ala Leu Leu Gln Val
        515                 520                 525

Leu Lys Lys Tyr Glu Leu Arg Val Asn Tyr His Leu Val Asn Val Lys
    530                 535                 540

Gly Glu Asn Ile Thr Asn Ala Pro Glu Leu Gln Pro Asn Ala Val Thr
545                 550                 555                 560

Trp Gly Ile Phe Pro Gly Arg Glu Ile Ile Gln Pro Thr Val Val Asp
                565                 570                 575

Pro Val Ser Phe Met Phe Trp Lys Asp Glu Ala Phe Ala Leu Trp Ile
            580                 585                 590

Glu Arg Trp Gly Lys Leu Tyr Glu Glu Glu Ser Pro Ser Arg Thr Ile
        595                 600                 605

Ile Gln Tyr Ile His Asp Asn Tyr Phe Leu Val Asn Leu Val Asp Asn
    610                 615                 620

Asp Phe Pro Leu Asp Asn Cys Leu Trp Gln Val Val Glu Asp Thr Leu
625                 630                 635                 640

Glu Leu Leu Asn Arg Pro Thr Gln Asn Ala Arg Glu Thr Glu Ala Pro
                645                 650                 655


<210> SEQ ID NO 35
<211> LENGTH: 3834
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (117)...(1949)
<223> OTHER INFORMATION: Nucleotide sequence encoding selectin E (SELE)

<400> SEQUENCE: 35

cctgagacag aggcagcagt gatacccacc tgagagatcc tgtgtttgaa caactgcttc     60

ccaaaacgga aagtatttca agcctaaacc tttgggtgaa aagaactctt gaagtc atg    119
                                                                  Met
                                                                   1

att gct tca cag ttt ctc tca gct ctc act ttg gtg ctt ctc att aaa      167
Ile Ala Ser Gln Phe Leu Ser Ala Leu Thr Leu Val Leu Leu Ile Lys
             5                  10                  15

gag agt gga gcc tgg tct tac aac acc tcc acg gaa gct atg act tat      215
Glu Ser Gly Ala Trp Ser Tyr Asn Thr Ser Thr Glu Ala Met Thr Tyr
         20                  25                  30

gat gag gcc agt gct tat tgt cag caa agg tac aca cac ctg gtt gca      263
Asp Glu Ala Ser Ala Tyr Cys Gln Gln Arg Tyr Thr His Leu Val Ala
     35                  40                  45

att caa aac aaa gaa gag att gag tac cta aac tcc ata ttg agc tat      311
Ile Gln Asn Lys Glu Glu Ile Glu Tyr Leu Asn Ser Ile Leu Ser Tyr
 50                  55                  60                  65
```

-continued

```
tca cca agt tat tac tgg att gga atc aga aaa gtc aac aat gtg tgg      359
Ser Pro Ser Tyr Tyr Trp Ile Gly Ile Arg Lys Val Asn Asn Val Trp
                 70                  75                  80

gtc tgg gta gga acc cag aaa cct ctg aca gaa gaa gcc aag aac tgg      407
Val Trp Val Gly Thr Gln Lys Pro Leu Thr Glu Glu Ala Lys Asn Trp
             85                  90                  95

gct cca ggt gaa ccc aac aat agg caa aaa gat gag gac tgc gtg gag      455
Ala Pro Gly Glu Pro Asn Asn Arg Gln Lys Asp Glu Asp Cys Val Glu
        100                 105                 110

atc tac atc aag aga gaa aaa gat gtg ggc atg tgg aat gat gag agg      503
Ile Tyr Ile Lys Arg Glu Lys Asp Val Gly Met Trp Asn Asp Glu Arg
    115                 120                 125

tgc agc aag aag aag ctt gcc cta tgc tac aca gct gcc tgt acc aat      551
Cys Ser Lys Lys Lys Leu Ala Leu Cys Tyr Thr Ala Ala Cys Thr Asn
130                 135                 140                 145

aca tcc tgc agt ggc cac ggt gaa tgt gta gag acc atc aat aat tac      599
Thr Ser Cys Ser Gly His Gly Glu Cys Val Glu Thr Ile Asn Asn Tyr
                150                 155                 160

act tgc aag tgt gac cct ggc ttc agt gga ctc aag tgt gag caa att      647
Thr Cys Lys Cys Asp Pro Gly Phe Ser Gly Leu Lys Cys Glu Gln Ile
            165                 170                 175

gtg aac tgt aca gcc ctg gaa tcc cct gag cat gga agc ctg gtt tgc      695
Val Asn Cys Thr Ala Leu Glu Ser Pro Glu His Gly Ser Leu Val Cys
        180                 185                 190

agt cac cca ctg gga aac ttc agc tac aat tct tcc tgc tct atc agc      743
Ser His Pro Leu Gly Asn Phe Ser Tyr Asn Ser Ser Cys Ser Ile Ser
    195                 200                 205

tgt gat agg ggt tac ctg cca agc agc atg gag acc atg cag tgt atg      791
Cys Asp Arg Gly Tyr Leu Pro Ser Ser Met Glu Thr Met Gln Cys Met
210                 215                 220                 225

tcc tct gga gaa tgg agt gct cct att cca gcc tgc aat gtg gtt gag      839
Ser Ser Gly Glu Trp Ser Ala Pro Ile Pro Ala Cys Asn Val Val Glu
                230                 235                 240

tgt gat gct gtg aca aat cca gcc aat ggg ttc gtg gaa tgt ttc caa      887
Cys Asp Ala Val Thr Asn Pro Ala Asn Gly Phe Val Glu Cys Phe Gln
            245                 250                 255

aac cct gga agc ttc cca tgg aac aca acc tgt aca ttt gac tgt gaa      935
Asn Pro Gly Ser Phe Pro Trp Asn Thr Thr Cys Thr Phe Asp Cys Glu
        260                 265                 270

gaa gga ttt gaa cta atg gga gcc cag agc ctt cag tgt acc tca tct      983
Glu Gly Phe Glu Leu Met Gly Ala Gln Ser Leu Gln Cys Thr Ser Ser
    275                 280                 285

ggg aat tgg gac aac gag aag cca acg tgt aaa gct gtg aca tgc agg     1031
Gly Asn Trp Asp Asn Glu Lys Pro Thr Cys Lys Ala Val Thr Cys Arg
290                 295                 300                 305

gcc gtc cgc cag cct cag aat ggc tct gtg agg tgc agc cat tcc cct     1079
Ala Val Arg Gln Pro Gln Asn Gly Ser Val Arg Cys Ser His Ser Pro
                310                 315                 320

gct gga gag ttc acc ttc aaa tca tcc tgc aac ttc acc tgt gag gaa     1127
Ala Gly Glu Phe Thr Phe Lys Ser Ser Cys Asn Phe Thr Cys Glu Glu
            325                 330                 335

ggc ttc atg ttg cag gga cca gcc cag gtt gaa tgc acc act caa ggg     1175
Gly Phe Met Leu Gln Gly Pro Ala Gln Val Glu Cys Thr Thr Gln Gly
        340                 345                 350

cag tgg aca cag caa atc cca gtt tgt gaa gct ttc cag tgc aca gcc     1223
Gln Trp Thr Gln Gln Ile Pro Val Cys Glu Ala Phe Gln Cys Thr Ala
    355                 360                 365
```

-continued

```
ttg tcc aac ccc gag cga ggc tac atg aat tgt ctt cct agt gct tct     1271
Leu Ser Asn Pro Glu Arg Gly Tyr Met Asn Cys Leu Pro Ser Ala Ser
370                 375                 380                 385

ggc agt ttc cgt tat ggg tcc agc tgt gag ttc tcc tgt gag cag ggt     1319
Gly Ser Phe Arg Tyr Gly Ser Ser Cys Glu Phe Ser Cys Glu Gln Gly
                390                 395                 400

ttt gtg ttg aag gga tcc aaa agg ctc caa tgt ggc ccc aca ggg gag     1367
Phe Val Leu Lys Gly Ser Lys Arg Leu Gln Cys Gly Pro Thr Gly Glu
            405                 410                 415

tgg gac aac gag aag ccc aca tgt gaa gct gtg aga tgc gat gct gtc     1415
Trp Asp Asn Glu Lys Pro Thr Cys Glu Ala Val Arg Cys Asp Ala Val
        420                 425                 430

cac cag ccc ccg aag ggt ttg gtg agg tgt gct cat tcc cct att gga     1463
His Gln Pro Pro Lys Gly Leu Val Arg Cys Ala His Ser Pro Ile Gly
    435                 440                 445

gaa ttc acc tac aag tcc tct tgt gcc ttc agc tgt gag gag gga ttt     1511
Glu Phe Thr Tyr Lys Ser Ser Cys Ala Phe Ser Cys Glu Glu Gly Phe
450                 455                 460                 465

gaa tta tat gga tca act caa ctt gag tgc aca tct cag gga caa tgg     1559
Glu Leu Tyr Gly Ser Thr Gln Leu Glu Cys Thr Ser Gln Gly Gln Trp
                470                 475                 480

aca gaa gag gtt cct tcc tgc caa gtg gta aaa tgt tca agc ctg gca     1607
Thr Glu Glu Val Pro Ser Cys Gln Val Val Lys Cys Ser Ser Leu Ala
            485                 490                 495

gtt ccg gga aag atc aac atg agc tgc agt ggg gag ccc gtg ttt ggc     1655
Val Pro Gly Lys Ile Asn Met Ser Cys Ser Gly Glu Pro Val Phe Gly
        500                 505                 510

act gtg tgc aag ttc gcc tgt cct gaa gga tgg acg ctc aat ggc tct     1703
Thr Val Cys Lys Phe Ala Cys Pro Glu Gly Trp Thr Leu Asn Gly Ser
    515                 520                 525

gca gct cgg aca tgt gga gcc aca gga cac tgg tct ggc ctg cta cct     1751
Ala Ala Arg Thr Cys Gly Ala Thr Gly His Trp Ser Gly Leu Leu Pro
530                 535                 540                 545

acc tgt gaa gct ccc act gag tcc aac att ccc ttg gta gct gga ctt     1799
Thr Cys Glu Ala Pro Thr Glu Ser Asn Ile Pro Leu Val Ala Gly Leu
                550                 555                 560

tct gct gct gga ctc tcc ctc ctg aca tta gca cca ttt ctc ctc tgg     1847
Ser Ala Ala Gly Leu Ser Leu Leu Thr Leu Ala Pro Phe Leu Leu Trp
            565                 570                 575

ctt cgg aaa tgc tta cgg aaa gca aag aaa ttt gtt cct gcc agc agc     1895
Leu Arg Lys Cys Leu Arg Lys Ala Lys Lys Phe Val Pro Ala Ser Ser
        580                 585                 590

tgc caa agc ctt gaa tca gac gga agc tac caa aag cct tct tac atc     1943
Cys Gln Ser Leu Glu Ser Asp Gly Ser Tyr Gln Lys Pro Ser Tyr Ile
    595                 600                 605

ctt taa gttcaaaaga atcagaaaca ggtgcatctg gggaactaga gggatacact      1999
Leu  *
610

gaagttaaca gagacagata actctcctcg ggtctctggc ccttcttgcc tactatgcca   2059

gatgccttta tggctgaaac cgcaacaccc atcaccactt caatagatca aagtccagca   2119

ggcaaggacg gccttcaact gaaaagactc agtgttccct ttcctactct caggatcaag   2179

aaagtgttgg ctaatgaagg gaaaggatat tttcttccaa gcaaaggtga agagaccaag   2239

actctgaaat ctcagaattc cttttctaac tctcccttgc tcgctgtaaa atcttggcac   2299

agaaacacaa tattttgtgg ctttctttct tttgcccttc acagtgtttc gacagctgat   2359
```

-continued

tacacagttg ctgtcataag aatgaataat aattatccag agtttagagg aaaaaaatga 2419

ctaaaaatat tataacttaa aaaaatgaca gatgttgaat gcccacaggc aaatgcatgg 2479

agggttgtta atggtgcaaa tcctactgaa tgctctgtgc gagggttact atgcacaatt 2539

taatcacttt catccctatg ggattcagtg cttcttaaag agttcttaag gattgtgata 2599

tttttacttg cattgaatat attataatct tccatacttc ttcattcaat acaagtgtgg 2659

tagggactta aaaaacttgt aaatgctgtc aactatgata tggtaaaagt tacttattct 2719

agattacccc ctcattgttt attaacaaat tatgttacat ctgttttaaa tttatttcaa 2779

aaagggaaac tattgtcccc tagcaaggca tgatgttaac cagaataaag ttctgagtgt 2839

ttttactaca gttgtttttt gaaaacatgg tagaattgga gagtaaaaac tgaatggaag 2899

gtttgtatat tgtcagatat tttttcagaa atatgtggtt tccacgatga aaaacttcca 2959

tgaggccaaa cgttttgaac taataaaagc ataaatgcaa acacacaaag gtataatttt 3019

atgaatgtct ttgttggaaa agaatacaga aagatggatg tgctttgcat tcctacaaag 3079

atgtttgtca gatgtgatat gtaaacataa ttcttgtata ttatggaaga ttttaaattc 3139

acaatagaaa ctcaccatgt aaaagagtca tctggtagat ttttaacgaa tgaagatgtc 3199

taatagttat tccctatttg ttttcttctg tatgttaggg tgctctggaa gagaggaatg 3259

cctgtgtgag caagcattta tgtttattta taagcagatt taacaattcc aaaggaatct 3319

ccagttttca gttgatcact ggcaatgaaa aattctcagt cagtaattgc caaagctgct 3379

ctagccttga ggagtgtgag aatcaaaact ctcctacact tccattaact tagcatgtgt 3439

tgaaaaaaaa agtttcagag aagttctggc tgaacactgg caacgacaaa gccaacagtc 3499

aaaacagaga tgtgataagg atcagaacag cagaggttct tttaaagggg cagaaaaact 3559

ctgggaaata agagagaaca actactgtga tcaggctatg tatggaatac agtgttattt 3619

tctttgaaat tgtttaagtg ttgtaaatat ttatgtaaac tgcattagaa attagctgtg 3679

tgaaatacca gtgtggtttg tgtttgagtt ttattgagaa ttttaaatta taacttaaaa 3739

tattttataa tttttaaagt atatatttat ttaagcttat gtcagaccta tttgacataa 3799

cactataaag gttgacaata aatgtgctta tgttt 3834

<210> SEQ ID NO 36
<211> LENGTH: 610
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 36

Met Ile Ala Ser Gln Phe Leu Ser Ala Leu Thr Leu Val Leu Leu Ile
 1   5   10   15

Lys Glu Ser Gly Ala Trp Ser Tyr Asn Thr Ser Thr Glu Ala Met Thr
            20   25   30

Tyr Asp Glu Ala Ser Ala Tyr Cys Gln Gln Arg Tyr Thr His Leu Val
        35   40   45

Ala Ile Gln Asn Lys Glu Glu Ile Glu Tyr Leu Asn Ser Ile Leu Ser
    50   55   60

Tyr Ser Pro Ser Tyr Tyr Trp Ile Gly Ile Arg Lys Val Asn Asn Val
65   70   75   80

Trp Val Trp Val Gly Thr Gln Lys Pro Leu Thr Glu Glu Ala Lys Asn
                85   90   95

-continued

```
Trp Ala Pro Gly Glu Pro Asn Asn Arg Gln Lys Asp Glu Asp Cys Val
            100                 105                 110

Glu Ile Tyr Ile Lys Arg Glu Lys Asp Val Gly Met Trp Asn Asp Glu
        115                 120                 125

Arg Cys Ser Lys Lys Lys Leu Ala Leu Cys Tyr Thr Ala Ala Cys Thr
    130                 135                 140

Asn Thr Ser Cys Ser Gly His Gly Glu Cys Val Glu Thr Ile Asn Asn
145                 150                 155                 160

Tyr Thr Cys Lys Cys Asp Pro Gly Phe Ser Gly Leu Lys Cys Glu Gln
                165                 170                 175

Ile Val Asn Cys Thr Ala Leu Glu Ser Pro Glu His Gly Ser Leu Val
            180                 185                 190

Cys Ser His Pro Leu Gly Asn Phe Ser Tyr Asn Ser Ser Cys Ser Ile
        195                 200                 205

Ser Cys Asp Arg Gly Tyr Leu Pro Ser Ser Met Glu Thr Met Gln Cys
    210                 215                 220

Met Ser Ser Gly Glu Trp Ser Ala Pro Ile Pro Ala Cys Asn Val Val
225                 230                 235                 240

Glu Cys Asp Ala Val Thr Asn Pro Ala Asn Gly Phe Val Glu Cys Phe
                245                 250                 255

Gln Asn Pro Gly Ser Phe Pro Trp Asn Thr Thr Cys Thr Phe Asp Cys
            260                 265                 270

Glu Glu Gly Phe Glu Leu Met Gly Ala Gln Ser Leu Gln Cys Thr Ser
        275                 280                 285

Ser Gly Asn Trp Asp Asn Glu Lys Pro Thr Cys Lys Ala Val Thr Cys
    290                 295                 300

Arg Ala Val Arg Gln Pro Gln Asn Gly Ser Val Arg Cys Ser His Ser
305                 310                 315                 320

Pro Ala Gly Glu Phe Thr Phe Lys Ser Ser Cys Asn Phe Thr Cys Glu
                325                 330                 335

Glu Gly Phe Met Leu Gln Gly Pro Ala Gln Val Glu Cys Thr Thr Gln
            340                 345                 350

Gly Gln Trp Thr Gln Gln Ile Pro Val Cys Glu Ala Phe Gln Cys Thr
        355                 360                 365

Ala Leu Ser Asn Pro Glu Arg Gly Tyr Met Asn Cys Leu Pro Ser Ala
    370                 375                 380

Ser Gly Ser Phe Arg Tyr Gly Ser Ser Cys Glu Phe Ser Cys Glu Gln
385                 390                 395                 400

Gly Phe Val Leu Lys Gly Ser Lys Arg Leu Gln Cys Gly Pro Thr Gly
                405                 410                 415

Glu Trp Asp Asn Glu Lys Pro Thr Cys Glu Ala Val Arg Cys Asp Ala
            420                 425                 430

Val His Gln Pro Pro Lys Gly Leu Val Arg Cys Ala His Ser Pro Ile
        435                 440                 445

Gly Glu Phe Thr Tyr Lys Ser Ser Cys Ala Phe Ser Cys Glu Glu Gly
    450                 455                 460

Phe Glu Leu Tyr Gly Ser Thr Gln Leu Glu Cys Thr Ser Gln Gly Gln
465                 470                 475                 480

Trp Thr Glu Glu Val Pro Ser Cys Gln Val Val Lys Cys Ser Ser Leu
                485                 490                 495
```

-continued

```
Ala Val Pro Gly Lys Ile Asn Met Ser Cys Ser Gly Glu Pro Val Phe
            500                 505                 510

Gly Thr Val Cys Lys Phe Ala Cys Pro Glu Gly Trp Thr Leu Asn Gly
        515                 520                 525

Ser Ala Ala Arg Thr Cys Gly Ala Thr Gly His Trp Ser Gly Leu Leu
    530                 535                 540

Pro Thr Cys Glu Ala Pro Thr Glu Ser Asn Ile Pro Leu Val Ala Gly
545                 550                 555                 560

Leu Ser Ala Ala Gly Leu Ser Leu Leu Thr Leu Ala Pro Phe Leu Leu
                565                 570                 575

Trp Leu Arg Lys Cys Leu Arg Lys Ala Lys Lys Phe Val Pro Ala Ser
            580                 585                 590

Ser Cys Gln Ser Leu Glu Ser Asp Gly Ser Tyr Gln Lys Pro Ser Tyr
        595                 600                 605

Ile Leu
    610
```

<210> SEQ ID NO 37
<211> LENGTH: 1922
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (406)...(1428)
<223> OTHER INFORMATION: Nucleotide sequence encoding nucleotide binding protein (G Protein), beta polypeptide 3 (GNB3)

<400> SEQUENCE: 37

```
ccacaatagg ggcagacctg tccatccttc tctgtgggtc ccctgtacct ttctccccca     60

acaggatcag acccagaggc agctggttgg ggtttgtcga gaagaaggat tatccagatc    120

agtcctttct aatctcagct cctgcctgta ccctcccata ctcaccaaac cctcttcccc    180

accaccctga gctgaggagc acagtttgag gccccccaa ccccccgccg gtcggggcca    240

ggccaggcca ggccagctcc tctggcagca gagcctgggc aggtgacggg cgggcgcggg    300

cgtcgcagct gagggagtaa ggaggctccc aggaaccgga gctggaaacc cggccgaggt    360

ccagccagag cccaagagcc agagtgaccc ctcgacctgt cagcc atg ggg gag atg    417
                                                 Met Gly Glu Met
                                                   1

gag caa ctg cgt cag gaa gcg gag cag ctc aag aag cag att gca gat      465
Glu Gln Leu Arg Gln Glu Ala Glu Gln Leu Lys Lys Gln Ile Ala Asp
 5                  10                  15                  20

gcc agg aaa gcc tgt gct gac gtt act ctg gca gag ctg gtg tct ggc      513
Ala Arg Lys Ala Cys Ala Asp Val Thr Leu Ala Glu Leu Val Ser Gly
                25                  30                  35

cta gag gtg gtg gga cga gtc cag atg cgg acg cgg cgg acg tta agg      561
Leu Glu Val Val Gly Arg Val Gln Met Arg Thr Arg Arg Thr Leu Arg
            40                  45                  50

gga cac ctg gcc aag att tac gcc atg cac tgg gcc act gat tct aag      609
Gly His Leu Ala Lys Ile Tyr Ala Met His Trp Ala Thr Asp Ser Lys
        55                  60                  65

ctg ctg gta agt gcc tcg caa gat ggg aag ctg atc gtg tgg gac agc      657
Leu Leu Val Ser Ala Ser Gln Asp Gly Lys Leu Ile Val Trp Asp Ser
    70                  75                  80

tac acc acc aac aag gtg cac gcc atc cca ctg cgc tcc tcc tgg gtc      705
Tyr Thr Thr Asn Lys Val His Ala Ile Pro Leu Arg Ser Ser Trp Val
 85                  90                  95                  100
```

-continued

```
atg acc tgt gcc tat gcc cca tca ggg aac ttt gtg gca tgt ggg ggg      753
Met Thr Cys Ala Tyr Ala Pro Ser Gly Asn Phe Val Ala Cys Gly Gly
                105                 110                 115

ctg gac aac atg tgt tcc atc tac aac ctc aaa tcc cgt gag ggc aat      801
Leu Asp Asn Met Cys Ser Ile Tyr Asn Leu Lys Ser Arg Glu Gly Asn
            120                 125                 130

gtc aag gtc agc cgg gag ctt tct gct cac aca ggt tat ctc tcc tgc      849
Val Lys Val Ser Arg Glu Leu Ser Ala His Thr Gly Tyr Leu Ser Cys
        135                 140                 145

tgc cgc ttc ctg gat gac aac aat att gtg acc agc tcg ggg gac acc      897
Cys Arg Phe Leu Asp Asp Asn Asn Ile Val Thr Ser Ser Gly Asp Thr
    150                 155                 160

acg tgt gcc ttg tgg gac att gag act ggg cag cag aag act gta ttt      945
Thr Cys Ala Leu Trp Asp Ile Glu Thr Gly Gln Gln Lys Thr Val Phe
165                 170                 175                 180

gtg gga cac acg ggt gac tgc atg agc ctg gct gtg tct cct gac ttc      993
Val Gly His Thr Gly Asp Cys Met Ser Leu Ala Val Ser Pro Asp Phe
                185                 190                 195

aat ctc ttc att tcg ggg gcc tgt gat gcc agt gcc aag ctc tgg gat     1041
Asn Leu Phe Ile Ser Gly Ala Cys Asp Ala Ser Ala Lys Leu Trp Asp
            200                 205                 210

gtg cga gag ggg acc tgc cgt cag act ttc act ggc cac gag tcg gac     1089
Val Arg Glu Gly Thr Cys Arg Gln Thr Phe Thr Gly His Glu Ser Asp
        215                 220                 225

atc aac gcc atc tgt ttc ttc ccc aat gga gag gcc atc tgc acg ggc     1137
Ile Asn Ala Ile Cys Phe Phe Pro Asn Gly Glu Ala Ile Cys Thr Gly
    230                 235                 240

tcg gat gac gct tcc tgc cgc ttg ttt gac ctg cgg gca gac cag gag     1185
Ser Asp Asp Ala Ser Cys Arg Leu Phe Asp Leu Arg Ala Asp Gln Glu
245                 250                 255                 260

ctg atc tgc ttc tcc cac gag agc atc atc tgc ggc atc acg tcc gtg     1233
Leu Ile Cys Phe Ser His Glu Ser Ile Ile Cys Gly Ile Thr Ser Val
                265                 270                 275

gcc ttc tcc ctc agt ggc cgc cta cta ttc gct ggc tac gac gac ttc     1281
Ala Phe Ser Leu Ser Gly Arg Leu Leu Phe Ala Gly Tyr Asp Asp Phe
            280                 285                 290

aac tgc aat gtc tgg gac tcc atg aag tct gag cgt gtg ggc atc ctc     1329
Asn Cys Asn Val Trp Asp Ser Met Lys Ser Glu Arg Val Gly Ile Leu
        295                 300                 305

tct ggc cac gat aac agg gtg agc tgc ctg gga gtc aca gct gac ggg     1377
Ser Gly His Asp Asn Arg Val Ser Cys Leu Gly Val Thr Ala Asp Gly
    310                 315                 320

atg gct gtg gcc aca ggt tcc tgg gac agc ttc ctc aaa atc tgg aac     1425
Met Ala Val Ala Thr Gly Ser Trp Asp Ser Phe Leu Lys Ile Trp Asn
325                 330                 335                 340

tga ggaggctgga gaaagggaag tggaaggcag tgaacacact cagcagcccc          1478
 *

ctgcccgacc ccatctcatt caggtgttct cttctatatt ccgggtgcca ttcccactaa   1538

gctttctcct ttgagggcag tggggagcat gggactgtgc ctttgggagg cagcatcagg   1598

gacacagggg caaagaactg ccccatctcc tcccatggcc ttccctcccc acagtcctca   1658

cagcctctcc cttaatgagc aaggacaacc tgcccctccc cagccctttg caggcccagc   1718

agacttgagt ctgaggcccc aggccctagg attcctcccc cagagccact acctttgtcc   1778

aggcctgggt ggtatagggc gtttggccct gtgactatgg ctctggcacc actagggtcc   1838
```

-continued

tggccctctt cttattcatg ctttctcctt tttctacctt tttttctctc ctaagacacc 1898

tgcaataaag tgtagcaccc tggt 1922

<210> SEQ ID NO 38
<211> LENGTH: 340
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 38

Met Gly Glu Met Glu Gln Leu Arg Gln Glu Ala Glu Gln Leu Lys Lys
1 5 10 15

Gln Ile Ala Asp Ala Arg Lys Ala Cys Ala Asp Val Thr Leu Ala Glu
20 25 30

Leu Val Ser Gly Leu Glu Val Val Gly Arg Val Gln Met Arg Thr Arg
35 40 45

Arg Thr Leu Arg Gly His Leu Ala Lys Ile Tyr Ala Met His Trp Ala
50 55 60

Thr Asp Ser Lys Leu Leu Val Ser Ala Ser Gln Asp Gly Lys Leu Ile
65 70 75 80

Val Trp Asp Ser Tyr Thr Thr Asn Lys Val His Ala Ile Pro Leu Arg
85 90 95

Ser Ser Trp Val Met Thr Cys Ala Tyr Ala Pro Ser Gly Asn Phe Val
100 105 110

Ala Cys Gly Gly Leu Asp Asn Met Cys Ser Ile Tyr Asn Leu Lys Ser
115 120 125

Arg Glu Gly Asn Val Lys Val Ser Arg Glu Leu Ser Ala His Thr Gly
130 135 140

Tyr Leu Ser Cys Cys Arg Phe Leu Asp Asp Asn Asn Ile Val Thr Ser
145 150 155 160

Ser Gly Asp Thr Thr Cys Ala Leu Trp Asp Ile Glu Thr Gly Gln Gln
165 170 175

Lys Thr Val Phe Val Gly His Thr Gly Asp Cys Met Ser Leu Ala Val
180 185 190

Ser Pro Asp Phe Asn Leu Phe Ile Ser Gly Ala Cys Asp Ala Ser Ala
195 200 205

Lys Leu Trp Asp Val Arg Glu Gly Thr Cys Arg Gln Thr Phe Thr Gly
210 215 220

His Glu Ser Asp Ile Asn Ala Ile Cys Phe Phe Pro Asn Gly Glu Ala
225 230 235 240

Ile Cys Thr Gly Ser Asp Asp Ala Ser Cys Arg Leu Phe Asp Leu Arg
245 250 255

Ala Asp Gln Glu Leu Ile Cys Phe Ser His Glu Ser Ile Ile Cys Gly
260 265 270

Ile Thr Ser Val Ala Phe Ser Leu Ser Gly Arg Leu Leu Phe Ala Gly
275 280 285

Tyr Asp Asp Phe Asn Cys Asn Val Trp Asp Ser Met Lys Ser Glu Arg
290 295 300

Val Gly Ile Leu Ser Gly His Asp Asn Arg Val Ser Cys Leu Gly Val
305 310 315 320

Thr Ala Asp Gly Met Ala Val Ala Thr Gly Ser Trp Asp Ser Phe Leu
325 330 335

-continued

```
Lys Ile Trp Asn
            340


<210> SEQ ID NO 39
<211> LENGTH: 2443
<212> TYPE: DNA
<213> ORGANISM: Homo sapien
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (162)...(1253)
<223> OTHER INFORMATION: Nucleotide sequence encoding angiotensin
      receptor 2  (AGTR2)

<400> SEQUENCE: 39

acgtcccagc gtctgagaga acgagtaagc aagaattcaa agcattctgc agcctgaatt     60

ttgaaggagt gtgtttaggc actaagcaag ctgatttatg ataactgctt taaacttcaa    120

caaccaaagg cataagaact aggagctgct gacatttcaa t atg aag ggc aac tcc    176
                                              Met Lys Gly Asn Ser
                                               1               5

acc ctt gcc act act agc aaa aac att acc agc ggt ctt cac ttc ggg      224
Thr Leu Ala Thr Thr Ser Lys Asn Ile Thr Ser Gly Leu His Phe Gly
                10                  15                  20

ctt gtg aac atc tct ggc aac aat gag tct acc ttg aac tgt tca cag      272
Leu Val Asn Ile Ser Gly Asn Asn Glu Ser Thr Leu Asn Cys Ser Gln
            25                  30                  35

aaa cca tca gat aag cat tta gat gca att cct att ctt tac tac att      320
Lys Pro Ser Asp Lys His Leu Asp Ala Ile Pro Ile Leu Tyr Tyr Ile
        40                  45                  50

ata ttt gta att gga ttt ctg gtc aat att gtc gtg gtt aca ctg ttt      368
Ile Phe Val Ile Gly Phe Leu Val Asn Ile Val Val Val Thr Leu Phe
    55                  60                  65

tgt tgt caa aag ggt cct aaa aag gtt tct agc ata tac atc ttc aac      416
Cys Cys Gln Lys Gly Pro Lys Lys Val Ser Ser Ile Tyr Ile Phe Asn
70                  75                  80                  85

ctc gct gtg gct gat tta ctc ctt ttg gct act ctt cct cta tgg gca      464
Leu Ala Val Ala Asp Leu Leu Leu Leu Ala Thr Leu Pro Leu Trp Ala
                90                  95                  100

acc tat tat tct tat aga tat gac tgg ctc ttt gga cct gtg atg tgc      512
Thr Tyr Tyr Ser Tyr Arg Tyr Asp Trp Leu Phe Gly Pro Val Met Cys
            105                 110                 115

aaa gtt ttt ggt tct ttt ctt acc ctg aac atg ttt gca agc att ttt      560
Lys Val Phe Gly Ser Phe Leu Thr Leu Asn Met Phe Ala Ser Ile Phe
        120                 125                 130

ttt atc acc tgc atg agt gtt gat agg tac caa tct gtc atc tac ccc      608
Phe Ile Thr Cys Met Ser Val Asp Arg Tyr Gln Ser Val Ile Tyr Pro
    135                 140                 145

ttt ctg tct caa aga aga aat ccc tgg caa gca tct tat ata gtt ccc      656
Phe Leu Ser Gln Arg Arg Asn Pro Trp Gln Ala Ser Tyr Ile Val Pro
150                 155                 160                 165

ctt gtt tgg tgt atg gcc tgt ttg tcc tca ttg cca aca ttt tat ttt      704
Leu Val Trp Cys Met Ala Cys Leu Ser Ser Leu Pro Thr Phe Tyr Phe
                170                 175                 180

cga gac gtc aga acc att gaa tac tta gga gtg aat gct tgc att atg      752
Arg Asp Val Arg Thr Ile Glu Tyr Leu Gly Val Asn Ala Cys Ile Met
            185                 190                 195

gct ttc cca cct gag aaa tat gcc caa tgg tca gct ggg att gcc tta      800
Ala Phe Pro Pro Glu Lys Tyr Ala Gln Trp Ser Ala Gly Ile Ala Leu
        200                 205                 210
```

-continued

```
atg aaa aat atc ctt ggt ttt att atc cct tta ata ttc ata gca aca      848
Met Lys Asn Ile Leu Gly Phe Ile Ile Pro Leu Ile Phe Ile Ala Thr
    215                 220                 225

tgc tat ttt gga att aga aaa cac tta ctg aag acg aat agc tat ggg      896
Cys Tyr Phe Gly Ile Arg Lys His Leu Leu Lys Thr Asn Ser Tyr Gly
230                 235                 240                 245

aag aac agg ata acc cgt gac caa gtc ctg aag atg gca gct gct gtt      944
Lys Asn Arg Ile Thr Arg Asp Gln Val Leu Lys Met Ala Ala Ala Val
                250                 255                 260

gtt ctg gcc ttc atc att tgg tgc ctt ccc ttc cat gtt ctg acc ttc      992
Val Leu Ala Phe Ile Ile Trp Cys Leu Pro Phe His Val Leu Thr Phe
            265                 270                 275

ctg gat gct ctg gcc tgg atg ggt gtc att aat agc tgc gaa gtt ata     1040
Leu Asp Ala Leu Ala Trp Met Gly Val Ile Asn Ser Cys Glu Val Ile
        280                 285                 290

gca gtc att gac ctg gca ctt cct ttt gcc atc ctc ttg gga ttc acc     1088
Ala Val Ile Asp Leu Ala Leu Pro Phe Ala Ile Leu Leu Gly Phe Thr
    295                 300                 305

aac agc tgc gtt aat ccg ttt ctg tat tgt ttt gtt gga aac cgg ttc     1136
Asn Ser Cys Val Asn Pro Phe Leu Tyr Cys Phe Val Gly Asn Arg Phe
310                 315                 320                 325

caa cag aag ctc cgc agt gtg ttt agg gtt cca att act tgg ctc caa     1184
Gln Gln Lys Leu Arg Ser Val Phe Arg Val Pro Ile Thr Trp Leu Gln
                330                 335                 340

ggg aaa aga gag agt atg tct tgc cgg aaa agc agt tct ctt aga gaa     1232
Gly Lys Arg Glu Ser Met Ser Cys Arg Lys Ser Ser Ser Leu Arg Glu
            345                 350                 355

atg gag acc ttt gtg tct taa acggagagca aaatgcatgt aatcaacatg        1283
Met Glu Thr Phe Val Ser  *
        360

gctacttgct ttgaggctca ccagaattat ttttaagtgg ttttaataaa ataataaaat   1343

ttcccctaat cttttctgaa tcttctgaaa ccaaatgtaa ctatgtttat cgtccagtga   1403

ctttcaggaa tgcccattgt tttctgatat gtttgtacaa gatttcattg gtgagacata   1463

tttacaacct agaagtaact ggtgatatat ctcaaattgt aattaataat agattgtgaa   1523

taatgatttg gggattcaga tttctctttg aaacatgctt gtgtttctta gtggggtttt   1583

atatccattt ttatcaggat ttcctcttga accagaacca gtctttcaac tcattgcatc   1643

atttacaaga caacattgta agagagatga gcacttctaa gttgagtata ttataataga   1703

ttagtactgg attattcagg ctttaggcat atgcttcttt aaaaacgcta taaattatat   1763

tcctcttgca tttcacttga gtggaggttt atagttaatc tataactaca tattgaatag   1823

ggctaggaat atagattaaa tcatactcct atgctttagc ttatttttac agttatagaa   1883

agcaagatgt actataacat agaattgcaa tctataatat ttgtgtgttc actaaactct   1943

gaataagcac tttttaaaaa actttctact cattttaatg attgtttaaa ggtttctatt   2003

ttctctgata ctttttttgaa atcagtaaac actgtgtatt gttgtaaaat gtaaaggtca   2063

cttttcacat ccttgacttt ttagatgtgc tgctttgata tataggacat tgatttgatt   2123

tttattatta atgctttggt tctgggttgt ttcctaaaat atctgggtgg cttaaaaaaa   2183

actctttaac ttgtaataaa cccttaactg gcataggaaa tggtatccag aatggaattt   2243

tgctacatgg ggtctgggtg ggggcaaaga gacccagtca attacatgtt tggtaccaag   2303

aaaggaacct gtcagggcag tacaatgtga ctttgaaaat atataccgtg ggggtagttt   2363
```

-continued

taccctatat ctataaacac tgtttgttcc agaatctgta tgattctatg gagctatttt 2423

aaaccaattg caggtctaga 2443

<210> SEQ ID NO 40
<211> LENGTH: 363
<212> TYPE: PRT
<213> ORGANISM: Homo sapien

<400> SEQUENCE: 40

Met Lys Gly Asn Ser Thr Leu Ala Thr Thr Ser Lys Asn Ile Thr Ser
1 5 10 15

Gly Leu His Phe Gly Leu Val Asn Ile Ser Gly Asn Asn Glu Ser Thr
20 25 30

Leu Asn Cys Ser Gln Lys Pro Ser Asp Lys His Leu Asp Ala Ile Pro
35 40 45

Ile Leu Tyr Tyr Ile Ile Phe Val Ile Gly Phe Leu Val Asn Ile Val
50 55 60

Val Val Thr Leu Phe Cys Cys Gln Lys Gly Pro Lys Lys Val Ser Ser
65 70 75 80

Ile Tyr Ile Phe Asn Leu Ala Val Ala Asp Leu Leu Leu Leu Ala Thr
85 90 95

Leu Pro Leu Trp Ala Thr Tyr Tyr Ser Tyr Arg Tyr Asp Trp Leu Phe
100 105 110

Gly Pro Val Met Cys Lys Val Phe Gly Ser Phe Leu Thr Leu Asn Met
115 120 125

Phe Ala Ser Ile Phe Phe Ile Thr Cys Met Ser Val Asp Arg Tyr Gln
130 135 140

Ser Val Ile Tyr Pro Phe Leu Ser Gln Arg Arg Asn Pro Trp Gln Ala
145 150 155 160

Ser Tyr Ile Val Pro Leu Val Trp Cys Met Ala Cys Leu Ser Ser Leu
165 170 175

Pro Thr Phe Tyr Phe Arg Asp Val Arg Thr Ile Glu Tyr Leu Gly Val
180 185 190

Asn Ala Cys Ile Met Ala Phe Pro Pro Glu Lys Tyr Ala Gln Trp Ser
195 200 205

Ala Gly Ile Ala Leu Met Lys Asn Ile Leu Gly Phe Ile Ile Pro Leu
210 215 220

Ile Phe Ile Ala Thr Cys Tyr Phe Gly Ile Arg Lys His Leu Leu Lys
225 230 235 240

Thr Asn Ser Tyr Gly Lys Asn Arg Ile Thr Arg Asp Gln Val Leu Lys
245 250 255

Met Ala Ala Ala Val Val Leu Ala Phe Ile Ile Trp Cys Leu Pro Phe
260 265 270

His Val Leu Thr Phe Leu Asp Ala Leu Ala Trp Met Gly Val Ile Asn
275 280 285

Ser Cys Glu Val Ile Ala Val Ile Asp Leu Ala Leu Pro Phe Ala Ile
290 295 300

Leu Leu Gly Phe Thr Asn Ser Cys Val Asn Pro Phe Leu Tyr Cys Phe
305 310 315 320

Val Gly Asn Arg Phe Gln Gln Lys Leu Arg Ser Val Phe Arg Val Pro
325 330 335

-continued

Ile Thr Trp Leu Gln Gly Lys Arg Glu Ser Met Ser Cys Arg Lys Ser
340 345 350

Ser Ser Leu Arg Glu Met Glu Thr Phe Val Ser
355 360

<210> SEQ ID NO 41
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 41

actgcctgat aaccatgctg 20

<210> SEQ ID NO 42
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 42

atacttacac accaggaggg 20

<210> SEQ ID NO 43
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 43

atgcctgctc caaaggcac 19

<210> SEQ ID NO 44
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 44

atgcctgctc caaaggcacc 20

<210> SEQ ID NO 45
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 45

atgcctgctc caaaggcaca t 21

<210> SEQ ID NO 46
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

-continued

<400> SEQUENCE: 46

tacttctggt tctctgagcg 20

<210> SEQ ID NO 47
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 47

actcaccttg aactcgtctc 20

<210> SEQ ID NO 48
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 48

tggttctctg agcgagtctt 20

<210> SEQ ID NO 49
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 49

tggttctctg agcgagtctt c 21

<210> SEQ ID NO 50
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 50

tggttctctg agcgagtctt tc 22

<210> SEQ ID NO 51
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 51

tgcagatgga ctttggcttc 20

<210> SEQ ID NO 52
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 52

tgcttgcctt ctgctacaag 20

-continued

<210> SEQ ID NO 53
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 53

cttccctgag cacctgctg 19

<210> SEQ ID NO 54
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 54

cttccctgag cacctgctgg t 21

<210> SEQ ID NO 55
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 55

cttccctgag cacctgctga 20

<210> SEQ ID NO 56
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 56

aacagctcag gacgaaactg 20

<210> SEQ ID NO 57
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 57

agaaggagtt gaccttgtcc 20

<210> SEQ ID NO 58
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 58

ggaagctcaa gtggccttc 19

<210> SEQ ID NO 59
<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 59

ggaagctcaa gtggccttcc 20

<210> SEQ ID NO 60
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 60

ggaagctcaa gtggccttca ac 22

<210> SEQ ID NO 61
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 61

aagtcactgg cagagctgg 19

<210> SEQ ID NO 62
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 62

gcaccagggc tttgttgaag 20

<210> SEQ ID NO 63
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 63

ttttccccgt agggctcca 19

<210> SEQ ID NO 64
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 64

ttttccccgt agggctccac 20

<210> SEQ ID NO 65
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

-continued

<400> SEQUENCE: 65

ttttccccgt agggctccag c 21

<210> SEQ ID NO 66
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 66

tgcagaagtc actggcagag 20

<210> SEQ ID NO 67
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 67

gttgaagttt tccccgtagg 20

<210> SEQ ID NO 68
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Aritificial sequence

<400> SEQUENCE: 68

actcctccac ctgctggtc 19

<210> SEQ ID NO 69
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 69

actcctccac ctgctggtcc 20

<210> SEQ ID NO 70
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 70

actcctccac ctgctggtct a 21

<210> SEQ ID NO 71
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 71

aggacgtgcg tggcaacctg 20

-continued

<210> SEQ ID NO 72
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 72

agctctgcca gtgacttctg 20

<210> SEQ ID NO 73
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 73

gtgacttctg cagcccctc 19

<210> SEQ ID NO 74
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artitifical sequence

<400> SEQUENCE: 74

gtgacttctg cagccctca 20

<210> SEQ ID NO 75
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 75

gtgacttctg cagccctcg gt 22

<210> SEQ ID NO 76
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 76

cctgaccttc cagatgaag 19

<210> SEQ ID NO 77
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 77

tcaggttgcc acgcacgtc 19

<210> SEQ ID NO 78
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

-continued

<400> SEQUENCE: 78

caggatctcg gccagtgc 18

<210> SEQ ID NO 79
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 79

caggatctcg gccagtgcc 19

<210> SEQ ID NO 80
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 80

caggatctcg gccagtgctg 20

<210> SEQ ID NO 81
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 81

acctgcgaga gcttcagcag 20

<210> SEQ ID NO 82
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 82

tctccatgcg ctgtgcgtag 20

<210> SEQ ID NO 83
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 83

agctgcgcac ccaggtca 18

<210> SEQ ID NO 84
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 84

agctgcgcac ccaggtcaa 19

-continued

<210> SEQ ID NO 85
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 85

agctgcgcac ccaggtcagc 20

<210> SEQ ID NO 86
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 86

tgtccaagga gctgcaggc 19

<210> SEQ ID NO 87
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 87

cttacgcagc ttgcgcaggt 20

<210> SEQ ID NO 88
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 88

gcggacatgg aggacgtg 18

<210> SEQ ID NO 89
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 89

gcggacatgg aggacgtgc 19

<210> SEQ ID NO 90
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 90

gcggacatgg aggacgtgtg 20

<210> SEQ ID NO 91
<211> LENGTH: 20

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 91

gttgtagaaa gaaccgctgc 20

<210> SEQ ID NO 92
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 92

gagaacgagt cttcaggtac 20

<210> SEQ ID NO 93
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 93

acaatctggg ctatgagatc a 21

<210> SEQ ID NO 94
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 94

acaatctggg ctatgagatc aa 22

<210> SEQ ID NO 95
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 95

acaatctggg ctatgagatc agt 23

<210> SEQ ID NO 96
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 96

cactctacac tgcatgtctc 20

<210> SEQ ID NO 97
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

-continued

<400> SEQUENCE: 97

accctttctga aaaggagagg 20

<210> SEQ ID NO 98
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 98

gaggagagac aaggcagata 20

<210> SEQ ID NO 99
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 99

gaggagagac aaggcagata t 21

<210> SEQ ID NO 100
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 100

gaggagagac aaggcagata gt 22

<210> SEQ ID NO 101
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 101

aaaggttcag ttgctgctgc 20

<210> SEQ ID NO 102
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 102

gctggggaag gtctaataac 20

<210> SEQ ID NO 103
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 103

gttgctgctg cctcgaatc 19

-continued

<210> SEQ ID NO 104
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 104

gttgctgctg cctcgaatcc 20

<210> SEQ ID NO 105
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 105

gttgctgctg cctcgaatct g 21

<210> SEQ ID NO 106
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 106

cgtctttctc cagatgatgc 20

<210> SEQ ID NO 107
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 107

agtgtcctat gggctgtttg 20

<210> SEQ ID NO 108
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 108

ggatgccatt catacctta c 21

<210> SEQ ID NO 109
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 109

ggatgccatt catacctta cc 22

<210> SEQ ID NO 110
<211> LENGTH: 23

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 110

ggatgccatt catacctta cgc 23

<210> SEQ ID NO 111
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 111

tgggaaaaca gtgcagtgtg 20

<210> SEQ ID NO 112
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 112

tgatcgtctt cagaacgagg 20

<210> SEQ ID NO 113
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 113

ccagaccatc atcatcccat gga 23

<210> SEQ ID NO 114
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 114

ccagaccatc atcccatgga a 21

<210> SEQ ID NO 115
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 115

ccagaccatc atcccatgga gc 22

<210> SEQ ID NO 116
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

-continued

<400> SEQUENCE: 116

cagcaatcgt ctttctccag 20

<210> SEQ ID NO 117
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 117

tcctatgggc tgtttgatgc 20

<210> SEQ ID NO 118
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 118

gtctttctcc agatgatgcc a 21

<210> SEQ ID NO 119
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 119

gtctttctcc agatgatgcc aa 22

<210> SEQ ID NO 120
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 120

gtctttctcc agatgatgcc agt 23

<210> SEQ ID NO 121
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 121

agcggataac aatttcacac agg 23

<210> SEQ ID NO 122
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

-continued

<400> SEQUENCE: 122

ggcgcacgcc tccacg 16

What is claimed:

1. A method for detecting the presence or absence in a subject of at least one allelic variant of a polymorphic region of a gene associated with cardiovascular disease, comprising:

the step of detecting the presence or absence of an allelic variant of a polymorphic region of a cytochrome C oxidase subunit VIb (COX6B) gene of the subject that is associated with high serum cholesterol or an allelic variant of a polymorphic region of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene of the subject that is associated with low serum high density lipoprotein (HDL).

2. The method of claim 1, wherein the allelic variant is of a polymorphic region of the cytochrome C oxidase subunit VIb (COX6B) gene.

3. The method of claim 1, wherein the allelic variant is of a polymorphic region of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

4. The method of claim 1, further comprising detecting the presence or absence in a subject of least one allelic variant of another gene associated with cardiovascular disease.

5. The method of claim 4, wherein the other gene is selected from the group consisting of cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apopliporotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

6. The method of claim 2, wherein the polymorphic region is a single nucleotide polymorphism (SNP).

7. The method of claim 3, wherein the polymorphic region is a single nucleotide polymorphism (SNP).

8. The method of claim 3, wherein the SNP is at position 86 of the cytochrome C oxidase subunit VIb (COX6B) gene coding sequence and the allelic variant is represented by a T nucleotide in the sense strand or an A nucleotide in the corresponding position in the antisense strand.

9. The method of claim 7, wherein the SNP is at position 2577 of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene sequence and the allelic variant is represented by an A nucleotide in the sense strand or a T nucleotide in the corresponding position in the antisense strand.

10. The method of claim 1, wherein the detecting step is by a method selected from the group consisting of allele specific hybridization, primer specific extension, oligonucleotide ligation assay, restriction enzyme site analysis and single-stranded conformation polymorphism analysis.

11. The method of claim 8, further comprising:

(a) hybridizing a target nucleic acid comprising a cytochrome C oxidase subunit VIb (COX6B)-encoding nucleic acid or fragment thereof with a nucleic acid primer that hybridizes adjacent to nucleotide 86 of the coding sequence of the COX6B gene;

(b) extending the nucleic acid primer using the target nucleic acid as a template; and

(c) determining the mass of the extended primer to identify the nucleotide present at position 86, thereby determining the presence or absence of the allelic variant.

12. The method of claim 9, further comprising:

(a) hybridizing a target nucleic acid comprising a N-acetylgluosaminyl transferase component GPI-1 (GPI-1)-encoding nucleic acid or fragment thereof with a nucleic acid primer that hybridizes adjacent to nucleotide 2577 of the GPI-1 gene;

(b) extending the nucleic acid primer using the target nucleic acid as a template; and

(c) determining the mass of the extended primer to identify the nucleotide present at position 2577, thereby determining the presence or absence of the allelic variant.

13. The method of claim 1, wherein the detecting step comprises mass spectrometry.

14. The method of claim 1, wherein the detecting step utilizes a signal moiety selected from the group consisting of: radioisotopes, enzymes, antigens, antibodies, spectrophotometric reagents, chemiluminescent reagents, fluorescent reagents and other light producing reagents.

15. The method of claims 11, wherein the nucleic acid primer is extended in the presence of at least one dideoxynucleotide.

16. The method of claim 12, wherein the nucleic acid primer is extended in the presence of at least one dideoxynucleotide.

17. The method of claim 15, wherein the dideoxynucleotide is dideoxyguanosine (ddG).

18. The method of claim 16, wherein the dideoxynucleotide is dideoxyguanosine (ddG).

19. The method of claim 11, wherein the primer is extended in the presence at least two dideoxynucleotides and the dideoxynucleotides are dideoxyguanosine (ddG) and dideoxycytosine (ddC).

20. The method of claim 12, wherein the primer is extended in the presence of at least two dideoxynucleotides and the dideoxy-nucleotides are dideoxyguanosine (ddG) and dideoxycytosine (ddC).

21. A method for indicating a predisposition to cardiovascular disease in a subject, comprising:

the step of detecting in a target nucleic acid obtained from the subject the presence or absence of at least one allelic variant of polymorphic regions of a cytochrome C oxidase subunit VIb (COX6B) gene associated with high serum cholesterol or at least one allelic variant of polymorphic regions of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene associated with low serum HDL wherein the presence of an allelic variant is indicative of a predisposition to cardiovascular disease compared to a subject who does not comprise the allelic variant.

22. The method of claim 21, wherein the allelic variant is of a polymorphic region of the cytochrome C oxidase subunit VIb (COX6B) gene.

23. The method of claim 21, wherein the allelic variant is of a polymorphic region of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

24. The method of claim 22, wherein the polymorphic region is a single nucleotide polymorphism (SNP).

25. The method of claim 23, wherein the polymorphic region is a single nucleotide polymorphism (SNP).

26. The method of claim 24, wherein the SNP is at position 86 of the cytochrome C oxidase subunit VIb (COX6B) gene coding sequence and the allelic variant is represented by a T nucleotide in the sense strand or an A nucleotide in the corresponding position in the antisense strand.

27. The method of claim 25, wherein the SNP is at position 2577 of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene sequence and the allelic variant is represented by an A nucleotide in the sense strand or a T nucleotide in the corresponding position in the antisense strand.

28. The method of claim 21, wherein the detecting step is by a method selected from the group consisting of allele specific hybridization, primer specific extension, oligonucleotide ligation assay, restriction enzyme site analysis and single-stranded conformation polymorphism analysis.

29. The method of claim 26, further comprising:

(a) hybridizing a target nucleic acid comprising a cytochrome C oxidase subunit VIb (COX6B)-encoding nucleic acid or fragment thereof with a nucleic acid primer that hybridizes adjacent to nucleotide 86 of the coding sequence of the COX6B gene;

(b) extending the nucleic acid primer using the target nucleic acid as a template; and

(c) determining the mass of the extended primer to identify the nucleotide present at position 86, thereby determining the presence or absence of the allelic variant.

30. The method of claim 27, further comprising:

(a) hybridizing a target nucleic acid comprising a N-acetylgluosaminyl transferase component GPI-1 (GPI-1)-encoding nucleic acid or fragment thereof with a nucleic acid primer that hybridizes adjacent to nucleotide 2577 of the GPI-1 gene;

(b) extending the nucleic acid primer using the target nucleic acid as a template; and

(c) determining the mass of the extended primer to identify the nucleotide present at position 2577, thereby determining the presence or absence of the allelic variant.

31. The method of claim 21, wherein the detecting step comprises mass spectrometry.

32. The method of claim 21, wherein the detecting step utilizes a signal moiety selected from the group consisting of: radioisotopes, enzymes, antigens, antibodies, spectrophotometric reagents, chemiluminescent reagents, fluorescent reagents and other light producing reagents.

33. The method of claim 21, further comprising detecting the presence or absence of at least one allelic variant of polymorphic regions of another gene associated with cardiovascular disease, wherein the presence of the two allelic variants is associated with a predisposition to cardiovascular disease compared to a subject who does not comprise the combination of allelic variants.

34. The method of claim 33, wherein the other gene is selected from the group consisting of cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

35. The method of claim 33, wherein the two allelic variants are of the cytochrome C oxidase subunit VIb (COX6B) gene and the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

36. A method of screening for biologically active agents that modulate serum cholesterol, comprising:

(a) combining a candidate agent with a cell comprising a nucleotide sequence encoding an allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene associated with high levels of serum cholesterol and operably linked to a promoter such that the nucleotide sequence is expressed as a COX6B protein in the cell; and

(b) determining the affect of the agent upon the expression and/or activity of the COX6B protein.

37. A method of screening for biologically active agents that modulate serum cholesterol, comprising:

(a) combining a candidate agent with a transgenic mouse comprising a transgenic nucleotide sequence stably integrated into the genome of the mouse a transgenic nucleotide sequence encoding an allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene which has been associated with high levels of serum cholesterol and operably linked to a promoter, wherein the transgenic nucleotide sequence is expressed and the transgenic animal develops a high level of serum cholesterol; and

(b) determining the affect of the agent upon the serum cholesterol level.

38. The method of claim 36, wherein the allelic variant is at position 86 of the cytochrome C oxidase subunit VIb (COX6B) gene.

39. The method of claims **37**, wherein the allelic variant is at position 86 of the cytochrome C oxidase subunit VIb (COX6B) gene.

40. A method of screening for biologically active agents that modulate serum high density lipoprotein (HDL), comprising:

(a) combining a candidate agent with a cell comprising a nucleotide sequence encoding an allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene associated with low levels of serum HDL and operably linked to a promoter such that the nucleotide sequence is expressed as a GPI-1 protein in the cell; and

(b) determining the affect of the agent upon the expression and/or activity of the GPI-1 protein.

41. A method of screening for biologically active agents that modulate serum high density lipoprotein (HDL), comprising:

(a) combining a candidate agent with a transgenic mouse comprising a transgenic nucleotide sequence stably integrated into the genome of the mouse encoding an allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene associated with low levels of serum HDL operably linked to a promoter, wherein the transgenic nucleotide sequence is expressed and the transgenic animal develops a low level of serum HDL; and

(b) determining the affect of the agent upon the serum HDL level.

42. The method of claim 40, wherein the allelic variant is at position 2577 of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

43. The method of claim 41, wherein the allelic variant is at position 2577 of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

44. A method for predicting a response of a subject to a cardiovascular drug, comprising:

detecting the presence or absence of at least one allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene of the subject associated with high serum cholesterol or at least one allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene of the subject associated with low serum high density lipoprotein (HDL);

wherein the presence of at least one allelic variant is indicative of a positive response.

45. The method of claim 44, wherein the allelic variant is of the cytochrome C oxidase subunit VIb (COX6B) gene.

46. The method of claim 44, wherein the allelic variant is of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

47. A method for predicting a response of a subject to a cardiovascular drug, comprising:

detecting the presence or absence of at least one allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene of the subject associated with high serum cholesterol; and

detecting the presence or absence of or at least one allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene of the subject associated with low serum high density lipoprotein (HDL);

wherein the presence of at least one allelic variant of the COX6B and at least one allelic variant of the GPI-1 gene is indicative of a positive response.

48. A method for predicting a response of a subject to a biologically active agent that modulates serum cholesterol, comprising:

detecting the presence or absence of at least one allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene of the subject associated with high cholesterol;

wherein the presence of at least one allelic variant is indicative of a positive response.

49. A method for predicting a response of a subject to a biologically active agent that modulates serum cholesterol, comprising:

detecting the presence or absence of at least one allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene of the subject associated with high cholesterol; and

detecting the presence or absence of an allelic variant of at least one other gene of the subject associated with cardiovascular disease, wherein the presence of both allelic variants is indicative of a positive response.

50. The method of claim 48, wherein the allelic variant of the cytochrome C oxidase subunit VIb (COX6B) gene is at position 86.

51. The method of claims **49**, wherein the allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene is at position 86.

52. A method for predicting a response of a subject to a biologically active agent that modulates serum high density lipoprotein (HDL), comprising:

detecting the presence or absence of at least one allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene of the subject associated with low HDL; wherein the presence of an allelic variant is indicative of a positive response.

53. A method for predicting a response of a subject to a biologically active agent that modulates serum high density lipoprotein (HDL) levels, comprising:

(a) detecting the presence or absence of at least one allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene associated with low HDL of the subject; and

(b) detecting the presence or absence of an allelic variant in at least one other gene of subject associated with cardiovascular disease, wherein the presence of both allelic variants is indicative of a positive response.

54. The method of claim 52, wherein the allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene is at position 2577.

55. The method of claims **53**, wherein the allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene is at position 2577.

56. The method of claim 49, wherein the other gene associated with cardiovascular disease is selected from the group of genes consisting of N-acetylgluosaminyl transferase component GPI (GPI-1) gene, cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r

reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

57. The method of claim 53, wherein the other gene associated with cardiovascular disease is selected from the group of genes consisting of cytochrome C oxidase subunit VIb (COX6B); cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

58. A primer or probe that specifically hybridizes adjacent to or at a polymorphic region of a cytochrome C oxidase subunit VIb (COX6B) gene associated with high serum cholesterol in combination with a primer or probe that specifically hybridizes adjacent to or at a polymorphic region of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene associated with low HDL.

59. The primers or probes of claim 58, further comprising primers or probes that specifically hybridizes adjacent to or at a polymorphic region of another gene associated with cardiovascular disease.

60. The primers or probes of claim 58, wherein the polymorphic region of the cytochrome C oxidase subunit VIb (COX6B) gene comprises nucleotide 86 of the coding strand and the polymorphic region of the N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene comprises nucleotide 2577.

61. The primers or probes of claim 59, wherein the other gene associated with cardiovascular disease is selected from the group of genes consisting of cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

62. A kit for indicating whether a subject has a predisposition to developing cardiovascular disease, comprising:

(a) at least one probe or primer that specifically hybridizes adjacent to or at a polymorphic region of a cytochrome C oxidase subunit VIb (COX6B) gene associated with high serum cholesterol.

63. The kit of claim 62 further comprising instructions for use.

64. The kit of claim 62, wherein the polymorphic region comprises nucleotide 86 of the coding strand.

65. A kit for indicating whether a subject has a predisposition to developing cardiovascular disease, comprising:

(a) at least one probe or primer which specifically hybridizes adjacent to or at a polymorphic region of a cytochrome C oxidase subunit VIb (COX6B) gene associated with high cholesterol; and

(b) at least one probe or primer which specifically hybridizes adjacent to or at a polymorphic region of another gene associated with cardiovascular disease.

66. The kit of claim 65, further comprising instructions for use.

67. The kit of claim 65, wherein the other gene associated with cardiovascular disease is selected from the group of genes consisting of N-acetylgluosaminyl transferase component GPI-1 (GPI-1); cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

68. A kit for indicating whether a subject has a predisposition to developing cardiovascular disease, comprising:

(a) at least one probe or primer that specifically hybridizes adjacent to or at a polymorphic region of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene associated with low serum high density lipoprotein (HDL).

69. The kit of claim 68 further comprising instructions for use.

70. The kit of claim 68, wherein the polymorphic region comprises nucleotide 2577 of the coding strand.

71. A kit for indicating whether a subject has a predisposition to developing cardiovascular disease, comprising:

(a) at least one probe or primer which specifically hybridizes adjacent to or at a polymorphic region of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene associated with low serum high density lipoprotein (HDL); and

(b) at least one probe or primer which specifically hybridizes adjacent to or at a polymorphic region of another gene associated with cardiovascular disease.

72. The kit of claim 71, further comprising instructions for use.

73. The kit of claim 71, wherein the other gene associated with cardiovascular disease is selected from the group of genes consisting of cytochrome C oxidase subunit VIb (COX6B); cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

74. A kit for indicating whether a subject has a predisposition to developing cardiovascular disease, comprising:

(a) at least one probe or primer which specifically hybridizes adjacent to or at a polymorphic region of a cytochrome C oxidase subunit VIb (COX6B) gene associated with high cholesterol; and

(b) at least one probe or primer which specifically hybridizes adjacent to or at a polymorphic region of a N-acetylgluosaminyl transferase component GPI-1 (GP1-1) gene associated with low HDL.

75. The kit of claim 74, further comprising instructions for use.

76. The kit of claim 74, further comprising at least one probe or primer which specifically hybridizes adjacent to or at a polymorphic region of another gene associated with cardiovascular disease.

77. The kit of claim 76, wherein the other gene associated with cardiovascular disease is selected from the group of genes consisting of cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

78. A method of diagnosing a predisposition to cardiovascular disease in a human, said method comprising the steps of:

(a) obtaining a biological sample from the human;

(b) isolating DNA from the biological sample; and

(c) detecting the presence or absence of at least one allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene in the DNA.

79. The method of claim 78, wherein at least one variant is a C to T transversion at position 86 of the cytochrome C oxidase subunit VIb gene (COX6B) coding region.

80. The method of claim 78, further comprising the step of:

detecting the presence or absence of at least one allelic variant of a second gene associated with cardiovascular disease.

81. The method of claim 80, wherein the second gene is selected from the group consisting of human N-acetylgluosaminyl transferase component GPI-1 (GPI-1); cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene.

82. A method of diagnosing a predisposition to cardiovascular disease in a human, said method comprising the steps of:

(a) obtaining a biological sample from the human;

(b) isolating DNA from the biological sample; and

(c) detecting the presence or absence of at least one allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene in the DNA.

83. The method of claim 82, wherein at least one variant is a G to A transversion at position 2577 of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

84. A method of determining a response of a human to a cardiovascular drug, said method comprising the steps of:

(a) obtaining a biological sample from the human;

(b) isolating DNA from the biological sample; and

(c) detecting the presence or absence of at least one allelic variant of a cytochrome C oxidase subunit VIb (COX6B) gene in the DNA or at least one allelic variant of a N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene in the DNA.

85. The method of claim 78, wherein the detecting step is performed by an assay selected from the group consisting of allele specific hybridization, primer specific extension, oligonucleotide ligation, restriction enzyme site analysis, and single-stranded conformation polymorphism analysis.

86. The method of claim 82, wherein the detecting step is performed by an assay selected from the group consisting of allele specific hybridization, primer specific extension, oligonucleotide ligation, restriction enzyme site analysis, and single-stranded conformation polymorphism analysis.

87. The method of claim 84, wherein the detecting step is performed by an assay selected from the group consisting of allele specific hybridization, primer specific extension, oligonucleotide ligation, restriction enzyme site analysis, and single-stranded conformation polymorphism analysis.

88. A microarray, comprising a nucleic acid having a sequence of a polymorphic region from a human cytochrome C oxidase subunit VIb (COX6B) gene.

89. The microarray of claim 88, wherein the polymorphic region comprises position 86 of the human cytochrome C oxidase subunit VIb (COX6B) coding region.

90. A microarray comprising a nucleic acid having a sequence of a polymorphic region from a human N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

91. The microarray of claim 90, wherein the polymorphic region comprises a locus selected from the group consisting of position 2577 of the human N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene, position 2829 of the human GPI-1 gene, position 2519 of the human GPI-1 gene, position 2289 of the human GPI-1 gene, position 1938 of the human GPI-1 gene, position 1563 of the human GPI-1 gene, position 2656 of the human GPI-1 gene, and position 2664 of the human GPI-1 gene.

92. The microarray of claim 91, wherein the polymorphic region comprises position 2577 of the human N-acetylgluosaminyl transferase component GPI-1 (GPI-1) gene.

93. A kit comprising:

(a) at least one probe specific for a polymorphic region of a human gene selected from the group consisting of cytochrome C oxidase subunit VIb (COX6B); N-acetylgluosaminyl transferase component GPI-1 (GPI-1); cholesterol ester transfer protein, plasma (CETP); apolipoprotein A-IV (APO A4); apolipoprotein A-I (APO A1); apolipoprotein E (APO E); apolipoprotein B (APO B); apolipoprotein C-III (APO C3); a gene encoding lipoprotein lipase (LPL); ATP-binding cassette transporter (ABC 1); paraoxonase 1 (PON 1); paraoxonase 2 (PON 2); 5,10-methylenetetrahydrofolate r reductase (MTHFR); a gene encoding hepatic lipase, E-selectin, G protein beta 3 subunit and angiotensin II type 1 receptor gene; and

(b) instructions for use.

* * * * *